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Abstract
Recent strategies within health and social care state policies and interventions should be 
selected on the basis of evidence available to demonstrate their benefits. The provision of 
services for drug users is no exception to this. Harm reduction is a broad term used to 
describe drug policies and interventions that aim to reduce the risks to the individual and 
society, recognising that drug use is an inevitable part of society. Arguably, attention has 
largely focused on establishing the evidence of the benefits of harm reduction 
interventions that affect society, with little attention paid to those that are for the benefit of 
the individual alone. The work presented here explores two aspects of harm reduction 
interventions, using a combination of pharmaceutical science and social science. The first 
is a laboratory-based study that gathered evidence to establish the role of filters and
acidifiers in the injection preparation processes. No previous work had been done in this
/
field, yet anecdotal evidence shows that such materials are being provided by some UK 
drugs services. The illegal nature of drug use means that the results from this work 
cannot be taken as absolutes. Instead, they are indicators of the consequence that will 
result from using such paraphernalia. The results suggest that providing syringe filters to 
injecting drug users could reduce the incidence of health problems cause by the injection 
of insoluble materials, because the filters were found to greatly reduce the content of 
insoluble particles in injections prepared with street drugs and tablets, simulating 
techniques established from information collected from injecting drug users, drugs 
workers and published materials. Makeshift filters were also tested. These were cigarette 
filters, hand rolling cigarette filters and cotton bud tips. They caused some reduction in 
particle content, to a lesser extent than that seen with the syringe filters. There is concern 
regarding their use due to them not being designed for this purpose and the potential risk 
of fibre shedding from their fibrous materials. The work also illustrated the need for 
acidifiers to promote the solubility of street heroin obtained in the base form. However, 
this also raises questions around their use and safety, indicating the pathway of future 
work.
The second aspect of this work was a case study to explore the provision of a 
pharmacist-led information and advice service at a voluntary sector drugs agency. This 
work was done because much emphasis is placed on the importance of multidisciplinary 
teamwork within drugs services. However, the benefit of including an expert on drugs, 
namely the pharmacist, has been previously overlooked. This work was undertaken as a 
field study, monitoring and evaluating the role of a pharmacist within a voluntary sector 
drugs service. The environment in which the work was conducted and the combination of
factors and people involved will have Influenced the work of the pharmacist and the 
findings. Therefore the results can be Interpreted to show that it is possible to implement 
such a service and future study should expand on such service provision to investigate 
this matter further in a multi-centred study. Further work should also pay more attention to 
establishing the benefits or otherwise of such services to the team and clients. Overall, 
this work has provided foundation evidence to support the provision of certain harm 
reduction interventions that have previously been unexplored. It also illustrates how the 
knowledge and skills of pharmacists can be used to conduct unique research in this field.
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Chapter One
Introduction
1.1 W hy do people use psvchoactive drugs despite the risks o f harm?
Beginning a thesis with a question that requires an answer outwith the remit of the work is 
not usually considered prudent. However, the purpose of posing this question is not to 
generate an all-encompassing answer through detailed analysis of human behaviour. 
Instead, it serves as a prompt to allow a summary to be given of the rationale behind the 
use of harm reduction interventions in response to drug (mis)use, a concept that at first 
glance may seem irrational. After all, if drug use has the potential to cause harm, why do 
people choose to do it? Why do those who experience harm not always stop doing it? It is 
only once these issues have been addressed that it can be understood why harm 
reduction practices and consequently harm reduction research, are necessary.
1.1.1 The benefits of using psychoactive drugs \
As a crude summary, people who use psychoactive drugs (PDs) do so because they 
expect to benefit. The expected or perceived benefits may include the attainment of 
pleasurable feelings (i.e. fun), increased social interaction (i.e. reduced inhibitions), 
alteration of the person’s psychological condition to a more desirable state (i.e. escapism) 
or avoidance of withdrawal symptoms (Gossop, 1993). Benefits from some PD use 
extend into the community and society at large. For example, the opening of a distillery 
brings the benefits of new jobs and revenue from the sale of the alcoholic products 
produced.
1.1.2 The harm from using psychoactive drugs
The harms from PDs are not equivalent. Their incidence and nature vary with the drug 
and individual concerned and their circumstances. Examples of such variables include the 
drug substance, presence of impurities, the dose, the frequency of use, the route of
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administration, the legal status of the drug, related social and financial circumstances, the 
personality of the individual drug user and its interaction between their drug use and 
lifestyle. Some harm associated with PD use can occur at any point, whereas some tends 
to increase with the extent of use. Harms from some PD use also extend into 
communities and society, for example, the financial and social costs to the community of 
drug related crime and the cost to society of criminal justice proceedings (Gossop, ibid.). 
Such harms are often associated with dependent drug use, which is described in section 
1.1.5.
1.1.3 The balance of benefits vs. harms
If the benefits from PD use are experienced before the harm, or to a greater extent than 
the harm, positive endorsement of drug taking occurs (Tober, 1989). If the person 
perceives the benefits to outweigh the harms or risk of harms, use of the drug may 
continue. The level of control the person has over their drug use will be a consequence of 
the interaction between the drug, the individual and their circumstances. The level of 
control will influence the balance between the benefits and harms. For example, with 
controlled use harms can be prevented or contained. In uncontrolled use, harms can 
escalate (Zinberg, 1984). Uncontrolled use is a characteristic of dependence on PDs.
\\
1.1.4 Examples of harm
The complex nature of drug use means that many varied harms can result, relating, for 
example, to health, welfare and social well-being. Not all drug users are at the same risk, 
so do not require the same interventions. It is impossible and unnecessary to list all 
potential risks. This work relates to health related risks, so a few examples of this nature 
will now be given.
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1.1.4.1 Harm experienced by the individual
General health may deteriorate in dependent people if lifestyle factors such as diet and 
self-care are poor. Drug users who inject are at risk of HIV, hepatitis B and C and other 
blood borne infections if they share injecting equipment. Injecting can also result in 
damage to tissue and the circulatory system. This is largely due to the unintentional 
injection of solid materials and bacteria and frequent vascular access. Some people may
2
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sell sex to gain money for drugs or In exchange for drugs, which can result in physical 
and psychological damage. Dependency and the behaviours it may drive can cause 
psychological distress.
1.1.4.2 Harm experienced by communities and society
Drug related crime impacts on communities by causing economic harm and compromises 
community safety. The families and friends of drug users may experience psychological 
distress. Society suffers economic harm from the expense caused by drug related crime 
(e.g. police and criminal justice costs and raised insurance premiums). Dependence on 
illegal drugs (e.g. heroin) tends to cause greater harm at community and societal level 
than dependence on legal drugs (e.g. alcohol and nicotine). At this level, legal drugs tend 
to be perceived to produce greater benefits, such as revenue from sales and employment 
in production.
1.1.4.3 The prevalence of drug use in the UK
Drug taking is a difficult activity to quantify. By nature, it is not a static activity, so the 
numbers of people using drugs will vary. Additionally, not all drug use causes problems, 
either for the individual or society, so figures that describe factors Such as the number of 
young people who have ever taken an illegal drug in a particular survey do not equate 
with the number of people experiencing drug related harm. Additionally not all drug users 
who are experiencing harm necessarily also harm their communities, or conversely some 
may harm their communities but experience little harm themselves. However, statistics 
collected over several years suggest that drug use, and within this, problem drug use, is 
increasing within Scotland and elsewhere in the UK. In the literature review for the second 
part of this thesis, further information and illustration is given to show the extent of known 
problem drug use In the UK (7.2.1).
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1.1.5 Drug dependence
Drug dependence is defined by the World Health Organisation (WHO) as:
'a cluster of psychological, behavioural and cognitive phenomena of variable intensity, in 
which the use of a psychoactive drug (or drugs) takes on a high priority. The necessary 
descriptive characteristics are preoccupation with a desire to obtain and take the drug and 
persistent drug seeking behavior’.
(WHO, 1993)
Although the creation of a dependent state will be influenced by the pharmacology, dose, 
and frequency of.use of the PD(s) concerned, factors related to the person and their 
environment have also been shown to influence the level of control an individual has over 
his or her drug use (Zinberg, 1984). This was demonstrated to apply even to drugs 
considered to be highly physically addictive such as opiates. Dependency is however, 
often associated with opiate use. Factors that motivate drug use in dependent individuals 
include the avoidance < of physiological and/or psychological withdrawal effects. 
Dependence on a drug prevents the individual who is unable or unwilling to endure the 
withdrawal effects, from stopping their drug use and hence avoiding drug related harm.
1.1.6 The stages of change in dependent behaviour. \
It is recognised that there are six stages involved in changing dependent behaviour. It is 
important to be aware of these stages as they show how harm reduction interventions are 
more realistic than only enforcing all drug users to become abstinent. These stages were 
first characterised by Prochaska and DiClemente (1983) in their cycle of change model in 
relation to nicotine dependence. This model was later modified and shown to apply to 
dependence on other psychoactive drugs (Prochaska et al, 1992). The model is illustrated 
in appendix 1. The stages can be briefly described as follows:
The pre-contemplation stage: People at this stage perceive the benefits from their drug 
use to outweigh any harm. They may experience harm but often remote from their drug 
use, so it has lesser immediate importance. It may be that others see the person's drug 
use as problematic but they themselves do not. People at the pre-contemplation stage 
are not motivated to stop using drugs.
i
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The contemplation stage: People at this stage are experiencing increased harm and/or 
a reduced level of benefit from their drug use. The harm will be recognised and may be 
considered to outweigh some of the benefits. The individual has begun to feel motivated 
to change but not made a commitment to do so. if the perspn is dependent on drug(s), 
they may be unable to stop or change, at least immediately.
The preparation stage: People at this stage have begun to make small changes and are 
motivated to make big changes very soon.
The action stage: People at this stage are making behavioural changes that require a 
considerable amount of effort. They are motivated to change their drug use and lifestyles, 
so as to reduce or eliminate the harm experienced. They are prepared to experience 
immediate discomfort in the anticipation of long term gain. People at this stage need to 
replace the benefits gained from drugs with benefits from other sources.
The maintenance stage: People at this stage are maintaining the changes made in their 
drug use, usually by gaining continued benefit from their drug-free or altered drug use 
pattern. The maintenance stage may involve considerable effort in order to avoid relapse. 
In order fo sustain this stage the harm, although no longer experienced, must still be 
considered to outweigh the benefits of reverting back to using drugs, i.e. the person must 
consolidate their gains from their changed behaviour.
\
\
Relapse: This stage was not included in the model proposed by Prochaska et al (1992), 
although its significance was implied. Relapse occurs when the person is unable to 
maintain the changes they have made and revert to gaining benefits from drug use.
The length of time at each stage in the model will vary with the individual and their 
previous experience of attempting to change. People can move from any one stage to 
another, change does not necessarily always occur in the order used above. Prochaska 
et al (ibid) showed that in a cohort group the number of successes (i.e. sustained change) 
increased with time and the more action stages experienced by the individual the better 
the prognosis. At all stages when the person is participating in drug taking there may be a 
risk of harm to themselves and their communities. However, only people at the action 
stage are likely to benefit from interventions that are abstinence orientated. Therefore 
since the risk of harm occurs at many stages when motivation and ability to stop using 
drugs is low, a pragmatic solution is to reduce the risk and level of harm experienced by 
the individual and others as far as possible.
5
Chapter 1
1.2 Harm reduction
1.2.1 Philosophy and practice
Harm reduction (HR) is an umbrella term used to describe a range of actions that reduce 
the risks from harmful activity, whilst participation continues, often because the individual 
is dependent on the activity. The aim of HR is to achieve harm minimisation, that is, the 
lowest level of risk of harm from the given activity (Strang, 1993). More specifically, HR 
has come to be associated with the philosophy and practices of certain services for PD 
users. Such services make interventions and deliver care appropriate to the stage in the 
process of change that the individual is at, rather than enforcing change that the individual 
has no motivation to maintain. Prochaska et al (1992) reported that the vast majority of 
dependent people are at the pre-contemplation stage of change and argued that 
treatment services should reflect this need, instead of only being focused on the action 
stage. HR interventions aim to work with the individual to achieve small realistic goals to 
reduce the risks faced by both themselves and their communities from their drug use. 
Such goals are arranged hierarchically. The individual is supported to achieve the level 
realistic for them at the present time. If further goals become realistically possible i.e. 
through motivational change, they are supported to achieve them. If and when they move 
through the process of change, the interventions are adapted to meet the needs of the 
individual.
I]
HR interventions are aimed at those who are already using drugs. It is important that they 
are targeted at these individuals, with their intention made explicit, both to the user, their 
families and society in general. This is paramount to avoid the interventions being seen as 
condoning drug use.
HR can involve a range of professionals from different disciplines, e.g. doctors, drugs 
workers, nurses, pharmacists, psychologists and social workers. This diversity of 
professions contributes to the difficulties evident from the literature in defining the term 
harm reduction (Erickson, 1995, Single, 1995, Wodak and Saunders, 1995). To date, no 
one definition appears to be acceptable to all. HR will mean different things to different 
people because their professional background will influence their interpretation. Also, the 
emphasis they place on their own contribution will differ from that placed by others. For 
example, in a paper in the Journal of the American Medical Association, Cotton (1994) 
describes medicine as the cornerstone of...harm reduction’. The author goes on to argue 
a tangible case for HR policy based on the belief that drug (ab)use is a ‘biological 
phenomenon’ and likens it to disease states such as diabetes. In her analysis of a case
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study of a young female drug user, the psychologist, Gillian Tober (1989) presents a 
different view. Tober describes the prescribing of substitute drugs as an important 
intervention, but defines drug taking as a learned behaviour, with positive and negative 
reinforcements being the factors influencing motivation to change. Both authors support 
using harm reduction interventions to achieve the same result [in this case giving 
methadone to reduce the need for heroin injection]. However, they have fundamental 
differences in opinion as to what has caused the person to take drugs. The desired 
outcome from harm reduction interventions is a reduced level of harm experienced by the 
individual and in many cases, their community and society at large.
1.2.2 Development of harm reduction within the UK public health care system.
1.2.2.1 The first harm reduction policy
The philosophy of harm reduction is intrinsically linked with human behaviour as the 
reduction of harm is an act of self-preservation. However, its incorporation into public 
health care policy and practice is a relatively recent development. Although Berridge 
(1993) reports anecdotal evidence of opium maintenance doses being used to stabilise 
dependent people in the 19th century, the first recommendation that any harm reduction 
intervention should be policy, was made in 1926 by the Rolleston Committee (Tyler,
1995). The Dangerous Drugs Act (1920) had given control of the distribution of many 
psychoactive drugs to doctors and pharmacists, making people who were dependent on 
such drugs criminalized by obtaining them (Stimson and Oppenheimer, 1982). The 
medical-based Committee were asked to review the need for substitute prescribing to 
these dependent individuals. The committee concluded that prescribing the smallest 
amount of drug needed to prevent withdrawal effects may be justified when everything 
possible had been tried to make the person drug-free and failed (Berridge, 1993, Stimson 
and Oppenheimer, 1982). The Rolleston Committee recommendations were made 
regarding persons who had largely become dependent on drugs prior to the 
implementation of legislative controls. However, legislative controls failed to prevent some 
people from beginning to use PDs, so a small number of people continued to require 
treatment. Thus, physicians in private practice undertook harm reduction in the form of 
substitute prescribing for approximately the next forty years (Berridge, 1993, Stimson and 
Oppenheimer, 1982, Tyler, 1995).
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1.2.2.2 The NHS and legislative consolidation
In 1948 the National Health Service (NHS) was established to provide health care for all. 
However, the NHS did not provide substitute prescribing or other harm reduction 
interventions. The needs of the small numbers of PD users appeared to be catered for by 
private practitioners (Derricott et al, 1999). However, the 1950s and ‘60s saw an increase 
in the number of people using illegal PDs whilst the use of the injectable route increased, 
with many of these new users from the working classes (Derricott et al, ibid, Stimson and 
Choopanya, 1998, Stimson and Oppenheimer, 1982). When a hepatitis B outbreak 
occurred amongst injectors, the NHS found itself having to provide care (Derricott et al, 
ibid). Rolleston had been concerned with, in the main, a small number of middle class 
medical professionals who had become dependent on opiates. Growing numbers of drug 
users meant the Rolleston method of private practitioner managed maintenance therapy 
was not thought to be meeting all needs or achieving politically desirable outcomes 
(Stimson and Oppenheimer, 1982). It was considered that the NHS needed to provide 
treatment, so specialist clinics were set up attached to hospital psychiatric departments 
(Stimson and Oppenheimer, ibid). Their remit was to provide programmes that focused 
only on abstinence rather than the reduction of harm in achievable stages. However, 
there are anecdotal reports of unofficial harm reduction interventions being made by 
some clinic workers, at least in London (Strang, 1993). Erickson (1995) notes that 
recommendation of the harm reduction approach was made in the literature in the 1970s 
and early 1980s. Morally, there was objection to harm reduction, so thè focus of treatment 
remained abstinence and legislative control was tightened. The various pieces of 
legislation that had been introduced since the Dangerous Drugs Act (1920) were 
consolidated in the Misuse of Drugs Act (1971). This act forms the current legislation in 
place today. The act also established the Advisory Council on the Misuse of Drugs 
(ACMD), with a remit to inform the government on drugs liable to misuse and advise on 
policy (Tyler, 1995).
1.2.2.3 The move towards community based care
In 1982, the ACMD recommended an end to the psychiatric approach to managing drug 
users and advocated the provision of care in the community setting by a multidisciplinary 
team (Advisory Council on the Misuse of Drugs, 1982). Regions began a revision of their 
drugs services. Although there was increasing discontent amongst some in public health 
towards the abstinence focused approach, resistance to policy change was great. This 
was despite the literature support for alternatives (Erickson, 1995). Harm reduction was
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seen as contradictory to the strong moral stance that was being taken in the fight against 
drug use (Erickson, ibid, Tyler, 1995). The abstinence only approach remained the focus 
of community care services. Those who were at stages other than action in their drug use 
were not provided with interventions to protect their health (Tyler, 1995). For example, 
between 1982 and 1986 the council of the Royal Pharmaceutical Society instructed 
members not to sell sterile injecting equipment to injecting drug users (IDUs) (Anon, 
1986).
1.2.2.4 The impact of HIV
The identification of the human immunodeficiency virus (HIV) in 1983 and recognition of 
unprotected sexual intercourse and the sharing of injecting equipment as vectors for 
transmission was the catalyst that promoted a rapid change in drug policy (Carbello and 
Rezza, 1990, Stimson, 1995). It was realised that IDUs who may be at risk of HIV through 
sharing injecting equipment could be having unprotected sex with non-injectors (Stimson, 
ibid). Consequently,' IDUs began to be seen as part of society and not as an isolated 
population from which non-drug users could be separated, as the threat of an acquired 
immunodeficiency syndrome (AIDS) epidemic brought the realisation that efforts aimed 
only at achieving abstinence would not adequately respond to the very real and 
immediate dangers faced by almost every country in the world (Berridge, 1993). HIV 
projection figures suggested that if the high incidence of sharing seert in Edinburgh1 was 
replicated elsewhere, within ten years 50% of IDUs would be infected with HIV (Stimson,
1995). The concept of harm reduction began to gain popularity on a wider scale 
(Berridge, 1993). In 1986, some areas of the UK introduced needle exchange (NX) 
schemes into their newly established community-based services. Some voluntary sector 
drugs agencies had also begun an exchange service (Stimson, 1995). The aim was to 
reduce HIV transmission by removing the need for sharing. In 1987 the Department of 
Health and Social Security commissioned a pilot study and then a national evaluation into 
the effectiveness of the schemes. The report showed the schemes were utilised by large 
numbers of injectors, some of which had no contact with other health care services 
(Stimson et al, 1988). ,
In 1988, the ACMD issued part one of its report ‘AIDS and Drug Misuse’. The overview on 
page 1 stated that ‘ HIV is a greater threat to public and individual health than drug 
misuse’ (Advisory Council on the Misuse of Drugs, 1988). It supported the principle of 
minimising the risks from drug use, acknowledging that drug use may continue in some 
people, even those who come in contact with services. It outlined the hierarchy of goals
9
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that agencies should work towards, acknowledging the need to tailor services to the 
individual. It also recommended an increase in availability of clean injecting equipment 
from exchanges and community pharmacy sales. Part two of the report endorsed support 
for community care and made recommendations for drugs services (Advisory Council on 
the Misuse of Drugs, 1989). These included adaptability to meet differing needs, the 
provision of medical and welfare rights support and the explicit provision of safer injecting 
advice. It also recommended that services should attempt to attract more clients and 
endorsed the use of outreach. The reports also endorsed the need for effective 
prevention strategies. The ACMD reports echoed the findings of the Scottish Committee 
on HIV Infection and Intravenous Drug Misuse, reported in ‘HIV Infection in Scotland' 
(Scottish Home and Health Department, 1986).
1.2.2.5 The expansion of harm reduction within health and social care.
In the 1990s, harm reduction strategies continued to develop, both in the statutory and 
voluntary sectors. The publication by HMSO in 1991 of the 2nd edition of ‘Drug Misuse 
and Dependence: Guidelines on Clinical Management’, endorsed a hierarchical approach 
to setting goals in substitute prescribing. NX schemes and access to substitute therapies 
grew within the community setting, including greater involvement of community 
pharmacists (Roberts and Bryson, 1999). It became apparent from HIV prevalence 
monitoring in the 1990s that the level predicted in the mid 1980s was not reached. This 
was attributed to the rapid response to HIV within the UK (Stimson, 1995).
Endorsement of the harm reduction approach was given by independent reviews into drug 
services in Scotland (Scottish Drugs Task Force, 1995) and England (Polkinghorne,
1996). Performance indicators in Scotland have been set on the basis of these reports 
(The Scottish Office, 1997) and are shortly to be introduced in England, following the 
publication of the governments 10 year strategy, ‘Tackling Drugs to Build a Better Britain' 
(UK Government, 1999). The Scottish strategy 'Tackling Drugs in Scotland: Action in 
Partnership’ outlines the current Scottish strategy, with an emphasis on joint 
commissioning and working (The Scottish Office, 1999). These strategies acknowledge 
the impact harm reduction has made over the past 15 years in preventing HIV and other 
drug-related infections. In Jersey, the philosophy of harm reduction underpins the current 
drugs strategy (President’s Policy Group, 1999).
Modern drugs services may provide a range of interventions (Derricott et al, 1999). For 
example, in addition to NX, advice may be given on drugs and their effects, safer sex,
'  A t this tim e, betw een 60 and 80%  o f IDUs in Edinburgh w ere thought to  share  in jecting equ ipm en t (Robertson, 1990).
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safer injecting, viral protection, treatment options and welfare rights. One-to-one and 
group support for drug users and their families may be provided and training for other 
professionals undertaken. A variety of methods of delivery may be used to encourage 
contact with services and help them meet needs. For example, outreach and detached 
work, protected time for women only, joint working with other services and peer 
education. The recent formation of user activist groups indicates a willingness of some 
drug users to be identified and have their views represented.
Changes in drug policy and practice have been discussed with respect to harm reduction. 
There are other components to drug policies and practice that are also important, but not 
part of this work. These include prevention strategies that are aimed at people who do not 
use drugs, in order to prevent them from becoming drug users and detoxification 
programmes to assist people in becoming drug-free. Also, law enforcement strategies 
which are aimed at both drug users and non users and welfare strategies which are 
aimed at factors associated with drug use such as poverty, social exclusion, inequalities 
in health, education, unemployment and social care. A combination of all these are 
important in providing a comprehensive drugs strategy. The focus of this work is harm 
reduction strategies with the aim of protecting and promoting the health of people who 
use drugs.
1.2.3 The future for harm reduction \
1.2.3.1 Evidence based practice
To improve the quality of care and management of resources, the current UK health care 
system is moving towards one of evidence-based practice (Sackett et al, 1996). 
Interventions and treatments require evaluation to establish if there is justification for their 
provision, in terms of clinical benefit and cost. The recently published 3rd edition of ‘Drug 
Misuse and Dependence: Guidelines on Clinical Management’ (Department of Health, 
1999) endorses the need for evidence based treatments for drug users. This view is also 
held by the WHO (1999). Evaluation of some HR interventions has already been carried 
out. For example, the reduction of HIV transmission by the provision of NX has been 
shown both at national level (Stimson, 1995) and global level (Stimson, Des Jarlais and 
Ball, 1998). There is also substantial evidence to support the provision of substitute 
therapies. Ward et al (1994) reviewed the impact of methadone on health, illicit drug use 
and drug related crime. The authors found maintenance dosing of at least 50 mg per day 
provided sustained benefits in the areas investigated. Evidence continues to be gathered.
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The National Treatment Outcome Research Study, commissioned by the English Task 
Force that reviewed drugs services (Polkinghorne, 1996), is evaluating the outcomes from 
four treatment modes2. Although not complete, the study has shown that both residential 
programmes and all methadone treatments substantially improve physical and mental 
health, reduce injecting and reduce involvement in drug related crime, with these benefits 
being sustained two years after study intake. Problem drinking however, did not improve 
(Gossop et al, 1999). There is also some evidence to suggest that the prescription of 
heroin may benefit mental health and social well-being and reduce involvement in drug 
related crime amongst individuals who are resistant to conventional treatments (Perneger 
et al, 1998).
As new harm reduction techniques and services develop, the demand for evidence 
means they will have to be based on research rather than just a belief that they will 
benefit the recipient. The process of undertaking such research will have several 
compartments, from initial investigation, through to implementation and development then 
evaluation in practice.
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1.2.3.2 Harm reduction research: the role of the pharmacist
Through their training, pharmacists gain a unique combination of knowledge and skills. 
They have an understanding of science-based subjects such 'as pharmacology, 
chemistry, therapeutics and formulation and social science subjects such as health 
psychology and communication. They also have the ability to combine their knowledge 
and translate it into everyday language, to convey information and deliver health care to 
the public. They can conduct laboratory-based investigations using analytical research 
techniques and practice-based research using social science techniques. This wide range 
of knowledge and skills means pharmacists can gather evidence to support the provision 
of health care in a variety of settings, using a variety of means, which arguably, other 
professionals can not do so readily. One example where pharmacists have done such 
work is the development of high-tech healthcare at home services for cancer patients 
(Sewell and Hong, 1997). Laboratory-based research has been done to develop stable, 
accurate drug delivery systems, whereas practice based research has ensured that such 
systems are manageable by patients and their carers and established their education 
needs. The area of harm reduction lends itself to similar laboratory and practice-based 
research that could potentially be undertaken pharmacists. *
* T hese  m odes being: (i) inpatient units, (ii) residentia l program m es, (iii) ou tpa tien t/com m un ity  based m ethadone reduction 
and (iv) ou tpa tien t m ethadone m aintenance.
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1.3 The research plan and thesis structure
Chapter 1
1.3.1 The original plan of work
At the start of this PhD project, the original plan of work differed from what was actually 
undertaken. The original plan was to collect information from IDUs on their injection 
preparation techniques and translate this into a laboratory simulation that could be used 
to investigate the effectiveness of filters used to remove insoluble material from injections 
made with street drugs. If appropriate, the findings would then be used to support the 
provision of filters through all needle exchanges in Grampian3. It was proposed to assess 
the clinical impact of this filter supply through two means. Firstly, it was planned to 
establish a nurse-led injection site injury clinic at the specialist drugs agency, Drugs 
Action. Through this clinic, ‘before and after’ data on the incidence of injection site injuries 
linked with the administration of insoluble materials could be gained from clients. 
Secondly, at the start of this work an audit of drug users use of the Accident and 
Emergency (A&E) services at Aberdeen Royal Infirmary was being undertaken. Part of 
this audit recorded the clinical conditions that presented, so therefore those linked to the 
injection of insoluble materials could be identified. It was proposed that the audit would be 
repeated in two years, which would mean a reassessment of the incidence of clinical 
problems linked to the injection of insoluble materials could be made, with the supply of 
filters having commenced before the re-audit. Discussion with the A&E researchers 
established that a sub-section could also be inserted into the audit questionnaire to gather, 
further information on the use of filters amongst the patient group.
However, as the work began it became clear that such plans were over-ambitious for a 
project of this size with limited funds and not possible due to several factors that will now 
be described. Arrangement of the provision of street drugs from the police for the 
laboratory work took longer than expected, so that experimental work with heroin could 
only begin 15 months after the project started. Also the quantity of heroin available was 
limited. Similarly, it took 11 months to gain approval from the Crown Office and Procurator 
Fiscal to allow the distribution of filters to injecting drug users. Before this work started 
neither the researcher or the supervisory team knew that distribution would require legal 
dispensation to be granted. Access to laboratory equipment was limited by other 
researchers and undergraduate needs and no automated equipment was available. This 
was further compounded by the Coulter Counter being broken when it was moved by staff 
during building work. There was a delay of six months in raising the funds to repair it and 
getting this done as it had to be returned to the manufacturer. An application for funds for
3 A t the s ta rt o f th is w ork there  w ere e ight pharm acy based exchanges and one spec ia lis t serv ice  (D rugs Action).
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the injection site injuries clinic was rejected, enforcing reconsideration of this proposed 
part of the work. Additionally the audit of A&E services was also delayed. At the time of 
writing the re-audit has not been undertaken (Summer 2000).
1.3.2 The revised plan of work
As a consequence of the factors described in 1.3.1 the proposed schedule of research 
was revised to allow a workable study to be carried out. The revisions and their 
justification will now be summarised.
Despite the equipment difficulties the laboratory work was undertaken although of the 
work was restricted by time and the drugs available. As the researcher began to consider 
the implications of distributing filters to IDUs she became aware that a pilot study to 
establish user, acceptability and a further small tightly controlled study to check their 
safety as< predicted ¡from the laboratory work would be required before large scale 
distribution could be undertaken. Hence a series of laboratory based experiments testing 
filters and aspects of the injection preparation process were carried out using a simulation 
technique based on data collected from IDUs. This was followed by a user acceptability 
pilot study of the most appropriate filter.
Whilst the researcher was collecting data from IDUs at Drugs Action on their injection 
preparation techniques, staff and clients often asked her for advice on pharmaceutical 
matters. It was during this period of data collection that the funding for the injection site 
injuries clinic was refused. The Drugs Action needle exchange worker, who was also an 
advisor to this project, and the researcher, both considered that there might be a place for 
a pharmacist-led information and advice clinic at Drugs Action. Such a service could be 
run on limited funds compared to the injection site injuries clinic. When a funding bid was 
successful for a six-month pharmacist-led information service at Drugs Action, it allowed 
this idea to be explored as a research project.
1.3.3 The structure of this thesis
The originally proposed laboratory-based and practice-based research (3.3.1) would have 
been connected through investigation into the effectiveness and clinical benefits of filters. 
However, the actual work that could be undertaken (3.3.2) was less closely linked. 
Consequently, this thesis is presented in two parts with hypotheses for each study that
■ i'
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was undertaken. Each part of the thesis begins with background information and a review 
of the literature. From this, the hypotheses and research questions posed for each study 
are derived.
The first study is presented in part one. It began by gathering information on injection 
preparation processes from IDUs and transferring this into the laboratory setting. There, 
laboratory-based research techniques were used to investigate aspects of the preparation 
process. The findings were then transferred back to the IDU environment for the pilot 
evaluation. Since each stage of the study informed the next, each is presented as a 
discreet chapter incorporating both the methods and results. The findings from all stages 
are discussed in the last chapter of part one, which ends with the study conclusions and 
describes the direction of future work.
The second study, presented in part two, investigated the delivery of a pharmacist-led 
information and advice service within the specialist drugs service environment. It is 
presented in the more traditional format of one chapter for methods, one for results and 
one for discussion. The conclusions from the study are given at the end of the discussion 
chapter, which also describes the areas for future work.
Finally, the last brief chapter of the thesis reflects on the work that has been undertaken 
and makes closing comments.
\I
1.4 Search strategies used
The databases initially searched for this thesis were Science Citation Index, Social 
Sciences Citation index, Medline and Pharmline, all on CD-ROM. The searches were 
repeated periodically and expanded later in the study when on-line searching became 
available, using EMBASE (Excerpta medica, EMBASE drugs and pharmacology and 
EMBASE psychiatry), Web of Science (Science Citation Index and Social Sciences 
Citation Index), Medline and Science Direct (Elsevier Science publications). The plurals 
and variations of the search terms used were checked and mapped headings included 
where applicable.
A variety of search terms were used for this study. An initial search was carried out using 
the terms ‘pharmacist’, ‘drug misuse', 'substance misuse4’ and ‘harm reduction’ to 
establish an insight into the nature of the literature. More specific searches were 
undertaken for the individual studies. For the work presented in part one, searches were
4 T he  te rm  ‘substance  m isuse ’ is som etim es used in the A m erican lite ra tu re  instead o f the te rm  'drug m isuse '.
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carried out using the terms filter’, ‘cotton5', ‘particle’, ‘illicit’, ‘drug abuse’, ‘drug misuse’, 
‘heroin’, ‘base’, fablet’, ‘inject’, ‘intravenous’, ‘injury’, ‘granuloma’, ‘harm reduction’ and 
‘complication’. The terms were combined or linked as considered appropriate. For the 
work presented in part two, searches were carried out using the terms ‘pharmacist’, ‘role 
of the pharmacist’, ‘service’, ‘pharmacy practice’, ‘community’, 'community pharmacist’, 
‘hospital pharmacist’, ‘information’, ‘advice’, ‘education’, framing’, ‘undergraduate’, 
‘postgraduate’, ‘drug misuse’, ‘substance misuse’, ‘illicit’, ‘drugs agency’, ‘voluntary sector’, 
freatment’ and ‘methadone’. In addition, searches were undertaken when required to 
assist with enquiry answering.
In addition, searches were carried on behalf of the researcher by the Institute for the 
Study of Drug Dependence (ISDD) library using the terms filter’, ‘injecting injury’ and 
‘pharmacist’. The email alerting service of the British Medical Journal, Lancet and 
Australian Medical Journal were used. Many web sites were searched during the course 
of this study including those of the Department of Health, the Scottish Office, the 
Information and Statistics Division (Scotland), the Lindesmith Center On-line Library 
(USA) and the National Institute on Drug Abuse (USA).
\
\
5 T he  term  ‘co tton ’ is used in the USA referring to filte rs used by IDUs,
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Investigation into aspects of the injection preparation process
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Chapter Two
Background, literature review and aims of this study.
2.1 Introduction
The intravenous route may be used by drug users for many reasons, a detailed 
description of which is outwith the scope of this work. Investigation into the circumstances 
that surround initiation into injecting show this to be a multifaceted issue (Crofts et al,
1996). Injection may be out of necessity, e.g. people who regularly use opiates will 
develop tolerance to the effects of the drugs and if dependence occurs they will have to 
use increasing quantities to achieve similar effects (Derricott et al, 1999). The intravenous 
route becomes the most economical route in such cases as it avoids first pass 
metabolism and the effects of absorption across membranes e.g. inhalation. Injection 
may be used to achieve rapid and powerful onset of effects i.e. euphoria. However there 
are social factors that dictate acceptability, injection is not perceived as acceptable by or
used by all drug users, even those who are dependent, hence only a proportion of drug
\
users will use injectable routes such as the intravenous route (Crofts et al, 1996).
The use of the intravenous route to administer drugs carries many potential risks. These 
may come from the drug product itself, the preparation or administration process or the 
bypassing of many of the body’s defence systems (Benet et al, 1996). The manufacture 
of pharmaceutical injections is subject to strict quality control to minimise the risks to the 
patient from the drug product (MCA, 1997, Hugo and Russell, 1987, Chapman, 1998). 
The preparation and administration of medical injections is also carefully controlled to 
minimise patient risk (Benet et al, 1996). Illicit drug use, commonly referred to as street 
drug use, is not subject to such controls, so potentially the health of the IDU is at great 
risk.
One area that is carefully controlled during the manufacture and preparation of 
pharmaceutical injections is that of particulate content, as the injection of insoluble 
materials can have adverse effects on health (Chapman, 1998, Barber, 1993). Several 
health problems seen in IDUs are caused by the injection of insoluble particles (Ben-Haim 
et al, 1988, Stein, 1990, Shesser et al, 1991, Haiart et al, 1992, Ruben and Morrison,
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1992, Wills, 1997). There is a potential role for harm reduction in reducing the risks from 
the injection of particulate matter.
2.2 Sources o f particulate matter in IDUs injections
Sources of particulate contamination in pharmaceutically prepared injections include the 
ingredients, the manufacturing process, packaging, the environment and personnel 
(Barber, 1993). The pharmaceutical industry applies strict controls to minimise particulate 
contamination (Barber 1993, Chapman, 1998). Limits are placed on the permitted 
particulate content in large volume parenterals (> 100 ml) (British Pharmacopoeia 
Commission, 1998). Illicit injecting is not subject to such controls. Although no study could 
be found examining sources of particulate matter in IDUs injections, when the concerns of 
industry are considered in the context of the IDU, several likely sources can be identified. 
These will now be discussed.
2.2.1 The drug substance
Powders that may be used to prepare illicit injections, such as street heroin and 
amphetamine, are produced in clandestine laboratories (Wills, 1997). It is assumed that 
the conditions under which illicit drugs are manufactured do not match' the standards of 
the pharmaceutical industry, since no legal control governs quality assurance. The 
injection of solid oral dosage forms, such as tablets, also occurs (Stein, 1990, Haiart et al, 
1992, Ruben and Morrison, 1992). Both illicit powders and tablets are potential sources of 
particulate matter. Poorly soluble and insoluble materials, such as talc1, are often used as 
excipients in tablets (Parfitt, 1999). Street drugs may contain insoluble materials due to 
lack of refinement in the manufacturing processes. The drug itself may not be in a soluble 
form. For example, heroin base, which has a low solubility, is prepared for vaporisation2, 
but is known to be used for injection in the UK (Derricott et al, 1999). Attempts are made 
by IDUs to convert the base to a soluble salt by heating the drug in the presence of acids 
such as citric or ascorbic acids, in powdered form or lemon juice, or acetic acid in the 
form of vinegar (Gossop, 1996, Tyler, 1995). Particles of undissolved base could be 
present if conversion is incomplete. The ‘cutting’ of illicit powders with insoluble or poorly 
soluble bulking agents such as talc, chalk, and at cold-water temperatures, starch, may 
cause particles in prepared injections (Ben-Haim et al, 1988, Shesser et al, 1991, Wills,
1997). However, the use of soluble cutting agents such as sugars appears from analysis
1 T a lc  is p redom inantly  com posed o f hydrated m agnesium  silicate. It m ay a lso contain  sm all am oun ts  o f a lum in ium  silicate 
and iron. It is practica lly  inso lub le  In w ater i.e. is has a solub ility  less than 1 in 10 000  (P arfitt, 1999).
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studies to be more common, so this cannot be assumed for all illicit powders (Love and 
Pannell, 1980, Kaa and Bent, 1986, Chiarotti et al, 1991, Kaa, 1994).
2.2.2 Packaging
Particles may be introduced into pharmaceutical injections from the packaging material or 
during the packaging process (Barber, 1993). The materials known to be used for the 
packaging of street drugs include plastic bags, cardboard and paper (Wills, 1997). These 
are possible sources of particulate contamination. Also, if assumed packaging of street 
drugs does not take place in a controlled environment, both the packer and the 
environment may contribute to the particle load. It is also known that street drugs may be 
repackaged several times before they reach the user (Tyler, 1995), which could increase 
the number of particles present.
2.2.3 Preparation methods, the IDU and the environment
The packaging used for pharmaceutical injections is such that particulate contamination 
from the handler or the environment during injection preparation is minimised (Chapman,
1998). The preparation stages used by IDUs described in the literature (Koester et al, 
1990, Derricott et al, 1999) indicate that several opportunities for particulate 
contamination exist. There may be several persons present, in an environment where air 
quality will be uncontrolled. This creates large numbers of environmental particles 
(Barber, 1993). The drug is exposed to the environment as the injection is prepared. The 
water used may be of uncontrolled quality since water for injection cannot be obtained 
without a prescription in the UK (RPSGB, 1999). Unprotected hands will again be a 
source of particles. Syringe barrels themselves have been shown to shed plastic particles 
(Barber, 1993).
2.3 Health problems seen in IDUs attributed to the in jection o f particles
When insoluble particles are injected intravenously, they may lodge in the lungs or 
continue around the circulation to other sites (Wills, 1997). Several of the health problems 
seen in IDUs that have been associated with the injection of particles will now be 
discussed. 2
2 The process o f inha ling heroin in the vaporised form  is known as 'chasing '.
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2.3.1 Granulomas
The formation of foreign body granulomas around injected particles is reported frequently 
in the literature (Stein, 1990, Shesser et al, 1991, Posner and Guill, 1985). Keul et al 
(1993) report the presence of granulomas in 30% of drug users at autopsy, however, do 
not explicitly state that these people were known injectors. Granulomas have been 
identified both locally and systematically (Posner and Guill, 1985, Stein, 1990, Shesser et 
al, 1991). The lungs are often the sites of granulomas, although other systemic sites are 
reported including the liver, kidney, retina and lymph nodes (Shesser et al, 1991, Wills,
1997). Multiple lung granulomas have been identified in IDUs (Tao et al, 1984, Ben-Haim 
et al, 1988). Pulmonary fibrosis, which may result from multiple granulomas leads to the 
formation of venous shunts, causing some blood to by-pass the lungs (Posner and Guill, 
1985). Clinical presentation includes dyspnoea, hypoxia, pulmonary hypertension leading 
to right sided heart failure, and emphysema (Sternbach et al, 1980, Posner and Guill, ibid, 
Wills, 1997). Granulomas have mimicked the symptoms of tumours, both in the lungs and 
at other sites (Feldman et al, 1999, Rohde et al, 1999). Talc has been particularly cited as 
a cause of permanent granulomas (Hopkins and Taylor, 1970, Stein, 1990) whereas 
starch, has been associated with transient pulmonary granulomas (Stein, ibid). The 
authors note it may take several decades for talc granulomas to form and cause clinical 
symptoms. It has been suggested that this is because the silicate has to be in the 
colloidal form before a granuloma occurs, a process that takes several years (Posner and 
Guill, 1985). Sterile abscesses have been attributed to the injection of particles and may 
eventually form granulomas (Stein, 1990). The subcutaneous route is commonly 
associated with these abscesses (Derricott et al, 1999).
2.3.2 Inflammation
Phlebitis is commonly seen in IDUs, and although also linked to frequent venous access 
(Derricott et al, ibid), injected particles are known to irritate the vein walls and contribute 
to the inflammatory response (Stein, 1990, Wills, 1997). Complications of phlebitis are 
discussed in section 2.3.3. In cases of cellulites, where infecting organisms were not 
found, tissue irritation due to the extravasation of injected particles as been suggested as 
the cause (Orangio et al, 1984, Stein, 1990).
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2.3.3 Emboli and associated problems
Emboli may be caused directly by particles, or indirectly by thrombi that form as a result of 
phlebitis (Stein, 1990, Wills, 1997). As a consequence of deep venous thrombosis, 
varicose ulcers and in extreme cases, gangrene has been seen (Haiart, 1992, Imbert, 
1997). Occlusion of pulmonary vessels has resulted in acute and chronic pulmonary 
hypertension (Shesser et al, 1991), which may lead to cardiac failure. Embolisms have 
also been held responsible for myocardial infarction in IDUs (Sternbach et al, 1980). 
Damage to the right side heart valve leaflets or endothelium has been linked with particle 
injection, giving rise to right sided endocarditis (Haverkos and Lange, 1990). 
Thrombophlebitis may lead to vein collapse and the consequent formation of venous 
shunt (Derricott et al, 1999). This in turn will impair vascular functioning, resulting in 
oedema of the extremities.
2.4 Factors relating to the in jection o f particles
2.4.1 What can realistically be achieved?
Particulate matter from the drug substance (2.2.1) and packaging (2.2.2) cannot be 
controlled in the context of illicit injecting. The extent to which factors relating to the I DU 
and their environment (2.2.3) can be realistically controlled is also limited. However, it 
may be possible to influence the preparation methods used (2.2.3). Given these factors, 
the most assured way to reduce the particulate content in illicit injections may be through 
an end-stage process factor, that is particle removal at the final stage of injection 
preparation. Before methods that could be used to do this are discussed, it is important to 
gain some idea of what can realistically be achieved.
In the pharmaceutical industry, the aim is to reduce particulate contamination to below the 
acceptable levels. In the case of large volume parenterals, this means to within 
compendia requirements (British Pharmacopoeia Commission, 1998). Although no limits 
are set for small volume parenterals due to quantification difficulties, manufacturing is 
designed to reduce contamination to a minimum. When considering particulate removal 
from illicit injections, the standards of the industry cannot be achieved due to the variables 
described in 2.2. Particle removal in any environment cannot be absolute and will be 
subject to variation. The extent of the variation is likely to be much greater with illicit 
injections due to lack of control over the factors in 2.2. Therefore in contrast to the 
industry where the aim is to reduce particulate contamination to within acceptable 
standards, the aim with illicit injections can be no more than to remove as many of the
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particles as possible and evaluate whether the levels that are achieved produce any 
significant benefits to health, both in the incidence of acute problems such as embolisms 
and inflammation and in conditions which appear over time such as granulomas.
2.4.2 Critical particle sizes
The limits placed on large volume parenterals in the British Pharmacopoeia state the 
number of particles over 5 pm and 10 pm that are acceptable (British Pharmacopoeia 
Commission, 1998). In the vascular system, capillaries are the smallest vessels, having a 
diameter between 5 and 9 microns, with the smallest capillaries situated in the lung 
(Guyton, 1984). It can be suggested that particles larger than 5 pm in diameter will 
obstruct pulmonary capillaries. Particles may pass through the lungs, due to their small 
size (< 5 pm) or the presence of shunts. It is known that talc particles can pass from the 
blood through the glomerular filter, as they have been detected in the urine of IDUs 
(Posner and Guill, 1985). This may be true of other particles, however it cannot be 
assumed on size alone since glomerular filtration also depends on ionic charge (Guyton, 
1984). Particles of any size may potentially damage circulatory valves or damage tissue if 
they leak through ruptured vessel walls.
2.5 Reducing the particulate content in illic it in jections !
2.5.1 The use of makeshift filters and safer injecting advice
In an attempt to remove insoluble particles, it is known that some IDUs draw their drug 
solution through a makeshift filter prior to loading it into the syringe. The filters reported to 
be used are prepared from readily available household items, such as cigarette filters, 
cotton wool from buds or balls, lint and clothing. (Harrison and Walls, 1990, Koester et al, 
1990, Power et al, 1994).
The use of makeshift filters is reported in training information for drugs workers (Health 
Education Authority, 1993, Derricott et al, 1999) and safer injecting advice given to IDUs 
describe their use (Exeter Drugs Project, 1992, HIT, 1997, Preston and Derricott, 1997, 
Viral Protection Campaign, 1998, Lifeline, 1999) (see appendix 2). In these leaflets IDUs 
are advised always to use a clean filter, never to share or reuse filters and to avoid using 
loose fibrous filters such as cotton wool. Suggestions are made such as ‘art alternative to 
using a filter is to tip the spoon carefully and keep the 'crap’ at the opposite end to where
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you draw up'(HIT, 1997). The specific recommendation to use cigarette filters is made in 
others (Exeter Drugs Project, 1992, Viral Protection Campaign, 1998, Lifeline, 1999).
Although the use of filters by IDUs has been identified in the literature, there appears to 
have been no investigation of the effectiveness of this practice in reducing particulate 
contamination. The only published investigations found that studied the effectiveness of 
filters at removing particulate matter were concerned with the therapeutic use of 
pharmaceutical products. No study involving laboratory analysis of illicit drug injections 
was found. Since this work was undertaken, two pieces of work examining illicit injections 
and filters have been published, however, neither relate to the effectiveness of filters on 
particulate matter. One was a Swiss study that examined the effects of syringe filters on 
bacterial contamination in 20 heroin injections (Caflisch et al, 1999). The other was 
performed in the USA. The authors developed an HPLC-EA forensic method for analysing 
the drug content in filters (Huettl et al, 1999). The effectiveness of filters for use by IDUs 
is an area that warrants investigation.
2.5.2 The reuse of filters by IDUs
Anecdotal reports from drugs workers and trainers suggested that some IDUs believe 
filters retain some of the drug substance as well as insoluble materials (Bruce, 1996, 
McDonald, 1996, Speed, 1996, Derricott, 1997). Although no study\ investigating this 
could be found in the literature, there is evidence to support this belief. Koester et al 
(1990) and Harrison and Walls (1990) note that some heroin injectors save used filters 
and mixed them with water at a later date to release trapped drug. The extent to which 
makeshift filters retain drug when used in the injection preparation process is therefore a 
further area for investigation.
2.5.3 Health issues
The use of makeshift filters and their reuse raises several health issues. The literature 
contains reports of health problems that have been linked to the use of makeshift filters. 
In a review of injecting complications, Stein (1990) notes that fibres shed from makeshift 
filters may be responsible for granulomas and embolisms. A febrile syndrome not fully 
understood has also been associated with the use of makeshift filters. This syndrome, 
referred to as ‘cotton fever’ can be mistaken for a more serious conditions such as 
infective endocarditis or pneumonia, due to similarities in presentation i.e. fever, chills,
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lethargy and pain. Harrison and Walls (1990) suggest the pyrogenic properties of cotton 
shed from filters may be responsible. The authors report no associated infection and 
resolution of the condition within a matter of hours. The authors note from the literature an 
association between presentation and the administration of injections prepared from 
previously used filters. This condition was also reported in a case study by Ferguson and 
Feeney (1993), but this time associated with systemic infection with Enterobacter 
agglomerans, known to heavily colonise cotton plants. This syndrome was also observed 
by Sternbach et al (1980), in association with the use of brown heroin, but the authors 
have not made any link with the use of filters. Derricott et al (1999) suggest ‘cotton fever’ 
or ‘dirty hits’ as they are termed in the UK, may be a response to the drug, an adulterant 
or a contaminant from the paraphernalia. This may be the case since many cigarette 
filters in the UK are made from cellulose acetate not cotton (Dobbin, 1998). It has also 
been suggested by the developers of ‘Steribox’, an injection paraphernalia kit available in 
France, that the condition is a response to a protein in the coat of the fungi Candida 
albicans, which may be present in brown heroin, lemon juice and vinegar (Imbert et al,
1999). The sharing of filters, as well as other injecting paraphernalia, has been associated 
with the transmission of blood-borne viruses. Koester et al (1990) and Power et al (1994) 
make this suggestion in relation to HIV transmission. The sharing of paraphernalia, 
including filters has also been implicated in the transmission of hepatitis C virus (HCV) 
(Crofts and Aitken, 1997, Crofts et al, 1999). The authors made this suggestion after 
identifying IDUs infected with HCV who reported never having shared needles and 
syringes, but who reported having shared injecting paraphernalia including filters. Further 
work is needed in this area to establish the role of each piece of paraphernalia in HIV and 
HCV transmission.
These reports raise some issues. The first is that IDUs must be encouraged not to share 
any injecting paraphernalia. This has been the focus of recent safer injecting campaigns 
(Preston and Derricott, 1997, Viral Protection Campaign, 1998). The second is that even 
if makeshift filters can be found which reduce the particle content of injections, they 
themselves may contribute to harm, especially if they are reused. Makeshift filters were 
not designed for the purpose for which IDUs use them. Hand rolling and cigarette filters 
for example are designed to remove smoke particles. This points to the suggestion that 
commercially produced filters made for injection filtration may be more appropriate for use 
by IDUs as they are designed to fit onto syringes and remove particles bigger than the 
stated pore size.
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2.5.4 The supply of commercially produced filters to IDUs
2.5.4.1 Disc-type syringe filters
Information was sought to establish whether commercially produced filters were being 
supplied to IDUs. It was established that commercially produced filters were being 
supplied abroad to IDUs and had been distributed in the UK in the past. Commercially 
produced disc syringe filters (SF) were promoted in information bulletins produced for 
IDUs by workers from NXs in New South Wales, Australia (Bergin, 1996, Anon, 1996). 
However, no details of filter type or pore sizes were given, although illustrations confirmed 
the disc type. The workers acknowledged in the text a lack of evidence of effectiveness of 
SFs. Further information established after this study began found SFs also recommended 
and illustrated in another Australian safer injecting leaflet (NDARC, 1998), but again with 
no details of make or pore size. Communication with an ex-worker from New South Wales 
Users Association established that syringe filters had been distributed from this 
association, but this had stopped due to the expense (Burrows, 1999). Again, no pore 
size, brand details or information on user acceptability were known.
Anecdotal reports from users of a drugs agency drop-in service in Aberdeen3 established 
that some had obtained filters some years ago from NXs in Edinburgh. They reported 
receiving filters which fitted the description of SFs. Contact was made with the director of 
the Centre for HIV and Drug Services in Edinburgh, who confirmed thai no filters were 
currently being distributed but provided contact details of NXs who had distributed filters 
in the past (Lewis, 1996). Discussion with these workers established that syringe filters 
had been given out, but this practice had stopped some years previously (Kerr, 1996, 
Stritch, 1996). The reason given for stopping by the workers was the opposition of the 
local public health department, who considered the lack of evidence of effectiveness did 
not allow responsible provision. Stritch provided contact details of the NX from which the 
filters had been bought. This agency was visited. Discussion with the co-ordinator 
(Simmonds, 1996) established that the filters they had distributed to IDUs and other 
agencies some years previously had come from Switzerland. However, the source was 
unknown by the current staff working at the exchange. Their description fitted that of SFs, 
but make and pore size could not be established.
Many disc-type SFs are available commercially for removing particulate matter from 
prepared injections in the medical or laboratory setting, e.g. those in the catalogues of
3 This  drop-in  service w as provided by Drugs Action. 48a Union Street, Aberdeen. It w as s ta ffed  by two drugs w orkers, to 
p rovide in form ation and advice to  any drug user who chose to  attend. N o appoin tm ent system  w as in operation.
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Gelman Sciences (1991) and Millipore (1996). These filters may be appropriate for use by 
IDUs, as they have been designed to remove particles with minimal shedding. Also, 
anecdotal information established that SFs have been distributed to IDUs in the past. 
However, before they could be considered acceptable for use by IDUs it would have to be 
demonstrated that they do reduce the particulate contamination in illicit injections. Issues 
around the potential for reuse would also have to be considered, as would the 
acceptability of the SFs to IDUs. For example, if the filter withheld drug, IDUs may either 
wish to release the trapped drug or be unwilling to use the filters in the first place. It 
appears from the literature that these issues have not been investigated.
2.5A.2 Cellulose acetate filters
During this study, injection preparation kits were identified which are sold or distributed to 
IDUs in some European countries. Two kits were obtained from Switzerland and one from 
France. The ‘Flash’ and ‘Safety Kit' kits were produced by Compet Medical AG, 
Bottighofen, Switzerland. The ‘Steribox’ kit was produced by Association Apothicom in 
association with Co-Pharm-EC, from Ivry-sur-Seine, France. The Safety Kit and Steribox 
both contain filters. The Safety Kit filter is a small fibre filter packed into a plastic casing 
that fits onto the end of the syringe, through which the liquid is drawn. The Steribox 
contains a small fibre filter resembling a hand rolling cigarette filter, which is placed in the 
preparation spoon, which is also provided. The producers of the kits wdre contacted to 
establish whether they had any information on the effectiveness of the filters. Contact with 
Compet Medical AG established that no work had been done investigating the 
effectiveness of the filters (Schilling, 1998). Although the filters in the Steribox kit have not 
been tested in the laboratory in any way, work has been done to investigate user 
acceptability of the filters. This study is contained in an unpublished report produced by 
the Association (Imbert, 1997). As a result of this work, the filter in the ‘Steribox 2’ kit was 
changed. It is a small cellulose acetate filter, a third of the size of the original hand rolling 
filters. Current collaborative work is on going with Association Apothicom to develop an 
appropriate fibre-free filter for inclusion in Steribox 2.
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2.6 Restrictions that apply to the provision o f in jecting paraphernalia to IDUs 
in the UK
2.6.1 Current legislation
Although safer injecting advice can be given to IDUs in the UK, the provision of injecting 
paraphernalia (IP) such as filters, acidifiers, spoons, water for injection4 and swabs is 
prevented by law. Section 9A of the Misuse of Drugs Act (1971) makes it an offence to 
supply any article if it is believed that it will be used for the unlawful preparation or 
administration of a controlled drug5. Subsection 1 states if the administration is unlawful
i.e. not in accordance with the Medicines Act (1969) or Misuse of Drugs Act, the supplier 
of administration equipment is guilty of an offence. Subsection 2 excludes needles and 
syringes from this ruling, thus allowing NX to be conducted6. Subsection'3 makes it an 
offence to supply materials that are to be used to prepare controlled drugs, if the 
preparation is unlawful. There has been no test case of this law, so it is not known what 
the ruling of the courts would be on such an incidence (Lutener, 1997). Derricot et al 
(1999) consider it unlikely that prosecution would ever occur, as it would not be in the 
public interest.
Many paraphernalia items such as makeshift filters (2.5.1) and acidifiers (2.2.1) are 
obtained from household items. Therefore, unlike needles and syringes, they can be 
obtained from a range of retail outlets. Enforcement of the law would be difficult, as it 
would have to be shown that the supplier was aware that the item was going to be used to 
prepare controlled drugs. However, this may be easier to prove in the case of supply from 
harm reduction service providers. It is unclear to what extent service providers are aware 
of the laws that prevent paraphernalia distribution, as this has not been studied. The 
researcher is aware of the supply of paraphernalia items, in some cases without legal 
approval. However, as the present law stands, legal supply, with the exception of clean 
needles and syringes, cannot be made.
2.6.2 The possibility of legal reform
Support for a change in the law to allow IP to be supplied to IDUs has been identified. 
Commenting on the Association of Chief Police Officers 1997 conference, Wray (1997)
4 W a te r fo r in jection is a lso  contro lled by the M edicines A ction (1969), restric ting  supply to p rescrip tion only.
5 S ection 9 A  w as inserted into the M isuse o f D rugs A c t by section 34 o f the Drug T ra ffick ing  O ffences A ct (1986).
6 In Scotland the com m on law  crim e o f reckless conduct m eans tha t in theory the supp ly  o f needles and syringes could 
am o u n t to  a crim ina l o ffence. The Lord A dvoca te ’s revised guidance sta tes tha t the p rosecution o f doctors, pharm acists or 
people  w ork ing  under the ir instruction to provide needle  exchange would  not be authorised. H owever, this s ta tem ent is not 
extended to all d rugs w orkers (The Scottish O ffice, 1998).
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notes support was given for legal reform. More recently, a press article reported a 
government official has stated that the law would be changed (Anon, 1999a), a statement 
that was repeated shortly after at a national conference (Goodman, 1999). The police and 
Crown Prosecution Service have been reported as unlikely to prosecute for the supply of 
IP (Derricott et al, 1999, Preston, 1999). The report of the Working Party on 
Pharmaceutical Services for Drug Misusers (1998) called for a change in the law to allow 
pharmacists to supply additional paraphernalia, including swabs, water for injection and 
citric acid. The Royal Pharmaceutical Society of Great Britain (RPSGB) have confirmed 
that they would not take disciplinary action on a member unless they were prosecuted 
(Preston, ibid) and more recently have reported they will be encouraging the relevant 
politicians to support a change in the law (Anon, 1999b). An independent enquiry 
established by the Police Foundation and The Prince’s Trust has also called for the 
supply of paraphernalia, advocating that section 9A be abolished entirely (Runciman,
2000). This information only demonstrates that the law is not being enforced and 
suggests support for change. Private communication established that a review of the 
Misuse of Drugs Act is currently being undertaken by the Home Office. However, it may 
be some time before the bill is put to Parliament, because amendment of the Prescription 
Only Medicines Order will also be necessary, to allow the prescription only status of 
Water for Injections to be changed (Mitchell, 1999).
2.6.3 The context in which the current laws place this research
\
\
Under current legislation, only information on the use of makeshift filters can be supplied 
to IDUs. Therefore, the findings of the work from this study on makeshift filters could be 
used to advise IDUs on the use of filters. There will be a time delay between present 
moves to change the paraphernalia laws and the application of this reform at service 
level. It is anticipated that in the event of legal reform, questions may arise such as what 
types of paraphernalia should be supplied. Conducting the work in this study relating to 
makeshift filters and acidifiers (discussed in 2.7) before legal reform means that 
information on their use would be available if and when the supply of IP becomes legal.
2.7 The use o f acidifiers in the preparation o f heroin in jections
2.7.1 Analytical studies of brown heroin
Analytical studies of seized heroin samples in Europe have found the drug to be present 
in either the base or hydrochloride form, or mixtures of both (Huizer, 1989, Kaa, 1991,
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Kaa, 1994, Chadron-Thozet et al, 1992). Kaa (1991) and Chadron-Thozet et al (ibid) both 
categorised the heroin according to colour and identified the forms present. Both studies 
reported white heroin to be in the hydrochloride form. Kaa found all but one beige sample 
to also be the hydrochloride. She described 'brownish’ colours as dominating the basic 
forms. Chadron-Thozet reported ‘off-white’ samples to be hydrochloride and light beige, 
beige and dark beige samples as being basic. Both authors employed methods to reduce 
subjectivity in colour classification. Kaa used one operator to categorise the samples, 
whereas Chadron-Thozet et al developed a coding system. Although this minimised 
subjectivity within the studies, there can be doubt as to whether Kaa and Chadron-Thozet 
et al’s perceptions of colour were equivalent i.e. is the colour ‘beige’ the same to both 
authors? However, the studies do suggest that darker coloured samples are likely to be in 
the basic form and white in the hydrochloride form.
2.7.2 The chemistry behind the use of acidifiers
In 1997 it was reported that over ninety percent of the heroin seized in the UK originates 
in South West Asia, being predominantly in the base form (King, 1997). Brown heroin is
c
used in the UK for injection, although it is illegally manufactured for smoking, which is why 
it is in the volatile basic form. (King, ibid, Tyler, 1995, Derricott et al, 1999). Base heroin 
has a solubility of 1 in 1700 parts of water, whereas salts of the drug have much greater 
solubility (Moffat, 1986). As said (2.2.1) acidifiers may be used during the preparation of 
heroin injections and probably convert the drug to a soluble salt. They are combined with 
the heroin and water then this mixture is heated to promote solubility (Wills, 1997). 
Acidifiers known to be used include citric acid powder and citric acid from lemon juice, 
which in theory could produce diamorphine citrate, ascorbic acid (vitamin C) powder, 
which in theory could produce diamorphine ascorbate and acetic acid, in the form of 
vinegar, which in theory could produce diamorphine acetate.
In the absence of acid to convert the diamorphine, the heroin powder containing the 
insoluble base would likely flocculate when mixed with water and the diamorphine not go 
into solution.
2.7.3 Safer injecting advice relating to acidifier use
Despite the chemistry that explains why acidifiers are required in the injection preparation 
process, the researcher became aware of anecdotal reports of safer injecting advice
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being given to IDUs that said that acidifiers were unnecessary (Speed, 1996, Derricott, 
1997). These reports said that IDUs were being told to either heat the drug for longer or 
use more water to promote drug solubility.
2.7.4 The need for information on the use of acidifiers
Despite information based on chemical theory (Mahan and Myers, 1987), no laboratory 
work could be found showing that acidifiers were needed to promote the solubility of 
diamorphine base in illicit heroin. Since this work aimed to investigate the use of filters in 
the preparation of illicit heroin injections, it was considered appropriate to conduct such an 
investigation at the same time. Such information would be useful for three reasons:
(1) to demonstrate to drugs workers and safer injecting trainers the effects of acidifiers 
versus the effects of adding more water or heating for longer without acid.
(2) to provide information to illustrate the need for acidifiers in the event of the 
paraphernalia laws being changed. Such information could also be used by drugs 
services seeking exemption from prosecution to allow them to distribute acidifiers.
(3) to provide information for injecting drug users on the effects of acidifiers.
2.8 Issues that require consideration before the use o f filte rs 'and  acidifiers  
can be studied
2.8.1 Simulation of the injection preparation process.
Before investigation could be carried out into the use of filters and acidifiers in the 
laboratory, the researcher had to ensure that the preparation methods used to make the 
injections were as close as possible to those used by IDUs. Therefore, the first stage of 
this study was to develop a simulation process for the preparation of illicit drug injections. 
Only then could work be done to address the research questions that have been 
identified.
2.8.2 UK legislation
It was important to ensure that the work for this project was carried out in strict adherence 
to the law so legal matters relating to the work had to be considered. No legal restriction
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prevents laboratory-based research into the effectiveness of IP. However, work involving 
the use of controlled drugs, is subject to controlled drug legislation relating to possession 
and destruction (Misuse of Drugs Act, 1971). The researcher would have to legally be 
allowed to possess the controlled drugs in questions and store and dispose of them as 
required by the Home Office. Also, the distribution of IP to IDUs, e.g. for investigation into 
user acceptability, would require exemption from prosecution to be granted by the 
regional procurator fiscal (PF).
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2.8.2 Ethical approval
Research that involved data collection from IDUs would require approval from the ethics 
committee of the institution from which the work was conducted. The researcher would 
have to ensure that any studies that distributed filters to IDUs did not expose them to any 
increased risk.
2.9 The hypothesis and research questions fo r th is study
This chapter has shown the need for laboratory-based research investigating the 
effectiveness of injecting paraphernalia as a first step towards developing an evidence-
l
base for the provision of information and, subject to legal reform, equipment, to IDUs. On 
this basis the hypothesis for this study was set as:
Through development of a simulated injection preparation process and analysis using 
laboratory-based experiments, it is possible to gather information on the effectiveness of 
injecting paraphernalia to inform harm reduction practice.
Based on this hypothesis, the following research questions were generated:
1. Can a simulation of the injection preparation process used by IDUs be developed, 
which can be used to conduct representative investigations in the laboratory setting?
If so,
2. Can a measure be made in the laboratory of the effectiveness of makeshift filters at 
removing insoluble particles?
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3. Are commercially available syringe filters more effective at removing insoluble particles 
from injections than makeshift filters?
4. Can the extent to which makeshift filters retain drug be established?
5. How does the amount of drug retained by syringe filters compare to the amounts 
retained by makeshift filters?
6. Is the most effective filter, according to the laboratory work, acceptable to IDUs and 
does it produce health benefits?
7. Does laboratory investigation support the need for acidifiers in the preparation of 
brown heroin for injection?
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Chapter Three
Design of the injection preparation technique 
simulated in the laboratory.
3.1 Methodological considerations
Several methodological factors had to be considered when choosing the methods used to 
simulate the injection preparation techniques used by IDUs. It was important for the 
simulation to represent what is done by IDUs as closely as possible, however, in order to 
conduct meaningful laboratory work, the simulation process also had to be reproducible. 
Hence the process had to be controlled, allowing all factors to be kept constant except the 
variable under investigation. It was anticipated that this work would focus on heroin, but 
the popularity of this drug had to be confirmed. Several processes had to be gone 
through to arrange the supply of heroin, so the conduction of preliminary work using 
pharmaceutical drugs was conducted in the interim.
\
3.1.1 IDU preparation vs. researcher simulation l
The highest degree of representation of true to life results would have come from the 
analysis of injections and filters prepared by IDUs in their own environments. However, 
this was considered not viable for the following reasons: Providing IDUs with controlled 
drugs (CDs) to prepare in their own environments and return for analysis would be illegal, 
because this would not be a lawful possession of a CD. Asking IDUs to supply their own 
injections and used filters would be unacceptable as again it would be an unlawful supply 
of a CD when the injections and filters were given to the researcher. Analytically this 
would also be unacceptable as it was important for analysis to be performed as soon as 
possible after preparation, to allow results to reflect those of an injection just about to be 
used. It would also be unlikely that IDUs would agree to surrender their drugs for 
research. The use of ex-IDUs as observing advisors in the laboratory was considered, but 
after discussion with ex-IDUs this was rejected, as they did not feel comfortable with this 
exposure. Therefore, simulation of the injection preparation technique by the researcher 
was selected. This allowed the work to be carried out in strict adherence with legal 
requirements and avoided ethical problems, as the researcher, who is a pharmacist, was
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able to ensure lawful supply and possession of CDs, as discussed in chapter 4. The 
decision to use the simulation technique presented further methodological issues.
3.1.2 How can the simulation technique be made as close as possible to ‘real life’?
To allow the laboratory investigation to give the most realistic results, it was important to 
copy the injection preparation techniques used by IDUs as closely as possible, using 
drugs commonly used by injection. To inform this process, information had to be collected 
from IDUs and other appropriate sources, which were considered to be published 
statistics, safer injecting information and drugs agencies. This information had to then be 
converted to a simulated process. Several methodological options had to be considered 
to allow the most appropriate methods for achieving the aim to be selected.
3.1.3 Establishing the drugs injected by IDUs.
To confirm the anticipated popularity of heroin amongst IDUs and to establish 
pharmaceutical drugs used by injection published national drug misuse statistics were 
consulted (ISD, 1996). However, since these statistics report data from new contacts with
drugs services only, it was considered prudent to confirm whether the most popular drugs
\
reported in this data were also commonly used by other IDUs. Sources of such 
information include drugs agencies and IDUs. Contact with drugs agencies established 
that the formal statistics recorded were those submitted to ISD, so no further information 
was available. Therefore, informal discussion with drugs workers was considered the 
most appropriate method of contact to establish whether they considered the statistics 
reflected drug use amongst their clients overall. Information about known preparation 
techniques was collected at the same time, as this was needed to inform the laboratory 
simulation. The methodological issues around consultation with IDUs are discussed 
below.
3.1.4 Consultation with IDUs.
3.1.4.1 Issues around the method of data collection
Consideration had to be given to the various methods that could be used to collect 
information from IDUs. The first option was to use non-participant observation of the
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injection preparation process. This would produce the highest degree of accuracy, by 
allowing the researcher to observe and make field notes on the drugs, preparation and 
administration techniques used (Amsel et al, 1976). This was rejected for several 
reasons: The length of time which was necessary to establish networks and gain trust for 
such work made it impractical for the purpose of this study. The illegal nature of injecting 
drug use and being present while it occurs carried ethical implications for the researcher, 
as a pharmacist.
The second option was to interview people with first hand experience of injecting drugs. 
This would provide data recalled on questioning, so included the chance of error in 
information recall and reporting, especially if they had not been asked to recall the 
information before or the activity had not occurred in their recent past (Moser and Kalton, 
1971). There was also the question of whether the information reported would be valid. It 
was considered possible that fear of disclosing illegal behaviour or feelings of shame may 
inhibit honesty. This matter has been investigated by previous researchers, as reviewed 
by Stephens (1972). The author describes the work of Cottrell and O’Donnell who 
compared data collected from 339 subjects by hospital admissions clerks with information 
obtained from the same subjects, at a later date, by a social scientist, in the interview 
setting. He also cites the work of Ball, who compared data collected from 59 narcotic 
users with medical, police and urinalysis records and the work of Robins and Murphy. 
They compared interview response with hospital and police records to investigate validity 
of self-reported heroin use in 235 male subjects. All studies concluded that a high degree 
of validity between the self reported data and that obtained from other sources had been 
found, demonstrating that respondents had been honest and truthful. Maddux and 
Desmond (1975) cite an investigation conducted by Maddux et al previously which studied 
interviews conducted by probation officers. They found a higher correlation between the 
data that was perceived as pleasing to the interviewer than unpleasing data. This 
suggests if the interviewee perceives pleasing responses may benefit them, then there 
may be a tendency towards inaccurate reporting of unpleasing information. This was not 
considered to be significant in this study as the researcher would have no influence over 
any treatment or legal issues relating to the IDU, unlike the probation study, so the 
interview method was considered the most appropriate. A semi-structured format was 
chosen as this allows the discussion to be guided, whilst allowing a range of responses to 
be given and further investigated (Moser and Kalton, 1971, Coolican, 1994).
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3.1.4.2 Issues around the recruitment of IDUs 
Randomised sampling
A random sample of interviewees taken from the I DU population would give the most 
representative sample, but is not possible because this population is unknown. Two lists 
of known IDUs were identified from which a random sample could potentially be obtained. 
These were the Addicts Index, held by the Home Office and the client list of the local 
Substance Misuse Service (SMS)1. Both would provide a list of people who were or had 
been in contact with prescribing services. The Addicts Index was held in London and not 
considered practical to use for an investigation this size as it would be too time consuming 
achieving access and locating subjects with experience of injecting drug use who would 
be willing and suitable for interview1 2. Also it would involve locating subjects at their home 
address, which would raise suspicion and encourage association with the authorities, 
which may not be conducive to encouraging honest answers (Maddux and Desmond, 
1975). The SMS client list was also considered unsuitable because interviewees would 
have to be made aware that they were accessed through the SMS. If any were currently 
injecting and receiving substitute therapy, they may fear that any injecting drug use 
revealed would become known to SMS staff, leading to inaccurate responses as 
described in section 3.1.4.1.
Non-randomised sampling
Three sources from which a non-random sample of IDUs could be obtained were 
identified. These were (1) known IDUs held within the local prison (2) the local drug 
counselling and needle exchange agency and (3) community pharmacies. Consideration 
was given to each option. The prison was rejected because it was felt there would be 
reluctance to reveal honest information, due to fear of disclosure. Also, injecting practices 
used whilst incarcerated may not be representative, due to the restricted access to 
equipment (Murray, 1996).
Aberdeen has one drug counselling and needle exchange agency, Drugs Action (DA). 
This is a non-statutory service, which was established in 1986 (Drugs Action, 1994). 
Previous research has shown that drug users trust the service and feel a good rapport 
with the staff (McKeganey et al, 1997). There is no prescribing arm to the service, so no 
conflict for clients in revealing current drug use exists. The agency confidentiality policy
1 A t the tim e o f th is work the Substance M isuse Service (SM S) w as know n as the D rug P rob lem  Service (DPS).
2 A t the tim e  o f th is work, the A dd icts  Index w as still active ly in use and kept a t the H om e O ffice, London.
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offers guaranteed confidentiality unless there is a serious risk to health or life from 
withholding information (Bruce, 1996). By approaching DA clients either in the needle 
exchange or drop-in, their drug use is being acknowledged from the outset. Therefore, it 
was decided that DA clients would have little reason to be dishonest, if they were located 
through this service. Apart from the client database, all other records are kept using the 
client’s initial and date of birth only. In theory the database could have provided names 
and addresses from which a random sample of clients could have been selected, but 
given the client led nature of the service and confidentiality policy, neither the researcher 
or staff considered this acceptable. Therefore, a quota sampling method was used 
instead to recruit DA clients for interview.
At the time of this work, none of the needle exchange pharmacies in Grampian had 
facilities suitable for private interview and the RGU School of Pharmacy safety officer was 
unwilling to approve the use of a remote location, such as a cafe for meeting IDUs. A 
community pharmacy with a private area and a large number of clients receiving 
substitute therapy was identified as a potential source of interviewees. It was assumed 
that many of these clients would have a history of injecting drug use. The pharmacist was 
known to be trusted and respected by these clients, which may have helped to instil trust 
in the researcher (Moser and Kalton, 1971). This may have been suitable for accessing 
IDUs who had never used drugs agency needle exchanges and allowed comparison of 
data between these people and specialist needle exchange agency clients. Contact was 
made with the pharmacist who was willing to assist in recruitment. However, the sudden 
death of the pharmacist involved, led to this not being pursued. Discussion was held with 
the subsequent relief manager, but she felt uncomfortable in assisting with recruitment. 
Also, many clients were known to be upset by the pharmacist’s death, so the researcher 
felt it inappropriate to pursuit the matter.
Ethical Approval
Because the proposed research involved contact with IDUs through a care provider, 
approval from the Joint Ethical Committee of Grampian Health Board and the University 
of Aberdeen was considered good practice. The purpose of the Committee is to ensure 
that research complies with ethical standards, including the provision of choice in 
participation, the collection of informed consent and the option to withdraw at any time. It 
also ensures that participation does not prejudice the care received from the care 
provider. Although RGU is not officially accountable to the committee, it was considered 
good practice to obtain their approval. The ethical standards that were applied to this 
work are described in the relevant section of the methods (3.2). The application form and
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ethical approval is shown in appendix 3. Relevant attachments that were included with the 
application are in later appendices and referred to in 3.2 where their use is explained.
3.1.5 Laboratory issues
Although the technique used in the laboratory to prepare injections had to simulate the 
way IDUs prepare injections, it also had to be such that all variables could be controlled, 
to allow results to be as reproducible and comparable as possible. In this sense, the 
laboratory technique had to be subject to controls that may not be present in real life. The 
variables had to be defined, such as quantities of drug, acid and water used and the 
heating time. A flow chart of the established preparation processes was considered the 
most appropriate way to represent this as it could be easily followed in the laboratory.
3.2 Methods
3.2.1 Review of published statistics
The most recent Scottish Drug Misuse Statistics were identified, which summarised 
information submitted by service providers on new client contacts over the time period 1 
April 1994 to 31 March 1995 (ISD, 1996)3. From these statistics, table 4, which details the 
main drugs used, and table 5a, which details all drugs used, have been copied with the 
permission of the publishers and are shown in appendix 44. From these statistics, the 
number of people who reported using a given drug by injection was calculated as a 
percentage of the total number of injectors. This was done for both Grampian and 
Scotland as a whole, to produce tables, ranking the drugs in percentage order. From this 
the perceived popularity of heroin and pharmaceutical drugs amongst new contacts to 
services could then be seen.
3 T hese  w ere the m ost recent s ta tis tics  at the tim e o f th is w ork. D eta ils  are  subm itted  to  IS D  on fo rm  SM R22 (medical 
serv ices) and S M R 23 (non-m edica l services).
4 Data recorded re la tes to  drug use in the m onth  preceding con tact only. ; , :
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3.2.2 Review of safer injecting leaflets and training materials
The safer injecting leaflets referred to in chapter 2 were gathered from drugs agencies. 
Health Education Authority (1993) training materials were obtained, no materials were 
available from the Health Education Board for Scotland at this time. In-house training 
materials produced by the Drugs Action (DA) needle exchange worker were also 
consulted (Drugs Action, 1996). A safer injecting training day for drugs workers was 
attended and notes made on the injection preparation process5. The information was 
subject to content analysis, to identify stages in the injection preparation process. This 
information was then used to produce a flow chart to illustrate the sequence of the 
stages. Variations identified in the content analysis were noted at each stage. The 
information on injection preparation established in the literature review was also noted 
(Koesteretal, 1990).
3.2.3 Consultation with needle exchange workers.
Drugs agencies in four UK cities were visited and discussions held with the needle 
exchange workers. These agencies are detailed in appendix 5. Workers were asked to 
describe the drugs and preparation methods they thought their clients used and safer 
injecting advice they gave. Qualitative data was collected in note form made at the time of 
meeting and follow up telephone calls were made if necessary to establish further 
information. Information was incorporated into the flow chart described in 3.2.2.
3.2.4 Consultation with injecting drug users.
Consultation with IDUs was undertaken to confirm that the stages in the injection 
preparation process identified were actually used and to establish quantitative information 
on the stages. The methods used to consult with IDUs will now be described.
3.2.4.1 Recruitment
A definite target number of interviewees was not set prior to commencement. It was 
important to identify if there were themes in the preparation techniques and it was 
unknown whether there would be large differences or similarities in the information 
gathered. Therefore, the quota was set as the interviews progressed. If consistent themes
5 H IT, S a fe r In jecting T ra in ing Day, held a t D rugs Action, 48a Union S treet, Aberdeen. M ay 1996. Trainer: Shaun Speed.
40
_________________________________________________________________________________________________Chapter 3
emerged the quota sample could be smaller than if large differences were found. The 
most recent.Drugs Action annual report gave the ratio of male to female clients as 62:38 
(Drugs Action, 1996). It was decided to try to represent these proportions in the sample 
interviewed.
3.2.4.2 Questionnaire design and piloting
Guidance on questionnaire design was obtained from Moser and Kalton (1971) and 
Bailey et al (1995). The original questionnaire asked for some demographic details about 
the IDU and drug use history, then used a series of questions with probes based on the 
information in the established flow chart (3.2.2 and 3.2.3). However, after piloting the 
questionnaire on four people a general open question was asked before the questions 
and probes were used. This was ‘Tell me how you prepare your injections'. Then 
questions on each preparation stage were asked if it had not been mentioned. The 
reason for this change was that in the pilot studies often information was given describing 
the whole preparation process in response to one of the questions, since the researcher 
had told the IDUs at the start that she wanted to know how they injected. Also it was felt 
that this open general question allowed more freedom.
The first section of the interview schedule gathered information about the interviewee and
\
established their current injecting status, to allow for variations in preparation technique to 
be compared against factors such as length of time injecting. Next, details of the drugs 
and equipment were gathered. Next the preparation techniques used investigated. The 
drug misuse statistics and the flow chart detailed in sections 3.2.2 and 3.2.3 were used to 
inform the questions. Closed questions where used when a dichotomous response was 
required, whereas open questions were used when more a variable response and 
detailed information was required. Both quantitative and qualitative data was collected. 
Leading questions were avoided, to minimise bias. Information was collected on the 
injection administration to assist the researcher in understanding the process. However, 
this data was not directly used for the work presented here. A copy of the schedule is 
shown in appendix 6.
Internal reliability
Internal reliability checks were in built to allow the reliability of the interviewee’s 
information to be checked. The interviewer repeated two of the questions at the end of
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the questionnaire to recheck the information originally given. These were chosen at the 
time of interview, to avoid asking a question that did not apply to the interviewee.
External validity
In order to validate the questionnaire, external validity was checked. As part of the 
interview, ‘age’, ‘age when first injected’, and ‘all drugs ever used by injection’ were 
asked. The responses of a selected number of interviewees to these questions were 
validated against similar information held at Drugs Action, as follows: At initial contact with 
DA, clients are asked to provide their date of birth (so age can be calculated), age when 
first injected and list all the drugs that they have injected in the past month. Although the 
latter may not be the same as ‘drugs ever used by injection’, those listed should have 
been included in the interview response to the ‘all drugs ever used by injection’ question, 
if a valid response was given.
The information recorded by DA at initial contact is held on the DA client database. 
Records can be retrieved from the database by either searching using the client’s initials 
and date of birth or by entering their name. As the interviewees were anonymous to the 
researcher, she could not directly search the DA database. Instead the DA advisor to this 
project, who was at the time of study also the NX/drop-in worker, retrieved the information 
from the database for the researcher. She was the principle worker who introduced clients 
to the researcher, so she was aware of which clients were interviewed.' She was also 
aware of their initials and date of birth as these are used on the records of all client 
contacts, including NX. It was agreed that the NX/drop-in worker would obtain the 
required information from the database on 20% of interviewees. This meant in practice 
that for every five interviews, the NX/drop-in worker provided information on one of the 
clients, whom she selected. She obtained the information on the day the interviews were 
conducted and identified the clients to the researcher by description. This was appropriate 
as only a small number of interviews were conducted each day, so a description of the 
client including their position in the daily interview order was satisfactory in allowing the 
researcher to compare the information from the interviews with the information from the 
database, hence undertaking validation.
3.2.4.3 The influence of the interviewer
The researcher conducted all interviews. How the interviewee feels about giving 
information to the interviewer may affect his response (Moser and Kalton, 1971). The
42
________________________________________________________________________________________________________________ C hap ter 3
authors advise a rapport should be established but highlight the danger of over-rapport. 
The interviewer must not be too familiar or this may make the subject feel uneasy. Ball 
(1970) suggests the interviewer must have past experience of the field, a knowledge of 
the drugs sub culture and ideally prior contact with the client before the interview. In an 
attempt to address some of these issues, the interviewer attended the DA drop-in for 
three months, prior to the interviews being conducted. The drop-in was an informal 
session with no appointment system. IDUs could use the session to have a drink and 
meet with workers and other IDUs. The session was used by the workers to make 
opportunistic interventions with people who may otherwise not attend a more formalised 
appointment system. Attendance by the researcher allowed observation of the drugs 
workers skills and familiarity with the ‘scene’ to be established. During the interview care 
was taken to use a friendly, respectful approach as used by the drugs workers, without 
over familiarity. The researcher made sure she was familiar with the interview schedule 
and the meanings of the terms used.
3.2.4.4 The Interview
Introduction of the interviewer to the NX clients
The researcher attended as many of the NX and DA drop-in sessions as possible, until a 
satisfactory number of interviews had been conducted. The NX was open for nine 3-hour 
sessions per week and the drop-in for one 3-hour session. The NX worker introduced 
clients to the researcher, stating where she was from, that she did not work for DA and 
that she was doing research into the use of filters. The researcher then explained the 
study was looking at the effectiveness of filters and that she was looking to interview IDUs 
to find out how they prepare and administer injections. She explained that the interview 
was anonymous, all information would be kept confidential and it was expected to last 
about 20 minutes. The clients were informed that they were free to withdraw at any time 
and participation or refusal would not affect the service they received from DA. The client 
was then asked if they would like to go into one of the private rooms to find out more and 
consider participating.
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Interview atmosphere
The interviews were conducted in a private room next to the needle exchange. Attempts 
were made to create a relaxed atmosphere by offering the Interviewee a cup of tea or 
coffee and allowing them to help themselves to cigarettes.
Information and consent
Information, as detailed at the beginning of the interview schedule, was told to the client, 
supported by a written information sheet. The client was then given time to read this and 
ask questions about the study. After this they were asked if they wished to proceed with 
an interview. If they agreed, the consent form was signed. The information sheet and 
consent form are shown in appendix 7. These were kept in a locked cabinet. Both the 
information sheet and consent form were included with the Ethical Committee application 
(appendix 3). The interviewee was then asked if they were comfortable with the interview 
being taped, having been assured that only the interviewer would listen to the tapes. They 
were also told that answers could be transcribed if preferred. Each tape was sequentially 
numbered, with only one interview recorded on a tape. Interviewees were told they did not 
have to answer all questions and could leave at any time. They were assured that the 
interview was not an investigation into safest injecting practice or a test of who followed 
DA advice and no information on injecting practices would be discussed with the workers. 
They were asked to be honest and open to help the research be ‘real’. This Was done to 
minimise the temptation to be untruthful if the interviewee found any questions 
uncomfortable.
The interview procedure
The researcher noted the time the interview commenced. After the data on the 
interviewee and drugs used was collected, the open question ‘Please tell me how you 
prepare your hits6’ was asked or ‘Please tell me how your hits are prepared' if the 
interviewees injections were prepared by someone else. This was done to allow 
information to be provided which was not influenced by the interview. The specific 
questions given under the headings on the interview schedule were asked if an 
interviewee did not mention or fully explain this step. For example, the researcher could 
make sure filter use was discussed, if the interviewee did not mention it. Probes, as 
detailed in brackets on the schedule, were used if the answer given was not full enough. 
The use of probes is discussed below.
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Another open question was then asked. ‘Please tell me how you inject’ or ‘Please tell me 
how you are injected’ if the person did not self-administer, based on revision after the pilot 
study. Specific questions and probes were again used. Although this information did not 
inform the laboratory simulated technique, it was gathered to give the researcher a 
complete insight into the injecting process.
Finally the interviewee’s opinions on the most effective methods for delivering harm 
reduction information and why they thought people did not always follow advice were 
sought using open questions. This was collected with the view that safer injecting 
information may be produced from this study. The interviewer closed the recording by 
stating the time of the interview to the nearest 5 minutes.
The use of probes
The interviewer was careful not to use the probes too soon, to prevent the interviewee 
interpreting the probe as the expected answer (Moser and Kalton, 1971). The researcher 
learnt how to identify inadequate response and use the probes only in order to gain an 
adequate response. Kahn and Cannell (1957) identified five types of inadequate 
response, as listed:
I. partial response, where the answer is relevant but not complete
II. irrelevant response, where the subject doesn’t answer the question'asked
III. inaccurate response, where the answer is biased or distorted
IV. the verbalised response, where the subject explains why he cannot answer the 
question, maybe because he doesn’t understand it or is not in a position to 
answer it because he does not know the answer
V. non-response, where there is no response or the subject refuses to answer.
Because the interview topic was considered to be of a sensitive nature, it was decided 
that any responses of the types (I) to (IV) warranted the use of probes. Type (V) 
responses would be acknowledged as an acceptable response and not probed further. 
This would respect the drug users privacy and avoid pressure to respond, which may lead 
to an inaccurate answer.
The te rm  ‘h its ' is slang, used by drug users to  refer to  in jections or the action  o f in jecting.
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Close of interview
After the interview was over, the clients were thanked for their time and participation and 
again assured of confidentiality. A selection of pens, note pads and sweets were offered 
as a token of appreciation for their time. Tapes were stored in a locked cabinet with 
access restricted to the researcher only.
3.2.4.5 Data Analysis
The complete recordings were transcribed. Interviewee information and drugs used by 
injection were collated In an Excel spreadsheet. Themes from the preparation and 
administration procedures were identified, based on the guidance of Bailey et al (1995). 
These were compared with the flow chart of injection preparation processes developed 
from the safer injecting advice and drugs workers (3.2.2 and 3.2.3). A revised flow chart 
of each stage was designed. The details for each procedure at each stage were 
highlighted on the transcription. The most commonly used procedures were selected for 
use in the laboratory. For example, the most commonly used quantity of heroin.
The answers to the final two questions were subject to content analysis and kept aside for 
later use.
3.3 Results
\
\
3.3.1 Drugs use by injection
3.3.1.1 Scottish Drug Misuse Statistics
The data tables derived from these statistics are given in appendix 8. Key results, 
rounded to the nearest whole number are quoted below. Heroin was by far the most 
commonly reported main drug used in the past month by injectors who were new contacts 
with services, both in Grampian (88%) and Scotland overall (81%). Buprenorphine, was 
the second most popular drug amongst injectors nationally (9%), but less popular in 
Grampian (<1%). The second most common main drug in Grampian was amphetamine 
(7%), with use greater than the national average (2%). Temazepam was also less 
common in Grampian (<1%) than nationally (2%). Morphine and methadone injecting 
showed similar figures at each level, with main use being less for Grampian (1%) than 
Scotland as a whole (2%). Dipipanone, which is combined with cyclizine in the
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pharmaceutical formulation Diconal®, showed equal incidence at both levels (1%). Other 
benzodiazepines and opiates were the main drugs of use in a small number of both 
Grampian and national injectors.
The results of all drugs used by injection in the past month showed that nationally 75% of 
new contact injectors had used Diconal®, with a figure of 61% for Grampian. In Grampian, 
75% of injectors had used morphine, whereas nationally this figure was 63%. Heroin had 
been used by 72% of injectors nationally and 66% in Grampian. Buprenorphine had been 
used by more injectors in Grampian (67%) than the national figure (63%). Nationally, 
amphetamine had been injected by 26% of injectors at some stage in the month prior to 
their contact with the service. In Grampian this figure was 38%. Temazepam and other 
benzodiazepines had been used by 25% of injectors nationally, and 11% of Grampian 
injectors. Methadone had been injected by 7% nationally and 5% in Grampian.
3.3.1.2 Information from needle exchange workers
The workers from all four needle exchanges reported the majority of their injecting clients 
used heroin. They reported amphetamine injectors also to be seen, but considered this to 
be less habitually than heroin. They reported knowledge of some clients injecting tablets, 
which varied with area, but all considered tablet injection to be less common than that of 
heroin or amphetamine. In Aberdeen and Dundee, Diconal® and buprenorphine were 
thought to be popular, with the Aberdeen worker also reporting known injection of MST87. 
The Edinburgh worker reported previous popularity of temazepam but considered use had 
recently declined. Injection of methadone tablets was considered to occur, with 
buprenorphine injection also known. The London worker reported clients receiving 
methadone and diamorphine ampoules on private prescription. This was considered a 
rare occurrence by the Scottish workers. The London worker reported frequently seeing 
cocaine injectors, which was considered rare by the Scottish workers. However, the 
injection of Diconal®, buprenorphine and temazepam was considered rare by the London 
worker. He also knew of the injection of methadone and morphine tablets, but considered 
this to happen only when ampoules were not available.
3.3.1.3 Information from interviewees
The drugs used by injection reported by the interviewees are detailed with the other 
interview results in section 3.3.4.6.
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3.3.2 Injection preparation methods reported in safer injecting leaflets and training 
information for drugs workers.
Two main injection preparation processes were identified, those used for heroin and 
those used for other drugs such as amphetamine and tablets. The difference between the 
processes was due to heroin requiring conversion to a soluble salt, not required by the 
others. Six stages in the preparation process of heroin were identified. The flow chart 
developed from this information is shown in figure 3.1 and discussed below.
Figure 3.1 Six stages in the heroin preparation process identified from safer injecting information.
Heroin is mixed with acid on a metal spoon. Citric and ascorbic acids are recommended 
over lemon juice and vinegar. Water is added. Sterile water is a prescription only 
medicine in the UK, so cannot be purchased or distributed without medical authority. 
Boiled and cooled water is therefore recommended (Health Education Authority, 1993, 
HIT, 1995, Exeter drugs Project, 1992, Lifeline, 1992). This mixture is then heated. The 
filter is then placed on the spoon and the liquid drawn through it into the syringe, ready for 7
7 MST® is a susta ined re lease form ulation o f m orphine sulphate, ava ilable in a series o f strengths.
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injection. Unsmoked cigarette filters are recommended in safer injecting booklets (Exeter 
Drugs Project, 1992, Lifeline 1992). Cotton wool and tissue paper are advised against as 
they are reported to shed coarse fibres and damage veins (Exeter Drugs Project, 1992, 
Health Education Authority, 1993, HIT, 1995 Lifeline, 1992).
It is advised that tablets and amphetamine are crushed as finely as possible (Exeter 
Drugs Project, 1992, HIT, 1995 Lifeline, 1992) and mixed with a small volume of water 
(HIT, 1995). No addition of acid or heating was mentioned. The use of filters is 
encouraged.
3.3.3 Injection preparation methods reported by needle exchange workers
The preparation stages for heroin cited by the drugs workers were the same as those in 
the published information discussed above. For the injection of tablets, many drugs 
workers reported that clients were thought not to crush the tablets. Instead, they were 
shaken in warm water in the syringe barrel to dissolve them. It was generally perceived 
that their clients do not use filters for tablets as they think this will cause them to ‘lose the 
hit’, which means reduce the amount of drug in the injection and hence reduce the 
effects. One of the agencies visited distributed hand-rolling cigarette filters to IDUs 
through their needle exchange. They reported them being used by placing thè whole filter 
in the spoon and drawing the liquid through. Another agency distributed Water for 
Injections. This was a statutory agency, which worked closely with one of the trust public 
health doctors. When the researcher asked how legal supply was arranged, she was told 
that the doctor had issued a ‘blanket’ prescription to cover all agency clients. The Water 
for Injections was distributed by the nurses who staffed the agency. As the prescriptions 
were not issued to named patients or the packages labelled with their names, the supply 
was not in fact legal.
3.3.4 Results from the injecting drug user interviews
3.3.4.1 Piloting
The pilot group were perceived to have the same understanding of the questions as the 
rest of the interviewees, only a lot of repetition existed due to them providing information 
earlier than it was formally asked. Since it was only the extent of repetition that was
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considered to differ the pilot group from the rest of the interviewees, their responses were 
included in the analysis.
3.3.4.2 Quota Sample
The pilot group gave very similar responses to each other and this trend continued to be 
seen. After ten interviews, all reporting similar stages, which were also identified from the 
safer injecting information and drugs workers, it was decided to set the quota at twenty. 
Twenty clients were interviewed over a period of six weeks. Four were recruited from the 
drop-in and 16 from the needle exchange. Eighteen were previous clients of the agency 
and two were new contacts. The desired quota of 8 women and 12 men, set to represent 
the DA client base, could not be reached in the time available. As a result 4 women and 
16 men were interviewed.
3.3.4.3 Data Recording
All twenty interviewees agreed to being taped. The average length of time of interview 
was 20 minutes, with the shortest being 15 minutes and the longest one-hour. Often the 
interviewee engaged in conversation after taping had stopped, which was not counted in 
the interview duration, although relevant information provided was noted. Details shared 
in this further conversation included information on interviewees drug using careers, 
personal lives and experiences.
3.3.4.4 Internal Reliability and External Validity Checks 
Reliability
No interviewee gave a response to the reliability questions which contradicted the initial 
response, although the repetition of the question often led to expansion of the information 
provided initially, which was included in the analysis.
Validity
The response given for age matched exactly for all interviewees. The age when first 
injected exactly matched for two interviewees and varied by two years for the other two.
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For drugs ever used by injection, all interviewees mentioned drugs that were recorded on 
the DA database at initial contact. Three interviewees reported all drugs that they had 
reported at initial contact, while one interviewee did not mention one drug reported at 
initial contact.
3.3.4.5 Interviewee statistics
The mean age of the interviewees was 25 years, with a range of 17 to 47 years. The 
mean age when first injected was 20 years with a range of 9 to 31 years. Nineteen of the 
twenty interviewees were currently injecting while one had not injected for one month. The 
reason given for stopping injecting was an inability to access veins, due to peripheral 
damage, prompting him to stop. The frequency of use of the 19 injectors varied from 
occasionally to six times a day. This is further discussed in section 3.3.4.6. Eighteen of 
the 20 interviewees prepared their own injections. Of these, 17 had learned to prepare by 
watching or being shown by someone who was already injecting. One reported learning 
from a feature film that gave detailed illustration of the process, although he later stated 
that his flatmate had been injecting longer than him and he had watched him prepare. 
Eleven had shown someone else how to prepare injections, six had not consciously 
shown someone else how to prepare and one did not answer this question. Two 
interviewees, who were both female, had their injections prepared by their partners.
i
i
3.3.4.6 The manner in which drugs are currently used 
Drugs ever used by injection
In considering both current and past use, nineteen of the interviewees had injected heroin 
and one had never injected heroin. Four of the 19 had injected heroin only, whereas the 
other 15 had injected other drugs. Nine had injected amphetamines, eight of which were 
also heroin injectors. Fifteen had injected pharmaceutical tablets. Five had injected 
Ecstasy tablets. Four reported having mixed more than one drug in an injection. The 
combinations reported were heroin and cocaine (n = 1), cyclizine and morphine (n = 1) 
and multiple combinations of pharmaceuticals and street drugs (n = 2). Table 3.1 
summarises the drugs the interviewees had ever used by injection.
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Drugs currently used by injection
The frequency of injection ranged between once or twice a week, to six times a day. The 
most common frequency was twice a day (n = 4) or three times a day (n =4). All those 
who injected tablets, reported using various drugs and formulations, depending on 
availability. The frequency of injecting was alluded to being less than for heroin. There 
was some suggestion that tablet injecting was done as a ‘treat1 for example at the 
weekends or on special occasions.
Those who had first injected many years ago had a tendency to have injected a greater 
number of drugs than those who reported recent initiation into injecting. However, the 
numbers are too small to make any association from this.
Drug ever injected No. o f  clients (n=20)
heroin 19
methadone3 9
dipipanone 9
amphetamine 9
buprénorphine 6
morphineb 5
ecstasy 5
temazepam0 3
other sedatives 3
diazepam 2
cocaine 2
other opiates 1
hallucinogens 1
other drugs 1
Table 3.1: Drug and number of clients who indicated they had used it by injection.
3 All 9 methadone injectors reported using Physeptone® tablets, while one had also used ampoules. 
b All 5 morphine injectors reported using MST® tablets, while one had also used ampoules and another had 
used morphine sulphate tablets.
All 3 temazepam injectors reported using capsules, while one had also used tablets.
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The quantities used varied, with interviewees stating that availability of drug, money, level 
of dependency and desired effect were factors that influenced the amount used. 
However, most heroin users described preparing ‘a quarter G bag* if the drug and money 
was available. Larger amounts were suggested by some if they wished to be under a 
greater influence of drug. In some cases the prepared injections were shared with another 
person. A ‘wrap’ was the quantity of amphetamine and cocaine reported by all who 
injected these drugs, which describes a quantity packaged for sale in a single dose 
amount (Wills, 1997). The amount of tablets prepared for injection also varied with the 
user, the drug and availability. Several interviewees stated the quantity used would 
depend on the level of dependency at the time. When indicating approximate amounts 
used, five was the most common number of buprénorphine tablets injected. Those who 
injected Diconal®9 stated usually one or two tablets were injected. Among those who 
injected methadone, all had injected tablets and two had also used ampoules. Nine was 
the most common quantity of tablets injected. One or two Ecstasy tablets were reported 
to be injected. For morphine, the quantity and formulation varied greatly, so no common 
amount and type can be concluded. For benzodiazepines the quantities used appeared to 
depend on other drugs with which they were mixed or the reason for using.
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3.3.4.7 Quantities used by injection
3.3.4.8 Preparation methods. i
The main factor that governed the overall preparation method used was the drug 
concerned. No fundamental differences were found between those who prepared for 
themselves and those who watched, or length of time since first injection.
Heroin
The six stages identified from the safer injecting literature and drugs workers, shown in 
figure 3.1, were reported by all interviewees who injected heroin (n=19). No additional 
stages were reported by anyone, although variations within some stages were identified. 
Two stages showed no variation. These were, Stage One ‘Put into metal spoon’ and 
Stage Four ‘Stir’. All interviewees identified a metal teaspoon as being used at stage one 
and at stage four the spoon contents was stirred using the sheath of the needle until 
homogenous. All heroin injectors reported using 1 ml insulin syringes, although 1 ml 
detachable syringes and orange or white sheathed needles were additionally used by one
® G is p ronounced 'gee '.
Diconal® is the on ly  ava ilab le  form ulation o f d ip lpanone.
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heroin user. Another had once used 0.5 ml insulin syringes. Four stages (Stage Two,
Stage Three, Stage Five and Stage Six) showed variations. These will be discussed
further.
I. Stage Two: Addition of Acids: All nineteen heroin users added acid to their heroin to 
facilitate solubility. Sixteen people reported citric acid to be used. One these reported a 
preference for vitamin C, but because the injection was prepared by and shared with 
their partner, citric acid was used because it was the partner’s preference. One person 
used citric acid or vitamin C. One person used vitamin C. One person said they used 
either citric acid or vitamin C, and had used lemon juice and vinegar. The quantity of 
acid added was described in various ways. Two interviewees quantified the amount by 
describing it as ‘about ten grains’ and ‘four or five grains’. Most of the interviewees (n = 
15) described the quantity as a ‘small pinch’ or other similar terms. Two people 
indicated the quantity may vary with the quantity of heroin injected. A few interviewees 
demonstrated the quantity in a ‘small pinch’ using soil from a plant in the room.
II. Stage Three: Source of water: Ten heroin users used water that was boiled from the
kettle. Nine said they used water straight from the tap. The quantity of water used 
varied, described in units of an insulin syringe. The amount used for a ‘quarter G' bag 
of heroin varied between 0.5 ml to 2.0 ml. Bigger quantities of water were indicated in 
some cases to be for shared injections. The amount most commonly reported was
0.8 ml. j .
III. Stage Five: Heating: All nineteen heroin users heated the drug during preparation. 
Nine said they stopped heating when the solution bubbled and eleven said they 
stopped heating when they could see the powder breakdown and the solution go clear. 
It was noted that some users perceived boiling to mean that they were evaporating 
some of the drug.
IV. Stage Six: Filtering: All nineteen heroin users filtered their solutions prior to injection. 
Filtering was perceived to remove solid particles from the liquid on the spoon. All 
injectors filtered using a piece of a cigarette end. This was described quantitatively by 
some as a ‘quarter’ of the filter or qualitatively as 'a piece' or similar terms. Nine 
reported having used a cotton bud or cotton wool, described in the case of the former 
as being the whole bud removed from the stalk and in the latter, a small piece rolled 
into a ball. Two people reported having used hand-rolling cigarette filters, placing the 
filter in the spoon and drawing the liquid through into the syringe. Two also reported 
having used tissue paper, again placing it in the spoon and drawing the liquid through.
' i ,
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One person had also used a torn piece of clothing. Two people reported having used 
commercial syringe filters, which one described as ‘a couple of centimetres across’ and 
the other as ‘the size of a 2p’. In both cases the filter was attached to a detachable 
syringe barrel and the liquid drawn through from the spoon. One person obtained them 
from a needle exchange in Edinburgh some time ago. The other person obtained them 
from his mother, who worked in a hospital.
Amphetamine:
Nine of the interviewees had injected amphetamine. Only one of these had not injected 
heroin. Only one person added acid to their amphetamine, and stated they prepared all 
drugs the same way for injection, including adding acid and heating. No one else heated 
the amphetamine. All mixed the amphetamine with water. Four people filtered prior to 
injection. Five people did not filter, they put the amphetamine powder straight into the 
syringe barrel and shook it with water. 1 ml insulin syringes were reported for 
amphetamine use.
Tablets
' l
Of the sixteen tablet injectors, 15 of whom had injected heroin and one who had injected 
amphetamine, four people stated they used 2 ml syringes and two people stated they 
used 5 ml syringes with detachable needles for tablets. This information was volunteered, 
not specifically asked, so it cannot be assumed that the others used 1 ml insulin syringes. 
For tablets, the preparation method appeared to vary depending on the drug and 
formulation, but not between users. Three variables were identified, when preparing 
tablets for injection:
I. Crushing: Coated formulations such as MST®, were crushed by all users before use. 
Ecstasy was also crushed. Various other tablets were reported by some not to be 
crushed and by others to be crushed. Specific details were not asked for. Methods of 
crushing reported chopping with a razor blade, pressing in the fold of a piece of paper 
and crushing between two spoons. I.
II. Addition o f acids and heating: Only one person added acid and heated tablets. The 
other fifteen who had injected tablets did not add acids or heat the solutions using a
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heat source. The addition of warm water to promote dissolution was reported as being 
adequate.
III. Filtering: One person (who also added acid and heated)., filtered tablets. One other 
person reported filtering everything except Diconal®, because it was perceived.that the 
effects were reduced. One person reported filtering MST®, but nothing else. The others 
who injected tablets did not filter as this was perceived to remove some of the drug.
Ampoules.
Ampoules were reported to be mixed with water and then injected, with no further 
preparation stages.
Reuse of filters
All 19 heroin injectors used filters with heroin and the non-heroin injector, who used 
amphetamine and Ecstasy, also filtered. Of the heroin injectors, 10 saved their filters for 
reuse, five did not reuse and four did not give a clear answer. The non-heroin injector did 
not reuse filters.
3.3.4.9 Injection techniques
Ten of the interviewees stated that they rotated their injecting sites, seven firmly stated 
that they did not while three did if they could, but stated it depended on available veins. 
Several reported difficulties accessing veins. Thirteen used a tourniquet, two did not and 
five did sometimes. All interviewees said drawing blood back into the syringe was done to 
check if the vein was accessed, which the definition of ‘flushing’ given at the time by the 
interviewer. The use of swabs varied, with 12 stating they swabbed prior to injection.
3.3.4.10 Safer injecting advice
Fifteen of the interviewees had received safer injecting advice, 14 of which said they’d 
received it from DA and one who received it from the Substance Misuse Service. Five 
people had not received safer injecting advice. The researcher told them such advice was 
available in booklets from DA workers.
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All twenty interviewees had experienced some adverse effects on health due to injecting. 
These included bruising, collapsed veins, abscesses, painless lumps taken to be 
granulomas, pain and swelling after injection and ‘track marks’ (thrombophlebitis). A few 
had sought assistance from Accident and Emergency (A&E) for severe symptoms, such 
as swelling and loss of feeling in a limb and in overdose situations. Two people 
specifically mentioned they had obtained illicit antibiotics to treat abscesses. Many had 
not sought medical advice but several reported they had asked a drugs worker for advice. 
In terms of how people could get treatment, several people said help is only sought if 
symptoms are severe. Suggestions included A&E, a homeless shelter with a nurse-run 
health clinic and having medical help at Drugs Action.
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3.3.4.11 Injecting injuries
3.3.4.12 Delivering harm reduction information 
Suggested methods
Several suggestions were made as to how HR information could be delivered. The most 
common suggestion was for drugs workers to talk to clients and listen. The distribution of 
leaflets was also specifically mentioned by seven interviewees, with one stating a cartoon 
style was preferred. Five interviewees specifically mentioned allowing users' to work at 
NXs. The use of videos was mentioned by one. Several interviewees mentioned that 
users share information. This is illustrated by this quote from one, who was a new contact 
to the service:
‘People pass on what they hear, so even if they don’t use the service here [at DA],
you might hear the advice through friends'.
Perceived barriers
When asked why people didn’t always follow safer injecting advice, eight people 
specifically mentioned being ‘strung out’, which means being in withdrawal. This was also 
linked to lack of access to clean injecting equipment. Some people stated specific cases 
such as weekends, night times and when remote from a NX. Three interviewees 
specifically mentioned information could not be followed while incarcerated, due to lack of 
access to clean equipment. Factors relating to the individual were also mentioned
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including laziness, feelings of no self worth, lack of intelligence, not caring and lack of 
trust for professionals. Two interviewees also highlighted a culture amongst drug users of 
not following advice.
3.4 Use o f results to develop the laboratory sim ulation technique
3.4.1 Selection of drugs for the laboratory investigation
Heroin
The decision was made to focus the study on heroin injections as it can be seen from the 
Scottish Drug Misuse Statistics it was by far the most common main drug used by IDUs 
(appendix 8, table 1, 2a and 2b). Nationally, 81 % of injectors reported it to be the main 
drug they used, with a figure of 88 % for Grampian. When all drugs used by injection are 
considered, 72 % of national injectors had used heroin in the past month, with this figure 
being 66 % for Grampian. This was also supported by heroin having been injected by 95 
% of the IDUs interviewed and perceived by the drugs workers to be the most commonly 
injected drug amongst their clients. The interviewees who injected the most frequently i.e. 
between one and six times daily, all injected heroin, illustrating frequent exposure to risk. 
It was anticipated that arrangement of a legal supply from seized samples would take 
some time, as discussed in chapter 4. While arrangements were b^ing made, 
investigation was conducted into injections prepared with tablets, as these could be 
obtained from pharmaceutical wholesalers. Amphetamine showed greater popularity at 
local level than nationally in the SDMS. However, it was not studied as it would also 
require to be obtained from seized samples and it was felt unreasonable to try to obtain 
more than one drug in this way. The study described In part 2 was also conducted in 
parallel to the tablet work being done.
Tablets
The tablets were selected on the basis of their overall popularity and with respect to 
specific identified issues. The decision was made to investigate three types initially, until it 
was known whether heroin samples could be arranged. From appendix 8 it can be seen 
that a range of tablets were reported in the SDMS as having been used intravenously, 
either as the main drug of misuse or at least once in the month preceding contact. 
Buprenorphine was popular nationally, this is also noted in the literature (Lavelle et al,
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1991, Makower et al, 1992, Simpson et al, 1993, Robinson et al, 1993), so it was 
selected. Temazepam and morphine were also popular, but since several formulations 
exist and the ones used are not reported in the SDMS, they couldn’t be selected10. 
Methadone and dipipanone (Diconal®) were also popular. Diconal® was specifically 
mentioned by the Aberdeen and Dundee drugs workers as being injected by some clients. 
Concerns were also being expressed locally about the injection of prescribed methadone 
tablets at this time. Therefore, Diconal® and methadone tablets were selected on the 
basis of local interest and their indicated use in the SDMS. Although formulation of 
methadone used cannot be obtained from the Scottish Drug Misuse Statistics, all 
interviewees who reported having injected methadone had used the tablets. Only one of 
these had also injected methadone ampoules and no interviewee reported injecting 
methadone liquid.
3.4.2 Quantities of drugs used in the laboratory investigation.
3.4.2.1 Quantity of heroin used
Ideally, a range of quantities of heroin would have been investigated based on the 
different quantities stated by the interviewees. However, the amount of heroin available 
for this study was limited, so the investigation was restricted to the most poplar amount. 
The quantity of heroin indicated as most commonly used in the interviews was ‘a quarter 
G’. This was sometimes injected by one person and sometimes prepared then split 
between two. The researcher needed to establish whether ‘a quarter G’ did equal 250 mg. 
Discussion with drugs workers indicated the units to be grams. Discussion with Grampian 
Police Forensic department established the weight of heroin in recently seized wraps had 
varied between 30 mg and 330 mg, with quantities at the higher end of the scale being 
more common (Wilkie, 1997). This suggests that the quantity in a wrap may vary greatly. 
As discussed in section 3.1, the use of IDUs or ex-IDUs to measure out approximate 
quantities of heroin would be illegal and unethical. It appeared from the police data that 
that the quantity in a wrap varied greatly. A study of dealer’s adulteration practices carried 
out by Coomber (1997), showed that dealers do split bulk drugs into multiples or divisions 
of grams. However, no validation of actual weights was conducted. Also, the survey was 
conducted using the world wide web, so inclusion depended on dealers having internet 
access, finding the site and volunteering to participate. Since no direct confirmation of the 
quantity could be made, it was decided to use the exact representation of a ‘quarter G’ i.e.
0 W ork investigating the filtra tion o f a range o f brands, form ula tions and strengths o f m orph ine  w as undertaken as an 
honours p ro ject a t R G U . T he  report by Lois Pollock, 'A  S tudy o f Drug A dd ic ts  F iltration T echn iques Using M orphine 
Sulphate P repara tions ’, d e ta ils  th is work and is ava ilab le  from  the School o f P harm acy (012224 262500).
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250 mg, for the experiments. This was within the range of seized wraps stated by the 
police.
3.4.2.2 Quantities of tablets used
Only one quantity for each drug was initially set for investigation, as this preliminary work 
was done until the heroin could be supplied. The most frequently reported number of 
Temgesic® tablets used to prepare an injection stated by the interviewees was five. 
Temgesic® is available in two strengths. The strength used was not asked and is not 
determinable from the SDMS. The colour of the packaging was cited by one interviewee, 
indicating the 200 microgram strength. Therefore, investigation was performed using 5 x 
200 microgram Temgesic® tablets per injection. Those who injected Diconal® stated either 
one or two tablets were injected. It is only available in one formulation containing 10 mg 
dipipanone and 30 mg cyclizine. Investigation was performed using 2 x Diconal® tablets 
per injection, as it was thought likely that two tablets would present a particulate scenario 
worse than one. Among those who injected Physeptone®, the most frequent quantity used 
was nine. Only one strength is made (5 mg). Investigation was performed using 9 x 5 mg 
Physeptone® tablets.
3.4.3 Injection preparation: simulated process for heroin. \
The six stage flow chart established from the safer injecting advice and discussion with 
drugs workers, was endorsed by the interviewee information. No further stages were 
identified. Therefore, these six stages were simulated in the laboratory with the interview 
information informing the setting of the factors controlled for each stage in the laboratory 
(e.g. length of time heating). The preparation process used is shown in figure 3.2 and the 
rationale discussed below.
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Figure 3.2. Preparation process used for heroin injections made in the laboratory.
3.4.3.1 The choice and quantity of acidifier
\
Citric acid and ascorbic acid were advocated in the safer injecting information, with 
vinegar and lemon juice being discouraged. All interviewees used citric acid with ascorbic 
acid being mentioned by four. Citric acid was chosen for the filter experiments because all 
the heroin injectors used it interviewed. The most common way of describing the amount 
used was ‘a small pinch’ or terms considered to mean the same. The quantity of citric acid 
used was established by weighing ten 'small pinches’ of acid and taking the average 
weight. This was 14.83 mg, which was rounded up to 15.0 mg
3.4.3.2 The source and quantity of water
The volume of water reported by the interviewees again varied, but the most commonly 
described quantity was 0.8 ml, so this was used for the study.
Although the interviewees reported water from the tap (45 %) almost as commonly as 
water from the kettle (55 %), the safer injecting information suggests the use of the latter. 
This was assumed to be because freshly boiled water is known to contain a reduced
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pyrogen load (Collett, 1990). It was freshly boiled and cooled to a temperature of 
approximately 40°C, which was the temperature of the water used for the first experiment, 
so set as the standard for all experiments.
The purpose of making the starting temperature constant was to make the effect of the 
length of time of heating reproducible. The water was decanted from the kettle into a 
mug, as observed in the literature (Koester, 1991) and described in the safer injecting 
information. A thermometer was used to monitor temperature. If the water cooled the 
temperature was raised to 40°C by the addition of hotter water from the kettle.
3.4.3.3 The stirring
The mixture was stirred with the needle sheath until it appeared homogenous, ensuring 
any lumps were broken down, as described by all the interviewees. 1 ml insulin syringes 
were used as they were reported by the interviewees and drugs workers to be commonly 
used for heroin injection.
3.4.3.4 Heating
The spoon was heated by holding the base over a candle flame. Lighters, the gas cooker, 
burning swabs and matches were used by the interviewees but it was not considered that 
the source of heat was significant, so for convenience and laboratory safety, a night light 
candle was used.
The height between the base of the spoon and top of the flame was measured as 30 mm 
on the first experiment and used for all further work. The time until the end point was 
described by the interviewees as either when the solution bubbles or when the powder 
breaks down and the solution goes clear. In practice, it was established that both these 
end points occur simultaneously, they had just been expressed differently. On the first 
experiment the time for this to happen was recorded as 45 seconds. This time of heating 
was used for all further work.
3.4.3.5 The selection of the makeshift filters to be tested
A range of makeshift filters were identified from the literature and safer injecting 
information (2.5.1) and several were mentioned by the interviewees. The cigarette was
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used by all interviewees and observed in the literature (Koester et al, 1990). The drugs 
workers also considered that they were used frequently. They were therefore selected for 
investigation. The cotton bud was mentioned by some interviewees (n = 9). The safer 
injecting information expresses concern around the shedding of large numbers of fibres 
from cotton wool. The cotton bud was therefore selected for investigation to see if it does 
result in a higher particle load in the filtrate than the others. The hand-rolling filter was 
selected because two interviewees had used them and also because they were 
distributed by one of the agencies visited, who were keen that they were tested. It was 
also considered that if the paraphernalia laws were changed to allow filter distribution, 
hand-rolling filters may be considered by some agencies, since the distribution of filters 
attached to cigarettes would be unlikely. Tissue paper, lint and clothing were rejected as 
they were not popular amongst the interviewees or mentioned by any of the drugs 
workers. Tissue paper was mentioned by two interviewees and clothing by one 
interviewee, but indicated only to be used if a cigarette filter was not available.
3.4.3.6 Selection of the commercially produced filter
As said in 2.5.4, the distribution of syringe filters to IDUs has been identified abroad and 
anecdotal evidence suggests they have been distributed in the UK in the past. Particles 
over 5 pm have been discussed as being of particular concern in injections (2.4.1). 
Therefore, a 5 pm syringe filter was selected for investigation in this study. 'Preliminary 
tests using injections prepared with Temgesic® tablets did investigate the feasibility of 
filtering through a 0.2 pm syringe filter (25 mm diameter), which would render the injection 
sterile, but the filter blocked and complete filtration could not be achieved. The 
illustrations in Australian IDU safer injecting information (Bergin, 1996, Anon, 1996) and 
descriptions from those who were aware of previous distribution indicated the 25 mm 
diameter syringe filter to have been used by IDUs. Also, this had a large surface area 
considered to aid quick filtration, so this was the diameter chosen. The Gelman Acrodisk® 
brand was chosen in the absence of information on brand type used by IDUs elsewhere, 
as this was the cheapest brand available.
3.4.3.7 Makeshift filter brand details and methods used to prepare for use
The methods described in the interviews were copied to prepare the filters for use in the 
lab, as detailed below:
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The cigarette filter (Lambert and Butler®, King Size)
The Lambert and Butler brand was selected because this brand was observed to be 
commonly smoked by the interviewees and other needle exchange clients. It was also 
known to be lower priced. The manufacturers were contacted and confirmed the filters are 
made by Filtrona (see below) and covered with coloured paper. The filter was broken off 
an unsmoked cigarette and loose tobacco removed. The paper from around the filter was 
also removed. The filter was torn in two lengthways. One portion was again halved, this 
time cut across it’s length, as described by the interviewees. This gave a quarter of the 
filter, which was used in the experiments. It was placed in the edge of the liquid and the 
liquid drawn through it until air bubbled into the syringe.
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The hand-rolling cigarette filter (Rizla+ Extras®, 7 mm acetate Streamline filter tips and 
Wilson & Co. of Sharrow, 7 mm Streamline filter tips)
The Rizla+ Extras brand was selected because they were distributed by one of the 
agencies visited. During the course of this project, the brand was discontinued. The 
supplier informed the researcher that the same filters were now being sold under the 
name Wilson & Co. of Sharrow11. To confirm this, a letter was written to Rizla and a 
response given by telephone from Imperial Tobacco, who own Rizla. Imperial Tobacco 
informed the researcher that the filters were made of cellulose acetate coated in triacetine
i
and purchased in long lengths, 7 mm in diameter, from the manufacturers, Filtrona. They 
were cut and packaged for sale as the Rizla+ Extra 7 mm brand. Filtrona were contacted 
by telephone and confirmed that the same manufactured material was supplied to 
Imperial Tobacco and Wilson & Co (Dobbin, 1998). Wilson & Co. were contacted by 
telephone. They confirmed their Streamline filters come from Filtrona and are exactly the 
same as the Rizla Streamline tips. The length and width of both brands of filter were 
measured and found to be equivalent. Therefore, the Rizla brand was used for the 
particle work and the Wilson & Co. brand used to continue the analysis work. The whole 
filter was placed in the edge of the liquid in the spoon and the liquid drawn through until 
air bubbled in the syringe barrel, as described by the two interviewees who had used 
them and the drugs workers at the agency where they were distributed.
11 T he  supp lie r w as B etty  W h ite s  T obacconists. 5 C righton Street, D undee. Tel: 01382 266719.
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The cotton  bi/cf(Unichem Cotton Buds)
The cotton bud tip was removed from the stalk by holding it at the base of the bud and 
twisting, as described by the interviewees. The loose fibres at the end were then rolled 
between the fingers to smooth them into a tight strand. IDUs had not been asked about 
brand of cotton bud, although this was considered likely to vary. The Unichem brand was 
an arbitrary choice. The packaging stated the buds to be 100% cotton. The cotton wool 
was placed in the edge of the liquid and the liquid drawn through it until air bubbled into 
the syringe.
The syringe filte r  (Sterile Acrodisk®, 5 microns, Gelman Sciences, product no. 4199)
The 5 micron Acrodisk® filter membrane is made of Versapor®. This is a hydrophilic acrylic 
co-polymer on a non-woven nylon support. It has a tensile strength of 3,000 psi, so was 
considered able to withstand the pressure of filtering a high particle load liquid, such as 
may be found in the case of IDUs injections. The female luer lock on the filter was 
attached to a 1 ml detachable syringe. The liquid was drawn through the nozzle, across 
the membrane and into the syringe, as suggested in the Australian IDU safer injecting 
information (Bergin, 1996, Anon, 1996) and by the interviewees who had experience of 
using syringe filters. The filtration was stopped when no more liquid was drawn into the 
syringe and the filter could be heard to be sucking in air.
A photograph of the filters prepared for use is shown below.
Acrodisk® 5 syringe filter
I
Cigarette filter % i— Cotton bud
Hand-rolling cigarette filter
65
3.4.4 Injection preparation: simulated process for tablets
The information established from the safer injecting information was expanded, based on 
the drugs workers and interview data. The experimental conditions used to investigate the 
effects of the filters on injections made from the tablets are shown in figure 3.3 and 
discussed below.
Chapter 3
Figure 3.3 Preparation process used for tablets in the laboratory.
3.4.4.1 Crushing
No consistency on crushing or correlation with tablet types under investigation could be 
made. The safer injecting leaflets state if tablets must be injected they should be crushed 
as finely as possible prior to dissolving in water. This was reported by some interviewees. 
However, others also split tablets and shook them with water in the syringe. It was 
considered possible that the particle load may vary depending on which method was 
used. Both methods were therefore investigated in the laboratory. Crushing was done by 
placing the tablets in the fold of a piece of paper and pressing on them with the spoon.
66
________________________________________________________________________________________________________________C hap ter 3
3.4.4.2 Transferring onto the spoon.
The spoon was needed as a vessel from which filtration could take place. Crushed tablets 
had to be transferred onto a spoon prior to mixing with water. Tablets that were split and 
shaken were transferred after they had been mixed in the syringe. No acid was added as 
the interviews and published information indicated that this is not normally done. Also, the 
drugs in the formulations are in the hydrochloride form, which are soluble (Parfitt, 1999) 
so this stage was considered unnecessary.
3.4.4.3 Addition of water
Boiled and cooled water from the kettle was used. The volumes used were derived as the 
most popular stated in the interviews and were as follows. Physeptone® = 5 ml, Diconal® 
= 2 ml, Temgesic® 2 ml. Five ml and 2 ml syringes were used respectively.
3.4.4.4 Stirring
The crushed powder was stirred using the sheath of an orange needle attached to the 
syringe, until it all appeared to be wetted and evenly distributed within the liquid on the 
spoon. The mixture of split tablets that was shaken in the syringe was poured onto the 
spoon without further agitation.
3.4.4.5 Filtration
The filters used were the same as those described for the heroin work, used in the same 
way (3.4.3.6).
3.4.5 Investigation into the use of acidifiers
The simulation process used to investigate the use of acidifiers was that used for heroin 
(fig. 3.3), with the amount and type of acid being the variable under investigation. The 
filter type used had to therefore be kept constant. Since the cigarette filter was the most 
popular filter amongst the interviewees, it was used for this work.
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3.5 Chapter summary
Chapter 3
The methods used to establish the types of drugs commonly injected by IDUs and their 
injection preparation techniques have been described in this chapter, followed by the 
results from these investigations. From these results, simulations of the injection 
preparation processes have been developed to allow controlled investigation in the 
laboratory. The next chapter will describe the methods used to conduct the laboratory 
investigation and the consequent results from this work.
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Chapter Four
The laboratory investigation
4.1 M ethodological issues
4.1.1 Procurement of drugs
4.1.1.1 Tablets
The researcher had to ensure that the drugs used for this study were obtained, stored 
and destroyed according to the legal requirements of the Misuse of Drugs Regulations 
(1985). Methadone and dipipanone containing products are controlled by schedule 2 of 
the regulations whereas buprénorphine is controlled by schedule 3. Pharmacists can 
lawfully obtain these drugs from licensed wholesalers and possess them for the purpose 
of professional duties. Discussion with the Home Office inspector for the area, confirmed 
that they were in agreement with these tablets being obtained from a pharmaceutical 
wholesaler for this work (Morgan, 1997). \
4.1.1.2 Heroin
The Home Office inspector also confirmed they had no objection to the work and that no 
license would be required for the possession of heroin, as long as it was obtained from a 
lawful supply. A lawful supply was termed as obtaining police samples that have been 
released by the courts for destruction (Evans, 1997, Napier, 1997a). Contact was made 
with all Scottish police forces and it was established that the procedure for destruction 
varied between regions. In Grampian, the drugs are returned to the police forensic 
laboratory for destruction (Wilkie, 1997). The police agreed to make the supply, if the 
Procurator Fiscal (PF) was in agreement. Contact was made with the PF who referred the 
matter to the Crown Office, as they considered their approval more appropriate in 
Scotland than that of the Home Office. The Crown Office informed the PF they had no 
objection to this research, which in turn gave approval to the researcher (Napier, 1997b). 
A copy of this approval is given in appendix 9. The whole approval process took nine
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months from initial contact with the Home Office to supply from the police. The storage 
and destruction method used are explained in section 4.2. Reference compounds could 
be obtained from licensed wholesalers so no further legal approval was required for 
these.
4.1.2 Selection of appropriate particle size analysis equipment
No previous particle analysis work on IDUs injections could be found in the literature, so a 
method had to be developed. The two principles on which particle size analysis may be 
based are light extinction and the Coulter principle.
4.1.2.1 Light extinction
The light extinction method is now the B.P stated method for particle size analysis (British 
Pharmacopoeia Commission, 1998). It uses laser light, which is diffracted when the beam 
is broken by a particle. The extent of the diffraction is measured to give particle count and 
sizing. The equipment can be fully automated, quick and easy to use with built in software 
that allows storage of data. Water is a suitable dispersant for samples. Although the
minimum volume for analysis (8 ml) exceeds the volume of the prepared injections,
\
sample dilution to 8 ml with filtered water would have been appropriate. However, at the 
time of study this equipment was not available within the School of Pharmacy. Although 
the equipment was available at other RGU sites, use of this equipment was not 
considered appropriate due to storage and transport issues regarding the controlled 
drugs.
4.1.2.2 Electrical zone sensing
The electrical zone sensing technique [Coulter principle] quantifies the effects of particles 
on the flow of electrical current. The Coulter Multisizer operates on this principle. The 
number and size of particles suspended in a sample of conductive liquid are determined 
as follows: A sample of the material under investigation is added to the conductive fluid 
and the particles are kept in suspension by a glass paddle. Two electrodes are immersed 
in the conductive liquid, the cathode inside a glass tube that has a small orifice in it and 
the anode outside. Particles are drawn through the orifice, the flow being controlled by a 
mercury manometer. As each particle passes through the orifice it causes a change in the
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resistance between the two electrodes. Voltage pulses are generated with amplitudes 
proportional to the particle volume, thus allowing the number and size of particles passing 
through the orifice to be determined. Because the sample is diluted in the conductive 
liquid, liquids with a heavy particle load can be analysed by adding only a small number of 
drops. A diagram of the equipment is given in appendix 10 (part A).
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4.1.2.3 Advantages and disadvantages of the Coulter Multisizer
Setting up and calibration of the Multisizer can be lengthy, and operation may be 
disrupted e.g. by a blocked orifice. If this happens, the sample must be discarded and the 
measurement repeated. However, once optimised, the Multisizer performs rapid 
measurement (Barber, 1993). Particle colour, composition or refractive index does not 
affect response, unlike light extinction methods. However, the Multisizer is less sensitive 
to particle shape than laser diffraction machines. This may mean that long thin particles 
are not sized accurately. Different types of particle cannot be discriminated, so if more 
than one kind are present they cannot be separated. This meant particle type and 
possible source could not be studied, however, this would also be the case for light 
extinction. The Multisizer counts for a given time or to a given number, it cannot count all 
particles present in the conducting fluid. Addition of the same sample volume and analysis 
over the same time period allowed suitable comparison of the results. For the purpose of 
this work, this was satisfactory, as the aim was to establish measurements that allowed 
comparison between unfiltered injections and injections prepared using the different 
methods of filtration. As long as each measurement was made in the same way they 
could be compared. Background vibration such as a nearby centrifuge can cause reading 
errors, so it was important to ensure such equipment did not operate at the same time as 
analysis was performed. Temperature of the conducting fluid must be approximately 
constant, to prevent variation in response recorded, so this was again controlled as 
described in section 4.2. It was considered that for the purpose of this study the Multisizer 
could give satisfactory results, providing the factors described above were controlled. A 
Coulter Multisizer (Mark lie) (Coulter Electronics) was kept within the School of Pharmacy 
and was available for sole use by the researcher in a non-teaching lab, which meant the 
settings would not be adjusted by others in use and attention would not be drawn to the 
work with controlled drugs. This was considered an important security measure. The 
Multisizer was therefore selected for this work.
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4.1.2.4 Selection of the Coulter Multisizer orifice size
The Multisizer can measure particles within the size range 0.4 to 1200 pm. However, to 
cover this range a series of orifice sizes needs to be used. The experiments performed 
for this study would have been repeated using several orifice sizes to determine if a large 
spectrum of particles sizes existed in the injections. However, changing the orifice and 
conducting fluid several times was not satisfactory, as this would take too much time for 
one operator to prepare the machine, so the sample would not be fresh when analysed. 
Not enough street heroin was available to allow the preparation of fresh samples for a 
range of orifice sizes. Therefore, one size range had to be selected. The Multisizer 
determines particles within the size range of 2 to 60 % of the diameter of the orifice being 
used. The 100 micron diameter orifice was chosen because it determines particles 
between 2 and 60 pm, a range which includes the sizes of critical interest in relation to 
capillary blockage, discussed in chapter 2, section 2.4.1. Using this orifice, particles less 
than 2 pm and over 60 pm will be sized, but the accuracy in these ranges will be reduced. 
Particles over 100 pm would block the orifice. When the orifice blocks, this is indicated on 
the in-built monitor screen.
4.1.3 Selection of appropriate drug analysis equipment.
It was anticipated that diamorphine would be the principle psychoactive drug in’ the street 
heroin and it was diamorphine content that would therefore be used to compare the filters. 
A method had to be found which would allow this to be confirmed and could be used to 
measure the amount of diamorphine in the injections and filters. Diamorphine rapidly 
degrades to 6-monoacetylmorphine (6-MAM) and morphine in aqueous solution and both 
compounds are psychoactive (Parfitt, 1999). Although they would contribute to some 
extent to the effects experienced by the IDU, they are likely to be present in smaller 
amounts compared to the diamorphine. However, if a significantly different amount of 
diamorphine was measured in an analysed injection, an awareness of the amount of 6- 
MAM and morphine also present would be useful, since this would indicate whether the 
reduction was due to retention of diamorphine in the filter or decomposition of the 
diamorphine. In the latter case, the amount of diamorphine would be reduced and the 
amounts of 6-MAM and morphine increased. In the former case, only the amount of 
diamorphine would be reduced. An appropriate method had to be found to measure 
diamorphine, 6-MAM and morphine.
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4.1.3.1 High Performance Liquid Chromatography
Love and Pannell (1980) developed a reverse phase high performance liquid 
chromatography (HPLC) system for the analysis of illicit heroin. Kaa and co-workers used 
this method as the basis for analysis techniques used to study heroin samples seized in 
Denmark over a 12 year period (Kaa and Bent 1986, Kaa 1991 and Kaa 1994). The Love 
and Pannall method has been criticised by Lurie et al (1982), who found diamorphine was 
not separated from quinine, an adulterant the authors report to be commonly found in 
their samples. However, Lurie et al analysed heroin seized in Virginia, USA. Analysis of 
heroin seized in Europe, namely, France (Chaudron-Thozet et al, 1992), Rome (Chiarotti 
et al, 1991) and Denmark (Kaa, 1991) has failed to detect quinine. Quinine has a similar 
bitter taste to street heroin and may be added as a bulking agent, (Stein, 1990). This is 
thought to be done once the heroin is in the USA, because the average purity of heroin is 
much lower than that found in Europe (Kaa, 1991, Gossop 1993). Given the acceptability 
of the Love and Pannall method to other European investigators, it was. chosen for 
investigation for suitability for this work. Also, HPLC is known to be robust and give good 
reproducibility, when optimised. Equipment is readily available in the School of Pharmacy. 
Also, the Love and Pannall method would be relatively cheap.
Love and Pannall used a 30 cm microbondpak column, which was not available to the 
researcher. Instead, the ratio of water to acetonitrile in the solvent was increased in an 
attempt to prolong retention time to compensate for the shorter column. Preliminary work 
found diamorphine, 6-MAM, and morphine could be isolated using different ratios of 
solvent, but no one ratio separated them all within a satisfactory time, giving sharp peaks. 
It was therefore decided that a gradient elution system would be necessary. However, the 
necessary equipment was not available, so an alternative available analysis method was 
sought.
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4.1.3.2 Capillary Zone Electrophoresis
At this time, Dr Ann Low, also from the Robert Gordon University, School of Pharmacy 
was completing her Ph.D. project (Low, 1998). In her work, Low developed, optimised and 
compared methods of analysis for a range of opiates, including diamorphine, 6-MAM and 
morphine, extracted from urine. The analysis methods Low investigated were: thin layer 
chromatography (TLC), gas chromatography (GC), both reverse and normal phase 
HPLC, capillary zone electrophoresis (CZE) and liquid chromatography coupled with 
mass spectrometry (LC-MS). Low and co-workers concluded that the CZE method was
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preferred over the others due to its greater resolution, increased speed and minimal use 
of solvents (Taylor et al, 1996, Low, 1998). This suggested that this method may be 
appropriate for this work. In collaboration with Low, her CZE method was used to conduct 
a preliminary investigation using a sample of the street- heroin. This showed that 
diamorphine, 6-MAM, morphine and papaverine1 present in the sample could be 
separated satisfactorily using a UV light detection method with a wavelength of 220 nm. 
Caffeine, which is a common adulterant in street heroin (Kaa, 1991, Kaa, 1994) does not 
absorb at this wavelength, so would not interfere with the analysis. Low's CZE method 
was used for this work, with the permission of Low. The general principles, benefits and 
problems of CZE will now be described.
The Capillary Electrophoresis Principle
CZE uses the principle of capillary electrophoresis. A diagrammatical representation of 
the equipment is given in appendix 11 (part A). The solutes of interest are injected onto a 
capillary made of fused silica. Applying a high voltage to the capillary filled with buffer 
creates an electrical field. The solutes separate on the basis of their mobility in the electric 
field. Mobility is influenced by electro-osmotic flow (see below), balanced against the 
frictional drag that it experiences. Factors that will influence movement include ionic 
charge of the solute, molecular size and the viscosity of the liquid with which the capillary 
is filled. In a given medium, smaller, more highly charged molecules will reach the 
detector first (Heiger, 1997).
Electro-osmotic Flow (EOF)
The application of a voltage across a capillary filled with buffer (electrolyte) causes a flow 
of solution along the capillary. This flow pumps solute ions along the capillary towards the 
detector. This flow occurs because of ionisation of acidic silanol groups on the inside of 
the capillary, when in contact with the buffer solution. At a high pH, these groups are 
dissociated resulting in a negatively charged surface. To maintain electro-neutrality 
cations build up near the surface. When a voltage is applied, these cations migrate to the 
cathode. Water molecules solvating the cations also move causing a net solution flow 
along the capillary. The extent of flow is related to the charge on the capillary, the buffer 
viscosity and the dielectric constant of the buffer. Generally, positively charged ions 
(cations) will reach the cathode first, followed by neutrals then negatively charged ions
1 P apaverine is a non-psychoactive  opiate, w h ich  com es from  raw  op ium  (P arfitt, 1999). It Is p resent in s tree t heroin due to 
lack o f re finem ent in the p reparation process.
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(anions) (Heiger, ibid). This is represented in figure 4.1. The grey circles represent 
cationic molecules and the black represent anionic molecules. N represents neutral 
molecules. The arrows represent electro-osmotic flow. The detector will be at the cathode 
end of the capillary.
Figure 4.1. Diagrammatical representation of solute migration influenced by electro-osmotic flow in
Capillary injection techniques
In generally, three injection techniques can be used. These are pressure, gravity and 
electrokinetic injection. The first two result in homogenous sample volumes being loaded 
onto the capillary, whereas the last can result in a degree of bias. Electrokinetic (EK) 
injection was used in this work. In EK injection, the sampling end of the capillary plus a 
high voltage electrode are inserted into the sample vial, a voltage is applied causing 
solute ions to enter the capillary by electrophoretic migration and electro-osmotic flow. 
The more mobile ions enter first, so bias is encountered. However, this increases 
sensitivity. The bias means non-reproducible peak heights are encountered. To 
compensate for this, yet to maintain the advantage of the increased sensitivity, an internal 
standard (IS) is used. The use of the IS is detailed in section 4.4.3.
Advantages and Disadvantages of CZE
CZE requires only small sample sizes, which is an advantage if the amount of material 
under investigation is limited. However, this was not the case in this work. The equipment 
is easy to operate and quick, especially automated machines. CZE uses small amounts of 
relatively simple buffer. Not only does this keep costs low, it also means buffer pH and 
concentration can be easily varied for optimisation. The capillary itself is also relatively 
cheap. It is long, so efficiency is high, which gives good separation (i.e. high selectivity). 
As said, the bias of EK injection means sensitivity is high, which is also an advantage.
A  ~  _
CZE.
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This disadvantages of CZE are that the peaks are not reproducible so an IS has to be 
used. Also, the high voltage used is potentially dangerous, so stringent safety systems 
have to be applied. The disadvantage of non-automated equipment means if there is an 
error encountered with the chart recorded, the analysis data is lost.
Automated equipment was the first choice for this work, as it would have allowed 
analysed data to be stored and recalled if required. It would also conduct automatic data 
manipulation, which would be quicker than manual measurement and calculation. It would 
also have avoided loss of data, for example through failure of the chart recorder. This was 
considered especially important since the amount of heroin available for this work was 
limited by the quantity that the police were able to supply. However, at the time of this 
work, only manual equipment was available at the RGU School of Pharmacy for use by 
the researcher, so this had to be used.
4.2 Procurement, storage and disposal o f the drugs used in the laboratory  
investigation
4.2.1 Procurement
4.2.1.1 Heroin
\
i
Grampian Police toxicology laboratory supplied 19.61 g of brown heroin to the researcher, 
which came in four bags from three separate cases. Due to the potential for variation 
between the samples, they were mixed together to give one batch for the experimental 
work, allowing the results to be compared. The mixing was done in a mortar and pestle 
then the powder was transferred into a jar. No information on the sample content was 
available from the police, as only diamorphine content of individual samples is measured 
and results from closed cases are not kept in the department.
4.2.1.2 Tablets
The tablets were obtained from a local wholesaler, AAH, East Tullos, Aberdeen. The 
managing director was contacted prior to ordering as it was thought that the company 
might query a sudden increase in the amount of CDs being ordered by the School of 
Pharmacy. As agreed, an outline of the research project was sent to the manager, who 
then confirmed to the researcher that his company were willing to make the supply to the 
School of Pharmacy (Cooper, 1996).
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4.2.2 Storage, destruction and disposal
The Home Office Inspector for the area, Mr Y Morgan, visited the School of Pharmacy in 
May 1997 to ensure storage and disposal methods were, satisfactory. The following 
arrangements were agreed:
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4.2.2.1 Storage
All drugs were stored according to the controlled drug regulations (RPSGB, 1999). The 
schedule 2 drugs2 were kept in an approved locked cabinet. Buprenorphine, although a 
schedule 3 drug is also subject to schedule 2 storage requirements, so was also stored in 
the cabinet. The cabinet was within the School of Pharmacy dispensary. The drugs for 
this work were separated from other cupboard contents by being stored on a separate 
shelf in a box marked with the researchers name. Access to the cupboard was restricted 
to the researcher and designated staff who were all pharmacists. For security, knowledge 
of the presence of the research materials was restricted to only these people. Both 
schedule 2 and 3 CDs are subject to CD record requirements (RPSGB, ibid.). These were 
satisfied as follows. Quantities of tablets received were recorded in the dispensary 
controlled drug register. As they were removed for research, this was entered in the 
register, with the person authorised to receive them being the researcher. For the street 
heroin, a controlled drug book was made to record the quantity received and usage. This 
was done to distinguish it from pharmaceutical diamorphine, as requested by the Home 
Office inspector. This register was kept in a locked cabinet in the researcher’s office. 
Each quantity of heroin removed was recorded in the register.
The reference compounds that the researcher used were stored in the controlled drug 
cupboard and again recorded in the reference compound register, which was in use prior 
to this study.
4.2.2.2 Destruction and disposal
It was agreed with the inspector that tablets remaining at the end of the study could be 
left in the cupboard for use in student teaching. Any remaining heroin would be required 
to be destroyed under the Misuse of Drugs Act certificated procedure. This means the 
area pharmaceutical inspector, police pharmacy liaison officer or Home Office inspector
2 i.e. d iam orphine  including s tree t heroin, m ethadone and dipipanone.
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would have to witness the destruction. All of the street heroin was used in the study so 
this procedure was not necessary. After analysis, the remaining sample solutions were 
disposed of immediately, as advised by the inspector, as follows: Both aqueous and 
methanolic solutions were mixed with quantities of a noxious. compound such as 
acetonitrile and diluted with water. Further quantities of water were added to produce 
dilute solutions. These were added to either aqueous or organic waste containers and 
disposed of following standard laboratory procedure.
4.3 Particle size analysis method used fo r th is study
4.3.1 Conductive fluid preparation
The conductive fluid used for this work was normal saline, prepared in-house. Variation 
between batches may cause variation in electrical conduction, so it was important to be 
exact in the preparation. Batches of 2 litres were prepared by weighing 18g of sodium 
chloride (Fison Scientific Equipment, Loughborough), which was transferred into a 2 litre 
volumetric flask. The sodium chloride was dissolved in sufficient de-ionised water, which 
was prepared in-house using the Milli-Q ion exchange system (Millipore, Watford). The 
weighing boat was rinsed with some water into the flask. The solution was made up to the 
mark with water. The resulting saline was filtered twice through 0.2 pm filter paper 
(German, Michigan, USA) to minimise particulate contamination. The filteV paper was 
changed after each batch was prepared. The saline was left to equilibrate at room 
temperature before use.
4.3.2 Equipment handling
Deionised water was rinsed through the Multisizer before and after use to prevent and 
remove salt deposits. The conductive fluid jar was handled carefully to minimise 
particulate contamination. Conducting fluid was run through the system before use to 
remove any water. The sample beaker and stirrer were cleaned with deionised water and 
rinsed with conducting fluid prior to use. When not in use, the beaker was covered and 
stored within the sampling stand to minimise atmospheric contamination.
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4.3.3 Multisizer settings
The Multisizer was set to count and measure linear diameter of the particles. The output 
gives a size distribution curve for the measured sample. An example of a Multisizer data 
output screen reproduced from the Multisizer Operational Manual with permission from 
Beckman Coulter is given in appendix 10 (part B). On the data output screen, the 
following information is given. The total number of particles (N) is the raw count of the 
machine during the analysis period. The coincidence corrected count (N) is also given. 
This is the particle count that the machine considers to represent the actual number of 
particles, once the correction factor has been applied. This factor takes into account 
possible errors such as two particles passing through the orifice together, being counted 
as one. The correction factor that is being applied as analysis is undertaken is shown on 
the percentage indicator, left of the y-axis. This is shown as the percentage of the total 
count. For N to be accurate, this should be below 20 % (Coulter Electronics, 1988). 
During operation, results were only recorded if this 20 % or less was achieved, otherwise 
the experiment was repeated. Cursors on the screen can be moved to either side of the 
size range of interest, giving the number of particles in this range on the screen 
(represented by Z). The cursors can also be moved to allow a count for each channel to 
be determined. The Multisizer was set to measure the standard 256 channels. The 
standard time option of 12 seconds was selected. The total number of particles that are 
drawn from the sample beaker through the orifice in this time is counted. The sample 
stirrer was set to speed 2 for all analysis to keep the particles suspended. The conducting 
fluid was used at room temperature. This allowed comparisons in particle load to be 
made, as all samples were measured under the same conditions.
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4.3.4 Background count
Although care was taken in the saline preparation and equipment set-up to avoid 
contamination with particles, the introduction of particles into the system may not have 
been avoided altogether. Therefore analysis was performed by recording a background 
count for the saline and subtracting this from the sample count. Communication with 
Coulter Electronics confirmed that a background count of approximately 200 or below was 
considered satisfactory for non-diagnostic analysis (Crouch, 1997). If the background 
count was above this, the saline in the sample beaker was discarded and the 
measurement repeated with fresh saline. This was done until a satisfactory background 
medium was achieved.
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4.3.5 Calibration
The Multisizer was calibrated to 256 channels using a standardised suspension of latex 
beads (Coulter Electronics, Luton) with a label stated diameter of 14.1 pm. The label 
stated diameter on each standard is determined for each batch of latex by the 
manufacturer. Calibration gives a measured calibration constant, known as the Kd value. 
The expected Kd value for the 100 pm orifice stated by the manufacturers is 930.00. A 
measure calibration constant within 10 % of this value is considered acceptable. On 
calibration, the width of each channel is equal, but the minimum and maximum values on 
the range will vary slightly, hence channel borders vary with calibration. The machine was 
re-calibrated after a period of non-use greater than one week, as recommended (Coulter 
Electronics, 1988).
4.3.6 Validation
Validation of the Multisizer was necessary to allow confidence to be placed in the results 
obtained. It was performed using calibration standard latex beads of a range of stated 
label sizes. The greatest number of particles in the distribution should be equal to or close 
to the stated label size of the latex beads. For the validation work, the channel that
contained the peak number of the particles in the distribution was recorded (i.e. the
\
measured size of the majority of the latex beads in the calibration standard). For 
comparison purposes an actual particle size was needed, not a size range, so this was 
taken to be the median of the channel. The particle size range (i.e. the base width of the 
particle size distribution) was recorded as follows: the smallest particle was taken to be 
the lower size of the smallest channel and the largest particle was taken to be the bigger 
size of the biggest channel.
No previously published method could be found describing Coulter Multisizer validation, 
so validation methods had to be designed. This was done on the basis of standard factors 
usually assessed in other experimental work as described in 4.3.6.1 to 4.3.6.5.
Relative standard deviation (RSD) was chosen as the value used to measure the validity 
of the experimental equipment for both the Coulter Multisizer and CZE work, because it 
allows the variation in the results, termed the standard deviation (SD), to be compared 
with the mean from the set. As an example, in theory, the results obtained from a 
repeated set of analyses of the same material should be the same, but in practice they
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rarely are. The acceptable RSD is the limits of variation allowed in order for the results to 
be considered valid.
As said, no previous guidance on conducting validation experiments with the Coulter 
Multisizer could be found. Therefore no guidance existed on the acceptable RSD value 
that could be used to determine whether the results of the validation experiments were 
indeed valid. However, since RSD values are usually below 5%, a value of 4% was 
considered to be acceptable for this work, following discussion with the Director of 
Studies, who has experience in the particle size analysis field.
4.3.6.1 Reliability
A reliable machine should give consistent results when a measurement is repeated, 
assuming the sample is standardised. Separate analyses were done on four sample 
suspensions each containing three drops of 13.7 pm latex. The peak base width and 
height were recorded. The readings were compared by calculating their RSDs.
4.3.6.2 Precision
Latex beads do not dissolve or swell in saline, so repeated measurements on one 
suspended sample should be the same. To check the precision of the Multisizer, three 
drops of latex (13.7 pm diameter) were added to the sample beaker. Four readings were 
taken over a period of approximately fifteen minutes from the same sample suspension. 
The same readings were taken as for 4.3.6.1 and RSDs again calculated.
4.3.6.3 Accuracy
To check accuracy, five latex calibration standards of the label stated sizes 5.96, 9.5, 
13.7, 14.1 and 19.2 pm were analysed. The mode size was compared with the stated 
label size to investigate how close the measurement was to the manufacturer’s 
measurement.
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4.3.6.4 Within-day variation
Latex calibration standards of the stated label sizes 5.96, 9.5, 13.7, 14.1 and 19.2 pm 
were analysed four times within the same day, with measurements taken as in 4.3.6.1 
and results compared by calculating the RSDs.
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4.3.6.5 Day to day variation
Latex calibration standards of the stated label sizes 5.96, 9.5, 13.7, 14.1 and 19.2 pm 
were analysed four times over the period of one week, with measurements taken as in
4.3.6.1. The RSDs were again calculated.
4.3.7 Experimental work comparing the effectiveness of the filters
4.3.7.1 Sample readings
For each sample, the value of N was recorded. The number of particles within the size 
ranges of interest was obtained, by moving the cursors to the size range limits. These 
size ranges were set as follows:
i
• 2 to < 5 pm
• 5 to <10 pm
• 10 to <20 pm
• 20 to 50 pm
The size range 2 to <5 pm was selected because it would show the presence of particles 
smaller than lung capillaries. The range 5 to <10 pm would show particles that may 
potentially block lung capillaries. The other sizes were set because the terminal arterioles 
of the vascular system are between 20 and 50 pm (Friedman et al, 1996), so particles 
within these size ranges may block these small vessels. The size range was split in two to 
give more detail of the size of the particles in this range of interest. Because the channel 
limits vary with each calibration, actual sizes were rounded up or down, whichever was 
nearest, to the above size limits.
To make calculation quicker, background and sample readings were input into a Microsoft 
Excel (ver.5) spreadsheet, where subtraction was performed automatically, to give the
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adjusted results. Each experiment was performed three times. The average N and 
average number of particles in each size range were calculated from the three 
experiments. The average number of particles in each size range was then calculated as 
a percentage of the average N to shown the distribution of the particles in the size ranges 
measured.
4.3.7.2 Sample addition
The volume of analyte added for each measurement was 50 pi, removed using an 
automatic pipette, which had been previously validated. It was considered possible that a 
reduction in particle count may occur due to particles dissolving when stirred in the saline 
To minimise this effect, analysis was performed immediately after the sample dispersed“' 
If the orifice blocked, the sample was discarded and the injection prepared again.
4.3J.3 Controls
To check the contribution to the particle load of the injecting paraphernalia and other 
factors involved in the preparation process (e.g. operator and environment), controls were 
performed. Both water from the kettle and Water For Injections (WFI) were used as this 
also allowed comparison of the resulting particle load between water with an uncontrolled 
particulate count (kettle water) and water prepared under conditions to minimise 
particulate contamination (WFI). The controls were performed as follows:
2 ml of water was put onto the spoon. It was stirred with the needle sheath and heated 
until it bubbled. Unfiltered samples were analysed. Samples that had been filtered with 
the four filters under investigation were analysed. Also tested was 2 ml water put into the 
2 ml syringe barrel and shaken then the sample removed.
4.3.7.4 Experimental data comparison
Direct comparison of samples removed from the same injection before and after filtration 
was not considered possible. Initially, this was attempted but after some difficulties it was 
decided to compare filtered injections with separate unfiltered injections, prepared in 
exactly the same way, safe for the filtering. The difficulties experienced when attempting 
to remove the sample before and after filtration from the same injection were: (1) the first
3 The (» lo u re d  nature  o f the in jections m ade it possib le  for this to  be observed.
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work done was with the tablets. The unfiltered sample commonly blocked the orifice so 
the injection had to be discarded and the experiment repeated. This became quite 
wasteful of drug and was viewed as a potential problem in the heroin experiments due to 
the limited amount of drug anticipated. (2) removal of liquid .from the unfiltered material 
reduced the volume of the final injection, which at the time was considered unacceptable, 
as it would prevent the final injection representing exactly what the IDU would obtain. (3) 
while the analysis of the unfiltered sample was performed and the Multisizer prepared for 
the filtered sample analysis, the filtered injection would be waiting, so it would not be 
analysed ‘fresh’ and hence not represent as close as possible what the IDUs inject. (4) 
physically, it was difficult for all the work to be performed by one person quickly, 
especially since the equipment was not automated.
The experiments with unfiltered injections made using tablets were performed using both 
tablets that had been crushed prior to mixing with water, as described in safer injecting 
leaflets, and tablets which had been split in two and mixed with water, as described by 
some of the interviewees. This was to determine which method resulted in the least 
particulate contamination. For the comparison with filtered injections made from tablets, 
the results from the injections prepared by crushing the tablets were used as this practice 
is suggested in safer injecting leaflets.
To summarise the work that was done for each drug. Each type of filter was used to 
prepare three injections. Immediately after preparation, particle size analysis was 
performed on a sample removed from the injection. The average results were taken and 
particle size distributions in the injections produced. The filters were compared by 
calculating the percentage reduction that they produced in the total N. This was done by 
taking the average N from three analyses of unfiltered injections to represent 100% and 
calculating the average N from the filtered injections as a percentage of this. Although in 
diagnostic and formulation work this type of comparison would be inaccurate, it was 
considered appropriate for this work given that the particle count and distribution will vary 
greatly. Exact results would be meaningless in this situation, but the overall trends gave 
an indication of the effects of the filters.
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4.4 Heroin quantification methods
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4.4.1 Equipment and Materials
The ISCO Model 3850 Capillary Electropherograph with built in ultraviolet detectors was 
used. The wavelength of detected used was 220 nm, as Low found this to be the optimum 
wavelength for opiate detection in her work. A further advantage is that caffeine does not 
absorb at this wavelength, so interference from caffeine that may be present in the 
samples (Huizer, 1983, Kaa, 1991, Kaa, 1994) is not an issue. The capillary was 
unmodified silica, Lincoln ISCO Quality CE, 50 pm in diameter and length of 1 metre. The 
chart recorder used an ABB Servogor SE120, set at a speed of 1 cm min'1.
Water was prepared to HPLC grade in-house, using a Millipore Milli-Q system (Millipore, 
Watford). HPLC grade methanol was obtained from Ratheburn (Walkerburn, UK). 
Disodium hydrogen orthophosphate and orthophosphoric acid were of AnalaR grade 
supplied from Fisons (Loughborough, UK). Standard compounds were diamorphine and 
levallorphan from D.M Wood, (Aberdeen UK), morphine from Sigma (Poole, UK) 6- 
monoacetylmorphine from McFarlane Smith (Edinburgh, Scotland) and papaverine from 
BDH (Poole, UK).
4.4.2 Electrolyte
The optimum electrolyte that Low established was used. This contained disodium 
hydrogen orthophosphate 100 mM, buffered to pH 6 with orthophosphoric acid. It was 
prepared in 1 litre volumes, and degassed by filtration through a 0.45 pm Acrodisk 
(Gelman, Ml, USA) prior to use. The system was run for 10 minutes before use to allow it 
to equilibrate.
4.4.3 Internal Standard
As explained (4.1.3.5), an internal standard (IS) was required to allow results to be 
compared. Levallorphan was used, as Low had shown it had similar mobility to the 
analytes of interest in the buffer used. This would mean there would not be a long delay 
between IS peak and sample peak detection. A stock solution of levallorphan in methanol 
was made at concentration of 104 pgml'1. This was used for all the work except the 
preliminary analysis of heroin where a stock solution of 112 pgrril'1 was used.
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4.4.4 Data collection.
Low had shown that the first three injections from an aliquot of sample gave satisfactory 
linear response. Further injections lost linearity. Therefore, for each analysis the resulting 
peak heights from the initial electropherogram and two consecutive runs were taken. The 
peak height ratio to the internal standard was calculated for each and the average ratio 
taken. This average ratio was used to calculate the amount of diamorphine, 6-MAM and 
morphine in the sample solutions and consequently, the prepared injections.
4.4.5 Preliminary analysis of street heroin
Prior to validation, preliminary analysis was performed on a small quantity of street heroin. 
This was done for three reasons:
1. To confirm whether Low's method could give a satisfactory separation of the peaks 
seen from the analysis.
2. To investigate for the presence of the opiates that were expected to be contained in 
the sample (diamorphine, 6-monoacetylmorphine, morphine and papaverine) and 
investigate whether other peaks were seen at the 220 nm wavelength of determination.
\
3. To determine the percentage content of the opiates under investigation in the street 
heroin, allowing appropriate dilution factors to be used in the sample preparation 
process.
A standard solution containing diamorphine 5.06 pgrril'1, 6-MAM 2.24 pgrril'1, morphine
1.00 pgml'1 and papaverine 1.02 (igrnl'1 was prepared. 10.9 mg4 of street heroin was 
dissolved in 50 ml of methanol. Methanol was used to ensure complete dissolution, 
because opiates are more soluble in methanol than water (Parfitt, 1999). Two 10 ml flasks 
were taken, into each 0.2 ml of IS (112 ngml'1) was added. In one, 0.2 ml of the standard 
solution was added, while 0.2 ml of the street heroin solution was added to the other. Both 
were made up to 10 ml using water and analysed. The electropherogram produced from 
the standard was compared with that of the sample as follows: Migration times were 
measured and compared. The electropherograms were visually inspected for satisfactory
4 From the work of Low (1998), the quantity of street heroin, the dilutions factors used to prepare the sample 
and the corresponding sensitivity setting of the CZE equipment could be estimated. This was based on the 
assumption, as identified in the literature that the diamorphine content of street heroin might be between 40 
and 60% (King, 1997). It was predicted that a dilution as described of approximately 10 mg of street drug 
would be satisfactory and-allow the settings to be optimised. 10.9 mg was the exact weight achieved
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peak separation and the presence of any other peaks. 0.2 ml of the standard solution was 
added to the sample flask and analysis of the sample repeated. This was done to confirm 
the identity of the peaks. Since the concentration of opiates in the standard solution was 
known, the peak height ratios of the opiate peaks to IS could be used to determine the 
concentration of opiates in the sample flask using simultaneous equations. Consequently 
the percentage content of the opiates of interest in the street heroin could be calculated.
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4.4.6 Linearity
To ensure the results could be used to accurately determine the amount of opiates in the 
analysed samples, the linearity of the analysis method over the range of concentrations 
had to be checked. A range of concentrations was made from stock solutions, which 
encompassed the concentration range of the analysed samples. These were injected with 
internal standard, at a concentration of 10.0 pgml'1 (6-MAM and morphine) and 11.2 
pgml'1 for the diamorphine. A greater concentration range of diamorphine was 
investigated due to its greater content in the street heroin, as was determined by the 
preliminary analysis. The resulting peak height ratio was plotted against concentration, 
using Excel (2000), and linear regression analysis performed. The correlation co-efficient, 
slope, standard deviation of the slope and y-intercept were all determined. The 
concentration ranges investigated are shown in pgml'1 in table 4.1.
Diamorphine 6-MAM Morphine
0.00 0.00 0.00
11.54 1.00 2.50
23.00 5.00 5.00
34.50 10.00 10.00
46.00 - -
57.50 - -
Table 4.1 Concentration shown in pgmf1 of solutions used to investigate the linearity of responses 
obtained using the CZE experimental method.
4.4.7 Validation
To ensure confidence could be placed in the results obtained and the experiments 
conducted over time were meaningful, the CZE method had to be validated. Although Low
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had conducted extensive validation in her work, the equipment used for this work was of a 
different model and the researcher was different, so validation had to be performed. RSD 
was chosen as the method of assessment for the same reasons as given in 4.3.6.
In her CZE analysis of opiate solutions, Low (1998) considered that RSD values of less 
than 3.5 % indicate a method has sufficient ruggedness to allow analysis to be 
undertaken. Although Low was considering peak area ratios as opposed to peak height 
ratios, as they are computed from the same data output, this was also considered an 
acceptable limit for this study.
4.4.7.1 Within day variation
A standard solution containing diamorphine 9.28 pgrril'1' 6-MAM 9.23 figml'1 morphine 
9.31 pgmL1 and IS 10.4 pgml-1 was prepared. Analysis was performed five times within 
one day. The average peak height ratio for each drug was taken and the SD and RSD of 
the average ratios calculated.
4.4.7.2 Day-to-day precision
A standard solution containing diamorphine 9.28 pgml'1, 6-MAM 9.23 jagml'1, morphine 
9.31 (.igml1 and IS 10.4 pgml1 was prepared. Analysis was performed daily over a five-day 
period. The average peak height ratio for each drug was taken and the SD and RSD of 
the average ratios calculated.
4.4.8 Standard solutions
One set of standard stock solutions was prepared for use in all the injection and filter 
analysis work. They contained diamorphine 92.8 /.tgml , 6-MAM 92.3f.igmi , morpm.ic
93.0 pgml1 and levallorphan 104.0 pgrril1 respectively. Low had shown deterioration of 
these compounds when dissolved in HPLC grade water, so the stock solutions were 
prepared using methanol and stored in the refrigerator. Further analysis showed them to 
be stable over the period of study. Each day, these standard solutions were allowed to 
equilibrate to room temperature then used to prepare a solution. This was done by mixing 
1 ml of each and diluting to 10 ml with HPLC grade water. The ratio ot stanaaro peaK 
height to IS peak height was calculated When samples were run the ratio of sample
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peak to IS peak was also calculated. Using simultaneous equations, the amount of drug 
in the injections was calculated.
4.4.9 Analysis of blank injections (controls)
To be sure that factors in the injection preparation process other than the drugs were not 
contributing to the peaks seen, blank injections were analysed. They were equivalent to 
the analysed injections, prepared in the same way (fig. 3.3), but without the addition of 
drug. One was prepared using each of the four filters to be tested and analysed. One was 
also prepared using ascorbic acid (15 mg) instead of citric acid and filtered through the 
cigarette filter. They were analysed in the same way as described for the injections 
(4.4.10).
4.4.10 Analysis of the filtered injections.
Injections were prepared from street heroin, as detailed in chapter 3 and figure 3.3. They 
were diluted for analysis as follows: The resulting injection was transferred into a 100 ml 
flask. The syringe was rinsed with methanol and the washings transferred to the same 
flask, which was made up to the mark with methanol. These flasks were stored in a 
refrigerator in case of a need for reanalysis. 1 ml of this methanolic solution was mixed 
with 1 ml of the IS stock solution in a I0 ml flask. Tins was maue up io me maix mu 
water to give the sample for analysis. For each filter, the experiment was repeated five 
times. The amount of diamorphine, 6-MAM and morphine in the analysed sample was 
calculated by comparing the peak height ratios with those of the standard. After 
considering the dilution factors applied, the amount of opiates in the 100 ml methanol 
flask and hence the prepared injection was calculated.
To compare the effects of the different filters on the amount of diamorphine in the 
prepared injections, the calculated quantities of diamorphine were compared statistically 
using Tukey’s Honestly Significant Difference (HSD) (95% c.i, one-way) (Li Wan Po,
1998), which was performed using Statistical Package for the Social Sciences v.6.0 
(SPSS inc, Illinois). This test was chosen after consultation with RGU statistician, Alex 
Wilson. It considers all results not just the average in a set of data, so gives greater 
sensitivity over tests that only use averages, such as the student t-test.
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4.4.11 Analysis of the drug retained in the filters.
The filters used for the above experiments were analysed. For the makeshift filters, the 
whole filter was dropped in a 25 ml flask containing approximately 10 ml. of methanol and 
shaken. For the syringe filter, the filter was flushed with methanol twice in both directions 
into a 25 ml flask. In all cases the resulting solution was made up to the mark with 
methanol. Samples for analysis were prepared by mixing 1 ml of this methanolic solution 
with 1 ml of IS and diluting with water to 10 ml. The calculated quantities of diamorphine 
released from the filters were compared statistically, again using Tukey’s HSD test (95% 
c.i, one-way), as in 4.4.10.
The filters were also weighed before and after use to find out the weight of material that 
they retained.
4.4.12 The effects of acidifiers, water and the preparation process
As said in chapter 2, the purpose of conducting experiments investigating the effects of 
acidifiers was to show that acidifiers are required in the preparation of brown heroin and 
to test the belief that heating the injection for longer and adding more water would not 
increase the amount of diamorphine in the injections.
The cigarette filter was used to filter all the injections prepared in the \ acidifier 
experiments. Injections were diluted and analysed as in 4.4.10.
Altering the quantity of acid
The quantities of acid investigated were based on fractions or multiples of the pinch (15 
mg) that was used for the filter work. This was to allow the findings to be explained in 
IDUs terms. The amount of heroin available was limited. As citric acid was the most 
popular acid, three quantities were tested. These were 30 mg (‘two pinches’), 7 mg ('half 
a pinch’) and 3 mg (‘quarter a pinch’). The last quantity was tested instead of no acid, 
which was initially planned. The first attempt to filter a mixture with no acid established 
that this couldn’t be done as the flocculated suspension of heroin was too thick and very 
little fluid could be drawn into the syringe.
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Two quantities of ascorbic acid were tested. These were 15 mg (to allow comparison with 
the 15 mg citric acid results) and 60 mg (to illustrate the effects of using a significantly 
greater quantity).
pH
The pHs of the injections were measured using a pH meter with a probe small enough to 
fit into a small vial (Corning, model 12). The injections were decanted into the vial, then 
washed into the 100 ml flask for analysis sample preparation. All experiments were 
performed three times and the average results taken.
Increasing the quantity of water
Three experiments were performed using 15 mg of citric acid and increasing the quantity 
of water by 50 % from 0.8 ml to 1.2 ml. The average amount of diamorphine in the 
injections was calculated.
Detection of drug lost in preparation
\
!
Qualitative tests were performed to identify whether diamorphine could be found on the 
spoon, on the tip of the needle sheath and in the vapour that evaporated from the spoon 
on heating. The solid material remaining on the spoon after one of each of the 
experiments conducted with the four filters was washed with approximately 10 ml of 
methanol into a beaker. From this, 1 ml of the solution was diluted to 25 ml with methanol. 
1 ml of this was mixed with 1ml of IS in a 10ml flask and made up to the mark with water. 
A sample of this was then analysed. Vapour from the bubbling liquid on the spoon was 
collected in a watch glass above the spoon. This vapour was washed from the watch- 
glass using methanol, into a beaker. 1 ml of this was mixed with 0.5 ml of IS and made up 
to 10 ml with water, a sample of which was analysed. A used needle sheath from one of 
each of the experiments was stirred in about 1ml of methanol and analysed in the same 
way as the washings from the watch-glass were. These qualitative experiments were only 
performed once.
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4.5 Tablet q uan tifica tion  by o ther researchers
Time restraints prevented the analysis work for the tablets being performed. Instead, 
RGU students carried out work investigating Diconal® and morphine as undergraduate 
honours projects. There are not discussed, as this researcher did not perform them. 
Instead the reader is referred to the reports of Heney (1998) and Pollock (1998), available 
from the Robert Gordon University, School of Pharmacy, tel. 01224 262500.
4.6 R esults: Partic le  size analysis
4.6.1 Calibration
The Multisizer was calibrated four times during this work, once before validation, once 
after the tablet work had been performed and twice during the heroin work. All Kd values 
were within the acceptable range, with the value furthest away from the expected Kd 
value (930.00), being 909.22.
4.6.2 Validation
4.6.2.1 Reliability
The results from the reliability check are given in table 4.2.
Mode particle size 
(pm)
Smallest size in distribution 
(pm)
Biggest size in 
distribution (pm)
14.06 11.05 18.02
14.54 10.81 17.72
14.06 11.05 17.54
14.3 10.81 18.02
M e a n 14.24 10.93 17.83
S D 0.23 0.14 0.24
R S D  % 1.62 1.28 1.35
T a b le  4 .2  R e s u lts  o f  th e  r e l ia b il i ty  c h e c k  p e r fo r m e d  fo u r  t im e s  u s in g  c a lib r a t io n  s ta n d a r d  la te x  b e a d s  
1 3 .7  p m  d ia m e te r .
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4.6.2.2 Precision
The results from the precision check are given in table 4.3.
Mode particle size 
(pm)
Smallest size in 
distribution (pm)
Biggest size in 
distribution (pm)
14.06 10.81 18.26
14.3 10.81 17.06
14.06 11.05 18.02
13.82 10.57 17.78
Mean 14.06 10.81 17.78
SD 0.20 0.20 0.52
RSD % 1.42 1.85 2.92
Table 4.3 Results of the precision check performed four times over a fifteen-minute period using one 
sample of calibration standard latex beads 13.7 pm diameter.
4.6.2.3 Accuracy
The results from the accuracy check are given in table 4.4.
\
\
Stated Latex 
Diameter
Mode channel size
5.96 5.769-6.009
9.5 9.134-9.615
13.7 13.7-13.94
14.1 14.18-14.66
19.2 18.99-19.23
Table 4.4 Accuracy of Muttisizer measurement (n » 1).
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The results from the within-day variation measurements are given in table 4.5.
Labelled latex size (pm)
5.96 9.5 13.7 14.1 19.2
Mean 5.68 9.25 14.06 14.69 18.96
SD 0.06 0.00 0.20 0.11 0.41
RSD % 1.06 0.00 1.42 0.74 2.16
Table 4.5. Within day variation of Multisizer measurements (n = 4)
4.6.2.5 Day-to-day variation
The results from the day-to-day variation measurements are given in table 4.6.
Labelled latex size (pm)
5.96 9.5 13.7 14.1 19.2
Mean 5.95 9.28 13.97 14.33 19.17
SD 0.3 0.21 0.15 0.2 0.12
RSD % 5.04 2.26 1.07 1.40 0.63
Table 4.6. Day-to- day variation of Multisizer measurements (n = 4)
4.6.3 Controls
The results from the controls are shown in table 4.7 and 4.8.
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4.6.3.1 Kettle water
Shake in 
Syringe
Stir on 
Spoon
Cigarette
filter
Hand 
rolling- 
filter
Cotton bud 
filter
Syringe
filter
N avg. 41 30 23 65 39 77
Particle size d is tribu tion : avg.num ber o f particles (% of total N)
2 -5  pm 38 (92.7) 23 (76.7) 18(78.3) 58 (89.2) 31 (79.5) 77(100.0)
5 -1 0  pm 1 (2-4) 2 (6.6) 3 (13.0) 5 (7.7) 7 (17.9) 0
10-20  pm 2 (4.9) 4(13.3) 1 (4.4) 2(3.1) 1 (26) 0
20 - 50 pm 0 0 1 (4.4) 1 (15) 0 0
Table 4.7 Average coincidence corrected particle count and average particle size distribution (shown 
to the nearest whole particle) in blank injections prepared with kettle water (n = 3).
4.6.3.2 Water for Injections
Shake in Syringe Stir on 
Spoon
Cigarette
filter
Hand
rolling
filter
Cotton bud 
filter
Syringe
\
: filter
N avg. 107 8 16 17 112 9
Particle size d istribu tion : avg.num ber o f particles (% o f total N)
2 -5  pm 96 (89.7) 8 (100.0) 14(87.5) 12(70.6) 104 (92.9) 4 (44.4)
5 -1 0  pm 7(6.5 0 1 (6-3) 2(11.8) 7 (6.3) 1(11.1)
10•20  pm 2(1.9) 0 1 (6.3) 2 (11.8) 1 (0.9) 4 (44.4)
20 - 50 pm 3(2.8) 0 0 0 1 (0.9) 0
Table 4.8. Average coincidence corrected particle count and average particle size distribution (shown 
to the nearest whole particle) In blank Injections prepared with Water for Injections (n = 3).
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4.6.4 Effects of filters on particle content of heroin injections 
Observations on use:
All four filters were quick and simple to use. The needle did not block during the filtrations 
performed through the needle i.e. the makeshift filter experiments. The syringe filter 
required slightly longer than the makeshift filters, as time had to be allowed to draw the 
liquid out of the filter disc and air through, after all the liquid from the spoon had been 
removed. All four filter times and processes were considered likely to be acceptable to 
IDUs. All four filters took on a brown appearance on use with undissolved material 
obviously attached to the makeshift filters and drawn into the tip of the SF.
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The results from the filter experiments on heroin injections are given in table 4.9.
Unfiltered
injection
Cigarette
filter
Hand
rolling filter
Cotton bud 
filter
Syringe
filter
N avg. 2326 487 225 255 63
Particle size d is tribu tion : avg.num ber o f partic les (% o f to ta l N)
2 -5  pm 1895 (81.5) 477 (98.0) 210(93.3) 208 (81.6) 59 (93.7)
5 •10  pm 347 (14.9) 6(1.2) 11 (48.8) 32 (12.5) 3 (4.8)
\
10-20  pm 7 (0.3) 4 (0.8) 4(1.8) 11 (4.3) 2 (3.2)
20 - 50 pm 14 (0.6) 0 0 5 (2.0) 0
Table 4.9 Average coincidence corrected particle count and average particle size distribution (shown 
to the nearest whole particle) in Injections prepared with street heroin (n = 3).
4.6.5 Effects of filters on Physeptone® injections 
Observations on use:
When the Physeptone® was mixed on the spoon with the water, the mixture was thick and 
had several clumps of undissolved tablet material in it. When attempts were made to filter 
it, only a small amount of liquid could be drawn through any of the filters immediately. The 
needle blocked in some cases and liquid had to be discharged to unblock it. With further 
filtration, larger quantities could be filtered, but this required longer time periods and
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several unblocking actions, giving an overall process considered to be unacceptable to 
IDUs. Therefore, the only preparations that were analysed were the unfiltered injections. 
These results are given in table 4.10.
Crush & mix on 
spoon
Split & shake in 
syringe
N avg. 40844 26009
Particle size distribution: avg.number of 
particles (% of total N)
2 - <5 pm 12613(30.9) 12937 (49.7)
5 - <10 pm 9239 (22.6) 4744 (18.2)
10 - <20 pm 17571 (43.0) 6729 (25.9)
20 - 50 pm 1356 (3.3) 1620 (6.2)
Table 4.10. Average coincidence corrected particle count and average particle size distribution  
(shown to the nearest whole particle) in injections prepared with Physeptone ' tablets (n = 3).
4.6.6 Effects of filters on D iconar injections 
Observations on use:
The Diconal® injections did filter immediately, with similar ease to the heroin. The filtration 
time and process was considered likely to be acceptable to IDUs.
The results are given in table 4.11.
4.6.7 Effects of filters on Temgesic® injections 
Observations on use:
The Temgesic injection filtered quickly with all four filters, again with similar ease to the 
heroin and Diconal® injections, so again were considered potentially acceptable to IDUs. 
The results are given in table 4.12.
9 7
Crush & mix 
on spoon
Split & 
shake in 
syringe
Cigarette
filter
Hand
rolling filter
Cotton bud 
filter
Syringe
filter
N avg. 21132 17520 16033 13662 14440 238
Particle size d is tribu tion : avg.num ber of particles (% of total N)
2 - <5 pm 6158 (29.1) 6498 (37.1) 8214(51.2) 6062 (44.4) 6131 (42.5) 233 (97.9)
5 •< 1 0  pm 5623 (26.6) 4471 (25.5) 4302 (26.8) 3819(28.0) 4224 (29.3) 4(1.7)
10 -<20 pm 8793 (41.6) 5971 (34.1) 3484 (21.7) 3738 (27.4) 4017(27.8) 1 (0.4)
20- 50 pm 778 (3.7) 582 (3.3) 34 (0.2) 44 (0.3) 56 (0.4) 0
Table 4.11 Average coincidence corrected particle count and average particle size distribution (shown 
to the nearest whole particle) in injections prepared with DiconaP tablets (n = 3).
Crush & mix 
on spoon
Split & 
shake in 
syringe
Cigarette
filter
Hand-rolling
filter
Cotton bud 
filter
Syringe
filter
N avg. 20121 16491 16460 12587 9893 32
Particle size d istribu tion : avg.num ber o f particles (%) ‘
2 - <5 pm 1904 (9.5) 1695 (10.3) 2505 (15.2) 2204(17.5) 2514 (25.4) 25 (78.2)
5 -<10 pm 6209 (30.9) 5581 (33.8) 7010(42.6) 4650 (36.9) 3490 (35.3) 5(15.6)
10 - <20 pm 11632 8643 (52.4) 6862 (41.7) 5460 (43.4) 3757 (38.0) 2 (6.3)
(57.8)
20 - 50 pm 378 (1.89) 574 (3.5) 84 (0.5) 273 (2.2) 132(1.3) 0
Table 4.12. Average coincidence corrected particle count and average particle size distribution 
(shown to the nearest whole particle) in injections prepared with Temgesic 0.2 mg tablets (n = 3).
It was observed that for all unfiltered injections prepared with tablets, some sediment 
remained at the bottom of the syringe barrel after the prepared injection had been 
discharged into glass vial. Although not quantified, the amount remaining from the 
injection prepared by splitting and shaking the tablets appeared visually to be greater.
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A series of graphs will now be presented which summarise the particle size data and 
compares the effects of the filters on particulate matter.
Figure 4.2 shows the average total particle counts for the experiments performed with 
each drug. The results obtained with the controls are included also. Figure 4.3 shows the 
same results but with the removal of the Physeptone® results which were very large, to 
allow clearer viewing of the other results. Since the injections prepared with tablets 
contained much greater numbers of particles compared to the injection prepared with 
heroin, the results of the work with heroin and the controls are shown again in figure 4.4a 
and with the control values removed in figure 4.4b. These are shown for clarity and 
because heroin was the main focus of this work.
45000 -I 
40000 - 
35000 - 
Z | 30000 - 
® 25000 -
S 20000 - >
<  15000 - 
10000 -  
5000 - 
0  - ■
S h a ke
E x p e r im e n ta l v a r ia b le
□  K e ttle
□  W FI
□  H e ro in
□  P hysep .
□  D ico n a l
□  T em ges.
C o tto n  SF
Figure 4.2 Average total number o f particles detected during standardised analysis o f samples from all 
drug injections and the controls (n = 3). Shake = shaken in syringe barrel, no filtration. S tir = stirred  on 
spoon then drawn into syringe, no filtration. Cig. = filtered through the cigarette filte r then drawn into 
syringe. Hand Roll. = filtered through the Hand-rolling tobacco filte r then drawn into the syringe. 
Cotton = filtered through the cotton bud then drawn into the syringe. SF = filtered though the syringe 
filte r then drawn into the syringe.
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S h a ke S t ir  C ig . H and R o ll C o tto n  SF
E x p e rim e n ta l v a ria b le
□  K e ttle
□  W FI
□  H e ro in
□  D ico n a l
□  T e m g e s.
Figure 4.3 Average total number o f particles detected during standardised analysis o f samples from  
heroin, Diconal' and Temgesic® 0.2 mg injections and the controls (n = 3). Abbreviations as fo r fig. 
4.2.
E x p e rim e n ta l v a r ia b le
□  K e ttle
□  W FI
□  H e ro in
Figure 4.4a Average total number o f particles detected during standardised analysis o f samples from  
heroin injections and the controls (n = 3). Abbreviations as fo r fig. 4.2.
100
Chapter 4
E x p e rim e n ta l v a ria b le
Figure 4.4b Average total number o f particles detected during standardised analysis o f samples from  
heroin injections (controls not shown) (n = 3). Abbreviations as fo r fig. 4.2.
Taking the total number of particles detected from the sample of unfiltered injections as 
100 %, the percentage reduction produced by each filter with each drug can be calculated. 
This is shown diagrammatically in figure 4.5. Note, the results from the unfiltered 
injections prepared by crushing the tablets and mixing the resulting powder on the spoon 
were taken as 100 % as this practice was used to prepare the filtered injections as it is 
advocated in safer injecting leaflets (Exeter Drugs Project, 1991, HIT, 1997).
□  S h a ke
□  C ig .
□  H and R o ll
□  C o tto n
□  SF
D ru g
Figure 4.5 Percentage reduction in the total number o f particles in filtered injections, taking the 
average total number o f particles in unfiltered injections to be 100%.
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To illustrate the effects of filtration on the particles in each size range, figures 4.6, 4.7 and
4.8 show the percentage change in particle count after filtration. A positive value shows 
the count was higher for the filtered injection and a negative value shows it was lower. 
Note for the heroin results, only the 2 to <5 pm and 5 to <10 pm data is shown as the 
number of particles in the larger size ranges were so low that the effects from the operator 
and environment were not considered distinguishable from the filter effects.
□  C ig .
□  H and ro ll.
□  C o tto n
□  SF
Figure 4.6 Percentage change in the number o f particles in each size range o f interest after filtration o f 
heroin injections by the filtration methods stated.
% c h a n g e  in  n o . o f 
p a rt ic le s  c o m p a re d  to  
c ru s h  an d  sh a k e n  
u n filte re d  in j.
2 t o < 5 u m  5 t o < 1 0 u m  10 to  <20 um  20 to  50 um
□  C ig .
□  H and ro ll.
□  C o tto n
□  SF
Figure 4.7 Percentage change in the number o f particles in each size range o f interest after filtration o f 
DiconaP' injections by the filtration methods stated.
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2 to  <5 um  5 t o < 1 0 u m  10 to  <20 u m  20 to  50 um
% c h a n g e  in  no. o f  
p a rt ic le s  c o m p a re d  to  
c ru s h  a n d  sh a k e n  
u n filte re d  in j.
O C ig .
□  H and ro ll.
□  C o tto n
□  SF
Figure 4.8 Percentage change in the number o f particles in each size range o f interest after filtration o f 
Temgesic injections by the filtration methods stated.
4.8 R esults: CZE analysis
4.8.1 Controls
No peaks were seen with any of the control injections prepared without the addition of 
heroin. This gave confidence that the peaks seen in the analysed injections were due to 
the drug and not other aspects of the preparation process.
4.8.2 Preliminary analysis o f street heroin
The initial analysis identified the IS peak and five peaks in the heroin sample at 220 nm. 
Overlaying the sample electropherogram with the standard and standard addition to the 
sample identified the first peak as morphine, the third peak as 6-MAM, the fourth peak as 
diamorphine and the final peak as papaverine. As papaverine would not contribute to the 
psychoactive effects of street heroin or be involved in diamorphine decomposition, it was 
not considered further (Parfitt, 1999). The second peak may have been acetylcodeine that 
was also noted to be common in heroin sample analysis reported in the literature (Love 
and Pannali, 1980, Kaa, 1991, Kaa, 1994), however, a standard could not be obtained to 
confirm this.
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Satisfactory separation of the peaks on the electropherogram was demonstrated by the 
preliminary analysis, with morphine eluting first at 6.40 minutes, followed by 6-MAM at 
6.55 minutes and diamorphine at 6.65 minutes. A heroin electropherogram is shown in 
appendix 11, part B.
The content of the three opiates of interest
diamorphine
6-MAM
morphine
in the street heroin sample was as follows: 
55.68 % w/w 
6.64 % w/w 
3.60 % w/w
4.8.3 Linearity
The results of the linearity checks are given in table 4.13
Std cone. Peak Height Correlation Slope Intercept
(ngm l'1) Ratio co-effic ient (+/- SD)
Diamorphine
0.0 0.00
11.54 1.45
23.0 3.12 0.997 0.14 -0.12
34.5 4.39 (3.63x1 O'3)
46 6.31
57.5 8.02
6-MAM
0.0 0.0
1.0 0.18 0.993 0.11 0.04
5.0 0.59 (4.61 x10"3)
10.0 1.12
Morphine
0.00 0.0
2.5 0.31 0.997 0.11 1.80x102
5.0 0.54 (3.26x1 O'3)
10.0 1.07
Table 4.13. Results of the linearity checks performed for the CZE equipment
The linear response graphs are shown in figures.4.9a and 4.9b. Diamorphine is shown on 
a separate graph for clarity as the concentration range used was much greater than that
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tested for 6MAM and morphine. Note the slope of the diamorphine line differs from those 
of the 6-MAM and morphine because the concentration of IS that was added differed from 
that used for 6-MAM and morphine.
9 -
Figure 4.9a Linear regression graph fo r diamorphine
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Fig. 4.9b Linear regression graph fo r 6-MAM and morphine
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4.8.4 Validation
4.8.4.1 Within day variation
The within day validation results are given in table 4.14.
A vg.peak 
height 
ratio  (n = 3)
RSD % Avg. m igration 
tim e 
(n = 3)
RSD %
Diam orphine 0.72 1.39 6.95 1.25
6 MAM 0.78 1.28 6.78 1.53
M orphine 0.90 1.92 6.62 1.15
Table 4.14. Within day validation results
4.8.4.2 Day-to-day precision
The results for the day-to-day precision check are shown in table 4.15
A vg.peak 
height 
ratio (n = 4)
RSD % Avg. m igration 
time 
(n = 4)
RSD %
\
Diamorphine 0.88 1.14 6.41 1.61
6 MAM 0.92 2.28 6.30 1.83
Morphine 1.02 2.61 6.14 1.22
Table 4.15. Day to day validation results.
4.8.5 Injection analysis
4.8.5.1 Amount of drug detected in injections
The peak height corresponding to morphine was too small to allow accurate calculation at 
the sensitivity required for the diamorphine and 6-MAM. The time between the detection 
of the 6-MAM and the morphine peaks was short (approx. 0.15 second), making it 
impractical to change the sensitivity before the morphine peak (this would have increased 
peak size). The comparatively small morphine peak suggests that the quantity of
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morphine in the resulting injections was small compared to the quantities of diamorphine 
and 6-MAM, hence its contribution to the psychoactive effects would be small. 
Calculations were performed for diamorphine, 6-MAM and morphine, but the purpose of 
calculating for morphine was only to check for any large increases, which would indicate 
degradation. The calculated quantities in the resulting injections for each experiment are 
shown in table 4.16.
It was observed that some insoluble material remained on the spoon after filtration with 
the makeshift filters. This material was solid in nature, with an appearance that could be 
likened to wet sand. Liquid was observed to be drawn from it during the filtration process. 
When removed from the spoon, the filters were observed to have some of this solid 
material attached to them also. Discussion of this matter with two ex-IDUs identified that 
in their experience, presence of this material may lead to the addition of further acidifier 
and water during preparation. Alternatively, the remaining material on the spoon and filter 
may be used to produce a second injection, possibly given to another IDU who does not 
have their own drugs.
The syringe filter was observed to behave like a vacuum cleaner, in that most of the solid 
material was drawn from the spoon towards the syringe. This material formed a plug in 
the nozzle of the filter, which was removed with by flushing methanol from the syringe 
through the filter, when the filter remains were removed for analysis It could also be 
removed by the expulsion of air from the syringe through the filter.
4.8.5.2 Statistical comparison of diamorphine content
Tukey’s HSD test (95% c.i, one-way) showed there to be significant differences Detween 
the amounts of diamorphine in the injections filtered with the hand-rolling filter and the 
injections filtered with both the cigarette filter and the cotton bud. From table 4.22 it can 
be seen that the quantity in the hand-rolling filter injections would be statistically less. 
There was no significant difference between the syringe filter and any of the makeshift 
filters.
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Quantity o f drug in resulting in jection (mg)
Cigarette filte r Hand-rolling filte r Cotton Bud Syringe filte r
Diamorphine
Expt.1 31.16 21.65 27.72 29.94
Expt. 2 30.06 24.75 27.49 18.69
Expt. 3 27.42 16.76 27.84 27.53
Expt. 4 29.09 24.06 27.96 26.38
Expt. 5 25.89 18.80 30.93 25.55
mean 28.72 21.20 28.39 25.62
SD 2.10 3.41 1.43 4.21
6-MAM
Expt. 1 8.86 7.83 8.72 6.27
Expt. 2 7.75 7.10 9.10 4.62
Expt. 3 7.26 4.97 8.72 7.99
Expt. 4 7.88 7.53 9.36 7.05
Expt. 5 7.61 5.59 8.52 8.71
mean 7.87 6.60 8.88 6.93
SD 0.60 1.26 0.34 1.59
Morphine
Expt.1 0.63 0.66 0.61 0.52
Expt. 2 0.53 0.78 0.61 0.31
Expt. 3 0.85 0.52 0.48 0.62 t
Expt. 4 0.64 0.54 0.73 0.52
Expt. 5 0.54 0.54 0.72 0.72
m ean  0.64 0.60 0.63 0.54
SO 0.13 0.11 0.10 0.15
Table 4.16 Quantities of diamorphine, 6-MAM and morphine In resulting injections filtered using the 
stated methods (Each sample was analysed three times and the average taken).
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4.8.6.1 Amount of drug released from used filters
Table 4.17 shows the amount of diamorphine released from the used filters
Q uantity o f d iam orphine released from  filte rs  (mg)
Cigarette filte r Hand-rolling
filte r
Cotton Bud Syringe
filte r
Expt.1 7.31 8.37 8.27 16.05
Expt. 2 8.38 8.56 7.63 23.02
Expt. 3 13.37 13.78 8.96 17.75
Expt. 4 7.62 9.13 6.84 18.09
E x p t 5 6.30 13.71 9.15 16.37
mean 8.60 10.71 8.17 18.26
SD 2.77 2.78 0.96 2.80
Table 4.17. Amount of drugs released from the used filters (Each sample was analysed three times 
and the average taken).
4.8.6.2 Statistical analysis
Tukey’s HSD test (95% c.i, one-way) showed there to be a significant difference between 
the amounts of diamorphine released from the syringe filter and the amount released 
from all three of the makeshift filters. From table 4.17 it can be seen that the quantity 
released from the syringe filter was significantly greater than the makeshift filters. No 
significant differences were found between the makeshift filters.
4.8.6.3 Weight differences before and after filter use
The mean difference in weights of the filters before and immediately after use is given in 
table 4.18.
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C igarette
filte r
H and-ro lling
filte r
C otton
bud
Syringe
filte r
mean w e ig h t d iff. 66.66 225.40 .80.58 262.53
(mg)
SD 8.54 86.26 19.09 62.10
T a b le  4 .1 8 . D if fe r e n c e  in  w e ig h t  o f  f i lte rs  b e fo re  a n d  a f te r  u s e , fo r  e a c h  e x p e r im e n t  (n  = 5).
4.8.7 Results of the experiments to study the effects of acidifiers
4.8.7.1 Varying quantities of citric acid
Table 4.19 shows the mean amount of drug in the resulting injections prepared using the 
stated quantities of citric acid The results are illustrated graphically in figure 4 10
C itric  acid q ua n tity Q uan tity  o f 
d ia m o rph in e  in 
re su ltin g  in je c tio n  (mg)
3  m g m e a n 6.47
S D 0.62
7 m g m e a n 13.90
S D 1.42
1 5  m g 5 m e a n 28.72
S D 2.10
3 0  m g m e a n 53.62
S D 1.29
T a b le  4 .1 9  M e a n  q u a n t i ty  o f  d ru g  in  in je c t io n s  p r e p a r e d  u s in g  th e  s ta te d  q u a n t it ie s  o f  c itr ic  a c id  a n d  
th e ir  c o r re s p o n d in g  s ta n d a r d  d e v ia t io n s  (n  = 3).
5 The results quoted for 15 mg citric acid are from the filter comparison experiments, cigarette filter results The mean 
quoted is the mean of the five experiments that were performed.
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3 m g 7 m g 15 m g 30 m g
Q u a n tity  o f  c it r ic  a c id  added
F ig u re  4 .1 0  E ffe c t o f  q u a n tity  o f  c itric  a c id  on d ia m o rp h in e  co n c e n tra tio n  in  in je c tio n s  (n  = 3).
4.8.7.2 Varying quantities of ascorbic acid
Table 4.20 shows the mean amount of drug in the resulting injections prepared using the 
stated quantities of ascorbic acid. The results are illustrated graphically in figure 4.11.
A s c o rb ic  ac id  q u a n tity Q u an tity  o f d ia m o rp h in e  in 
re s u ltin g  in je c tio n  (mg)
1 5  m g m e a n 9.80
S D 0.59
6 0  m g m e a n 46.93
S D 2.56
Tab le  4 .2 0  The m e a n  q u a n tity  o f  d ia m o rp h in e  in  in je c tio n s  p re p a re d  u s in g  th e  s ta te d  q u a n tities  o f  
as c o rb ic  a c id  a n d  th e ir  c o rre s p o n d in g  s ta n d a rd  d ev ia tio n s  (n  = 3).
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Q u a n tity  o f  a s c o rb ic  ac id  added
F ig u re  4 .11  E ffe c t o f  q u a n tity  o f  a s c o rb ic  a c id  on d ru g  c o n c e n tra tio n  in  in je c tio n s  (n  = 3).
4 .8 .7 .3  pH
The pH meter was checked for accuracy using acidic and alkali standards of known pH 
prior to measurement of the pH of the 15 mg citric acid injections. Accuracy was later 
checked after the 3 mg and 7 mg measurements, however, the meter was found to be 
giving inaccurate results. It was re-calibrated and checked prior to the measurement of the 
30 mg citric acid and ascorbic acid injections. Due to the likelihood of inaccuracies in the 3 
mg and 7 mg results, they have been excluded from this work. The results are shown in 
table 4.21.
A c id if ie r pH
n o  a c id 7.5
1 5  m g  c it r ic 6.3
3 0  m g  c it r ic 5.8
1 5  m g  a s c o r b ic 6.7
6 0  m g  a s c o r b ic 6.2
Tab le  4 .21. p H  m e a s u re m e n ts  fro m  s e le c te d  a c id ifie r  in v e s tig a tio n s  (n  = 3).
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4.8.7.4 Amount of water varied and identification of opiates lost in preparation 
process.
When the volume of water was increased to 1.2 ml, the effect on the amount of 
diamorphine in the resulting injection is shown in table 4.22. Including the results using 0.8 
ml of water, this can be represented graphically, as shown in figure 4.12.
A m o u n t  o f  w a t e r  a d d e d  Q u a n t i t y  o f  d ia m o r p h in e  in
r e s u l t in g  in je c t io n  (m g )
1 .2  m l m e a n 28.99
S D 2.78
Tab le  4 .2 2  A v e ra g e  a m o u n t o f  d ia m o rp h in e  d e te c te d  in  in jec tio n s  p re p a re d  w ith  1 .2  m l w a te r (n  = 3).
50
.72 <n =  5 > 28.9$(n =  3 )
0.8 m l 1.2 m l
V o lu m e  o f  w a te r  a d d ed
F ig u re  4 .1 2  E ffe c t o f  va ry in g  q u a n tity  o f  w a te r  on  a m o u n t o f  d ia m o rp h in e  d e te c te d  in  re su ltin g  
in jec tio n s .
The spoons, the washings from the watch-glass and the needle sheaths all tested positive 
for diamorphine.
1 1 3
4.9 Chapter summary
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The methods used to conduct the laboratory investigation into aspects of the injection 
preparation process have been described in this chapter, followed by the results from 
these experiments. The results showed that the Acrodisk® syringe filter achieved much 
greater reductions in particle content of the injections than the makeshift filters. There 
was no statistical difference between the amounts of drug in the Acrodisk®-filtered 
injections and any of the injections filtered with the makeshift filters. Although the amount 
of drug removed from the used Acrodisk® filters was statistically greater than that 
removed from any of the makeshift filters, observation suggested that the Acrodisk® 
‘sucked up’ drug that remained on the spoon when the makeshift filters were used. These 
results suggested that the Acrodisk® might be more appropriate than the makeshift filters 
used by IDUs. The next stage in this study was to establish the acceptability of the 
Acrodisks® to IDUs. This work is presented in the next chapter.
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Chapter Five
The user acceptability pilot study
5.1 The in itia l research concept
As said in chapter one (1.3.1), at the beginning of this project, it was proposed that after 
the laboratory study, the work would continue to establish whether the most effective filter 
in the laboratory was acceptable to IDUs. If it proved to be acceptable, the work would 
then go on to establish the health outcomes from its supply. It is also explained in chapter 
one (1.3.2) why it was not possible all this work to be done. The importance of 
undertaking a small pilot study where the supply and use of the filters was tightly 
controlled during their initial distribution, for safety reasons, became evident to the 
researcher as more experience was gained in the field. With the time and resources 
available is was possible to undertake this pilot work as part of this study, leaving the full- 
scale user acceptability study and health outcomes work for future research. What follows 
is a description of the pilot study that was carried out.
5.2 M ethodological considerations
5.2.1 Legal approval of filter distribution
As said in chapter two, section 2.7, the distribution of filters to IDUs is illegal. Therefore, 
permission had to be obtained from the Procurator Fiscal (PF) in Grampian to allow 
distribution with exemption from prosecution. Details of the proposed study, including the 
pilot study, were submitted to the PF’s office, who referred the matter to the Crown Office 
in Edinburgh. The Crown Office liaised with the Chief Scientist at the Scottish Office. 
Initially, permission to conduct the pilot study was applied for, with the aim of extending 
this application to allow a full-scale study once the pilot study results were available. 
Eleven months after the initial contact, the PF was able to grant approval for the pilot 
work. A copy of the approval letter is given in appendix 12.
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The pilot project was designed to contain several safety precautions. Although the 
laboratory data suggested that the SF would remove large amounts of particulate matter 
without significantly changing the amount of opiates in the prepared injections, this data 
related to one quantity of heroin tested. The researcher could not control the quantity, 
purity and content of heroin and amount of acid used in the IDUs environment. For this 
reason, safety precautions were in-built into the pilot study recruitment process, to 
minimise the risk of any harm resulting from the use of the SFs. At later stages in a large- 
scale evaluation these could be relaxed, if appropriate. These safety measures are 
described in 5.3.2, where participant inclusion criteria are discussed. In-building the safety 
precautions influenced the study design. The participants had to be heroin injectors, 
recruited from somewhere where the researcher could access information on their self 
reported drug use and gauge their reliability in providing follow up information. The 
researcher also had to spend time with potential recruits to confirm their suitability for 
inclusion. On this basis, sampling for inclusion had to be done on a quota rather than 
random system. For these reasons, the collaborating agency on this project, Drugs 
Action, was chosen as the base for this study. Details of self reported drug use is 
recorded on clients needle exchange cards and private rooms are available for 
consultation. Anonymity of participants was not considered acceptable as follow up could 
not be initiated by the researcher, if the participants failed to report in the allotted time. 
Therefore, the researcher had to be explicitly clear regarding the confidentiality of the 
personal information provided and what action would be taken in the event of failure to 
report. Data collection from the participants had to be quick and simple. It was not 
practical for the researcher to be present at DA during all opening hours after the filters 
were distributed, to await the client’s return. Therefore, a paper-based questionnaire was 
chosen as the method of data collection. Completion of the questionnaire was overseen 
by the needle exchange workers, therefore the participants had to be clear that the 
workers would be aware of their inclusion in the study, and that this information would be 
kept confidential by the researcher and DA. The notional target number for inclusion in 
the pilot study was ten.
5.2.3 Ethical approval
The study design and proposed procedures were submitted to and approved by the Joint 
Ethical Committee of Grampian Health Board and the University of Aberdeen. The remit 
of the committee has been previously described in chapter 2. A copy of the submission
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form and approval letter is given in appendix 13. All relevant paperwork, including the 
participant information sheet, study protocol, participant instruction sheet and consent 
form was included with this application. They are discussed in detail in further sections of 
this chapter, where referral is made to the appropriate appendices in which they can be 
viewed. The Ethical Committee raised three question relating to the application, which 
were (i) clarification of the proposed method of filter disposal, (ii) the position of RGU on 
project audit by external bodies and (iii) inclusion in the participant information sheet of a 
statement to say that participation or refusal to participate would not impinge on the 
services received from Drugs Action. These issues were addressed, disposal of the filters 
is described in the methods section, and the final approval granted, as shown in appendix 
13.
5.3 Methods
5.3.1 Drugs Action staff team approval
The DA staff team approved the proposed study design during a team meeting, where the 
researcher explained the study and discussed relevant issues with the drugs workers.
5.3.2 Criteria for inclusion
5.3.2.1 Not be under medical care for drug problems
Ethically and for safety, it was decided that the people recruited to test the filters were not 
to be under medical care for a drug problem i.e. not receiving a prescription for substitute 
medication. The Ethical Committee require that if a person is included in a study that may 
affect their health, other health care providers who provide them with care should be 
informed of the study. This notification would mean client confidentiality could not be 
maintained. Also, the risk of overdose is higher if heroin is used in addition to prescribed 
substitutes such as methadone, so for the pilot study such people were excluded to avoid 
any implications for the researcher.
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5.3.2.2 Agree not to use other drugs at the same time
Again for safety reasons, the participants had to agree not to take other drugs at the 
same time as they administered the heroin injections filtered-with the SF. They also had 
to agree only to use the SFs for heroin injections.
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5.3.2.3 Have an established dependence on heroin
The laboratory study showed that the SF removed the majority of particulate matter from 
the heroin injections without causing any significant change in the amount of opiates 
present. However, only one scenario could be tested in the laboratory and the preparation 
methods used by the participants could not be controlled. To minimise the risks from any 
significant difference between the amount of opiates in the SF injections compared with 
the participants usual filters, especially any significant increase and to exclude new 
injectors who potentially may be using on a more recreational basis and not have an 
established opiate tolerance level, the following criteria were set. The participants had to 
have been injecting heroin for at least three months, they had to be habitual users, 
defined as injecting at least twice a day and using at least one £20 bag of heroin per day. 
Participants also had to agree not to test all filters on consecutive injections, but to use 
the SFs for one in every four injections or less frequently.
5.3.2.4 Agreement to adhere to study requirements
The participants had to be willing to follow the given instruction sheet (5.3.4) and dispose 
of the filters in the cin bin provided. They also had to agree to provide feedback on their 
experiences with the filters including notification if they withdrew from the study. They also 
had to agree not to give the filters to anybody else, as they may not meet the safety 
requirements. Lastly, they had to agree not to reuse them, as this had not been 
investigated in the laboratory and may be unsafe.
5.3.2.5 Frequent attendees with good return rates at the DA needle exchange
To maximise the chances of receiving participant feedback and ensuring safe disposal of 
the injecting equipment and filters that were distributed, the clients had to be frequent 
attendees of the DA NX with a good record of returning used equipment. This was
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defined by the researcher as visiting at least once a fortnight and returning at least 50 % 
of the number of needles with which they were issued. This percentage was an arbitrary 
choice of value that the researchers considered indicated an acceptable level of reliability 
to return used equipment. Also, clients had to be current users of the NX, which was 
defined as having visited in the past two weeks. The maximum number of sets of injecting 
equipment allowed to be issued under the Lord Advocate’s guidelines is fifteen per visit, 
so in practice, a regular heroin injector may attend the NX every two or three days if they 
do not use pharmacy NXs.
5.3.3 Identification of potential recruits
Explaining the outline of the study to every DA NX client, asking if they were willing to be 
considered for inclusion, then going through the protocol with them to assess suitability 
was not considered an appropriate way to recruit the quota sample for the pilot study. The 
reason for this was (i) It was known that a large-scale study could not follow on 
immediately from the pilot study, as the time span for this project was almost finished. 
Informing all NX clients that filters were being distributed for investigation may have 
created a false expectation amongst IDUs that filters were or would shortly be available 
from DA. (ii) The time involved in doing so would be unreasonable from both the 
researchers point of view and the use of the private rooms at DA. Instead, clients were 
identified who could be targeted for inclusion, using two methods. >
5.3.3.1 Identification by drugs workers
DA workers were told of the inclusion criteria, asked to consider their client case load and 
inform the researcher if they knew of any potential recruits. If the client was known to use 
the NX, the drugs worker gave their card to the researcher. If the client was not known to 
use the NX i.e. if they received home visits, the researcher gave the worker an 
information sheet for potential recruits and asked them to discuss with their client whether 
they would be willing to meet with the researcher to discuss the study further.
5.3.3.2 Identification by the researcher
Clients who use DA are identified only by their initials and date of birth. These are marked 
on their NX card. The cards are filed alphabetically, according to surname first initial and
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then by first name first initial, in two drawers of a large filing cabinet. A copy of one side of 
a blank NX card is given in appendix 14. Non-numerical information is recorded using a 
coding system. From a client’s record, details of the drugs they use by injection and a 
history of their attendance and return rate at the NX established. The researcher reviewed 
the DA NX cards and identified all clients who fitted the inclusion criteria described in 
5.3.2, which could be established from the cards. A yellow adhesive label with the words 
‘Possible for Filter Study’ written on it, was attached to the card.
The marked cards were replaced in the NX cabinet. When a client with a marked card 
attended, the NX worker gave the client an information sheet on the study, described in 
5.3.4. The sheets were stored in a pocket attached to the side of the filing cabinet. The 
worker marked the adhesive sticker to indicate that this had been done. The next time the 
person presented, they were asked by the worker if they were interested in participation. 
If they indicated they were, contact with the researcher was arrange, as described in 5.3.5
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5.3.4 Information sheet
The double-sided information sheet for potential recruits detailed the purpose of the 
study, explained who was carrying it out and summarised the inclusion criteria. It assured 
confidentiality within the agency and that inclusion or refusal to take part would not alter 
the service received from Drugs Action. A copy of the sheet is given in appendix 15. This 
was included in the Ethical Committee submission (5.2.3).
5.3.5 The recruitment process
All worker activity and DA appointments are recorded in the agency diary, which has a 
day per page divided into a section for each worker plus one extra anonymous slot. With 
the agreement of the team, the researcher used this anonymous slot to indicate whether 
she would be present or absent at all sessions over the four week period allocated for the 
study. This allowed staff to give potential recruits details of guaranteed times when the
researcher would be in the agency.
%
On meeting, the researcher outlined the study and explained that the inclusion criteria 
would be checked by asking a series of questions. The IDU was discreetly asked if they 
were comfortable reading and following printed information, to identify difficulties in 
following the instruction sheet and highlight that instruction had to be followed. It was
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explained that name and contact details were required for safety, and emphasised that 
this information would be kept confidential to the researcher and not shared with the DA 
staff or any third party. Assurance was given that this information would be destroyed 
once the person had made a further visit to DA and returned their filters, either used or 
unused. It was also explained that knowledge of who was included, in terms of initials and 
date of birth, would be known to the NX workers using the cabinet. It was ensured that at 
this point the option to decline was given, in case the IDU felt uncomfortable with this. It 
was ensured that it was clear that the researcher had special permission to distribute 
filters for the study and explained it was still illegal to distribute filters, so the results from 
the study would not mean that filters could then be given out by DA. It was also stressed 
that detachable syringes would have to be used, to again give the IDU the opportunity to 
decline if this was unacceptable. It was explained that a short questionnaire would have to 
be completed the next time the participant attended the NX and emphasised that this 
could not be taken away. If the person was keen to participate, the flow-chart ‘Inclusion 
criteria for volunteers’ shown in appendix 16 was used to determine suitability. This chart 
was included in the Ethical Committee submission.
If the person fitted the inclusion criteria, they were asked if they wished to test a filter with 
water to help them decide if they wished to participate in the study. This allowed them to 
assess the filters for possible ease of use within their injecting procedure, including the 
use of detachable syringes.
IDUs who remained keen to test the filters were then asked if they were prepared to test 
the filters according to the instruction sheet, and given a copy to read (appendix 17). This 
sheet was included in the Ethical Committee submission. If they agreed, they were told to 
keep the sheet for reference.
5.3.6 Informed consent
A consent form, which complied with Joint Ethical Committee requirements, was 
designed. It is included with the ethical application in appendix 13. A copy was signed by 
each recruit and kept in a locked cabinet until the study was over, then destroyed by 
shredding. A blank copy was included in the Ethical Committee submission.
\
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5.3.7 Filter distribution.
The name by which the participant was known and their contact details were recorded by 
the researcher. Their initials and date of birth were noted to allow their NX card to be 
located. Each participant was assigned a number. The researcher emphasised that an 
honest evaluation of the filters was required, therefore, if the participant did not like them, 
it was important to say so and that this was just as important as knowing if they were 
liked. It was stated that the recruit did not have to agree to test all four SFs given. Both 
used and unused filters had to be put into the cin bin provided and returned to DA. They 
were told they would be asked to confirm this on return.
The opportunity to ask questions was given. Recruits were reminded that they were free 
to withdraw at any time without giving a reason. All that was asked was that they reported 
on their next visit that they had withdrawn so this could be noted by the worker on the 
sticker on their NX card. Recruits were given four packaged SFs of the type tested in the 
laboratory, four detachable barrels and four needles, in the size of their choice. Four 
swabs and two cin bins, one for filters and one for needles, were offered. If the recruit 
stated they already had a cin bin, they were given one for the returned filters. Recruits 
were also offered a copy of the booklet 'The Safer Injecting Handbook' by Derricott and 
Preston (1997).
5.3.8 The data collection tool
5.3.8.1 Questionnaire design
A copy of the questionnaire is shown in appendix 18. It was important for the 
questionnaire to be short and uncomplex to encourage accurate self-completion, as 
advocated by Bailey et al (1995). Closed questions were used to establish facts, followed 
by open questions to gather opinions on the SF experience.
Firstly it was established what kind of filter was usually used by the recruit. Next the 
number of SFs that were tested was asked. If not all the filters were used it was asked 
why this was so. ..Next it was asked what injecting sites were currently used This was 
important, as users of deep veins may already use two-piece equipment, as longer 
needles may be required, so the SF may be less disruptive to their current practice. To 
check this, they were next asked if they usually use insulin syringes. If they did, they were 
asked if they found detachable needles a problems and if so, to explain the problems.
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Next the participant was asked to state any problems they had using the SF. It was then 
asked if the feeling experienced from the injection were any different when the SF was 
used, and if yes, to explain. Next, volunteers were asked to compare the SF with their 
usual filter for ease of use. They were then asked to decide whether they thought the SF 
or their usual filter was better or if there was no difference and to comment on why they 
thought this. They were then asked if they thought other users would require practice to 
get used to using the SF. Finally, they were asked whether they would prefer their usual 
filter or the SF to be distributed by NXs, if the law was changed The opportunity to make 
further comments was given.
5.3.8.2 Validation
The completed questionnaire given had the recruit number on it so validation using one 
question could be carried out. After the questionnaires were completed, the researcher 
accessed the clients NX record to establish whether or not insulin syringes were the 
predominant type collected and this information compared to their response to Q. 4.
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5.3.8.3 The data collection process
After a volunteer was recruited into the study, the researcher attached a numbered 
questionnaire (5.3.9) in an envelope to their NX card. This number corresponded to their 
recruit number. The envelope had the client’s recruit number written on it, in case it 
became detached. The next time the recruit came to the NX they were asked by the 
worker to complete the questionnaire in one of the adjoining rooms. Recruits put the 
completed questionnaire back in the envelope, sealed it and gave it to the duty worker 
who put it in a collection pocket in the NX filing cabinet. The worker asked for the cin bin 
used to dispose of the filters or the unused filters and noted on the adhesive sticker what 
was received. Unused filters were left with the completed questionnaires.
5.3.8.4 Data analysis
The closed question responses were quantified. The open questions analysed to identify 
the opinions expressed, noting any similarities and differences. Although no conclusions 
can be drawn from a pilot study, and indication of the feasibility of future research could 
be gained and the need for modification of the methods used.
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5.3.9 Appreciation of involvement
Before they left the NX, the duty worker gave the recruit a sealed envelope that was 
attached to their NX card. This contained a £5 gift voucher for a local supermarket and a 
university compliments slip, thanking them for their participation.
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5.4 Results
5.4.1 Recruits
The recruitment period lasted two weeks. Fourteen information sheets were distributed to 
potential recruits during this time. It was not recorded how many people with marked NX 
cards were told about the study but did not wish further information Seven people who 
considered themselves suitable for inclusion expressed an interest in participation so 
discussed recruitment with the researcher. Of these six people were recruited into the 
study. One person declined to participate as she did not wish to use detachable needles 
and syringes. Recruit details are given in table 5.1.
Recruit number Sex Age
1 Female 33
2 Male 22
3 Male 38
4 Male 36
5 Male 26
6 Female 25
Table 5.1. User evaluation of filters: participant demographics
All recruits except no. 5 tested the filters at DA with water prior to inclusion. No. 5 did not 
wish to do this as he considered handling needles would make him ‘rattle’ which means 
bring on feelings of wanting to inject. All recruits asked questions about the filters when 
given the opportunity, these included questions about whether the filters were known to 
retain drug and questions about why they could not be distributed by NXs.
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All recruits returned to the needle exchange within two weeks, so the researcher did not 
have to initiate contact for follow up. All recruits were reported by the NX worker as 
having disposed of their filters in their cin-bins, which included the unused filters and other 
injecting equipment.
All the recruits showed an active interest in the study and were keen to offer suggestions 
on the types of filters that they perceived would be acceptable to IDUs. For example, one 
drew diagrams of his ‘ideal’ filter, including dimensions. Others described the concept of 
providing filters as welcomed, expressing a desire for something to reduce the number of 
injecting injuries experienced and help preserve veins. Some of the recruits were reported 
by drugs workers to have discussed their participation in the study with them further.
5.4.2 Questionnaire results
5.4.2.1 Usual filters used and injecting sites used with the SF injections
All six recruits reported usually using a cigarette filter to filter their heroin.
Six different injection sites were reported by the recruits to have been used when they 
tested the SFs. Users of peripheral veins (arms, hands and feet) reported using more 
than one site. Users of larger veins (groin and neck) only used one site. The sites and 
number who reported using them are given in table 5.2. ,
Recruit number Sites reported
1 neck
2 arms and hands
3 arms and feet
4 groin
5 arms and hands
6 groin
Table 5.2 Injection sites reported to be used when administering SF injections
\
5A.2.2 Validation question
All six recruits reported usually using insulin syringes usually (Q.4). The needle exchange 
records confirmed this to be the case for all recruits. Recruits nos. 1, 2, 4 and 6 had in
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addition received detachable needles and barrels, but the quantities of insulin syringes 
received were greater.
5.4.2.3 Use of detachable needles and syringes
When asked if it was a problem to use detachable needles and syringes, three people 
stated it was not a problem, with no further comment. One person (No. 3) stated it was 
not a problem but added they had a preference for insulin syringes because they 
considered there to be a greater risk of detachable needles being inadvertently left lying 
around. Two people said using detachable needles and syringes was a problem, for two 
different reasons. One person (No. 1) said detachable needles were difficult to attach and 
they worried they may detach in use. The other person (No. 2) said he found it more 
difficult to access smaller veins as he believed the orange needles to be thicker.
5.4.2.4 Use of syringe filter
\
Four people used all four SFs and two people used two SFs. The four who used all SFs 
reported they had no problems using them in Q.6. The two people who used two filters 
only (recruits No. 3 and 5) reported they did have problems. For explanation of the 
problems, both respondents referred to their answers given under the reasons why they 
did not use all the SFs (Q.2). The reason given by both for this was that the filters 
retained too much fluid. This is illustrated by the statements given:
7 found it difficult to draw all the gear up into the works. [I] lost 2 out of 5 units 
which necessitated blowing it back out of the dirty end back into [the] spoon'.
Recruit no. 3
they kept in too much fluid’
Recruit no. 5
When asked if they considered the effects experienced from the injection to be any 
different when filtered through the SF (Q.7), three people stated they did not think there 
was any difference, without further comment. This included no. 3 who said the filter 
retained too much fluid. One person did not mark an option but inferred from his response 
written underneath the question that he did not experience any differing effects. He wrote:
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7 never noticed any physical difference but I felt better knowing that most of the 
impurities had been removed which would probably be more noted over a longer 
period of use'
Recruit no 2
Two people stated they did feel different effects. One wrote the injections felt 
‘stronger/cleaner’ (no. 1) and the other, who reported that the filters retained too much 
fluid, felt there was less drug in the resulting injection (no. 5).
When asked how easy the SFs were to use compared to the person’s usual filter, which 
was the cigarette filter in all cases, four people selected the option ‘A bit more difficult'. 
One person, who was one of the people who reported the filters retained too much fluid, 
reported them to be ‘much easier’ to use. One person said there was ‘no difference'.
5.4.2.5 Comparison of syringe filter with usual filter
*
When asked to compare the SF overall with their usual filter, the two people who used 
only two filters, stated they preferred their usual filter. One person said the reason for this 
preference was that there was more involved in the preparation stage when using the SFs 
(recruit number 3). The other person (recruit number 5) stated two reasons for his 
preference for cigarette filters. The first was that a cigarette filter can be broken down to 
release trapped drug, so used to prepare further injections. The second reason was the 
repeated statement that the SFs retain too much fluid, equated with retaining drug. Three 
people stated they preferred the SFs. Two people gave one reason and one person gave 
three reasons for this preference. All stated they thought the resulting injection was a lot 
‘cleaner*. This term is used amongst drug users to refer to the removal of materials 
perceived to cause adverse effects and injury. The person who gave other reasons stated 
they felt the SF will ‘keep injecting sites better’ and ‘last longer’. One person (recruit 
number 2) circled both ‘The syringe filter is better’ and ‘There is no difference’. Although 
this was unclear, under the comment section he referred to his response quoted in 5.4.2.4 
as his reply to Q. 7.
%
When asked if users would need a bit of practice with the SFs to get used to using them, 
three people said no. This included respondent number 5. Three people said yes, one 
added he thought this because of the length of time required to draw the liquid into the 
syringe.
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5.4.2.6 Distribution preference
When asked to say which kind of filters they would prefer to be available from needle 
exchanges if the law changed and it became legal to give out.filters, four people said they 
would prefer the SFs to be available. Two people, the respondents who reported 
problems using the SFs, said they would prefer cigarette filters to be distributed.
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5.4.2.7 Additional comments
Three people added additional information under the further comments section as follows:
‘The filters are a good idea I think, because they would, in my opinion, drastically 
cut down the risk of getting a ‘dirty’ hit’
Recruit no. 2
This recruit also expressed difficult with the SF because it obscured his view of the spoon. 
He described it as ‘too bulky’ and suggested it may be better if a filter could be found 
which was the ‘width of a finger’. He gave further detail by suggesting it would ideally be 
‘around 1.5 times the size of a cigarette end’.
\
I think the filters I used [were] very good..a lot better than cigarette filters
Recruit no. 4
7 have been using détachables to draw up [the injection] and then transferring to 1 ml 
insulin to inject. To prevent injuries and loosing limbs they /syringe filters/ should be 
supplied. [It] does seem to take some concentration/time to use them correctly'.
Recruit no 1
5.5 Chapter sum mary
This chapter has described the methods employed to conduct a pilot evaluation of user 
acceptability of the SFs and given the results from this work. The next chapter provides a 
discussion of all the work conducted for this part of the thesis, which has been presented 
in chapters three, four and five. Conclusions from this part of the thesis are also 
presented.
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Chapter Six
Discussion
6.1 Chapter form at
Each stage in the part one study is discussed chronologically in this chapter. Critique of 
the methods and discussion of the findings are both undertaken, but have not been 
separated. This was considered necessary to achieve continuity in the chapter format.
6.2 Selection o f the drugs fo r the laboratory investigation
Heroin was proposed as the main drug for this work as it was perceived to be the most 
common drug injected by IDUs. However, in order to confirm this, information had to be 
established on illicit drugs used by injection. Data was also sought on other drugs used by 
injection by IDUs, as it was anticipated that it would take time to arrange supplies of street 
heroin for this study. The basis for selecting these other drugs was their popularity and 
the identification of specific factors of interest. As it transpired another factors that 
emerged in their selection were the ability to identify specific strengths and formulations 
used.
6.2.1 Use of the 1994/5 Scottish Drug Misuse Statistics
Data had to be identified that would allow the researcher to establish the popularity of 
drugs injected by IDUs. The Scottish Drug Misuse Statistics (SDMS) were considered to 
be the most suitable source of information as the route of administration is recorded.
6.2.1.1 Limits of the SDMS
The limits of the SDMS are that they only report data collected from IDUs who have 
contact with services, so those not in contact with services will not be represented.
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Furthermore, they only record information from new contacts on drug use in the preceding 
month. Therefore, any changing patterns in use that occur in existing service contacts, for 
example due to interventions made by the service providers, will not be shown. Also, it 
may be that drug use in the month preceding contact is particularly chaotic, prompting the 
I DU to seek help. Given these facts, the SDMS may not represent injecting drug use in 
the population overall. However, the clear popularity nationally of heroin as the main drug 
used by injection over other drugs (81.4% against the second most popular main drug, 
buprenorphine at 8.5%) suggests that the limits of the SDMS may not be significant in 
confirming the drugs popularity. Also, in the 1996-7 statistics bulletin, a summary of the 
previous 5 years data showed popularity of heroin injecting by age group (ISD, 1998). 
Although a decline in injecting has been seen in all groups since 1994, coupled with an 
increase in heroin smoking since 1993, overall, injecting is still the main route of heroin 
use reported by those who stated the drug to be their main drug used. Data from SDMS 
statistics over several years were not pooled together to establish popularity as trends in 
drug use are known to change so the researcher wanted to use the most recent figures. 
For example, temazepam was the main drug used by 1% of new contacts in 1995/6 but 
popularity diminished to give a non-returnable figure in the 1996/7 statistics (ISD, 1998).
6.2.1.2 Lack of consultation with IDUs who use pharmacies only.
A further criticism of using the SDMS is that data is not gathered from pharmacy NXs, so
l
IDUs who access only pharmacy services will not be represented in these statistics. 
However, Tucker (1997) conducted interviews with users of pharmacy NXs in two 
locations. He found that 62 % of the pharmacy NX users were in contact with other drugs 
services. New contacts with services reported in the SDMS are likely to include 
information on the drugs used by some pharmacy NX users. Consideration was given to 
gathering information from users of pharmacy NXs and identifying those who do not 
access other services. The local NX pharmacies were not suitable for private consultation 
with IDUs and use of remote locations was not permitted by RGU and although attempts 
were made to contact people through methadone services who had not used an agency 
NX, this wasn’t pursued for the reasons in 3.1.4.2. It is a criticism of this work that further 
attempts were not made to contact IDUs who only used pharmacy NXs, for example 
through NXs with private facilities in other regions of Scotland.
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6.2.1.3 Accuracy of the SDMS
It was established after this information was used that there is bias in the SDMS. In 
Aberdeen, Drugs Action returned statistics, on all new contacts, including needle 
exchange users. However, discussion with the leader of the ISD drug misuse information 
strategy team established that DA was the only agency to do this. Other reporting 
agencies do not include data from clients who only use their NX service, so this group will 
be under reported (McWalter, 1998).
The accuracy of the SDMS relies on both accurate self-reporting from IDUs and accurate 
recording by service providers. As reported by Maddux and Desmond (1975) and 
discussed in chapter 3, section 3.1.4.1, there may be a tendency by drug users to 
withhold information which is considered unpleasing or will result in their detriment. Given 
that some data in the 1994/5 statistics was gathered by services that are likely to have 
power to influence outcomes for the drug user, for example GPs and penal 
establishments, there may be inaccuracies reported. However, data from years after 
1994/5 reports the data collected from penal establishments separately, but heroin still 
remains the main drug used by injection (ISD, 1998). Also, the drugs used may be 
considered less sensitive information that other questions on the SMR22/23 forms such 
as involvement in drug related crime. This may mean data on drugs used is subject to 
less inaccuracies in reporting (Maddux and Desmond, ibid). The significance of any 
recording errors by service providers is unknown.
6.2.1.4 Defence of the use of the SDMS
Despite these limitations, the SDMS were considered the most appropriate source of 
information on drugs used by injection. The Addicts Index, which was still actively used at 
the start of this work only gave information on the use of certain notifiable drugs, not all 
drugs used by injection, and only in those who sought medical help. In comparison the 
SDMS offered a broader range of information since there is the freedom to include all 
drugs, data is collected from a range of services including doctors, and reporting 
distinguishes injecting drug use. Also, it was mistakenly thought that to access this
information the researcher would have to travel to London. It is a criticism of the
-\
researcher that this was not investigated, as it is now known that selected data can be 
requested and sent by post. Other sources of such information on injecting focus on 
studies done in particular localities or with particular groups, such as young people, so do 
not represent the general injecting population and do not usually distinguish main drug
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from other drugs or quote statistics for the route of administration. The benefits of using 
the SDMS were that they allowed route of use and main drug used to be distinguished, 
which were important for this work. Also, the SDMS allowed data from 2040 IDUs to be 
considered whereas local studies represented smaller numbers. Local data was 
considered from the SDMS but the emphasis was placed on the national statistics.
6.2.1.5 Tablets used by injection
The overall popularity of injecting tablets as the main drug of misuse was seen to be small 
from the SDMS, however experience of having injected tablets at least once in the month 
preceding contact was large. Data on formulation was not available, so consideration 
could only be given to drugs where there was either only one formulation or there was 
information from other sources i.e. drugs workers and IDUs. For example, although 
morphine showed relative popularity compared to many other drugs (except heroin), it 
was not studied due to the great range of formulations. Information collection from drugs 
workers and IDUs is discussed below.
6.2.2 The role of data collected from IDUs and drugs workers In informing the 
choice of drugs for this work
Less emphasis was placed on the data on drugs used by injection collected from the 
drugs workers and IDUs than the SDMS data, as the SDMS provided information on a 
national level from a greater number of people. The worker data was mainly used to help 
the researcher become familiar with the drugs ‘scene’ and inform decisions in the 
absence of information from elsewhere. The IDU information was mainly used to give 
information on formulations used, which is unavailable from the SDMS and the injection 
preparation process. The SDMS report the main drug injected, but do not report the 
frequency that this represents, although this information is collected on the SMR form. 
The interviewees reported a range of injecting frequencies (3.3.4.6) from once or twice 
weekly to six times a day. A criticism of the interviewee schedule is that although 
frequency of injection was asked, in people who reported currently injecting more than 
one drug, the frequency for each drug cannot be assumed, as the frequency for each 
drug was not explicitly asked. People with the greatest length of time since first injection 
had injected a greater number of drugs, although the sample group is too small to 
conclude that this would apply in the whole IDU population. The data gathered from the 
drugs workers and IDUs did give support for the decision to select heroin as the main
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drug on which this study focused, as they also reported it to be the most popular drug 
used by injection.
Information on the strengths and formulations of pharmaceuticals injected came from the 
interviews with IDUs. Since this number was small (n = 20) in comparison to national 
statistics, it cannot be taken to be representative of all IDUs. Some IDUs interviewed 
reported that the type of tablets used by injection is influenced not only by the IDUs 
preference but also by availability, so this may be subject to frequent change. It cannot be 
assumed that the tablets used for this study, Diconal®, Physeptone® and Temgesic® 0.2 
meg, are the most popular tablets used by injection. What has been established is that 
they are used by IDUs, making their investigation applicable. It is a criticism of this work 
that the strength of the tablets injected was not explicitly asked in the IDU interviews, so 
the selection of the 0.2 meg strength had to be based on the assumption that since it was 
prescribed to a greater extent, more may be available for injection and its reported use by 
one interviewee.
6.2.3 The quantities of drugs used in the laboratory
6.2.3.1 Heroin
As explained in chapter three, section 3.4.2.1, difficulty was experienced in establishing 
the actual weight of ‘a quarter G’ of heroin, the most commonly reported amount used to 
prepare injections. Use of the actual weight of 250 mg was considered the best option for 
this work, since it was within the range of quantities thought by the police to be used for 
single doses. The weights seized by the police ranged greatly and the interviewees 
indicated that the quantity used may vary depending on the desired effect and the amount 
of drug available for the person and those whom they shared drug with (i.e. a partner). 
The weight used for this study represents one of the weights likely to be used by IDUs. 
Had a greater amount of heroin been available for this study, investigations using a range 
of weights used to test all four filters would have been undertaken. Information that has 
since come to the attention of the researcher on the World Wide Web from the National 
Criminal Intelligence Service (NCIS)1 details the selling prices of heroin per gram in many 
UK cities. Contact with the NCIS established that these units are approximate but the 
range of weights of a ‘£20 bag', which is another term for ‘a quarter G’, has a mode of 
approximately 200 mg (Silver, 2000). This suggests that the weights used in this work 
may have been above the most common weight for a ‘quarter G‘, however both the NCIS *
http Vram indy sghm s ac.uk/new s/prices htm
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and the local police forensic information suggested that 250 mg was still within the range 
of weights packaged for injection.
6.2.3.2 Tablets
The quantities of tablets used in the experiments represented the most commonly 
reported amounts used by the interviewees, but the sample size does not allow 
generalisation. Furthermore, given the varying factors identified that influence use and the 
nature of illicit drug use, it was considered impossible to establish any overall consistency 
in amounts injected. All that can be said is that the amount investigated in the 
experiments represented one possible scenario in the injection of these tablets.
6.3 Collection o f inform ation to inform the in jection preparation simulation  
process
6.3.1 The role of safer Injecting information and drugs workers
The safer injecting information and discussions with drugs workers allowed the 
researcher to become familiar with the stages involved in the preparation of illicit 
injections but did not provide any specific details such as quantities used. The stages 
identified from all safer injecting information and workers were consistently the same. 
However, to confirm their use it was considered prudent to collect information from those 
with first hand experience of preparing illicit injections.
6.3.2 The role of the data collected from IDUs
The data collected from IDUs allowed the stages in injection preparation process 
identified previously to be confirmed, which supported their use. There was no variation in 
the stages of heroin preparation reported by all the interviewees. However, greater 
variation was seen amongst those who injected tablets. The interviews were also 
necessary to confirm specific details of the injection preparation process. However, it can 
be questioned whether data from the numbers interviewed was sufficient to confirm these 
details, but further questioned whether with such a variable and uncontrolled process any
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consensus could ever be reached, even if much greater numbers were interviewed. This 
of course is unknown.
The analysis of injections prepared by IDUs, the use of ex-IDUs as observing advisors on 
the preparation process and non-participant observation of the preparation process were 
rejected for the reasons stated in chapter 3 (3.1.1 and 3.1.4.1). However, consideration 
was not given to using a simulation technique to establish the preparation processes 
used. Placebo tablets, ‘fake’ heroin, ‘fake’ acidifiers and other paraphernalia could have 
been provided within the drugs agency setting and the researcher could have asked IDUs 
to simulate the preparation techniques they used and made notes and measurements of 
the processes. This is supported by the fact that some interviewees used the clean 
injecting equipment they had obtained prior to interview to demonstrate points, for 
example how much water was added or how the mixture on the spoon was stirred. Some 
used the soil from a plant pot to illustrate their use of citric acid. Although there are issues 
that would have to be explored before such a simulation could be used, this would be the 
choice of the researcher for future work.
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6.3.3 The use of the semi structured interview format to collect data from IDUs
6.3.3.1 Data collection tool design
\
A semi-structured questionnaire format was chosen to allow specific areas to be explored 
with the interviewee, however after piloting the schedule, the researcher chose to ask 
general open question on preparation and fill in any perceived gaps by using the schedule 
questions. Inclusion of the pilot information in the final analysis was considered 
appropriate since the actual data collected did not differ, just there was less repetition 
after amendment of the interview style. The researcher needed to have some knowledge 
of the approximate methods that may be reported, to allow her to understand the types of 
information that would be required for the laboratory work and to ensure the information 
she was collecting was understood. Without this understanding, the questionnaire and 
probes could not have been designed or used in a manner that conveyed familiarity with 
the subject, a factor reported to be important in interviewing (Moser and Kalton, 1971). 
Due to the lack of information on known preparation methods reported in the literature, 
safer injecting leaflets were used. A criticism of basing the data collection on safer 
injecting information is that the questionnaire may have appeared as a test of safer 
injecting and influenced a bias in response, especially since they were conducted within 
the setting of a harm reduction-based agency. Interviewees were assured of
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confidentiality from the researcher and asked to be honest, in an attempt to reduce the 
incidence of biased response. Fifteen of the 20 interviewees reported having received 
safer injecting advice, so exposure to such advice was high in the interview group 
However, the purpose of the interviews was to establish the preparation techniques used, 
so awareness of safer injecting information was not a barrier in this study. One example 
that shows a bias did not exist towards reporting safer injecting information is that of 
filters: All nineteen heroin injectors reported using a filter, however, fifteen of these had 
also injected tablets and only two used a filter with these. Had there been a bias towards 
reporting safer injecting information, it may have been expected that the tise of filters 
would have been reported with all drugs, as recommended in safer injecting information.
The main criticism of the data collection tool is that correlation was not possible between 
the quantities of water and acidifiers used and the amount of drug injected. For example, 
if someone said they injected ‘a quarter G’ bag of heroin it cannot explicitly be assumed 
that the quantity of acid relates to this amount of drug, as this was not asked. In many 
cases the interviewees did state the quantity of heroin that the amount of acid related to, 
but it is a criticism that this was not explicitly explored. This also applies to the quantities 
V  water.
A further criticism is that when asking about the mixing of drugs together in a syringe, 
only tablets were referred to so there may have been under-reporting of powders mixed 
together. This did not however, impact on this study. Similarly, prior to establishing
I
filtration methods, questions were asked on whether the IDU worried about bacteria and 
particles. This information was not reported, as it was not used for this study. It may be 
criticised that this may have biased the filter questions, however again the lack of filtering 
reported with tablets suggests this not to be the case.
The willingness of the IDUs to engage in conversation with the researcher after taping 
had stopped indicates a rapport with the researcher had developed. This was considered 
important by Moser and Kalton (1971). It may also suggest the interviewee relaxed more 
once taping stopped and for this reason relevant information reported after interview was 
noted and included in the data analysis.
6.3.3.2 Reliability and external validity
The reliability and validity checks were performed on four interviewees, the results of 
which suggest the questionnaire was reliable, as all respondents gave the same answer
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to the reliability checks as they gave when the questions were originally asked. The 
validation checks suggest that the questionnaire was also valid. Age matched exactly for 
all respondents. Age when first injected varied for two respondents by two years each, 
with the time reported in the interview since first injection being 8 years and 31 years 
respectively. For the interviewees where age since first injection matched exactly, the 
length of time since first injection was shorter (2 years and 4 years). Since the interviewee 
is not likely to be asked to recall this information as commonly as they are asked their 
age, and the difference in the responses that did not match exactly is relatively small, 
these responses were considered acceptable to suggest external validity. All drugs 
reported to be injected at initial contact with DA were recalled by the interviewees, except 
one interviewee who did not mention one drug that he reported at initial contact. However, 
five drugs were reported to have been used by injection, so the omission of one was 
considered to be been an omission on recall, not a sign of invalidity.
Reliability checks were performed on data relating to the preparation methods and validity 
on facts relating to the interviewee. It may be criticised that data on both areas should 
have been collected for both the reliability and the validation checks. However, since no 
externally collected information on preparation methods used by the interviewees was 
known to exist, in practice only further checks on reliability could have been performed. In 
future work this should be done.
6.3.3.3 Recruitment of IDUs and the sampling method
Consultation with IDUs only recruited from one source i.e. Drugs Action, is a limit of this 
study, as discussed in 6.2.1.2. Quota sampling was the only realistic option in IDU 
recruitment for interview as explained in 3.1.4.2. A criticism of the sampling method is that 
the number of people who declined to participate and their gender was not recorded. Had 
this information been recorded it would have given an overall indication of the willingness 
of DA clients to discuss their injecting practices with the researcher. For example, women 
were under represented in the sample, but it is unknown whether the refusal rate for 
participation was higher amongst females than men. The use of a quota sample may 
have meant that IDUs who were aware that their preparation processes did not follow the 
safer^injecting information given by DA refused to participate. However, potential 
interviewees chosen using a random sampling method would also have had to be given 
the choice to participate, so this factor could not be avoided.
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6.3.3.4 Offering of caffeine and tobacco
The offering of caffeine containing drinks and nicotine containing cigarettes to the 
interviewees may be criticised as these substances do not promote health and are subject 
to dependence. It was observed by the researcher during her time at the agency prior to 
the interview period, that many of the clients drink tea or coffee and smoke cigarettes 
when they spend time at the agency. The researcher considered it appropriate to make 
these items available to assist in the creation of a relaxed atmosphere. The decision to 
accept them was that of the interviewee, they were not pressured to accept them. Some 
may view this as inappropriate, however the researcher did not consider this to be so in 
the circumstances.
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6.4 The s im u la ted  preparation techn iques used in the labora tory
6.4.1 The heroin preparation simulation
Six stages in the heroin preparation process were identified from the safer injecting 
information and the drugs workers (fig. 3.1). No variations were found at all The 
preparation methods for heroin reported by the interviewees identified the same six 
stages. This suggests that the use of these six stages in the simulation process was
appropriate. However, the interview data found variations in the specific details of four of
\
these stages, reported by the interviewees. It may be criticised that if a greater number of 
IDUs had been interviewed, a consensus on the most commonly used factors would have 
been reached. Conversely, such variation may be expected, given the clandestine nature 
of drug misuse and freedom of individuals to use such variations. Practices used are 
unlikely to be exact and, as reported by many interviewees, subject to variation depending 
on the perceived strength of the heroin obtained. In a sense, when developing a 
simulation that tries to make an exact process out of an inexact one. there will always be 
the criticism that the simulation does not represent what is done in practice, because it 
cannot. Where a choice in what could be done in the laboratory was presented, the 
decision on which method to use was made by selecting the most popular option from the 
interviewees. This was necessary since a standardised method had to be used to test the 
filters to allow the results to be compared and not enough heroin was available to allow all 
options to be tested with all filters. Again, the small sample number may be criticised but 
the counter argument being that a greater number of interviewees may have led to 
greater variation. What the simulation technique used can be taken to represent is one 
method that is used in some situations by IDUs, but the specific quantities used are not
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universal so the simulation results cannot be applied as universal. The exact effects of the 
different filtration methods are likely to vary with these variations in practice. For example, 
using a different shaped spoon may achieve different shearing forced when stirred with 
the needle sheath. These in turn may affect the particle size before filtration, which in turn 
could affect the number of particles in the filtered injection. To determine these exact 
effects, more heroin for further study would be required to establish whether the results 
from this study remain true for all scenarios.
A further matter that requires discussion is the mixing of the different heroin samples 
obtained to give one batch to use for this work. Although the limitations on the amount of 
heroin available for this work justify the need to mix the samples together, it may be 
criticised that the resulting mix was not tested for homogeneity. Visually, the mixture was 
inspected for a homogenous appearance but no further tests were performed. Therefore, 
in further work that required small samples to be mixed more attention to the mixing 
process would be given by consulting powder technology literature. It is not known 
whether the mix of the sample would have influenced the results. However it is suspected 
that the level of attention paid to the mixing process in this study would be no less than 
that given to the mixing process by drug dealers, although this cannot be confirmed.
6.4.2 The tablet preparation simulation
The preparation techniques used for tablets was found from the interviews to vary with 
the type of tablets used. For example coated tablets were reported to be crushed or have 
the coating ‘chipped o ff prior to mixing them with water. Formulations perceived to be 
more readily soluble such as Temgesic®, which is designed for sublingual use, were 
merely shaken with water in the syringe. Even for the same drugs there appeared to be 
no consensus on whether the tablets were crushed prior to dissolution. For this reason, 
the laboratory investigation studied both options. Similar criticisms apply as for heroin 
(6.1.3.1) and what can be said is that the simulations used are likely to represent 
scenarios that apply to IDUs at some point, but they cannot be assumed to apply 
universally.
6.4.3 Source of water used
The source of the water used for the experiments performed was the tap. In Scotland, the 
water supply is described as ‘soft’ in that it does not contain large amounts of lime, unlike
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other areas of the country. Water for injection was used during the control tests, 
illustrating that there was little difference in the particle count of control injections made 
using tap water and water specifically prepared for injections. However, in other areas of 
the country where the amount of limescale deposits in the tap water is large, there may 
be a difference seen between the particle content of ‘blank' injections prepared using tap 
water and water for injections. Therefore, in further work it would be prudent to investigate 
this matter using tap water obtained from different areas of the UK.
6.5 The laboratory investigation
6.5.1 Equipment used
The equipment used for this work was largely dictated by availability within the School of 
Pharmacy. Although the validation of the Coulter Multisizer showed acceptable particle 
sizing (6.1.4.2), the equipment was difficult to optimise, for example, the pressure within 
the system was difficult to set. Pressure loss did occur during analysis on some
occasions, this is seen by failure of the orifice tube to fill with saline. If this occurred, the
\
sample had to be discarded. Similarly, if the orifice blocked, the sample had to be 
discarded. This however, only happened occasionally. At times, error occurred in 
establishing the current and again the analysis had to be discarded. When this occurred 
with the heroin work this led to loss of what was already a limited amount of material. The 
researcher became more familiar with the equipment over time and although not 
recorded, it is perceived that the incidence of analysis failure was more common with the 
initial tablet analysis work when the equipment was new to the researcher. A newer model 
of Multisizer that would allow downloading of results to a PC would have been an 
advantage as with the system that was used, results cannot be stored, so data recording 
all had to be done manually. A further criticism is that validation of particle counting 
cannot be carried out in the laboratory, since it is impossible to introduce a fixed number 
of particles into the system. Therefore that manufacturers assurance in the operating 
manual that up to 20,000 particles will be counted accurately within the 12-second 
counting period has to be taken as acceptable.
Some of drug was again wasted in the attempts to use the HPLC system. The CZE 
equipment was again dictated by availability. If a choice had been available, there would 
have been clear advantages in the use of automated equipment, as the results could 
have been stored and the inbuilt drug libraries could have been used in peak 
identification. However, the system used was found to be reliable. Dr Ann Low and Mr 
Raymond Reid gave some assistance in operation, for which the researcher is grateful.
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6.5.2 Validation of the Coulter Multisizer
6.5.2.1 Reliability
For the reliability checks the RSD values were all below the acceptable limit chosen (4%) 
and were all less than 2 % (table 4.2), suggesting the results from the Multisizer to be 
reliable. The mode particle sizes were however higher than the stated label size of the 
latex (mean =14.24 pm, stated latex size = 13.7 pm). This was also observed for the 
precision checks and is discussed in the next paragraph.
6.5.2.2 Precision
From table 4.3 it can be seen that the RSD values for the mode particle size and the 
distribution were less than 3 %, and considered acceptable for this work. The mode 
particle sizes were higher than the stated label size of the latex (mean =14.06 pm, stated 
latex size = 13.7 pm). This was also observed in the reliability checks. The mode particle 
Size represents the midpoint in the channel within which the greatest number of particles 
was detected. Therefore, the actual size of the particles will be anything within the 
channel size. The width of each of the 256 channels was 0.24 pm, so the actual size of 
the mode particles could be the quoted value ±0.12 pm. However, this adjustment only 
brings the precision check at 15 minutes to the latex stated label size. Although a small 
distribution would be seen when the latex was sized by the manufacturer, the 
accompanying information shows that the stated label size is the peak height in the 
sample distribution, so should be the same as the measured peak height (mode ±0.12 
pm). Possible reasons for a measured latex size greater than the stated label size could 
be some coalescence or agglomeration has occurred amongst the latex particles. This 
could happen if the latex suspension became unstable. At the time of manufacture and of 
this work, the storage requirements recommended by Coulter Electronics were in a cool, 
dark place'. The researcher stored the latex standards as instructed in a cool, dark 
drawer, and care was taken not to leave them exposed to sunlight. However, since this 
time, the new manufacturers Beckman Coulter have changed the recommendation to 
storage in a refrigerator above 4 °C. The latex standards used were several years old and 
cost restrictions prevented new standards being purchased for this work2. Although latex 
suspensions are usually stable for many years, the lack of refrigeration and the unknown 
storage conditions prior to this work, may have caused instability in the suspension, 
leading to an increase in the size of the particles and hence some slightly larger
2 Latex standards are made to order by the manufacturer. The approximate cost of one bottle is £100
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measured sizes. However, the Multisizer was shown to be accurate, so this suggests 
some conflict, which would require further investigation to be explained.
6.5.2.3 Accuracy
All the stated label latex diameters fell within the mode channel sizes measured toi the 
accuracy experiments. This demonstrates accuracy within the Multisizer measurements.
6.5.2.4 Within day and day-to-day variation.
The within day and day-to-day variation was investigated as a further test of reliability 
over a range of sizes. The results shown in table 4 5 show acceptable RSD values for the 
within day tests. Had latex standards been available that covered the whole size range of 
interest for this project i.e. up to 50 pm, these would have been used. However, 19 1 pm 
was the largest size available. Table 4.6 shows the day-to-day variation test results. The 
RSD values were again considered acceptable.
6.5.3 Particle size analysis results
6.5.3.1 Data recording
Direct comparison between filtered and unfiltered samples from the same injection was 
not done for the reasons given in 4.37.4. At the time this decision was made the 
researcher was concerned that if the orifice continued to block frequently with the 
unfiltered injections and many injections were discarded, there would not be enough 
heroin to perform all the experiments. In the case of the tablets, solid material remained 
dispersed so large amounts were sucked into the pipette tip. As it transpired, the heroin 
injections were less heavily contaminated and the solid material sank to the bottom of the 
spoon on heating, so this may not have been a problem with the heroin. However, it was 
considered important to do the same comparisons for the tablet injections as the heroin, 
so the results could be considered in similar terms, so the method was not changed. The 
concern about the removal of liquid from the unfiltered material reducing the volume of 
the final injection is now not considered a problem, as all filtered injections would have 
been subject to the same sample removal. However, the difficulty of one researcher 
performing ‘before’ and ‘after’ analysis on the un-automated machine was another reason
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in defence on not making this comparison. Consideration must be given to whether the 
method of comparison used was acceptable. The particulate contamination in injections 
will vary greatly, so the purpose of this work was to identify trends in the results, not to 
take the results as absolute. The results that were compared were from injections that 
had been prepared in exactly the same way, under the same conditions and for this 
reasons were considered acceptable in providing information to identify trends.
It must be remembered that the actual particle numbers recorded represent what was 
counted from the sample in 12 seconds, not the total count in the injection. The stirring 
and addition of the sample to the relatively large volume of saline may have caused some 
particles to dissolve that were present in the injection. It is unknown whether this effect 
would be seen when the injection is administered as the components of blood could 
cause precipitation of materials in the injections, hence increasing the risk of blockage, or 
dissolution of particles, depending on the interaction between the injection materials and 
the blood. These effects are unknown. In vitro experiments examining the effects of the 
injections in blood would be needed to establish such information, however, since blood 
cannot be used as the analysis medium for the Coulter Multisizer, such work may not 
achieve any greater representation. The variability between different batches of heroin 
again would make the actual situation in practice variable.
6.5.3.2 Controls
It must be remembered that the exact particle counts obtained from the Coulter Multisizer 
analysis are meaningless since they will be subject to great variation. Instead, the data is 
considered by looking for trends in the particle counts, as shown in figures 4.2 to 4.5. 
Unlike standard scientific experiments, the controls were not performed to show that in 
the absence of the material under investigation the equipment does not give a result 
when a ‘blank’ experiment is performed. In this work that would be impossible since some 
particles will come from the operator, environment and equipment. Instead, the controls 
were performed to see how the contribution made to the particle load by all factors 
involved in the injection preparation process, except the drug, compared to the particle 
load seen with the drug. The controls were also performed to find out whether the filters 
added to the particle load when water was passed through them i e by shedding 
particles. Both water for injection and kettle water were used to find out if using water 
specifically prepared for injection made any difference to the particle load in the controls 
or whether the contribution from the operator, environment and equipment over-ruled any 
possibility of benefit.
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From figures 4.2 to 4.5 it can be seen in comparison with the unfiltered drug injections, 
both the kettle water and water for injection controls, contained a much smaller particle 
load. The filters were not considered to contribute to the particle load as significantly as 
the drug. The Water for Injections (WFI) blank performed with the cotton bud and the 
kettle water blanks with the hand rolling filter and syringe filter appear on fig 4.4b to be 
raised but when compared to both waters when shaken in the syringe they are seen to be 
similar (fig. 4.4a). This suggests that the contribution from the filters cannot be 
distinguished from that of the background. Again, the WFI did not show consistently less 
particulate load compared to the kettle water, suggesting that the background contribution 
cancels any benefit from the WFI. It must of course be remembered that there are likely 
to be microbiological benefits from WFI being used by IDUs.
6.5.3.3 Impact of filters on the particle load of the heroin injections.
Table 4.9 and fig. 4.5 show the results from the heroin injection analysis. Here it can be 
seen that all methods of filtration caused reasonably large reductions in particle load The 
greatest reduction was seen, as hypothesised, with the syringe filter where the greatest 
proportion of the total number of particles were removed. Of the makeshift filters, the 
cigarette showed less reduction than the hand rolling and cotton bud filters.
\
Figure 4.6 shows the effects of the filters on particles in the two smallest size ranges of 
interest. The larger sizes were not included as the differences in numbers were small and 
not considered distinguishable from background effects. In the size range 5 to < 10 pm all 
the filters removed the great majority of particles. In the smaller size range, the SF 
performed best. Although the particles in this range are smaller than the SF pore size, the 
insoluble material itself may have acted as a filtration bed, as it coated the filter surface.
These results suggest that large levels of particle reduction in heroin injections can be 
achieved through the use of all types of filters, although the SF conveyed the greatest 
benefits.
It is not possible to distinguish the nature of the material of the particles measured with 
the Coulter Counter. Therefore, it cannot be said whether the particles measured were 
due to the drug, the filters or the environment. Analysis of the injections under a 
microscope could have been performed to establish whether the nature of the particles 
could have been identified. Future work would include this in the experimental process.
144
________________________________________________________________________________________________________________ C hapter 6
6.5.3.4 Impact of filters on the particle load of the tablet injections.
The Physeptone® experiments were not pursued as they could not be filtered using a 
process which the researcher considered would be acceptable to IDUs. The unfiltered 
injections showed particularly high levels of contamination (table 4.10 and fig.4.2). 
Confidence in the result from the sample that was crushed and mixed on the spoon must 
be low, as this far exceeds the suggested maximum particle load for the orifice, which is 
approximately 20,000 particles per 12 second count (Coulter Electronics, 1988). The 
Diconal® and Temgesic® injections were able to be satisfactorily filtered. As shown in fig. 
4.3, the makeshift filters brought about some reduction in particles. However, the SF 
produced a much greater reduction in the level of particles than the makeshift filters. 
When the size range data is considered for Diconal® (fig. 4.7) it can be seen that in the 2 
to < 5 pm range, only the SF produced any benefits. Similarly, in the 5 to < 10 pm range, 
only small reductions in load were caused by the makeshift filters, although the SF again 
produced very large reductions. The makeshift filters performed better in the 10 to < 20 
pm size range although the SF was clearly better. Only in the 20 to 50 pm range did the 
makeshift filters convey benefits close to those of the SF. For Temgesic® (fig. 4.8) the SF 
results are comparable to those it produced with Diconal . However, the makeshift filters 
showed poorer results.
6.5.4 Drug quantification equipment validation
6.5.4.1 Linearity
The CZE experimental method was shown to give a linear response over the 
concentration ranges of interest, as shown in table 4.13 and figures 4 9a and 4.9b This 
meant that the ratios of the experimental peak heights to the standard peak heights could 
reliably be used to calculate the concentration of diamorphine, 6-MAM and morphine in 
the injections.
6.5.4.2 Within day variation and day-to-day variation
For the validation experiments performed for this work, the average peak heights and 
average migration times from the within day variation checks all had an RSD value less 
than 3.5 % (table 4.14). For the day to day variation checks the RSD values for the 
average migration times and peak height ratios were also below 3.5 % (table 4.15). This
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shows that the CZE method used was sufficiently rugged to allow results to be compared 
that were collected over a period of time.
6.5.5 Drug quantification results
6.5.5 1 Controls
No peaks were found when the controls were analysed on the CZE system, illustrating 
that any peaks seen in the experiments are due to the heroin and not the preparation 
process.
6.5.5.2 Effect of filtration on the drug content of injections.
Table 4.16 shows the results of the amount of drug detected in the filtered injections. 
When compared statistically, the injection filtered with the hand-rolling filter was found to 
Contain significantly less diamorphine than the other injections. This may be attributed to 
its greater size than the other filters, as it will have the capacity to retain larger volumes of 
fluid, which will contain dissolved drug. On examination of the results in table 4.16, the 
amount of 6-MAM in the injections filtered with the hand-rolling filters also appears 
reduced. This suggests that dissolved 6-MAM is retained in the filter also. If the reduced 
diamorphine quantities had been due to greater decomposition in the hand-rolling filter 
injections, it would have been expected that the amount of morphine detected would have 
been higher In comparison to the other filtered injections. This does not however appear 
to be the case. The SF did not differ statistically from any of the makeshift filters, 
suggesting that it may be acceptable for use by IDUs.
6.5.5.3 The amount of diamorphine retained in the filters
The average weights of the hand-rolling filters and the syringe filters after use were much 
greater than those of the cigarette and cotton bud filters. The results discussed in 6.5.5.2 
suggest that the hand-rolling filter retained some of the drug that went into solution on the 
spoon. When the content of the filters were analysed, the syringe filter contained 
significantly greater amounts of diamorphine compared to the other filters. The reason for 
this is thought to be because not all the solid material dissolved when the injection was 
prepared, i.e. some of the basic diamorphine was not converted to salt. This was shown
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by the detection of diamorphine in the remains on the spoon (4.77.4). This happened 
because the quantity of citric acid used was not enough for this conversion to take place 
completely (see 6.5.5.5). The SF was observed to act like a vacuum cleaner, sucking up 
all the solid material from the spoon into the filter casing. In the case of the makeshift 
filters, some of the solid material remained on the spoon and some stuck to the filter. 
Therefore the fluid retained in the filters will have contained dissolved drug and 
undissolved drug will be present in the solid that the filters retained. Additionally, the solid 
material may possibly retain fluid, which could contain dissolved drug, although the 
sucking of air through the filters into the syringe to indicate complete filtration may have 
minimised this. The SF appeared visually to contain much more solid and it was found 
from the filter analysis to hold more drug. The volume of fluid that the SF is quoted by the 
manufacturers to retain is 50 pi (Gelman Sciences. 1991) Further work could be done to 
establish the amount of diamorphine retained if complete conversion to solution was 
achieved. The practice of IDUs retaining used filters to break down at a later date to 
prepare injections is known (Koester et al, 1990). This was also reported in informal 
discussions with IDUs and ex-IDUs. The donation of remains on the spoon to someone in 
the IDU’s group who did not have money for drugs was also identified from these 
discussions.
The experimental analysis of the filters shows their capacity for retaining some of the drug 
and highlights why there may be difficulties faced by drugs workers trying to persuade 
IDUs not to retain filters for further use. As said, this practice is associated with ‘cotton 
fever’. The solid material held in the SF could potentially be removed quite easily as the 
material forms a plug in the nozzle of the filter. Flushing the filter with water in the 
opposite direction to which the injections were filtered released the solid and returned the 
filter to a 'clean' appearance. Potentially, if this was known by IDUs it may encourage the 
sharing of the filter contents with others. The IDUs who took part in the user evaluation 
pilot study were not asked whether they found this out. This would be a useful point for 
investigation in further user evaluations.
6.5.5.4 The influence of the variables
Great care was taken in ensuring that the variables involved in the preparation process 
were kept constant to enable the results measured to be meaningful, as described in 
3.4.3. However from tables 4.16 and 4.17 it can be seen that the standard deviations of 
the concentration of diamorphine measured ranged between 0.96 and 4.21. Heating is 
considered to be the most difficult variable to control since only indirect controls could be
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used e.g. the length of time of heating and distance of the spoon from the flame could be 
measured and controlled, the quantity of energy input into the mixture could not be 
directly measured. Variations in the amount of energy input into the injections may have 
influenced the diamorphine concentration as more would break down if exposed to more 
energy. Smaller deviations that follow similar trends to the diamorphine standard 
deviations (table 4.16) can also be seen in the standard deviations of the 6-MAM and 
diamorphine concentrations shown in table 4.16. However, for single results where the 
diamorphine and 6-MAM contents seem to follow similar trends, but the morphine content 
did not always do so. This suggests that the lower diamorphine content found in some 
experiments could have been either due to increased diamorphine breakdown or less 
diamorphine being present initially, perhaps due to inconsistent mixing as discussed in
6.4.1. In table 4.17, only diamorphine content was measured so the speculation extends 
to these results but cannot be proven. Further work could investigate the effects of 
heating on drug content in injections more closely.
6.5.5.5 The acidifier investigations.
The structure of citric acid is shown in figure 6.1. One possible theory for the interaction 
between diamorphine and citric acid is as follows: When this acid is mixed with 
diamorphine, the three carboxylic groups dissociate and form complexes with the 
diamorphine molecules at each group. Alternatively, the acid may form a salt with the 
diamorphine. If full dissociation occurs, for every one molecule of citric acid, three 
molecules of diamorphine will complex with it. The extent of this dissociation depends on 
the amount of acid added (which will reduce the pH) and the pKa values of the groups 
and the pKa value of diamorphine. pKa is the log of the dissociation constant for the 
group, it indicates the ‘willingness’ of a reaction to happen. Because it is a log value, the 
lower the pKa, the higher the Ka and hence the stronger the acid. For example, the three 
carboxylic groups of citric acid have the pKa values 3.1, 4.7 and 6.4. Diamorphine has a 
higher pKa value (7.6) so the acid is ‘willing’ to dissociate and form complexes with the 
diamorphine, or conversely, the diamorphine is able to remove the H+from the acid
COOH
I
HOOC-CHjjC-CHjpOOH
I
OH
Figure 6.1 Two-dimensional representation o f the chemical structure o f c itric acid.
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The structure of ascorbic acid is shown in figure 6.. The pKa values of the two hydroxyl 
groups are 4.2 and 11.6 respectively. The 4.6 value shows that this group will dissociate 
and form a complex with the diamorphine. However, the 11.6 value won’t as the 
diamorphine (pKa 7.6) is not strong enough to remove the B \ This means that only one 
diamorphine molecule will complex with one ascorbic acid molecule.
Figure 6.2 Two-dimensional representation o f the chemical structure o f ascorbic acid.
When the effects of acids are considered in molar terms, it can be said that for every 
mole of diamorphine, one third of a mole of citric acid will be needed for complete 
dissociation. For the ascorbic acid, one mole of diamorphine will complex with one mole 
of ascorbic acid. When this is transferred into weight, the quantity of acid required for 
complete dissociation can be calculated. In terms of street heroin, if the diamorphine 
content of the heroin is known, the amount of acid required can be calculated
For the heroin used in this work, a diamorphine content of 55.68% was found. This means 
that in 250 mg, as used for the experiments, the diamorphine content will be 139.2 mg. 
To convert 139.2 mg of diamorphine to salt form, the following calculations can be 
applied:
C itric  acid: 1 mole of diamorphine requires 0.333 moles of citric acid. The weight of one 
mole of diamorphine is 369.4 g. The weight of one mole of citric acid is 210.1 g.
210.1 X 0.333 = 70 03g
By simple proportion, it can be calculated that for 139.2 mg of diamorphine, 26.39 mg of 
citric acid would be required.
A scorb ic  acid: 1 mole of diamorphine requires 1 mole of ascorbic acid, which weighs
176.1 g. The quantity required to convert 139.2 mg of diamorphine would be 66.36 mg.
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The weight of citric acid used for the filter comparison experiments was based on the 
information collected from the IDUs in interview. As said, consideration was not given to 
the use of simulation to establish the quantities used. As it is illegal to give citric acid to 
IDUs, and as it is known that some IDUs have difficulty in obtaining acidifiers for this 
reason, it would be unwise to actually use acids in a simulation process, as the IDUs may 
want to keep the acids. This would put the researcher in a difficult situation. However, an 
inert substance which looks similar to citric or ascorbic acid could be used, such as 
sodium chloride. As long as it was identified which type of acid the IDU was basing his or 
her simulation on, the weight of the sodium chloride could be used to calculate the weight 
of acid used. This could also be done to establish the approximate amount of heroin to 
which the quantity of acid relates, using a material such as fine grade sand, which is 
similar in appearance to brown heroin. It is regrettable that this was not considered when 
the preparation processes were being established.
However, this does not mean that the results from the filter experiments are meaningless. 
The diamorphine content of the heroin will vary, and the IDU has no way of knowing this 
quantity. The amount of acid to add will be a process of 'trial and error’ by the IDU. It is 
unknown from this work whether the amount of acidifier reported in the interviews was 
underestimated or whether IDUs do not achieve complete dissolution of the diamorphine 
when preparing injections. Of course the diamorphine content of street heroin will vary, a 
‘purity’ of around 50 % is considered average for UK heroin (Gossop, 1995). It is unlikely, 
on the basis of so many variables that an accurate simulation process that represents the 
practices of the majority of heroin injectors could be achieved, given that the scientific 
analysis required strict control of variables. If large amounts of heroin were available, 
experiments using heroin of different purities and a range of preparation practices could 
be undertaken. However, arranging enough heroin may take some time, since the 
willingness of police forces, destruction procedures used locally and availability of drugs 
from closed cases all dictate what is available. As an illustration, after the heroin for this 
work was obtained, no further samples were available from the police in the time scale of 
the laboratory work. An approximate simulation is probably as accurate as this kind of 
work can be. As established through informal discussion with IDUs, diamorphine 
remaining in filters and on spoons may be used to prepare further injections. It does 
however, highlight the difficulties in trying to transfer an inexact process such as heroin 
injecting into a scientific analysis procedure.
From the acidifier experiment results (fig 4 10 and 4 11) it can be seen how the amount 
of diamorphine in the resulting injection increases with the quantity of acid added. The 
injection prepared with no acid could not be filtered as the solid remained flocculated on
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the spoon. This illustrates the need for acidifiers when preparing base heroin for injection. 
Figure 4.12 shows how the addition of more water is ineffective in promoting the solubility 
of more diamorphine. It can also be seen from 4.10 and 4.11 that quantities of acid close 
to those calculated to be required for complete dissociation were tested in the laboratory, 
however, the resulting amount of diamorphine in the injections was much less than the
139.02 mg of diamorphine known to be in the injections. When the filters used in these 
experiments were analysed they contained an average of 12.55 mg of diamorphine for 
the citric acid experiments and 7.49 mg for the ascorbic acid experiments. The qualitative 
work showed that diamorphine was lost during the preparation process in the vapour on 
the watch-glass and on the needle sheath used to stir the mixture on the spoon.
pH
Table 4.21 shows the average values of the pH measurements recorded for some of the 
injections. It can be seen that, as expected, pH gets smaller as more acid is added The 
physiological effects of these injections on vein walls have not been investigated and the 
buffering effects of blood is unknown, so it is not confirmed if pHs in these ranges will be 
damaging. The injection of ascorbic acid has been shown to cause haemolysis in 
individuals with underlying blood disorders such as glucose-6-phosphate dehydrogenase 
deficiency, but has not been a problem in healthy individuals (Parfitt, 1999). The pH of 
pharmaceutical diamorphine is 4.0 (Evans Medical, 1998), presumably because this is 
within the pH range (3.8 -  4.4) at which it is most stable in solution (Parfitt, 1999). This 
illustrates that low pHs can be administered intravenously. The damage to veins 
anecdotally attributed to citric acid by IDUs and drugs workers may be augmented by 
frequent administration, using excess or leakage from the veins. However, further work is 
required to investigate this. In the mean time, the recommendation to rotate injecting sites 
can be endorsed. At this stage, it is known that the addition of acidifiers is necessary as 
injections could not be prepared without it. However, when acids are added, the pH of the 
injections decreases (the pH of street heroin mixed only with water was 7.5).
When injected, diamorphine salts are rapidly converted to the active metabolite 6-MAM 
then morphine. Citric acid is metabolised to carbon dioxide and water whereas ascorbic 
acid is metabolised to dehydroascorbic acid, which in turn is converted to ascorbate-2- 
sulphate and oxalic acid. The latter is known to be toxic in large quantities, causing 
ionisable calcium to be removed from the blood and tissues and deposit in the kidney 
forming calcium oxalate calculi. However, this has not been shown from the injection of 
ascorbic acid (Parfitt, 1999). The daily human requirement of ascorbic acid is 30 to 60mg 
and any excess is excreted unchanged in the urine. Further investigation would be
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needed to be sure that there were no cumulative or prolonged effects in IDUs who use 
ascorbic acid to prepare injections
6.5.6 Considering all laboratory results
An important lesson learned from this work is the difficulty in transferring such a variable 
process into a scientific laboratory experiment. The lack of access to all analysis 
equipment at the same time and availability of manual equipment also created difficulties. 
It is regrettable that the quantity of acid required for complete conversion of the 
diamorphine was not checked after the weight of 'a small pinch' of citric acid was found, 
at the time that the percentage content of the street heroin was established. The use of a 
simulation technique to establish information on preparation methods may be more useful 
and would certainly be used again in further work.
The results suggest that in terms of reducing the number of particles, if the paraphernalia 
laws changed, syringe filters may be beneficial if used by people who inject tablets, as 
they caused large reductions in the particles in the injections. However, care would need 
to be taken in how this harm reduction intervention was actually conducted, as it would 
have to be made explicitly clear that the SF would not make the injection of tablets 'safe', 
only it may reduce some of the risks. The makeshift filters did not produce a reduction in 
particle load to an extent close to that achieved with the SF.
For the heroin injections, the picture is less clear. The SF produced the greatest benefits 
in terms of particle load reduction. However, the makeshift filters did also reduce the load 
quite significantly. The hand rolling filter injections contained significantly less 
diamorphine than the injections filtered using other means and the syringe filter retained 
the most drug. However, it was found that not all the diamorphine in the street heroin was 
in solution. Solid drugs as well as liquid was retained in the filters, so in practice with 
differing quantities of drug in solution these results may change.
The results suggest that there may be health benefits for IDUs if they were to use syringe 
filters in the preparation of their injections, in terms of reducing the incidence of health 
problems that relate to the injection of particulate matter. Such benefits would depend on 
enough filters being available so they could be used for every time an injection was taken 
by an IDU. In order to measure the existence and extent of such benefits, further studies 
of the clinical outcomes of filter use in practice would be necessary and should be a future 
stage in this work.
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6.5.6.1 Issues around the supply of makeshift filters
Although there did not appear from the controls to be a large amount of particulate matter 
contributed from the filters, the issue of advising on the use of something not specifically 
designed for the purpose is still pertinent. If the paraphernalia laws changed and needle 
exchanges chose to supply filters, many issues would exist. The syringe filters would be 
much more expensive than makeshift filters, for example the hand rolling filters. The 
health benefits and treatment savings would have to be determined to allow the total 
costs of the filters to be established i.e. the direct and indirect costs would have to be 
known. The makeshift filters are not however, designed for the purpose for which the NXs 
would be distributing them. Although the hazard sheets for cellulose acetate and 
triacetine, which were obtained from Filtrona, do not show any toxicity risks from these 
chemicals, should any harm result i.e. from shed fibres, the needle exchange would be in 
a difficult situation, in terms of legal responsibility.
The makeshift filters were tested in this work according to the methods described by the 
IDUs and drugs workers. The hand rolling filter was used complete. However, it could also 
be cut down in size and a smaller amount used, as is done with the cigarette filter. This 
may potentially reduce the amount of drug retained. This could be investigated in further 
work.
Chapter 6
6.5.6.2 Issues around the supply of acidifiers
This study has shown that the addition of acidifiers is necessary in the preparation of 
base heroin for injection. However, the long term effects of citric and ascorbic acid, when 
used in this way require further investigation before their safety can be established. In the 
mean time the recommendation that injection sites should be rotated can be endorsed in 
an attempt to maintain vein patency. Also, the fact that the long-term safety of acidifiers is 
not known should be made clear to IDUs.
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6.6 The user acceptability p ilot study
C lia p w  o
6.6.1 The study design
6.6.1.1 Recruitment method
The recruitment of participants for the pilot study through the DA NX wa^ aporonriate 
because of the need to safety-screen potential recruits. The records held in the NX 
allowed this screening to be undertaken and the availability of counselling rooms allowed 
private discussion. Some potentially suitable clients may not have been identified if (i) 
they had recently been issued with a new NX card i.e. their previous card was full or had 
been misplaced, as they would have appeared from the NX card not to have an 
established attendance record, (ii) There had been an error in the code recording of 
information on the NX card. It is regrettable that the number of potential recruits that were 
identified through the NX card screening was not recorded, so the proportion that was 
recruited in the study period cannot be calculated. However, the limit on the time for 
recruitment prevents such a figure being meaningful in terms of identifying recruitment 
success of this method. It is the feeling of the researcher that a significant proportion of 
the NX clients were not considered acceptable for recruitment because it was noted on 
the card that they were taking methadone. The number of information sheets distributed 
was 14, seven of whom presented for consideration for inclusion in the recruitment time, 
six of whom were recruited. No follow up was made of those who received a sheet but did 
not present for inclusion.
6.6.1.2 Criteria for inclusion
The strict safety criteria imposed on the pilot study was considered necessary to 
safeguard the participants, DA and the researcher. Control over the amount of 
diamorphine in the heroin used to test the filters was impossible, so other safeguards to 
minimise the risk of adverse events were important. Also, at the time of this work much 
media attention locally was focusing on drugs services. Both DA and the researcher were 
keen that, in the event of attention being focused on filter distribution, safety precautions 
and accountability of the study could be demonstrated.
If the criteria for inclusion hadn’t been as strict, it may have been possible to recruit 
greater numbers of people into the study in the given time. However, ethically this would 
have been unacceptable.
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6.6.1.3 Anonymity and confidentiality
Participation in the study was not anonymous and ethically this has to be justified. The 
need for the first or nick names and contact details of the recruits was considered 
necessary as the researcher wanted a means of following up the recruits if they did not 
return to DA within the given time. This was to allow her to ensure that no harm had come 
from the filter tests. The names and details were kept confidential to the researcher and 
participants were assured of this. Several did ask to confirm that this would be the case 
before they agreed to participate. Once this was assured, the participants gave details, 
suggesting trust of the researcher.
Names of the participants were not revealed to the DA workers, however knowledge of 
who was participating, in terms of initials and dates of birth was known to those who saw 
the needle exchange card stickers and distributed the questionnaires. This system of 
identification was explained to the participants before they agreed to take part In all 
cases the participants stated that they had no concerns about DA staff knowing they were 
' taking part as they felt trust in the workers.
\
6.6.1.4 Trust
Trust was a key component of the pilot study. The researcher trusted the recruits not to 
give the filters to anyone else and to dispose of them as instructed. The recruits trusted 
the researcher not to expose them to harm and to keep their personal details confidential. 
Responsible disposal of the filters was measured in so far as all recruits returned a cin 
bin, which they said contained the SFs. Opening of the bins to confirm this was not 
considered safe for the researcher. The bins with transparent bottoms did not have wide 
enough openings to allow the filters to be disposed of in them. Therefore, the disposal 
information was taken on trust. In further studies commissioning the design of clear 
bottomed wide mouthed bins may be appropriate, although wide mouthed bins are not 
favoured by the DA workers are they allow the removal of their contents, encouraging 
reuse of injecting equipment.
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6.6.1.5 Number of syringe filters tested
The number of SFs given to the recruits was four. From the researchers experience in the 
laboratory, this was considered enough to allow the recruits to become familiar with their
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use. The two recruits who did not find the SFs acceptable did not test all four filters. It was 
not considered ethical or manageable to make it compulsory for recruits to agree to test 
all four filters at the outset. It is unknown from this work whether further experience with 
the remaining filters would have influenced the opinions of those who reported their use of 
the SFs to be unfavourable.
6.6.1.6 Questionnaire design x
/*•
The questionnaire was short and quick to complete. There were no issues» of ambiguity 
raised from the pilot group. The main criticism of the questionnaire, which was identified 
after it had been administered,- was that details of the preparation methods used for the 
injections filtered with the SF were not gathered. For example, the amount of heroin, type 
and approximate quantity of acid and water added and duration of heating should have 
been asked to inform the researcher of the circumstances under which the filters were 
used. Also, it was,not confirmed whether the filters were tested as detailed on the 
¡instruction sheet. Further work would include the collection of this information.
\  :
6.6.2 Discussion of the pilot study results
The pilot study group included both males and females with an age range of 22 to 38 
years. This was considered appropriate as it represents both sexes and a wide age 
range. Although it was known from the inclusion criteria that all participants had been 
injecting for at least 3 months, the length of time since they began injecting was not 
recorded. Such information would be useful for a larger evaluation as it would allow the 
data to be investigated for a correlation between injecting experience and opinion of the 
SFs.
The recruits used a range of injecting sites when they tested the SFs, This is significant 
because larger detachable needles are used when access to deeper veins such as the 
femoral vein is necessary, for example when surface veins are collapsed. This may in turn 
influence the acceptability of the filters. Although the use of detachable needles and 
syringes were a problem for two recruits, both gave favourable reports of their use of the 
SF. One of these people added in the additional information that she had overcome her 
dislike for detachable needles and syringes by transferring the injectable liquid into an 
insulin syringe for administration. On wide scale distribution, if this proved to be seen in a 
significant proportion of SF users, there would be issues around the need for greater
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amounts of injecting equipment. There are limits on the number of sets of needles and 
syringes that can be collected at any one time from a NX in Scotland, as stated in the 
Lord Advocate’s Guidelines (The Scottish Office, 1998), so more frequent visits to NXs 
would be needed, which carries implications for workload, resources and practicalities 
such as disposal and client convenience.
The pilot evaluation showed that the syringe filter was acceptable to four of the six IDUs 
in the pilot group, with three showing definite preference for it compared to their usual 
cigarette filter. Two of the IDUs had difficulties with the SF that related to it retaining fluid. 
One of these declined the offer to test the filters with water at DA before he agreed to 
participate. A larger study could investigate whether demonstration of filter use 
contributed to filter acceptability. One of the IDUs who was interviewed in the work 
reported in chapter 3, mentioned that he wet his filters before use. He gave a detailed 
explanation of the reason for this, the conclusion of which was to reduce the amount of 
drug-containing fluid retained. Since this practice was not explicitly asked about in the 
interviews reported in chapter 3, it is unknown whether this practice is done by other 
IDUs. Further work to establish injection preparation techniques could be combined with 
data collection on the testing of SFs. In this work the incidence of filter wetting should be 
addressed. Filter wetting may be an unknown factor that contributed to the difference in 
opinion seen in the pilot group.
Two people expressed an opinion that the effects from the injection were different, with 
one stating the injection felt stronger and cleaner and another stating the effects from the 
drug was reduced. The quote from recruit no. 2 (5.4.2.4) suggests a perception that the 
impurities in a heroin injection are those that do not dissolve. It is of course possible that 
soluble impurities may also be present in injections. From analysis studies it appears that 
common adulterants are soluble inert sugars such as lactose, but soluble active impurities 
may also exist such as caffeine (Kaa 1991, Chiarotti et al 1991, Chaudron-Thozet et al, 
1992, Kaa 1994). Further investigation of users perceptions of the benefits of SFs should 
include questions to establish whether there is a perception that filtering makes injections 
‘pure’. It would also be prudent to establish other perceived benefits of filtering, especially 
in relation to health.
Although no conclusions can be drawn from a pilot study, this work suggests that a larger 
scale investigation into user acceptability and use of the SFs would be worthwhile to 
establish whether filter acceptability or unacceptability predominates. Details of the 
preparation methods used would be collected to identify whether any differences in
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preparation method contributed to the IDU's opinion on the SFs and to gain more 
information on the range of preparation methods used.
The inclusion criteria would be relaxed for further studies in stages, as safety information 
emerged. The recording of participants contact details would be necessary for further 
work initially, until an indication of the safety profile for the SF had emerged. If nothing 
happened to question safety, further participation could be anonymous. As the study 
expanded, the number of participants lost to follow up may increase. However, this would 
be affordable once it was known that the filter did not increase the incidence of adverse 
risks. The return of used filters could be checked if a clear disposal bin was used. 
However, the risk of not getting back all filters that were distributed is likely to exist.
A final comment on the pilot study from the researchers viewpoint is that all the pilot 
group showed an active interest in the study. This may be expected since they agreed to 
participate, but the researcher felt that there was an interest in being listened to and an 
interest in helping with the development of this work to benefit IDUs as a group. This 
came from the participants’ provision of further comments, including the drawing of 
diagrams of possible ideal filters and discussion around the legal status of the provision of 
filters. The drugs workers also reported additional comments made at a later date, which 
showed interest. Given the difficulties found in establishing accurate information on the 
injection preparation process and the ethical and legal barrier that prevent non participant 
observation, as discussed in chapter 3, there may be a case for continued studies having 
a user involvement component. User involvement is advocated in the development of 
drugs services (The Scottish Office, 1999, UK Government, 1999) and anecdotal 
information suggests the number of users groups in the UK to be growing (Anon, 2000). 
This work suggests user involvement may also be appropriate in research. Areas that 
could be explored are user recruitment of participants into the SF study and using 
participant observation to record information on the SF tests and testers opinions.
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For further evaluation, the questionnaire would be expanded to establish how the filters 
were used, including details of approximate quantities. The testers would also be asked 
about issues around reuse of the filters. A user information leaflet summarising the 
laboratory findings in clear and understandable language would be needed in order to 
explain both the evidence on which the decision to distribute the filters was made and the 
limitations of the filters e.g. be explicitly clear that they will not prevent the transmission of 
blood borne viruses if equipment is shared. Long-term health gams would take time to 
measure.
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6.7 Conclusions and further w ork
The research questions that this study aimed to answer will now be returned to, to briefly 
give the conclusions of this work.
The first question was: can a simulation of the injection preparation process used by IDUs 
be developed, which can be used to conduct representative investigations in the 
laboratory setting?
A simulation process was developed that allowed controlled reproducible conditions of 
investigation in the laboratory. The extent to which large variables exist in the preparation 
of illicit heroin injections means that the process did not and could not represent the 
practices of all IDUs. Further work could be conducted to establish preparation 
techniques by asking IDUs to simulate their preparation processes using ‘fake’ drugs and 
acids. The quantifiable aspects of the process could be recorded. One person in the user 
evaluation pilot study did not wish to test the filters with water as he said using the 
‘equipment would make him crave heroin. If this was the case for many users, there may 
be an unwillingness amongst some to participate in a simulation process.
The second question was: can a measure be made in the laboratory of the effectiveness 
of makeshift filters at removing insoluble particles?
\
i
This was done using particle size analysis, performed on injections prepared with heroin 
and with Diconal®and Temgesic® tablets. For the tablet injections, the makeshift filters 
showed some success in the size ranges of interest, however contamination levels 
remained high. However, for the heroin injections a larger decrease in the particle content 
was seen.
The third question was: are commercially available syringe filters more effective at 
removing insoluble particles from injections than makeshift filters?
For both heroin and tablets, using a 5 pm Acrodisk® syringe filter, this was found to be the 
case for all drugs tested. The syringe filter was able to cope with heavy contamination as 
was seen with the tablet injections, whereas the makeshift filters exceeded their 
capabilities so were relatively less effective.
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The fourth question was: can the extent to which makeshift filters retain drug be 
established? And the fifth question was: how does the amount of drug retained by syringe 
filters compare to the amounts retained by makeshift filters?
This work was only conducted for the heroin injections. Because not all the diamorphine 
was converted into its soluble form in the injection preparation process, there are 
difficulties in drawing conclusions from the results of this part of the work. Some drug 
remained in the solid material left after filtration, some of which attached to the filter. The 
extent of this attachment was variable. Also, although the syringe filter retained the 
largest amount of drug, this was probably only because it removed most of the solid 
material from the spoon whereas the makeshift filters did not. The solid material was easy 
to remove by flushing water through the filter in the opposite direction to filtration. This 
raises issues around the reuse and sharing of syringe filters. However, if a greater 
quantity of acidifier had been used so as to cause all the diamorphine in the street heroin 
to go into solution, differing results may have been seen as the volume of fluid quoted by 
the manufactures to be retained by the Acrodisk® is small.
I
>£he sixth question was: is the most effective filter, according to the laboratory work, 
acceptable to IDUs and does it produce health benefits?
This aim was found to be over ambitious and work could only be begun to answer it. A 
pilot user evaluation was conducted that provided valuable information on the design of a
l
larger scale evaluation. Measurement of the health benefits from filter distribution would 
take time and resources greater than those available for this project, a factor that was not 
recognised by the researcher at the start of this work.
The last question was: does laboratory investigation support the need for acidifiers in the 
preparation of brown heroin for injection?
The results from this investigation illustrated in practice the chemical theory behind the 
use of acidifiers. They showed how the quantity of diamorphine in the resulting injections 
increased as the amount of acid increased. It was also shown that when the approximate 
quantities of citric acid and ascorbic acid necessary to dissolve all the diamorphine were 
used, similar amounts of diamorphine were found in the resulting injections. However, 
these quantities were still much less than expected. Diamorphine was shown to be 
retained in the filters used for this work. Qualitative work showed diamorphine to be 
present on the spoon in which the injection was mixed, on the needle sheath used as a
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stirrer and in the vapour that evaporated from the spoon, indicating the loss of some drug 
in the preparation process.
In view of the answers to the research questions discussed above, it can now be 
considered as to whether the original hypothesis set in has been upheld. In-chapter two 
the hypothesis was defined as follows: Through development of a simulated injection 
preparation process and analysis using laboratory-based experiments, it is possible to 
gather information on the effectiveness of injecting paraphernalia to .inform harm 
reduction practice. In chapters three it is shown that a simulated injection preparation 
process can be developed and in chapter four it is shown that this can be used in the 
laboratory to gather information on the effectiveness of some injecting paraphernalia, 
namely filters and acidifiers. The limits of the simulation have been discussed. These can 
be summarised as mainly being that the laboratory study requires an exact process 
whereas in ‘real life’ the process appears from the interviews with IDUs and safer injecting 
information to be inexact. The clandestine preparation methods of the street drugs also 
means results in practice are likely to vary depending on the nature and composition of 
ithe drugs.used, so exact replication of the results in practice cannot be expected, 
^owever the trends seen in the laboratory are considered to represent trends that would 
be seen if similar preparation methods are used in practice. Hence information has been 
gathered to inform harm reduction practice and further study, which was not available 
previous to this work being undertaken.
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Further work has been highlighted in this chapter. To summarise, a more accurate 
correlation between the quantities of acidifier added and the quantity of heroin used could 
be established by asking IDUs to simulate the preparation techniques they use with ‘fake’ 
materials. These materials could then be quantified and the weights of acidifier and heroin 
that they represent calculated. As the weight and density of heroin will vary, this would still 
be an approximate value. Further detail of the preparation processes used could also be 
observed.
Working using a bigger range of tablets with quantification of the effects of filtration on 
drug content in the injections is also desirable. Similarly, if further commercially produced 
filters that are cost effective and user-friendly can be identified, they could also be tested, 
using a range of quantities of drug, if available. The development of an effective, user- 
friendly virus filter should also be considered.
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Physiological investigation into the effects of acidifiers on the body is important to 
establish whether there is any long-term harm from their use. Similarly, the long-term 
benefits from commercially produced and makeshift filters should be assessed. The 
identification of long term risks from using makeshift filters is also vital to establish This is 
important in the light of recent calls for the paraphernalia laws to be abolished.
Once such information is established a large-sale user evaluation study could be 
undertaken. Using the information established, the health and economic effects of 
supplying effective paraphernalia to IDUs could be predicted. Such information would be 
necessary for purchasers of services for IDUs if the paraphernalia laws were changed.
I
x
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PART TWO
Investigation into the role of a pharmacist 
at a non-statutory drugs service
Chapter 7
Chapter Seven
Background, literature review and aims of this study
7.1 Background
The initial stimulus for this study came from the researcher's experience whilst conducting 
the work described in chapter three. The collaborating establishment for this project, 
Drugs Action (DA), is a non-statutory drugs service, in Aberdeen, Scotland. At the time of 
this work, the staff came from a range of backgrounds, including social work, sociology, 
community and youth work, but none came from health-based professions such as 
medicine, nursing or pharmacy1. A funding bid made by the agency to establish a nurse- 
led health clinic in 1996 was unsuccessful. The researcher, who is a pharmacist, found 
that whilst she was on the DA premises attending the client drop-in and conducting 
interviews, she was increasingly being asked by the staff and clients for her opinion and 
advice on a range of health and pharmaceutical issues. She therefore considered that 
there might be a role for a specialist pharmacist in providing information and advice at 
DA. If this was found to be the case, further investigation could go on to explore whether 
such a role also exists in other non-statutory and statutory drugs services. If so, this could 
potentially open up another extended role opportunity for pharmacists and benefit the 
clients and workers of drug services. The work presented here began exploring these 
proposals by undertaking a feasibility study to examine whether an information and advice 
giving role exists for a specialist pharmacist at Drugs Action.
Before the study is described, background information will be given, to set in context the 
number of people seeking help for drug problems in the UK. Then the literature will be 
examined to describe previous work that has studied the provision of information and 
advice on drug misuse by pharmacists and the possibility of developing an extended role 
in this area will be highlighted. Following on from this the hypotheses will be defined.
Since th is s tudy w as undertaken, the agency has em ployed team  m em bers from  nursing backgrounds.
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7.2 Literature review
7.2.1 Trends in problem drug use in the UK
There are difficulties in accurately quantifying the extent of problem drug use in the UK, as 
explained in 1.1.4.3. Data on the number of people presenting for care at drugs services is 
shown in figures 7.1 and 7.2. Figure 7.1 shows the trend in the number of new contacts or 
re-contacts after a period of at least six-months absence reported by service providers in 
Scotland for each financial year between April 1992 and March 1999. The collation of 
such statistics and their limits has previously been described (3.2.1 and 6.2.1.1.).
Financial year
Fig. 7.1 Trend in the number o f new contacts presenting fo r care in Scotland between April 1992 and 
March 1999. Source: Drug Misuse Statistics Scotland (ISD, 1999).
Figure 7.2 shows the trend in starting agency episodes reported by service providers in 
England and Wales for each financial year between April 1993 and March 1999. Note, the 
Welsh figures were taken from a summary in the English statistics and have not been 
viewed directly.
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Financial year
Fig. 7.2 Trend in the number o f agency episodes fo r all reporting agencies in England and Wales 
between April 1993 and March 1999. Source: Statistical Bulletin (Government Statistical Service, 1999)
The data in figs. 7.1 and 7.2 cannot be taken as an absolute representation of the 
prevalence of drug use in the UK. Not all drug users will present for care. In the time 
periods accounted for, the number of reporting drugs services and extent of service 
provision may have changed, consequently influencing opportunities to present. Although, 
the reporting agencies are similar in England and Wales to those in Scotland, the data 
should not be compared, even when adjusted to population percentages, since the 
Scottish statistics are adjusted to take into account presentation of an individual at more 
than one service whereas the English and Welsh statistics do not. The English statistics 
may therefore include several new contacts made by one person. Despite these 
limitations the data does show that the number of drug users presenting for care has 
increased over time.
7.2.2 The provision of pharmaceutical services to drug users
It may be assumed that some, but not all, of the people represented in figs.7.1 and 7.2 will 
require pharmaceutical services, for example the supply of substitution therapy. Similarly, 
there may be users of pharmacy needle exchanges not represented in the data because 
they do not use other drug services2. Therefore, the data cannot be taken as an indicator 
of the extent to which pharmaceutical services are required. No such work has been 
conducted. However, the extent to which pharmaceutical services are provided to drug 
users has been investigated.
2 Pharmacy needle exchanges do not submit information to the drug misuse statistics databases
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The most up to date English and Welsh statistics come from the work of Sheridan et al 
(1996 and 1997), who conducted a postal questionnaire of a random 1 in 4 stratified 
sample of community pharmacies (CPs), with a response rate of 74.8% (n = 1984). They 
found 50.1% of CPs surveyed to be dispensing controlled drugs for dependency, 34.5% 
to be selling injecting equipment and 18.9% participating in NX schemes (Sheridan et al, 
1996). Their questionnaire was based on that used seven years previously by Glanz et al 
(1989), who also conducted a one in four postal survey of CPs with a response rate of 
79% (n = 1946). A weighting was applied by Glanz to predict service provision from all 
community pharmacies. They concluded that 23.0% of CPs were dispensing controlled 
drugs for dependency, 28.0% were selling injecting equipment and 3.0% were 
participating in needle exchange (Glanz et al, 1989, Sheridan et al, 1996). Sheridan et al 
did not apply a weighting and advise caution in making direct comparisons between their 
results and those of Glanz. However, the authors conclude that the differences in the 
findings do show a sizeable increase in the provision of CP services. No such comparison 
data exists for Scotland, as only one national investigation has been conducted 
(Matheson et al, 1999). They surveyed all CPs using a postal questionnaire with a 
response rate of 79.1% (n = 864). The authors found 53.2% of respondents were 
dispensing methadone for drug dependency and 8.8% were providing NX.
The work of Sheridan et al (1996 and 1997) and Matheson et al (1999) illustrates that 
pharmacists have a significant level of contact with drug users If these pharmacists are 
already providing information and advice to drug users and drugs services, it may be 
unnecessary to develop a specialist service from within drugs services. Similarly if the 
current drug information network in the UK is fulfilling such a role it may be unnecessary 
to pursue this matter. These factors require exploration before it can be decided whether 
there may be an opening for a specialist pharmaceutical information and advice service at 
drugs services.
7.2.3 The pharmacist as a source of information and advice
Advice giving and information provision are inherent features in the role of pharmacists. 
Those who receive the advice or information may be professionals or members of the 
public. The process can be formal or informal, proactive or reactive (Stewart, 1998). In the 
UK, a network of drug information (Dl) centres is in place This network comprises local 
Dl centres, supported by regional centres. The centres are staffed by pharmacists and 
largely operate out of hospital pharmacy departments. Many regional centres specialise in 
particular areas, for example the regional centre in Newcastle specialises in drugs in 
pregnancy and poisoning and toxicology. The centres primarily operate a service for
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health professionals working in primary and secondary care, although some provide a 
help-line for patients recently discharged from the hospital where the centre is based 
(UKDIPG, 2000). Pharmacists working in community practice also provide information to 
health care professionals and routinely give information and advice to members of the 
public (Stewart, 1998). The easy access of community pharmacists makes them a 
frequent point of contact for information and advice by the public (Blenkinsopp et al, 
2000). As the availability of information to the public increases, for example with access to 
the internet becoming more widespread, community pharmacists are likely to see an 
increasing number of patients seeking professional opinion on materials they have 
retrieved from other sources such as web sites (Blenkinsopp et al, ibid).
7.2.4 Recognition of a role for pharmacists in the provision of information and 
advice on drug use
A role for pharmacists in the provision of information and advice relating to drug use has 
been suggested in several key documents. The Advisory Council on the Misuse of Drugs, 
in part one of their report ‘AIDS and drug misuse', recommended a role for pharmacists in 
providing health education to drug users (Advisory Council on the Misuse of Drugs, 1988, 
Anon, 1988). The Task Force that reviewed services for drug misusers in England in the 
mid 1990s also endorsed the role of the pharmacist in undertaking health promotion
(Polkinghorne, 1996). On an international level, a joint statement from the World Health
\
Organization (WHO) and the International Pharmaceutical Federation (FIP) in 1997 
highlighted the accessibility of pharmacists, their training in public health and contact with 
decision makers as key reasons why pharmacists should embrace an active role in HIV 
prevention. The statement gave guidance on how pharmacists should be involved. The 
provision of health education, multidisciplinary working and the development of inter­
professional networks were amongst the functions listed (Nakajima and Steinbach, 1997). 
The importance of the community pharmacist in advice giving and delivery of care is also 
highlighted in current clinical guidelines (The Scottish Office, 1996, Department of Health,
1999). The report of the RPSGB working party, which reviewed pharmaceutical services 
for drug misusers, identified pharmacists as an under utilised knowledge source for both 
drug users and professionals (Working Party on Pharmaceutical Services for Drug 
Misusers, 1998).
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7.2.5 The involvement of UK pharmacists in providing information and advice to 
drug users and professionals in the field
7.2.5.1 Community pharmacists
The extent of the provision of written and verbal advice to drug users by community 
pharmacists was investigated in the studies described in 7.2.2. Sheridan et al (1997) 
found the percentage of respondents who said they supplied information leaflets on HIV 
prevention and drug misuse to be 55%. This figure is less than the 68% identified by 
Glanz et al (1989). The percentage of pharmacists who said they gave verbal advice on 
HIV and drug misuse was also reduced slightly in the 1995 study (20%) compared to the 
1988 study (23%). Both studies did not separate HIV prevention and drug misuse, so it is 
not known whether the reductions reflect less information on drug misuse, or less 
information on HIV as respondents who gave a positive response may have only provided 
information on one of these areas. At the time of the work of Glanz et al, HIV was 
relatively new in its discovery and high on the public health agenda. The reductions found 
by Sheridan et al may have been due to HIV having a less prominent status in campaigns 
being run at the time of their work. However, as said (7.2.2) Sheridan et al did not apply a 
weighting to their results whereas Glanz et al did. Given that the percentage of non­
respondents in the Glanz et al study represented one fifth of community pharmacies in 
England and Wales and involvement in service provision might influence the decision to
respond to the questionnaire, the accuracy of the weighted results may be queried. Since
\
the differences found in the two studies are not large, the significance of these is open to 
question. When Matheson et al (1999) asked about information and advice provision, the 
authors separated the subjects of HIV and drug misuse. They also asked whether 
information provision was made ‘always’, ‘sometimes’ or ‘never’. However, the authors 
only asked the respondents who dispensed methadone about their involvement in 
information and advice provision (53.2%, n = 460). Therefore, pharmacies providing 
information and advice, but not involved in dispensing methadone will have been omitted 
from the results. Matheson et al found the majority of pharmacists who were dispensing 
methadone never gave information leaflets on drug misuse (61.9%) or HIV (60.2%), but it 
is unclear whether this means leaflets were not available for self-selection. Face to face 
advice on drug misuse was provided ‘always’ by 5.5%, ‘sometimes’ by 45.9% and ‘never’ 
by 48.6%. The figures for face-to-face advice on HIV were less, with 2.6% reporting they 
‘always’ gave advice, 28.0% reporting they ‘sometime’ gave advice and 69.6% reporting 
they ‘never’ gave advice.
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The extent to which the studies by Sheridan et al and Matheson et al give a true reflection 
of the activities of community pharmacists will depend on the accuracy of the reported 
information. This is the case with any method of self-reporting where validation of the 
information by other means is not or cannot be undertaken. Both authors sampled large 
numbers of pharmacists and achieved good response rates. Also, the questionnaires 
used were piloted prior to use. This will mean that ambiguity in the questionnaire will have 
been tested for. This suggests that overall the incidence and impact of errors in self- 
reporting will have been minimised.
No work could be found investigating the extent and nature of the involvement of 
community pharmacists in providing information to other professionals, despite such a 
role being identified in reports (7.2.4).
7.2.5.2 Hospital pharmacists
Drug information departments may receive enquiries from professionals and to lesser 
extent members of the public on drug misuse issues. However, information on the 
national incidence of such enquiries and responses could not be found. In 1987, Gerret et 
al reported the findings of their study into the provision of a specialist pharmacist 
information service on drug misuse, open to professionals from statutory and non- 
statutory drugs services. The service was based in a hospital drug information centre and 
contact made via the telephone. In a 12-month period, the service dealt with 68 enquiries 
from professionals. It was not a public service, however calls from members of the public 
were responded to (n = 7). The authors concluded that specialist pharmacists might make 
a valuable contribution to the work of statutory and voluntary sector drugs agencies, 
especially in a drug information capacity. However, no evaluation of the usefulness of the 
service was undertaken. The opinions expressed are those of the pharmacist who 
provided the service and not those of the information recipients.
In a paper by O’Connor et al (1995) describing the role of specialist addictions directorate 
pharmacists at the Maudsley hospital in London, the authors highlight information and 
advice provision to both clients and staff as being part of the role of these pharmacists. 
The researcher also became aware of anecdotal evidence of secondary care pharmacists 
working in drug dependency outpatient clinics and inpatient units. Contact with one 
pharmacist established part of her role was to supply information and advice to 
colleagues and clients (Robb, 1998). Such roles are identified in the report by the 
Working Party on Pharmaceutical Services for Drug Misusers (1998) and have been
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outlined in a specialist bulletin (Anon, 1998). However, published information on the 
nature and extent of this work could not be found.
7.2.5.3 The nature of the information and advice provided and outcomes
Although the extent to which community pharmacists are involved in the provision of 
information and advice has been explored (7.2.5.1), no study could be found investigating 
the nature of the information and advice given on drug misuse in any detail, or the 
outcomes from the provision of such information and advice. Similarly, the only 
investigation conducted in hospital appears to be the study by Gerret et al (1987), which 
reported statistics on the use of the service and the service providers opinions on it’s 
benefits. The authors do not describe the nature of the enquiries received or their 
outcomes.
7.2.6 The benefits of examining the role of the pharmacist in the provision of 
information and advice at drugs services.
7.2.6.1 Demonstrate whether a potential specialist role exists within drugs agency 
teams
As said in 7.2.5.2, Gerret et al (1987) considered that specialist pharmacists might have a 
role in the provision of information and advice to those working in drugs agencies. 
However, the service they studied was remote from the agency environment and not open 
to members of the public. A service in the location where it is required and open to the 
public might be better more accessible and allow opportunistic provision of health 
education, pharmaceutical information and advice. Although community pharmacists have 
a substantial amount of contact with drug users, there may be barriers to conducting an 
investigation in the CP setting. Sheridan and Barber (1996) conducted a pilot study (n = 
9) and Matheson (1998) a larger study (n = 124) exploring drug users opinions and 
experiences of community pharmacy services. They found the role of pharmacists in drug 
misuse perceived by drug users to be largely that of supply e.g. needles and syringes and 
substitute drugs. Matheson found that a large proportion recognised the pharmacist as an 
appropriate source of information and advice on general health matters, but only a few 
saw the pharmacist as a source of advice on matters relating to illicit drug use. For this 
reason, it may be difficult to explore the provision of advice and information from the CP 
setting if such information and advice is not sought in the first place. An alternative to this
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would be to place the pharmacist in a specialist drugs service, building on the 
recommendation of Gerret et al (1987) and explore the nature of the enquiries referred to 
the pharmacist by drugs workers and directly from clients. The findings could then be 
used to establish if an extended role for pharmacists, providing information and advice 
within the drugs agency setting, exists. In addition, the attitude of the drugs workers 
towards this service could be examined to establish the compatibility of the pharmacist 
within the agency team, an important factor in a climate where the emphasis is on 
multidisciplinary working (UK Government, 1999, The Scottish Office, 1999). The nature 
of the enquiries could be used to inform the development of training materials as 
suggested in 7.2.6.1. This assumes that drug users who use specialist services and those 
who use community pharmacies require similar information. Although this is unknown, it is 
known that many drug users use both pharmacy and specialist services so the client 
groups overlap (Tucker, 1997).
7.2.6.2 Inform the design of pharmacists education and training packages
The education and training needs of specialist pharmacists providing an information and 
advice service to drugs services could be examined through the implementation and 
study of such services. There is also evidence to suggest that pharmacists in general 
require specific training in drug misuse and working with users. In 1991, the Council of the 
RPSGB identified a need to address the education of pharmacists at both undergraduate 
and postgraduate level to enable pharmacists to provide a full service to drug users 
(Anon, 1991). In a study published by Sheridan and Barber (1993), exploring the attitudes 
of final year students (n = 85) and pre-registration graduates (n = 56) to drug misuse and 
HIV, the authors found 88% (n = 75) of undergraduates and 95% (n = 53) of pre­
registration pharmacists thought that the time spent teaching about drug misuse should 
be increased in the degree programme. When asked about competence in counselling 
about drug misuse, 74% (n = 63) of undergraduates and 67% (n = 37) of pre-registration 
pharmacists stated they did not feel competent. Those questioned were from one school 
of pharmacy only, so the opinions on education cannot be taken to apply to all schools of 
pharmacy. However, a survey of all schools undertaken for the Report of the Working 
Party on Pharmaceutical Services for Drug Misusers (1998) found a lacking in the areas 
of social aspects of drug misuse, harm reduction, treatment and drug policy. Sheridan et 
al (1994) found that student confidence in counselling could be increased by the provision 
of education. In the study by Sheridan and Barber the respondent's interpretation of the 
term ‘counselling’ may have varied. It is likely to have been interpreted as the provision of 
information and advice on health and the effective use of medicines, as this is the
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common meaning in relation to the work of pharmacists (Moody, 1998). However, it is 
possible that it may have been interpreted as the provision of psychological support 
through motivational interviewing, as undertaken by members of the British Association of 
Counsellors, so there is some ambiguity in interpreting the results. Despite these limits, 
the studies show that the group considered education at undergraduate level about drug 
misuse to be important.
At post-graduate level, a need for education and training has also been identified. In a 
survey of community pharmacists around the London area (n = 268, 74.4% response 
rate), Harding et al (1992) report 40% of respondents did not consider themselves to have 
the knowledge to deal with injecting drug users. The attitude statement to which this 
figure relates was 'Pharmacists do not have the knowledge to handle problem drug 
users’, illustrating that the response may not be limited to injectors as the authors 
suggest. Also, the authors do not explore the type of situations to which the respondents 
were interpreting the question to apply. However, the phrase implies the handling of the 
behaviour of people rather than handling their enquiries or problems. In the study 
described in 7.2.5.1, Sheridan et al (1997) found 72.6% of respondents agreed with the 
statement 7 need training on how to deal with drug misusers who may visit my premises'. 
However it is again not known what situations the pharmacist’s interpretation of the 
statement was referring to i.e. responding to enquiries from drug users or handling 
difficult behavioural situations. The authors considered training to be essential in order to 
capitalise on the opportunities pharmacists have to deliver information and advice to drug 
users. A paper from one NX pharmacy reports that the pharmacist felt medical and drug 
related enquiries from service users to be ‘beyond her knowledge and experience’ 
(Hollyoak and Wardlaw, 1992). Although this cannot be assumed to apply universally, it 
suggests there may be training needs in this field. The report of the Working Party on 
Pharmaceutical Services for Drug Misusers (1998) identified specific areas for education 
and training. It suggested that pharmacists might be the only contact some drug users 
have with health care, so should be equipped to respond to their health care needs. It 
may be assumed that this would include providing information and advice. From the 
researchers experience of providing training to pharmacists it is perceived that training in 
both matters relating to drug use and the handling of drug users is required.
The Council statement and the above studies and reports have identified a need for 
education and training of undergraduate and postgraduate pharmacists on drug misuse 
issues. As shown in 7.2.4, pharmacists are perceived to have a role to play in the health 
education to drug users. The extent to which this role is undertaken is unknown. The 
provision of information and advice on matters relating to drug misuse may be inhibited,
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possibly due to lack of confidence and knowledge, but also due to attitudes towards drug 
users (Sheridan et al (1997), Matheson et al (1999)). Matheson et al suggest that 
providing training may influence attitudes and possibly increase the level of service 
provision.
The report of the RPSGB working party (7.2.4) outlined general areas where training is 
required. It is not known whether pharmacists self-opinion of training needs reflects actual 
needs so work is underway to establish this and develop assessment tools (Cunningham, 
1999).
Information gathered from studying specialist information and advice services could not 
only Inform the education and training of these specialists, it may also be useful in 
informing the education and training of pharmacists in general, since, as discussed a 
large number of community pharmacists (the area where the majority of pharmacists are 
employed) have contact with drug misusers.
7.2.7 Statutory and voluntary sector drugs agencies.
The work of modern drugs agencies has already been described (1.2.2.5). The structure 
and skill mix of the agencies will vary. As said (7.2.5.2) pharmacists have been identified 
who are based within statutory sector drugs services, providing a supply and information 
service. Statutory sector agencies are funded by the regional health board/authorify and 
the workers are employees of either a community or hospital trust. Drugs agencies may 
also be part of the voluntary sector. These take various forms but are often registered 
charities that receive funding from a range of sources (Taylor, 1998). There appears to be 
little suggestion of pharmacists working for voluntary agencies in the literature. One 
American study, reported in 1982 by Powell et al examined the role of a pharmacist in a 
voluntary sector, multidisciplinary, community health education project. The project 
offered advice on four areas: nutrition, hypertension, drug use and misuse and alcohol 
and substance abuse. However, the term drug use and misuse referred to what in the UK 
is called compliance or concordance with prescribed treatment. The term substance 
abuse covered illicit psychoactive drug use. The pharmacist involved in the project only 
participated in the arm of the study that related to drug use and misuse. It is not clear 
from the paper why the pharmacist was not involved in the other aspects of the study, as 
they are all areas in which pharmacists have knowledge. The paper did not therefore 
have relevance to this work, other than indicating that an investigation had placed a 
pharmacist within the voluntary sector. Although the authors report the input of the
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pharmacist was welcomed, there is no description as to how this information was 
ascertained. No information in the literature reported pharmacists to be working in 
voluntary drugs services. Pharmacists are known to work for non-governmental 
organisations such as Voluntary Services Overseas (VSO) and Pharmaciens san 
Frontières (PSF). The organisations’ web sites3 do not suggest that work is done with 
drug users. Therefore, this project aimed to undertake investigation in a field that 
pharmacists have not previously been reported to work in. For this reason and the 
reasons in 7.2.6.2, it was considered important to establish the opinions and attitudes of 
the agency staff towards having a pharmacist included in the team. As funding is a 
pertinent issue for voluntary services (Taylor, 1998), it was considered useful to establish 
the approximate cost of providing a pharmacist-led information and advice service.
7.3 The hypotheses o f th is study and research questions
As shown above, the review of the literature found that several researchers and expert 
bodies have suggested that there is a role for pharmacists in providing information and 
advice to drug users and limited work has explored the nature and extent to which this is 
done by community pharmacists. Furthermore, it has been suggested that there is a 
potential role for pharmacists in providing information and advice from within specialist 
drugs agencies, supporting the proposal by the researcher described in 7.1. From the 
literature, no previous work could be found that had explored this suggestion, so it is 
unknown whether such a service could be implemented or what the benefits of such 
might be. As said, the first stage in exploring whether an extended role might exist for 
specialist pharmacists at drugs services, is to conduct a feasibility study in one agency. It 
is this work that is presented here Two hypotheses were set for this feasibility study as 
follows:
1. It is possible to implement a pharmacist-led information and advice service within 
a voluntary sector drugs service.
2. The pharmacist-led information and advice service would be of positive benefit to 
its users.
Based on these hypotheses, the following research questions were generated:
PSF: h ttp  / /w w w psf-pharrn .o rg /fram e.h tm  VS O : http ://w w w  vso.org  u fc /[A ccessed: 10.05 2000)
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1. Is there a role for a pharmacist in the provision of information and advice within a 
voluntary sector drugs agency?
2. What is the nature of the information and advice sought by people who consulted 
the pharmacist?
3. What knowledge and skills were required to provide the service?
4. What were the agency client outcomes from the service?
5. What were the opinions of the other agency staff on the service received?
6. What was the attitude of the other agency staff to the service?
\
r  '
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Chapter Eight
Methods
8.1 Design and implementation o f the pharm acist’s service
8.1.1 The location
The location for this case study was Drugs Action (DA), 48a Union Street, Aberdeen. This 
agency was chosen because: (a) it was the only non-statutory drugs agency in the area, 
(b) anecdotal experience as described in 7.1 had suggested there might be a role for a 
pharmacist at this service and (c) it was the collaborating agency for this project.
DA is a registered charity, which receives funds from a range of sources including 
Grampian Health Board, Aberdeen City Council, Aberdeenshire Council, The National 
Lottery Fund and Comic Relief. The DA philosophy is based on a non-judgmental harm 
reduction approach to drug use. A management committee oversee the agency, with day- 
to-day running undertaken by the co-ordinator. When this study began there were
i
fourteen drugs workers, including part time staff, from a range of backgrounds including 
sociology, community work, social work and health promotion.
The agency is based in the city centre, but service provision extends into urban 
communities through the use of outreach teams. The aim of the city outreach team is to 
take services to drug users in urban areas of high socio-economic deprivation who may 
not otherwise access services. At the time of this study a rural team was also funded. 
They took services to drug users who may not travel to the city from Banff and Buchan. 
This is a large rural area containing several small communities, approximately spanning a 
50-mile radius to the North and West of the city. Both teams liaised with community 
pharmacists to support and encourage service provision.
DA clients are drug users, family members and friends of users and other professionals 
who work with users. Among the drug-using clients, heroin predominates as the main 
problem-causing drug (Drugs Action, 1998). The agency is open to the public for nine 3- 
hour sessions per week. Outreach work is carried out during this time and at other times,
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including evenings. Services for drug users and their families and friends include the 
provision of information and advice through a telephone help-line, an appointment system 
for one-to-one support, a brief contact drop-in service and a HIV/Hepatitis C session run 
by a specialist worker. The Family Support Group, which has a fund-raising arm, The 
Hope Group, provide self-help for relatives of drug users. A women’s service focuses on 
issues specific to women. These include street-work with female prostitutes and joint 
working with Aberdeen Maternity Hospital and the Substance Misuse Service to provide a 
one-stop antenatal clinic, known as the ‘Golden Square Clinic'. At the time of this work a 
Criminal Justice worker provided support and after-care for offenders, working in 
Craiginches Prison, Aberdeen and the DA base. Incite, the recreational drugs team, 
deliver an outreach service in nightclubs and at dance events. Needle exchange is 
provided for injecting drug users. There is no prescribing or medical service at DA. A bid 
to establish funding for a nurse-led injection site injury clinic was unsuccessful. Services 
for professionals include the provision of information, training on drugs issues and advice 
on working with drug users.
Drugs Action was established in 1986, initially as an information and support agency for 
solvent users and developed in responses to need. The needle exchange opened on 20 
January 1993. In the first full financial year of operation, there were 1917 visits to the 
exchange, 202 of which were new contacts (Drugs Action, 1994). The most recent annual 
report states for the 1998/9 financial year there were 8005 visits to the exchange, 429 of 
which were new contacts (Drugs Action, 1999).
8.1.2 The pharmacist
The pharmacist who operated the service was the researcher. At the time the service 
commenced1 she had been registered as a pharmacist for 25 months. Her pre­
registration year was split equally between the pharmaceutical industry and hospital 
pharmacy. As a registered pharmacist she had worked 9 months full time as a basic 
grade hospital pharmacist prior to beginning this research. Since registration she has also 
worked regularly as a locum community pharmacist.
1 S ep tem ber 1997
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8.1.3 Consultation with the Drugs Action staff team
The initial proposal for this project was discussed with the DA advisor to the project and 
the co-ordinator. However, it was not discussed with other members of the team, as the 
researcher wished to measure their attitudes to the proposed service before she 
discussed the details or sought team approval. The researcher attended a DA team 
meeting. The attitude of the staff to a pharmacist being part of the team was measured as 
described in 8.3.3. Following this, the proposed study was discussed. Approval of the 
team was necessary to allow the service to be able to be implemented. It was also 
necessary to establish that the pharmacist could work as an independent professional 
within the team. This largely related to the handling of ethical dilemmas discussed in 
8.1.7.5. There were initial concerns amongst the team that pharmacists may operate on 
an abstinence-only approach to drug use. As discussed in chapter one, harm reduction 
does not preclude the attainment of abstinence, but works to achieve hierarchical goals, 
realistic to the individual’s present situation. Strategies other than the promotion of 
abstinence are therefore necessary. On explanation of the professional responsibilities of 
pharmacists to care for the health and well being of individuals and the public, and the 
researchers’ belief that moral values should not hinder this, the DA team were satisfied 
that the service had potential for exploration. They also agreed that the pharmacist 
required freedom to exercise her professional judgement. The pharmacist and the team 
agreed that if either side felt there was a conflict of professionalism the matter would be 
discussed and the option to terminate the service made available to both parties. The 
team also asked for clarification of the confidentiality which pharmacists''are ethically 
required to uphold. On discussion it was established that this was compatible with the 
confidentiality policy of the agency. This is further discussed in 8.1.7.
In accordance with DA practice for new staff, the pharmacist undertook the in-house 
training package ‘An Introduction to drug use’, which was part of the DA induction 
programme. The pharmacist had undertaken safer injecting training, which was also part 
of the induction, when she first began this research. The pharmacist shadowed each of 
the outreach teams for one day to become familiar with their working practices. She 
attended one in four team meetings, which was the required attendance of staff working 
less than 16 hours per week. The DA advisor was designated the pharmacist's 
supervisor. It was usual practice for new staff to shadow an existing team member and 
then work under observation during an induction period. However, the team did not 
consider this requirement necessary for the pharmacist’s service.
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8.1.4 The pharmacist’s service structure
8.1.4.1 ‘The pharmacist’s session’
The service was designed to make the pharmacist as accessible as possible, within the 
constraints of time and other agency activities. The pharmacist was present at the agency 
for one 3-hour session per week. During this session, DA staff, members of the public 
and professionals could make contact for information and advice. This was known as the 
‘Pharmacist’s Session’ (PS). When selecting the time to hold the PS, consideration had to 
be given to other agency activities and available space, as the pharmacist required a 
private room to be available. The potential for client contact had to be maximised, without 
compromising worker activity, e.g. by occupying a required counselling room. After 
discussion with the team, Tuesday afternoon was selected for several reasons: An 
afternoon was selected over a morning, as it was usual for client numbers to be greater in 
the afternoons. Tuesday was selected because both base and outreach work was carried 
out, so both could make use of the PS. The criminal justice worker was at the prison, so 
could refer enquiries. This also meant desk space was available for the pharmacist. Only 
one worker had one-to-one appointments, so a counselling room was free for use.
Members of the public and other professionals could make contact directly with the 
pharmacist during the PS, either in person or by telephone to the help-line. Additionally, 
drugs workers offered a referral to the pharmacist when they considered it appropriate. 
DA base workers could contact the pharmacist face to face, whereas the criminal justice 
and outreach workers could contact her by telephone. The pharmacist recorded all 
enquiries that she received on a purpose-designed form [form 1], shown in appendix 19.
8.1.4.2 The pharmacist’s service outwith the session times
During all other working hours2, the pharmacist was contactable by DA staff only, 
although enquiries could be made on behalf of others. This was similar to the traditional 
drug information structure whereby the pharmacist is remote from the enquirer Enquiries 
that required an answer before the next PS were made by telephone direct to the 
pharmacist’s office. An answer phone was used to collect messages if she was out of the 
office. This was kept in a locked drawer. For confidentiality reasons, client names or 
identifying details were not included in messages. Non-urgent enquiries could be made in 
writing on another form [form 2] (appendix 20). Blank copies were kept at DA in a marked
2 This refers to the w orking hours o f the agency staff: M onday 9 am  to 8pm , Tuesday 9 to  1pm, (Tuesday afternoon PS), 
W ednesday to  Friday, 9 am  to  5pm.
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box file, on a clip in the needle exchange and above the help-line desk. Once completed, 
forms were left in another marked box file and collected by the pharmacist when she was 
next at the agency. Both forms are discussed in section 8.2.1.1.
8.1.4.3 Service duration
The service commenced on 9 September 1997, for a six-month period. Service provision 
was continuous except for one break of one week in September 1997 due to annual leave 
and four days in December 1997 due to statutory holidays. This time was compensated 
for by extending the service for nine days after the six-month period had expired, to give a 
total duration of service provision of 26 weeks.
8.1.5 Publicity of the pharmacist’s service and sessions
Several publicity methods were designed and targeted at prospective service users, to 
promote use of the service. Publicity was initiated during the week prior to the service 
commencing and continued until the last session had been held.
8.1.5.1 Publicity materials (
Pharmacist’s session leaflet
This aimed to provide relevant information and help readers make a decision as to 
whether the service may useful to them. It explained the service was in place for a trial 
period only and could be accessed by drug users, family members and friends and people 
who work with drug users. It gave examples of types of information and advice that was 
considered relevant. The leaflet also stated that the service was free and confidential. The 
address of DA, a map and details how to access the service were given. A copy is in 
appendix 21.
Pharmacist’s session posters
Posters summarised what was contained in the leaflet. One type, for use outwith Drugs 
Action, gave the agency address and PS times and another type, for internal use, only 
detailed times. Posters were produced in colour, A3 and A4 size and laminated. A black 
and white A4 version of the poster for internal publicity is shown in appendix 22
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8.1.5.2 Targeting of prospective service users 
Drugs Action staff
The pharmacist attended the DA team meeting five days prior to the first session. Staff 
were reminded of the operation of the sessions, invited to use the service and refer 
others. Staff were given a written reminder and a sticker, detailing the day and time of the 
session and telephone number for contact outwith session times. It was suggested this 
was attached somewhere prominent e.g. telephone handset or diary cover. A3 posters 
were displayed throughout the agency, including staff-only areas, such as at the help-line 
desk and administration office. For the duration of each session, a flyer was attached to 
the front of the needle exchange filing cabinet. This reminded the duty workers that the 
pharmacist was on the premises. The sessions were also noted in the agency diary.
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Drugs Action clients
Posters were displayed in the waiting area of the needle exchange, the meeting room and 
in each counselling room. Leaflets were displayed in the waiting area, needle exchange 
and corridor alongside other leaflets. A3 posters and leaflets were also displayed at all 
outreach team locations within Aberdeen City and at the rural team base at Ugie Hospital, 
Peterhead. Staff encouraged clients to use the service when they felt it appropriate.
Professionals and their clients
The service was promoted to selected outside organisations. Services that may be 
accessed by people affected by drug use and not known to be providing health or medical 
services were identified from the DA mailing list. For example, the Cyrenians hostels for 
the homeless and young peoples’ projects. These selected groups were sent a letter 
outlining the service, stating that it was for a trial period only. They were invited to use the 
service and refer people if appropriate. Leaflets and an A4 poster were enclosed for 
display in client areas. The list of those who received publicity is given appendix 23.
Three groups providing health and medical services to drug users were informed of the 
service. These were the Substance Misuse Service, the Family Planning Centre and the 
genito-urinary medicine clinic. The first two were informed because they were working 
jointly with DA to provide a maternity service for drug users. The latter also has close links 
with DA and mutual clients. It was considered good practice to inform them the service 
was in place. In addition, the criminal justice worker informed the prison officer and 
medical team with whom he worked, of the pharmacist’s service and telephone number.
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The criminal justice worker and prison officer worked together to deliver an in-house 
drugs education package and supported prisoners with drug problems. The medical team 
offered a short detoxification programme on admission.
8.1.6 Resources
The pharmacist required access to certain resources to provide the service. Use of a 
telephone and photocopier was agreed and usage records kept so the costs incurred 
could be reimbursed to DA. The agency kept several key publications including the British 
National Formulary, The Data Sheet Compendium, The Patient Information Leaflet 
Compendium, specialist textbooks on drugs of abuse, drugs in pregnancy and UK 
legislation. It also kept 'Addiction' and ‘Druglink’. The pharmacist also acquired specialist 
texts, including ‘Drugs of abuse’ by Simon Wills (1997). Journal papers and Internet 
access were available through the University. Information leaflets held by the agency 
were available for distribution by the pharmacist. These included information on drugs and 
their effects, safer injecting, blood borne viruses, safer sex, legal matters, welfare rights, 
homelessness, rehabilitation, detoxification and advice for families and friends of drug 
users.
8.1.7 Responding to enquiries \
When planning the service, attention was paid to legal and ethical guidance for UK 
pharmacists (RPSGB, 1997) and the UK Drug Information Procedure Manual (UKDIPG, 
1997a and 1997b). Although these guidelines are intended for hospital based drug 
information services, the principles have generic application for all pharmacists involved in 
information provision. The procedures used will now be discussed.
8.1.7.1 Confidentiality
As required by professional ethics, information that became known to the pharmacist was 
treated confidentially. Enquirer identity and matters discussed were not disclosed to any 
third party without the enquirers' consent. Clients who discussed issues with the 
pharmacist in the presence of their drugs worker were assumed to be consenting to the 
matter being discussed between the pharmacist and the drugs worker. If the drugs worker 
wasn’t present and the pharmacist considered it appropriate to discuss the matter with the
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worker, permission from the client was sought. The pharmacist’s code of ethics was in 
keeping with the DA policy on confidentiality, which is based on the British Association for 
Councillors guidelines. The policy declares clients have the right to confidentiality, which 
will be maintained unless the client has given consent for information to be divulged either 
in their absence or presence. The exception to this is given as instances where there is 
considered to be risk of serious physical or mental harm to the client or others, which can 
be prevented by breeching confidentiality.
8.1.7.2 Anonymity
In other settings where the public ask pharmacists for information and advice, such as 
community pharmacies, very often contact is on an anonymous basis. Being able to 
access pharmacists without an appointment or the keeping of records are factors thought 
to encourage the public to use their services (Blenkinsopp et al, 2000). The UKDIPG 
(1997a) recommend that all enquirer details are recorded. However, it was considered 
that this would discourage use of the service and was not in line with DA procedures. The 
researcher considered it important that contact with clients could be traceable, on the 
grounds of accountability. Therefore, complete anonymity, such as could be given in the 
community pharmacy setting was not offered. However, a minimum amount of information 
that would allow the details of a recorded contact to be found was kept. Client first name 
initial, gender and the date of contact were recorded on the enquiry form. The names of 
DA workers and other professionals were recorded. '
8.1.7.3 Enquiry processing
The enquiry handling procedure used for this study was based on UKDIPG guidance 
(1997a). It is represented in figure 8.1 and will now be discussed.
Identify enquirer
First the status of the enquirer was established i.e. drugs worker, worker from outside 
organisation or client. Pharmacists are advised in the code of ethics (RPSGB, 1997 and
2000) that enquiries from the public can be handled, providing they ensure the wishes of 
the patient’s medical practitioner or pharmacist are not compromised. Therefore, for 
enquiries that related to particular individuals, it was established whether the person was 
under medical or pharmaceutical care and what information they had already received. 
Care was taken not to undermine any established therapeutic relationships Further
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consultation with the medical practitioner or pharmacist was encouraged and discussion 
on the clients behalf undertaken, if agreed.
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F ig u r e  8 .1 . E n q u ir y  h a n d lin g  p r o c e d u r e  u s e d  f o r  th e  p h a r m a c is t ’s  s e rv ic e .
Identify problem/enquiry
The enquirer was questioned to establish the details of their enquiry and gather relevant 
information that the pharmacist considered necessary. As much detail as possible was 
collected, including why the information was needed and an assessment of what was 
already known. This helped ensure the response could be tailored to the individuals 
needs and existing knowledge. Before any response was given, the enquiry, as ih t 
pharmacist understood it, was relayed back to the enquirer for confirmation that it had 
been correctly interpreted.
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It was made clear to the enquirer which type of response they were receiving. Where 
appropriate, the pharmacist translated technical information into a format suitable for 
members of the public and non-health professionals. Responses could be given verbally 
or in written form, including the preparation of information sheets or printed material.
Documentation and follow up
This is discussed in 8.2.1.
8.1.7.5 Ethical dilemmas
An ethical dilemma as defined by Kelly et al (1990) is:
‘..a situation that presents a conflict in competing values or perceived obligations 
in which one value or course of action must be chosen and in which respect for 
one value or obligation necessitates violation of another'.
Pharmacists sometimes receive requests for information that pose ethical dilemmas. As 
Kelly et al (ibid) state, these often, but not exclusively, arise when members of the public 
request information. When a dilemma presents, the pharmacist has to identify the 
competing values or obligations and decide which will be respected and which will be 
violated. In making this decision, the pharmacist must establish all relevant facts and use 
his/her professional judgement to decide where priority should lie. The pharmacist must 
also be able to justify his/her actions. Identification of the existence of an ethical dilemma 
and consequent professional judgement will be influenced by, not only knowledge of 
professional and legal responsibilities, but by knowledge and interpretation of the given 
situation and the potential consequences of possible actions. Moral beliefs of the 
pharmacist will also influence the decision making process. Therefore, each situation has 
its own unique set of variables, so procedures for handling such situations cannot be 
formulated. Instead, each situation must be considered individually, with reference to 
professional guidelines and published literature.
Because of the illegal nature of drug misuse, the complex social and medical issues 
which can be involved and the professional and ethical responsibilities of pharmacists, it 
was considered possible that issues may present during the service that posed one or 
more ethical dilemmas. In handling these, the pharmacist had to be able to exercise her 
professional judgement freely, without any risk this freedom being compromised (8.1.3). 
General discussion about dilemma situations held between the pharmacist and the DA
I t  -
I
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workers led to the conclusion that both had the common aim of promoting the health and 
well being of the patient/client whilst protecting the public from harm. The workers 
supported the need for freedom for the pharmacist to exercise her professional 
judgement.
8.2 Monitoring o f the pharm acist’s service
8.2.1 Enquiry monitoring and data manipulation
8.2.1.1 Paper-based forms
The paper-based forms used to record enquiry information are mentioned in 8.1.4.1 and
8.1.4.2 and shown in appendix 19 and 20. They will now be discussed in more detail. The 
forms were different colours to allow easy recognition. Form 1, which the pharmacist used 
to record enquiries she received, was green and form 2, which was completed by the 
workers for non-urgent enquiries, was yellow. A separate form was used to record each 
contact with the pharmacist. They were based on the form published by Gerret et al 
(1987) and the guidance given by the UKDIPG manual, chapter 8 (1997a) and appendix 
E(UKDIPG, 1997c).
Front of recording forms
The front of the forms were used to record information about the enquiry and only varied 
slightly, so can both be discussed together. As each contact was made, it was 
chronologically assigned a number. The date the contact was made was recorded. 
Enquiries made by telephone were marked with the symbol ( F )  The close proximity of 
the DA base to the university meant information could be delivered by the pharmacist in 
person if required at times outwith the session. This also meant that face-to-face 
enquiries from workers might be presented to the pharmacist at times other than session 
times. Method of contact used by DA staff could therefore be classified, as one of four 
categories: ‘During PS’, ‘At base, not PS’, ‘Telephone* or ‘In writing’ on form 2. Both 
‘During PS and ‘At base, not PS’ refer to face-to-face contact made by the workers when 
the pharmacist was present at the base. However, they were separated to allow use of 
the service during the designated session to be distinguished from use at other times 
when the pharmacist happened to be on the premises.
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Client initial and gender or worker first names and location if from outside organisation, 
were recorded. Enquirers were informed these and details of the enquiry would be 
recorded, and assured of confidentiality and anonymity in any service reporting. Details 
provided in the course of the service, such as names and .addresses e.g. for posting 
information, were recorded on a separate piece of paper, kept with the enquiry form After 
the response was sent the information was destroyed in a shredder. Workers were 
categorised according to the nature of their work at the time the enquiry was made, not 
their job title. This was to establish whether location of work affected use of the service 
For example, if an outreach worker made an enquiry in relation to duty work when 
covering at the base, the enquirer was recorded as a base worker not an outreach 
worker, since they were not acting in their outreach capacity. The following codes were 
used to categorise workers:
WB = worker at the base WP = worker when based at the prison
WO = worker in outreach location (city) WR = worker in outreach location (rural)
Clients were categorised according to their status in relation to drug use e g. primary drug 
user, or secondary to drug user, such as a parent or friend, and whether they self referred 
or were referred by a worker. This allowed investigation into whether clients using the 
service did so as their own decision or whether they were acting on the recommendation 
of a DA worker. Clients who were told about the service by an outside organisation worker 
were counted as having self referred since they had actively chosen to come to DA to 
seek out the pharmacist. The following codes were used to categorise clients:
C1S = Primary drug user, self referred C2S = Secondary to drug user,self referred 
C1W = Primary drug user, worker referred C2W = Secondary to drug user, worker
referred
Outside service workers were assigned the code OS. This included both self referral and 
referral by DA workers to the pharmacist Although the prison officer who had a specialist 
remit for drugs worked closely with the DA criminal justice worker, he was included in the 
outside service worker category as he was not a DA employee.
Information on use of the service was determined for each of the categories described 
above. However, to allow collective information to be reported in chapter 9 for each group 
of service users the following terms have also been used (see fig. 9.1 for illustration):
DA workers', refers to the collective results foi WB, WO, WP and WR, i.e. all contacts oi 
enquiries from the DA workers, not distinguishing for location when enquiry made.
Chapter 8
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‘Members of the public’ refers to the collective results for C1S, C1W, C2S, C2W, i.e. all 
contacts or enquiries from users of the service who were not DA workers or professionals 
from other agencies, not distinguishing between drug user status or method of referral. 
‘Outside service workers’ refers to the results for OS, i.e. all contacts or enquiries from 
professionals from other agencies.
‘Last Date of Use if Applicable’ or ‘A S A P ’ were recorded to allow the enquiry to be 
prioritised. For monitoring purposes, it allowed the number of immediate and non- 
immediate enquiries to be identified. Workers who used form 2 were given the option of 
stating their preferred method of reply from the following options: ‘verbal’, ‘written’ or 
‘published info, requested’. They were also reminded of the day of the PS and of the 
telephone number to call for a quicker response.
A summary of the enquiry was made. On form 1 this was done by the pharmacist, on 
form 2 the DA worker did it. In the case of form 2, if the pharmacist required further 
information, the worker was contacted. In the event of more than one enquiry resulting 
from a single contact, data and response information for each was recorded separately on 
the form.
The question ‘Would you consider asking a chemist in a shop about an enquiry such as 
this?’ was asked to clients only (form 1) and the response noted. It was asked after the 
response to the enquiry was given and included to investigate whether the client would 
consider using a community pharmacist as a reference source
A summary of the response given was made. References, written information and leaflets 
supplied were noted on the forms and copies of written materials produced were 
attached. This was in accordance with UKDIPG (1997b) guidance on copyright laws
Back of recording forms
Table 8.1 was printed on the back of the forms and used to record details of the response 
mechanism. The approximate time taken to prepare the response was recorded. 
Immediate was defined as a response prepared just after the request was received or 
during the course of the session. Non-immediate was any response that required the 
pharmacist to conduct a further information search and respond at a time later than the 
end of the session.
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Combined knowledge: Perceived to be largely based on core knowledge but requiring the 
addition of some further specialist information to enable the pharmacist to process the 
enquiry. It was considered that all pharmacists could process enquiries in this category if 
the necessary information was obtained. No specialisation in the area of drug misuse was 
considered necessary, but knowledge of and access to information sources would be 
required.
Sources of information recorded under further knowledge', ‘literature’ and 'other' were 
listed to provide a reference source to describe how the pharmacist acquired her 
specialist knowledge.
Skills used for enquiry processing
The enquiry responses were subject to content analysis and the skills the pharmacist 
used to provide the service were highlighted. These skills were then defined as being 
‘Core’ which meant they were perceived to be gained at undergraduate or pre-registration 
level or ‘Specialist’ which meant they were perceived to have been acquired specifically 
for delivery of the service. Again reference was made to the RPSGB undergraduate 
syllabus and the pre-registratioq manual. Sources from which the pharmacist learnt 
specialist skills were listed.
8.2.1.3 Data storage and manipulation
As enquiries were processed, information was transferred into a Microsoft Access® 
database for analysis. All computer-stored information was anonymous, so enquirers 
could not be identified from the database. The consecutive number assigned to the 
enquiry was used as the primary key, which identifies data in the database.
8.3 Evaluation o f the pharm acist’s service
8.3.1 Methods used to establish the benefits of service provision to DA clients.
The pharmacist’s service was evaluated by establishing outcomes that were attributed by 
the client or the drugs worker, to the provision of information and/or advice by the 
pharmacist. Client contact was anonymous in so far as only first initial, gender and date of 
contact were recorded. In many cases, clients who saw the pharmacist could have been 
traced through the DA database because the pharmacist became familiar with more
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identifying information during the contact. However, this was considered inappropriate 
and unethical, as it would invade client privacy and breach confidentiality. Instead, only 
clients who made further contact with the pharmacist or had had a three-way contact with 
the pharmacist and their drugs worker were followed up. This avoided any breech of 
confidentiality, since in the latter case, drugs workers were aware the pharmacist had 
given the client information or advice and clients were aware that both the drugs worker 
and pharmacist knew of their issue. These methods also allowed follow-up when client 
approached the agency, which is in keeping with the DA client-led service. The 
disadvantage was that not all clients who received information and advice from the 
pharmacist were followed-up and those who were did not come from a random sample.
8.3.1.1 Data collection
Clients who made contact with the pharmacist at a later date were asked to report on the 
issue that they presented initially to the pharmacist. In the case of three-way contact 
between the client, pharmacist and drugs worker, the drugs workers were asked to inform 
the pharmacist of further contact that related to the enquiry. The main points the 
pharmacist asked either the client or drugs worker were:
I. Was the information/advice followed?
II. What was the outcome?
III. Is further information required?
After a three-way contact, if the drugs worker did not report follow-up, the pharmacist 
periodically asked if such had occurred. The pharmacist recorded the reported 
information on the form shown in appendix 24 [form 3], which was attached to the 
associated enquiry form. The enquiry number was used as identification on form 3. The 
key issues that were identified at first contact with the pharmacist and information'arivicf- 
given in relation to them were recorded on the form. Then for each issue, the responses 
to the three points were recorded under ‘outcome’. Time between pharmacist’s input and 
reported outcome was recorded. If further information was required, it was provided to the 
drugs worker/client and the outcome from this again recorded. This method used informal 
information exchange, which Van Teijlingen and Huby (1998) note as being part of the 
information gathering process in evaluation. The pharmacist used the data on enquiries 
and follow-up to describe case studies that illustrated outcomes that may be attributable 
to input made.
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8.3.2 Methods used to gather staff opinion on the pharmacist’s service
Once the pharmacist’s service had finished, staff opinion was investigated using a 
discussion group. The methods used to conduct this group were based on guidance given 
on focus group discussion by Greenbaum (1993). Group discussion was chosen to 
explore staff opinions as it can generate large amounts of information and has the benefit 
of group interaction. Matters raised could be discussed, endorsed or contested within the 
group to reveal differing opinions. Also, the agency structure was conducive to holding a 
discussion group, as staff are familiar with debating issues and expressing their ideas, 
opinions, concerns and criticisms to and of their colleagues.
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8.3.2.1 Discussion group attendance and timing
A memo was circulated to all drugs workers and the DA co-ordinator one week prior to 
the group being held. This informed them of the intention to hold the group and that 
attendance was voluntary. Staff were informed that quotations used in the research would 
be anonymised. The discussion group was held one month after the pharmacist’s service 
finished. It was conducted prior td a staff team meeting at the DA base, in the meeting 
room. This was done to enable as many staff members as possible to attend, as agency 
services were closed on the morning of the team meetings. A post-service attitude 
questionnaire, which is detailed in 8.3.3, was completed first and the discussion group 
followed.
8.3.2.2 Discussion group format and data collection 
The questions
The discussions held with the DA advisor, co-ordinator and team prior to the service 
commencing (8.1.3) were used to identify the themes of the questions that guided the 
discussion group. Further points the researcher considered significant were also included. 
It was important that the discussion was not too long, to prevent participants from tiring or 
losing interest. Ninety minutes was the proposed duration, which was within the time 
suggested by Greenbaum. In this time it was estimated that six questions could be 
discussed, allowing 15 minutes per question. A list of questions for the discussion group 
were formulated and reviewed by the supervisory team. This was done to examine their 
clarity and purpose. The themes and exact wording of the questions as they were put to 
the group were as follows:
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The researcher specifically endorsed the need for honesty, as It was acknowledged that 
familiarity with the researcher might prevent negative opinions being expressed 
Therefore, participants were also asked to declare any opinions they felt unable to raise in 
the group, anonymously, In writing by post to the researcher..This was also stated in the 
memo circulated the previous week, giving contact details and a deadline of four weeks 
after the discussion group was held.
Round-table discussion was held first, whereby each person was given the opportunity to 
comment. This was followed by open floor discussion The researcher brought about 
closure by asking for any further comments before moving on to the next question. The 
team gave verbal consent the discussion being recorded. This was done using a micro 
cassette recorder, placed on the central table of the meeting room. It was pieviousiy 
checked by the researcher that the device gave a satisfactory recording in a similar 
situation.
8.3.2.3 Data verification and analysis
Immediately after the discussion was held it was fully transcribed. Data was then 
processed using the technique described by Bailey et al (1995). This involved coding the 
statements made into identified themes. The themes were then subjected to progressive 
focusing, to produce key themes that were supported by quotes from the original 
statements.
After the final date for submission of written comments, a report was produced, listing the 
key themes and supporting quotes. A copy was given to each of the discussion group 
participants. In a covering memo, they were asked to make notes on the report if they 
considered any of its content to be inaccurate. If they were satisfied with its content they 
were asked to write ‘approved’ on the top of the report. As this was a further opportunity 
to add comments on issues that were not raised in the group, it was done anonymously 
Participants were given one week in which to respond. The researcher knew how many 
reported had been distributed, so in the event of reports being not returned, the DA 
adviser would remind all participants to return their reports until all had been collected.
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8.3.3 Attitudes of the drugs workers to having a pharmacist attached to the team.
Attitude has been explored extensively in psychology and many theories and definitions of 
it appear to exist. Oppenheim (1992) offers a simple definition, satisfactory for the 
purpose of this study. He reports ‘attitude is a state of readiness, a tendency to respond in 
a certain manner when confronted with certain stimuli’.
Investigation was undertaken into the attitudes of the DA drugs workers towards having a 
pharmacist attached to the team. This was done before and after the period of the 
service, to identify if exposure had changed attitude. The investigation was based on the
method described by Moser and Kalton (1971). Oppenheim (1992) and Coolican (1994) 
using attitude scales on a questionnaire format.
8.3.3.1 Content setting discussion
Content setting discussion was held with the DA adviser to the project and DA co­
ordinator during the planning stage of the pharmacist's service. This was done to 
establish relevant areas concerning staff attitude towards having a pharmacist attached to 
the team. The four areas that emerged from the discussion were:
I. The pharmacist working with clients
II. Contribution of the pharmacist to the team
III. The pharmacist’s understanding of the psycho-social aspects of drug use
IV. The attitude of the pharmacist to drug use/users.
These areas were used to form a bank of attitude statements, used in the design of the 
questionnaire. This design will now be described.
8.3.3.2 Questionnaire design
More attitude statements were generated around areas I and II as the advise: identified a 
greater number of issues relating to these. The statements were worded so some were 
‘favourable’ and some were ’unfavourable’. A favourable statement was one whereby 
agreement with it would reflect a positive attitude to the subject and an unfavourable 
statement one where agreement with it would reflect a negative attitude to the subject. 
The number of favourable and unfavourable statements generated was equal. Neutral
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statements were avoided, as were double negatives or statements perceived to be 
ambiguous. Checks for ambiguity were performed during the validation process (8.3.3.4).
Statements were randomised using random number tables, to. establish the order in which 
they were presented. A summated ratings scale, also known as a Likert scale, was used 
to score the responses to the statements on the questionnaire. The scale allowed 
respondents to express their opinion by rating their agreement with a series of 
statements, as illustrated in the example below:
/ think a pharmacist could contribute positively to the work of the team.
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Statements were scored according to table 8.2. The total score for each respondent was 
achieved by adding up the score given to each response. Note how the scoring system 
was reversed for the unfavourable statements to ensure that attitude was scored in the 
same direction for ail statements i.e. as attitude became more positive the scores 
increased.
Response
Statement Strongly Agree Undecided Disagree Strongly
type Agree Disagree
Favourable 5 4 3 2 1
Unfavourable 1 2 3 4 5
Table 8.2: Scoring method used for the attitude scales.
After the attitude statements, some questions were included in the questionnaire. 
Different questions were used for the pre-service questionnaire and the post-service 
questionnaire. On the former, the following questions were asked, leaving space for 
response to be written:
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1. Please briefly describe what you see, if any, the main role of a pharmacist at Drags Action to be:
2. Please briefly describe reservations, if any, you have about a pharmacist coming to work at 1 >mg> w -mi:
On the post-service questionnaire, again leaving space for response, staff were asked:
1. Based on your knowledge, experience and opinion of the pharmacy sessions which were provided at 
Drags Action, do you think there is a role for a pharmacist as part of the team?
'i cs No
If you answered yes to the above question, please expand by stating what you see the main role to be:
If you answered no, please expand by explaining why you think no role exists:
The open questions were analysed and categorised into themes. Responses to the 
closed question options were counted.
8.3.3.3 Validation
Y  • ; 1 ■"v , . • • - „
The questionnaire had to be validated to check it would measure what it intended, which 
was attitude of the DA staff team to having a pharmacist working as part of the team. A 
valid questionnaire would allow differences in the scores of individuals to be interpreted 
as differences in their attitude to the subject. The questionnaire could not be piloted on a 
large enough sample to test validity or reliability because the total population i.e. all the 
DA drugs workers, was not large (n = 11, at pre-service measurement). The investigation 
was unique to the particular agency, therefore using drugs workers from another agency 
would not have given data that could be assumed comparable to DA. For this reason 
validity and reliability were checked using other means.
The questionnaire was subject to content validity, as follows. A team of judges, consisting 
of the director of studies, the two project supervisors and the adviser from Grampian 
Health Board were asked to examine the statements and questions. They were told of the 
four areas that had been identified through content setting discussion with the DA adviser. 
They were then asked to check whether they considered a full range of attitudes to be 
covered. As a result of this assessment, an additional statement was generated on 
knowledge of drugs of abuse.
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8.3.3.4 Piloting
The first draft of the pre-service questionnaire was piloted on two DA outreach workers to 
check that it was appropriate for the group under investigation. It was important to pilot 
the questionnaire on people who were part of the group. The purpose of the pilot was to 
review the statements for understanding and clarity. The workers were asked to respond 
to the statements, but when doing so they were also asked to write comments, thoughts 
or contradictions the statements generated in their mind beside the statements. The final 
pre and post service questionnaires are shown in appendix 25 and 26.
8.3.3.5 Reliability
It was important to check the attitude scale was reliable; meaning repeated measurement 
made under constant conditions would give the same results. Any statements not found 
to be reliable had to be removed from the scale. Reliability could not be checked by 
repeated measurement with the scale because constant conditions could not be 
controlled. For example, if the same respondents had been used to repeat the measure at 
a later date, they may remember their responses to the first test and repeat them exactly, 
thus indicating falsely high reliability. Alternatively, respondents may have considered the 
survey subject more in the interim period, for example the DA workers may have 
discussed the issues raised amongst themselves, with clients or another pharmacist, 
which may change their attitude and thus responses. Therefore, the pre-service 
questionnaire was administered and reliability checks performed subsequently.
Presenting three issues in both favourable and unfavourable forms checked internal 
reliability of the pre-service questionnaire. These were statement nos 4 & 5, 9 & 13 and 
10 & 16. The scores for each statement in the pair were compared. Reliability was 
assumed if these statement scores had no difference for the majority of respondents.
Internal reliability analysis was performed using SPSS version 6 { software (SPSS in; 
Illinois, USA) as described by Norusis (1992). The statistics requested were Inter-item 
correlations and Summaries of correlations, using 'descriptives for the scale if the item 
was deleted'. This was to ensure the item was not contributing to the total with which its 
correlation was being calculated. The Inter-item correlation calculation returned a 
correlation matrix. Negative and low numbers indicate items with no or little correlation. 
Also returned were the Item-total Statistics. This is a table that details the item-total 
correlation (Pearson’s co-efficient) and Cronbach's alpha if item deleted. Both these
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statistics are indicators of reliability. Pearson’s co-efficient should be above 0.2 (Streiner 
and Norman, 1989) to confirm correlation. The Summaries of correlations returned the 
Cronbach’s alpha for the overall scale, which is a reliability coefficient, giving a measure 
of internal consistency. The higher the alpha value the greater the overall reliability. This 
value should be above 0.7 (Bowling, 1997). Statements that gave many negative or low 
numbers on the correlation matrix indicated they should be removed from the scale. 
Statements that gave Item-total correlation below 0.2 also suggested they should be 
removed. The values of Cronbach’s alpha if item deleted for each statement also 
confirmed statements that on removal would increase the overall reliability of the scale. 
These checks were run and the relevant items removed from the scale. The value of 
Cronbach’s alpha after statement removal was checked to ensure reliability had been 
increased to a satisfactory level.
Attitude scores were calculated using only the statements that remained after the 
reliability analysis had been performed. For statements pairs that remained after the 
internal reliability analysis, their combined score was halved, since both statements asked 
the same thing.
i
8.3.3.6 Investigation into the impact of the pharmacist’s service on staff attitudes
Due to staffing changes, not all staff that completed the pre service questionnaire were 
available to complete the post service questionnaire. Attitude scores were calculated for 
staff that were able to complete both. A Wilcoxon Matched-Pairs Signed-Ranks test was 
performed using SPSS, to investigate if there was any significant difference between pre 
and post questionnaire scores. The test statistic, Z, was compared with the standard 
normal statistic, Z-score [one-tailed test at 95% confidence] to test whether there was 
any significant difference between the pre and post service attitude scores. If the test 
statistic fell outside of the Z-score on the distribution, the hypothesis that there was no 
significant difference between the pre and post service attitude scores could be rejected.
8.3.3J Administration of the attitude survey 
Pre-service questionnaire
The pre-service questionnaire was completed by DA drugs workers and the co-ordinator 
prior to the meeting where the proposal for the pharmacist’s service was taken to the 
team. Participation in the questionnaire was voluntary and anonymous. Care had been
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taken not to discuss the proposal with any team members except the DA adviser and co­
ordinator. These people were included in the respondent group. The team meeting setting 
was used because it allowed quick and co-ordinated distribution of questionnaires, 
ensuring discussion with fellow workers could not influence- response. The researcher 
asked the participants not to consider her or any particular pharmacist they knew, but to 
consider their opinions in relation to pharmacists in general. The questionnaires were 
completed and immediately returned to the researcher, to maximise response. Two 
workers who were not present at the meeting completed the questionnaire three working 
days later.
Post-service questionnaire
The post service questionnaire was completed again prior to a team meeting, one month 
after the service ended. Participation was again voluntary and anonymous, with staff 
being given one week’s notice. Respondents were asked to consider their attitude after 
exposure to the pharmacist’s service.
Coding
The researcher made a list of the order that the workers handed in the completed 
questionnaires. The names and corresponding questionnaires were numbered. This 
enabled the researcher to identify the respondent’s pre and post service questionnaires, 
allowing responses to be compared The respondents were not made aware of this 
coding.
8.3.4 Cost of the service provision
No pharmaco-economic evaluation of the service was conducted. However, calculation of 
the approximate cost of the provision of the service was done to give an indication of the 
funds that may be required for such a service. This was done using the information 
recorded on the monitoring forms and on the sheets that recorded use of DA resources 
The total time spent by the pharmacist providing the service was calculated by multiplying 
the hours spent providing the service by the rate that the School of Pharmacy charged for 
consultancy and locum work, which was £14.36 per hour. Ten percent was added for 
National Insurance. Photocopying costs were calculated at the estimated cost of 4p per 
sheet. Telephone call destination and duration had also been recorded. Costs were based 
on the current BT charges at the time the service ended, which were 2p per minute for
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local calls and 10pm per minute for national calls. A list of the leaflets and quantities 
distributed by the pharmacist was given to a DA administration worker, who calculated the 
cost of these to the agency. Papers requested from the university inter library loans (ILL) 
service for use in enquiry answering were costed at £5:00 each, as quoted by the School 
of Pharmacy subject librarian.
Chapter 9
Chapter Nine
Results
9.1 P harm acis t’s service  a c tiv ity  data
9.1.1 Number of contacts made with the pharmacist and enquirer categories.
A total of 77 contacts were made with the pharmacist during the 26 weeks that the service 
was in operation. Of the 77 contacts, 45 were with Drugs Action workers, 25 with 
members of the public and 7 with workers from outside organisations. Figure 9.1 shows 
these values as a percentage of the total number of contacts.
E n qu irer category
Figure 9.1 Percentage o f total number o f contacts (n = 77) made by each enquirer category
Use of the service by Drugs Action workers
Of the 45 contacts made by DA workers, 39 (87%) were made while working at the base, 
5 (11%) were made from a city outreach location and 1 (2%) was made from a rural 
outreach location. None came from a drugs worker at the prison.
Use o f the service by members o f the public
Of the 25 contacts made by members of the public, 22 (88%) were with drug users and 
three (12%) were with people secondary to a drug user. Of these, two were made by 
family members and one made by a friend. Of the 22 contacts with drug users, 21 (95%)
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were referred by a DA worker and 1 (5%) self referred. Of the 3 contacts with people 
secondary to a drug user, 2 (66%) were referred by a DA worker and 1 (33%) self 
referred. Overall, a DA worker referred 92% of the members of the public.
Use of the service by workers from outside organisations.
There were 7 contacts made with the pharmacist by people who worked for outside 
organisations. Of these, three were from a prison officer with a specialist remit for drugs 
education, one was from a police officer, two were from workers in care homes and one 
was from a nurse with a specialist remit for drug treatment.
Table 9.1 summarises the number of contacts broken down into each enquirer group and 
the percentage of the total number of contacts that these figures represent.
Service user group No. of contacts (n = 77) (% of total)
Drugs worker working at the base 39 (51%)
Primary drug user referred by worker 21 (27%)
Outside organisation worker 7 (9%)
Drugs worker at city outreach location 5 (7%)
Person secondary to drug user referred by 
worker
2 (3%)
Person secondary to drug user who self 
referred
1 (1%)
Primary drug user who self referred 1(1%)
Drugs worker at rural outreach location 1 (1%)
Drugs worker when based at the prison 0 (0%)
Tab le 9.1 N u m b e r a n d  p e rc e n ta g e  o f  co n ta c ts  th a t u s e d  the p h a rm a c is t ’s se rv ice , sh o w n  by ca teg ory  
o f  enquirer.
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Figure 9.2 shows the number of contacts each week, over the 26-week period. Note the 
pharmacist was on annual leave the week beginning 23.09.97, so this has not been 
included. Figure 9.3 shows same information as fig. 9.2 but broken down for each enquirer 
group.
W e e k  c o m m e n c in g
Figure 9.2 Number o f contacts per week made with the pharmacist
W e e k c o m m e n c in g
Figure 9.3 Number o f contacts made per week by each enquirer group
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9.1.2 Methods of Contact
Members of the public and workers from outside organisations could only access the 
pharmacist during the session on a Tuesday afternoon. DA workers could access the 
pharmacist during all working hours of the 26 weeks in which the service ran. The method 
of contact used by the DA workers is shown in table 9.2.
Method of Contact No. of contacts (n = 45) (% of total)
During pharmacist’s 22 (49%)
session
At base NOT session 7(15.5%)
Form 2 9 (20%)
Telephone 7 (15.5%)
Table 9.2 Methods o f contact used by Drugs Action workers
9.1.3 Number of enquiries made
The majority of contacts presented one enquiry (n = 69). However, six presented 2 
enquiries and two presented 3 enquiries. This gave a total of 87 enquiries received. Of 
these, 49 came from DA workers, 31 from members of the public and 7 from outside 
service workers. This is illustrated in figure 9.4.
E n qu irer category
Figure 9.4 Percentage o f the total number o f enquiries made by each group o f service users (n =87).
2 0 8
Chapter 9
9.1.4 Urgency with which contacts required a response
Forty-nine (64%) of the contacts presented enquiries that required a response as soon as 
possible. Of these, 24 were members of the public (49%),- 3 (6%) were from outside 
organisations and 22 (45%) were DA workers.
Of the 49 contacts that required a response as soon as possible, 94% received a 
response immediately, defined as straight away or within the duration of the Pharmacist’s 
Session or equivalent time frame. The remaining three received a response within 1 day, 
3 days and 6 days respectively.
9.1.5 Consideration given to using a community pharmacist to obtain information
The members of the public who used the pharmacist’s service reported in the main it 
would be unlikely that they would consider asking a community pharmacist a similar type 
of enquiry, although some said they may do so, depending on the nature of the question 
and their perceptions of the pharmacist. Some mentioned specific community 
pharmacists whom they perceived to have a positive attitude towards drug users, which 
may encourage them to ask for information. No one made any direct reference to 
perceived knowledge of pharmacists, although many indicated they associated Drugs 
Action with the provision of specialist information. The non-judgmental attitude of DA staff 
towards drug use was also cited as a reason for asking for advice at DA. Two people had 
consulted a community pharmacist but were not satisfied with the information they 
received, so they then contacted Drugs Action.
9.1.6 Categories o f enquiry
From the 87 enquiries received by the pharmacist, a total of 11 different categories were 
identified. These categories and the number of enquiries in each are shown in table 9.3. 
This table also details the abbreviations use to refer to the categories later in the text.
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Category Abbreviation use 
for category
Number of 
enquiries
% of total 
(n = 87)
Drug Information (.prescribed; DI v P y Î à l /U
Drug Information 
(not prescribed)
DI(NP) 14 16%
Drug Testing DT 13 15%
Health Problem (drug related) HP(D) 8 9%
Identification ID 7 8%
Harm reduction techniques HRT 7 8%
Other 0 7 8%
Medical Information Ml 6 7%
Pharmaceutical services PS 3 4%
Adverse drug reaction 
(prescribed)
ADR(P) 2 2%
Adverse drug reaction 
(not prescribed)
ADR(NP) 2 2%
Table 9.3 The categories of enquiry dealt with by the pharmacist’s service, abbreviation used, number 
of enquiries in each category and percentage of the total that this represents.
Although mostly self-explanatory, a brief description of the categories will now be given 
‘Drug Information (Prescribed) 1 ’ relates to requests for information on prescribed drugs 
whereas ‘Drug Information (Not Prescribed)’ relates to requests for information on non- 
prescribed drugs. ‘Drug Testing’ relates to enquiries about the testing of body fluids as an 
indicator of recent drug use. Enquiries in the category ‘Health Problem (Drug related)'
' in  all cases, the term  prescribed refers to  m ed ic ina l products taken under the d irection o f a m ed ica l practitioner or counter- 
p rescribed by a pharm acist. ' j
• i ■
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were about health problems that the pharmacist considered were attributable to the non­
medical use of drugs. ‘Identification’ was concerned with the identification of 
pharmaceuticals or street drugs. ‘Harm Reduction Techniques’ refers to enquiries that 
advised on techniques to reduce injecting related harm.- ‘Medical Information’ was 
concerned with the provision of information on medical as opposed to pharmaceutical 
matters. Enquiries about services from community pharmacists were grouped under 
‘Pharmaceutical Services’. Enquiries in the category ‘Adverse Drug Reaction (Prescribed)1 
related to adverse reactions to drugs that had been prescribed. Enquiries in the category 
‘Adverse Drug Reaction (Not Prescribed)’ related to adverse reactions to non-prescribed 
drugs. Enquiries that did not apply in any of the other identified categories and had no 
common theme between were placed in the category ‘O ther’.
Appendix 27 contains two examples of enquiries in each category. These are given to 
assist with understanding of the categorisation and to provide an insight into the nature of 
the enquiries received. Further examples are used later in the text, when discussing 
ethical dilemmas and client outcomes.
9.1.7 Methods of reply . '
The pharmacist used a total of nine different combinations of methods of reply. Table 9.4 
■shows these methods of reply and the percentage of contacts in each group whc were 
responded to using the method stated.
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E n q u ir e r  c a te g o r y
M e t h o d  o f  r e p l y
DA worker 
(n = 45) (%)
Member of the 
Public (n = 25) (%)
Outside service 
worker (n = 7) (%)
V e rb a l 22 (49) 19(76) 4 (5 7 )
V e rb a l &  L e a fle t 3(12)
V e rb a l & P u b lis h e d  
info.
8(1 8 )
V e rb a l & W ritten  info. 6(1 3 ) 2 (8 )
V e rb a l & W ritten  info. 
& L e a fle t
1 (4)
V e rb a l & W ritten  info. 
& P u b lis h e d  info.
1 (2)
W ritten  info. 6 (1 3 ) 1 (14)
W ritten  & P u b lis h e d  
info.
1 (2) 2 (28)
W ritten  & P u b lis h e d  
Info . & o th e r
1 (2)
Table 9.4 Methods of reply used to deliver Information from the pharmacist's service, shown as the 
number and percentage of the total no. enquiries from each group that received replies in the stated 
format.
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9.1.8 Ethical and moral dilemmas
Four areas arose that presented ethical and/or moral dilemmas. They were:
• Provision of information to third parties (two dilemmas)
• Verification of information from another professional source (three dilemmas)
• Provision of information on drug testing (six dilemmas)
• Identification of unknown tablets/capsules (six dilemmas)
After consideration and consultation of the literature, all the dilemmas were responded to, 
to varying degrees. The competing value considered to be at the greater risk from harm 
was the one that was given priority. The pharmacist attempted to achieved a balance 
between the competing values as far as possible. Further details of the dilemmas and the 
handling procedures used are described in appendix 28.
9.1.9 Knowledge requirements and categorisation
Of the 87 enquiries received, 45 were answered using core knowledge, 20 used specialist 
knowledge and 22 used a combination of both. The proportions of the total number of 
enquiries that these figures represent are shown in figure 9.5.
There were two categories of enquiry where the pharmacist considered core knowledge 
alone was not used to respond to any of the enquiries. These were harm reduction 
techniques and adverse drug reactions to non-prescribed drugs. At least one enquiry in 
all of the other categories had been answered using core knowledge alone. Core 
knowledge was used to answer all the drug information (prescribed) enquiries and many 
of the non-prescribed.
Specialist knowledge was used when responding to enquiries that fell into six of the 
categories. These were: drug testing, harm reduction techniques, adverse drug reactions 
(non-prescribed), identification, medical information and other.
Eight categories contained at least one enquiry that required a combination of core and 
specialist knowledge. These were health problem (drug related), harm reduction 
techniques, drug information (non-prescribed), drug information (prescribed), medical 
information, identification, adverse drug reaction (non-prescribed) and other.
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23%
□  C o re
□  S p e c ia lis t
□  C o m b in e d
Figure 9.5 Knowledge requirements needed to answer to enquiries received by the pharm acist (n = 
87).
The major topics of core knowledge that were involved in the enquiry answering process 
were:
• Knowledge of prescribed drugs
• Drug delivery routes
• Anatomy and physiology
• Therapeutics of substitute prescribing
• Assessment of presenting symptoms
• Ethics
• Pharmaceutical service provision
• Care planning
• Primary and secondary health-care systems
The major topics of specialist knowledge that were involved in the enquiry answering 
process were: •
• Drug testing in body fluids
• Harm reduction principles and techniques
• National and local statistic keeping
• Social services and welfare rights
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• 'Set and SettingK. the psychology, social context and associated factors that 
impinge on drug use
• Terms and expressions used by drug users
• The drug-using sub culture
The major topics of combined knowledge that were involved in the enquiry answering 
process were:
• Pharmacology of street drugs
• Risks and complications associated with injecting drug use
• Health problems associated with the use of street drugs
• Legal implications of drug taking
Information sources used by the pharmacist to acquire specialist knowledge necessary 
for the provision of the service were: •
• Text and resource books.
• Health Education Authority/Board publications.
• Specialist journals.
• Conference presentations and proceedings.
• Specialist services (inc. ISDD, HIT, Lifeline, Tic-Tac, National Poisons Unit).
• Data sheets and company literature.
• Postgraduate education packages and multidisciplinary seminars (e g. SCPPE, 
Safer Injecting Training Day (HIT, Liverpool)).
• Drugs Action in-house training materials
• Grampian Health Board.
• Home Office (Action Against Drugs Unit).
• World Wide Web.
• Discussion with drug users.
• Discussion with other professionals.
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9.1.10 Skill requirements in the provision of the pharmacist’s service
Core skills that were required when providing the service were:
• Information retrieval
• Information interpretation
• Patient and drug history taking
• Effective communication with other professionals.
• Effective, non-patronising communication with members of the public.
• Decision making with respect to the provision of information in the context of 
each situation.
• Relation of information to the individual circumstances and people concerned.
Specialist skills that were required:
• The ability to translate information into terms used in the drug culture.
\
This skill was learned by discussion with and observation of drugs workers in practice 
before the research began and through popular culture media.
9.2 Evaluation o f pharm acist’s service
9.2.1 Client follow-up
Of the 25 members of the public who used the pharmacist’s service, nine (36%) were 
followed up at a later date when they made contact with the agency. Four were followed 
up through direct contact with the pharmacist and five were reported via drugs workers. 
The nine cases presented 13 different issues from which to establish outcomes. All the 
outcomes, with the exception of one, were considered by the pharmacist to be positive. 
The negative outcome was when consented divulgence of information to a Substance 
Misuse Service nurse led to the patient being discharged from care Three of the cases 
received further input from the pharmacist at follow up: one directly relating to the matter 
concerned where the opportunity arose to give information and advice on warfarin and 
two where the clients presented for further unrelated assistance. These nine case studies 
including the outcomes are described in appendix 29.
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Nine drugs workers and the agency co-ordinator were present when the discussion group 
was held. The group lasted 80 minutes. No written comments-were received The labelled 
themes, which categorised the expressed opinions from the group discussion, are listed 
below. Quotes from the participants, which illustrate the themes are given.
Question 1: T o  those who used the pharmacist’s sessions, can you tell me what you 
thought of the service?'
Theme 1: The pharmacist enhanced the service provided by the multidisciplinary team at 
Drugs Action.
Supporting quotes:
'It has really enhanced the service and given us more knowledge than we 
would've had..and [given us] knowledge about where to go if you need to find out 
things'. \
(base worker)
‘It really did help..it complements a multidisciplinary team'
(prison worker)
'It has been a luxury...it has been really, really helpful and useful....it's been a 
great service.'
(base worker)
'Lots of help, lots of information, especially having a lot of knowledge about drugs 
and it's just been brilliant to be able to come to yourself
(HIV/Hep C worker)
7 found the responses very, very valuable and illuminating. '
(co-ordinator)
'Easily accessible, efficient, very thorough, user friendly in formation...[ it] raised 
issues I hadn't thought of which were of benefit to the client'
(base worker)
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Theme 2: The centre-based nature of the service determined the workers and clients who 
were able to make most use of the service. Workers based at outside locations were 
restricted in how much they could use the service because information has to be to hand 
when responding to clients.
'...’cause it was a centre based service, i got less service out of you as a 
pharmacist as I did when you did cover with the outreach team2.'
(outreach worker)
'...[I agree with] the point made by [name of outreach worker who made above 
comment] about not being centre based, but often I found information in my 
pigeonhole which I appreciated'
(prison worker)
Theme 3: The pharmacist played a role in resourcing information
’It's good to know there is somebody there who knows the stuff that you know and 
it saves us looking up reference books when you are the source of the information 
right there and we can just get hold of you and save us time and mucking about 
trying to find out bits and pieces'
(outreach worker)
'when we wanted to check details about the Release leaflet [information leaflet 
which was available from a youth project in Aberdeen, produced by the agency 
Release on urine testing for illicit drugs in schools].you contacted the National 
Poisons Unit. Also when trying to find a tablet, you contacted the Tic-Tac 
system..that was really useful.'
(outreach worker)
2
This  com m ent referred to  tim es when the pharm acist had gone to ou treach  locations w ith the w orkers to experience 
practice.
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Theme 4: The pharmacist increased drugs worker's knowledge and understanding of 
pharmaceutical and medical information
'It has saved us loads of time and not just time but ■really it has been easier to 
interpret information and I think it has been a brilliant resource.'
(base worker)
'Sometimes we know things but we don't know how we know them, you've given 
us a medical reason why certain drugs do things or why it's not right to prescribe 
whatever, it has been really good for us to challenge bad prescribing...we've got 
medical back up ourselves, so it enhances it [challenging preservers]'
(base worker)
'..explaining to me what certain tablets do that I don't know..very useful'
(outreach worker)
'..you gave good feedback on intramuscular injecting. I thought the potential to 
develop an agency leaflet is there and I'd like to explore that with you..'.
\ (co-ordinator)
Theme 5: The pharmacist played a role in discussing and explaining pharmaceutical care 
issues with clients and workers
7 was glad when you came into peoples’ appointments, [gives name of a client 
described in appendix 28, case study 7 and described scenario]..he was really 
scared about the effects it would have on his body and going through these....and 
when the withdrawals would happen. Even though I was trying to say things to 
help him, for the pharmacist to come in as well and say the same kind ol things 
but in more detail, was good and it was true what happened to him afterwards. He 
was shitting it that he'd have really bad withdrawal and you said he wouldn't and 
he didn't.'
(outreach worker)
'One of the things I found was that clients who had already seen you.. I was 
picking up on chats they had already had with you, and I was able to talk to you 
about clients. It meant next time I saw the same client I was informed about it'.
(prison worker)
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'It was very useful to have a pharmacist here, especially when I was dealing with a 
client and his partner, who I guess didn't really want to believe us and anything we 
were saying and the doctor was saying. But when Jenny was involved she sat and 
listened and instead of it being me or the male doctor-telling her how it was going 
to be, it was a woman speaking to her, a female pharmacist, who had the 
knowledge as well. That I found was incredibly useful for her to get a bit ot 
understanding about her husband's situation"
(HIV/Hep C worker)
Question 2: ‘Have your views and opinions on the skills of a pharmacist changed at all by 
having this service at DA?’
It was asked if this question was specific to the pharmacist who conducted the sessions 
or if it was referring to all pharmacists, so the question was rephrased as follows:
7 would say all pharmacists. Do you feel there were interventions made, things discussed, 
topics covered, which you didn't think were part of a pharmacist's job or do you think you 
weren't suprised by the kind of service delivered?'
Theme 1: The work of an individual cannot be perceived to represent that of the 
profession.
7 wouldn't generalise about all pharmacists based on the service that you 
provided. Attitude, knowledge and standards are based on individuals skills and 
would have to be proved by individual pharmacists....what I'm trying to say is, I'd 
have concerns about pharmacists in general and would have to base my opinions 
on individuals and not the profession'
(base worker)
Theme 2: It was felt that a specialist pharmacist is likely to have a greater level of 
knowledge and understanding of the drugs field than a community pharmacist.
'I'd be suprised if most other pharmacists had the level of knowledge that you 
have in such a specialised subject, my experience is that they've not seemed to 
have that insight into users, or effect (of drugs] etc'.
(outreach worker)
i •'I {
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'When you and Luan [the needle exchange worker] were doing training, things you 
were discussing and things they [community pharmacists who provide needle 
exchange] were coming out with [referring to questions raised] were things you 
knew, so there is a difference between you. '
(outreach worker)
Theme 3: The experience of the agency of having a specialist pharmacist was seen to 
have raised expectations of the workers from other pharmacists. However, it was thought 
that other pharmacists do have access to information and knowledge, but often drug 
users are discriminated against on the basis of morals.
'Knowing what Jenny knows, I think we can now expect them [community 
pharmacists] to tell us things and find things out..'
(outreach worker)
'All pharmacists should be able to put skills into practice, but they cannot be 
bothered [with drug users]'
(base worker)
\. I
'Even the basic stuff that pharmacists will know..they don't want to give 
information or, because of their attitudes, they don't want to enter into any 
conversation'
(HIV/Hep C worker)
'Without complimenting you, I think you're doing what pharmacists, I think, should 
be doing, which is work in a non discriminatory way, working actively, trying to 
look at a particular unsympathetic client group. '
(outreach worker)
Theme 4: Some health professionals, including pharmacists, were seen to have a lack of 
ability to view the person holistically, which was considered important.
7 think sometimes there is a tendency to generalise and maybe stereotype Sadly 
sometimes the stereotypes or experiences are true. In the medical profession and 
other professions like that, often we come up against people who devalue the 
human component, you know they are very reductionist and look at bits of people, 
they are not looking at the person and they don't have the values of respecting 
people'. (co-ordinator)
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Question 3: ‘One area of concern before the sessions started was about communication, 
pharmacist's communication with staff and particularly clients. Can you comment on 
communication with staff and clients?'
It was confirmed that this was referring to communication during the pharmacist's 
sessions not community pharmacists.
Theme 1: Response to queries from workers was delivered quickly.
'You were always quick to respond'
(outreach worker)
'Quick, information you gave came in next day or next two days..'
(outreach worker)
'Quick to respond'
(base worker)
Theme 2: Workers were confident in the responses they received from the pharmacist.
7 was clear about how much something was checked and how clear you were 
about it, what was speculation and what was fact and what could be proved and 
what couldn't.'
(outreach worked
7 always felt confident in the service you were providing, that it was always going 
to be good and the information you were providing was going to be accurate...'
(outreach worker)
'Communication with me, as a worker, was efficient and suited my needs'
(base worker)
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Theme 2: Communication with clients was clear and appropriate
'When you were speaking to clients you didn't speak in the medical words, it was 
all really easy to understand and not done in a patronising way or condescending 
at all. It was all just straight forward and cut through all the jargon'.
(base worker)
'You can explain things to them (clients) without patronising them. That's really 
important.'
(outreach worker)
'Also, when you did speak to them, you took time to make sure they understood 
what you'd said, which I think is really important and necessary. Once clients 
started a dialogue, they felt comfortable enough to ask more questions. ’
(HIV/Hep C worker)
Theme 3: If a query arose when the pharmacist wasn't present, sometimes the response
was not used if the client made no further contact.
\
'The only difficulty was relaying info to the clients that I see sporadically, i.e. if the 
query wasn't on a Tuesday afternoon and was therefore written, the clients 
sometimes didn't return for the info.'
(base worker)
Question 4: ‘The attitude of the pharmacist to drug users was expressed as another area 
of concern before the sessions started. Can you comment?’ [the group asked for further 
explanation, so the researcher added: '..concerns were expressed about being 
judgmental and how clients might feel].
Theme 1: The pharmacist was perceived to have a positive non-judgemental attitude 
appropriate for working with drug users.
'Your attitudes are obviously non-discriminatory and you have had a lot of positive 
contact with drug users'
(base worker)
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'Your attitudes are good'
(outreach worker)
'You were seeing the person as a whole, not just these are all drug users, 
therefore everything that is wrong with them is to do with their drug use'
(base worker)
'When I told you a client you'd seen had been in to see me, you were very 
concerned to know how his health was, to follow through the information from me. 
That showed nothing but a healthy attitude towards the needs of the client and 
showed genuine concerns about his long term health ...'
(prison worker)
'What you were displaying was the possibility and potential for a non- 
discriminatory practice.'
(co-ordinator)
Theme 2: Clients may have had perceptions about pharmacists based on past
\
experiences. However, the reputation that Drugs Action has with drug users, meant 
implicit trust was placed in the pharmacist.
'I've had to explain to someone that you're not here as a pharmacist in a chemists 
shop and you're not going to cut their 'script or things like that. I have had to do 
that. Once I'd explained it, they were all right, maybe a bit dubious because of 
their experiences with pharmacists from before, but once you show your actual 
attitude then they know you're all right'
(outreach worker)
A lot of it [attitudes and how clients might feel] is based simply on the fact that folk 
will have 'blind trust' -the recommendation from someone they trust, e.g. the drugs 
worker introduces client to pharmacist....it's like, you are another Drugs Action 
worker and that has been people's perceptions, partly because they've been 
guided, but there haven't been any blocks, I haven't heard any fears. People have 
been kind of glad that there is something they can access'.
(outreach worker)
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7 must admit I was a wee bit apprehensive as to how clients would be when we 
said we had a pharmacist and she can come and speak to you, I did wonder how 
that'd be..they were great. I think that is also a reflection on how they view our 
service as well'
(HIV/Hep C worker)
Question 5: ‘How do you think the clients felt about talking to me? Consider any 
feedback you may have got and consider confidentiality, that was something that was 
expressed that clients may not feel comfortable with...that the service that was being 
provided was confidential.’
Theme 1: It was felt confidentiality was perceived to be assured because of the reputation 
of the agency.
'..the fact you were a colleague, one or two needed reassured...[but] it was taken 
> as read that the confidentiality thing of the whole agency was taken to mean the 
pharmacist as well.' '
(HIV/Hep C worker)
I don't think there were any problems with that [client's trusting the service to be 
confidential], not in my experience.'
(HIV/Hep C worker)
'From what folk are saying, the confidentiality thing was the odd exception, which 
is what happens with us. There is the odd person who needs reassurance e.g. 'is 
getting works here going to affect my script?’
(outreach worker)
Question 6: 'Do you have any concerns you want to express about the service?’
Theme 1: It was perceived that the pharmacist's service had become an established part 
of Drugs Action services, withdrawing it because the study was over meant letting people 
down.
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'The main one [concern] is that we've raised expectations of clients for you to be 
here.'
(needle exchange worker)
'..some clients who've come along and got a bit of information, come back for 
some more information or help and support 'cause they knew you were here and 
again, it's about for the agency and directly for our clients..'
(HIV/Hep C worker)
'If I could say, okay we've had our own pharmacist, but you'll get this somewhere 
else...but, I don't think people are connecting with that...I think they'd be foolish to. 
I think they're right not to think I'll be able to go into a pharmacy and feel 
comfortable speaking to the pharmacist...'
(outreach worker)
7 have no concerns, but I would like to see a service provided with more sessions, 
so that communication [of information] to clients was improved'
(base worker)
All participants approved the discussion group report as being accurate within the given 
time frame.
9.2.3 Attitude Measurements of DA workers
Eleven out of the fourteen drugs workers employed at the start of the pharmacist's 
service completed the pre-service attitude questionnaire. Of the three who did not, one 
was on long-term sick leave, one was on maternity leave and one worked only one 
evening a fortnight and did not attend team meetings.
9.2.3.1 Piloting
As a result of the pilot study, statements relating to the provision of information on 
mandatory drug testing in prisons to workers and clients were removed, as the 
respondents considered it irrelevant. The balance between positive and negative 
statements was maintained.
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9.2.3.1 Reliability checks 
Internal reliability.
The responses to the paired statements are compared in table 9.5. The difference in 
scores for each pair of statements was calculated for each respondent. These are shown 
by the number of respondents who achieved the stated differences (minimum 0 and 
maximum 4) and the percentage of the total number of respondents (n = 11) that this 
represents.
Difference between statement scores
Statement Pairs 0 1 2 3 4
4 l think the clients would teel
comfortable talking to a pharmacist at 
DA.
6 4 1 0 0
5 I think the clients would not feel 
comfortable talking to a pharmacist at 
DA
(55%) (36%) (9%)
9 I think the clients would beneiit from
having a pharmacist at DA.
8 3 0 0 0
13 I think a pharmacist would not be 
much use to DA clients.
(73%) (27%)
10 I think a pharmacist would not be able 
to contribute positively to the team.
7 4 0 0 0
16 I think a pharmacist could contribute 
positively to the work of the team.
(64%) (36%)
Table 9.5. Difference in scores to paired statements, shown by number of respondents (n = 11) who 
achieved this score. (Percentage of the total number of respondents in brackets)
The majority of respondents scored both statements in the pair the same, suggesting the 
questionnaire had satisfactory internal reliability.
Reliability Analysis.
The statistical output from SPSS lead to the removal of some statements as explained: 
Statement number 1 was ignored by SPSS as all respondents gave the same response, 
so there was zero variance. Using the 19 statements that were left, the Cronbach's alpha 
achieved for the scale was 0.1807.
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'Alpha if Item Deleted' indicated removal of number 18 would greatly improve internal 
consistency. This was done and Cronbach's alpha became 0.7902. Looking at the 
Corrected Item-Total Correlation, three statements had a correlation of less than 0.2. 
These were statement numbers 5, 6 and 11. These were-removed and the analysis 
performed again. All statements now gave a Corrected Item-Total correlation above 0.2 
and the value of Cronbach's alpha was 0.8327. However, the Correlation Matrix indicated 
some statements still had low or negative correlation with others, although their overall 
correlation with the scale was adequate. These statements were numbers 4, 2, 19 and 
20. These were removed and again the analysis performed. The resulting Correlation 
Matrix indicated a positive correlation between all statements. All Corrected Item-Total 
Correlations were satisfactory and the value of Cronbach’s alpha had been raised to 
0 8641
Table 9.6 summarises the statements that were removed and those that were kept for the 
attitude comparison.
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Statements Used to Score Attitude Statements Removed
i
3, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17 1, 2, 4, 5, 6, 11, 18, 19, 20
Table 9.6 Results from reliability analysis
9.2.3.2 Attitude scores
The minimum attitude score possible with eleven statements was 9. This would indicate 
the most unfavourable attitude. The maximum score possible was 45, indicating the most 
favourable attitude.
Nine respondents completed both the before and after attitude questionnaires, so their 
pre- and post-service attitudes could be compared. The scores of the respondents are 
shown in table 9.7. Note, no respondent chose the ‘Not Applicable' option in response to 
any of the statements.
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Respondent Number Score before Score after
1 35 37
3 47 37
4 27 41
5 33.5 43
7 44.5 43
8 31 43
9 39 40
10 33 43
11 37 39
Mean 36.33 40.67
Table 9.7 Respondent attitude scores before and after pharmacist's service.
Attitude scores before and after the service was implemented are represented in figure 
9.6. Note, each coloured block represents the attitude of an individual drugs worker.
Increasing pos itiv ity  in attitude
Figure 9.6 Changes in drugs worker attitude to having a pharm acist as part o f the team based on 
attitude measurement made before and after the service was conducted.
From the Wilcoxon Matched-Pairs Signed-Ranks test, the test statistic Z was -1.661 (p = 
0.05). For a one-tailed test at 95% confidence the Z-score is 1.645. Because the test 
statistic is negative, it is compared with the negative Z-score. Since -1.661 is less than 
-1.645 (i.e. the test statistic is outside the critical value), the hypothesis that there is no 
significant difference between pre and post attitude score of the team can be rejected. In
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conclusion, the attitude of the team as a whole significantly shifted in a more favourable 
direction after exposure to the pharmacist's service.
9.2.3.3 Responses given to open questions on the attitude questionnaire
Eleven workers completed the questionnaires before the service was implemented and 
twelve completed it after. The responses of all are included, as the pre- and post-service 
questions are not directly comparable.
Responses to questions asked before the service was implemented
The first question was:
1. ‘ Please briefly describe what you see, if any, the main role of a pharmacist at Drugs Action to be:’
Five themes emerged in response to this question. These are now listed with description 
of specific factors raised.
(1) Support and compliment the existing staff team
• provision of information to workers. Topics specified were drugs and their 
effects, medical information and services and health issues.
• provision of advice to workers.
• supplement the skills already available within the team
• add to the professionalism of the agency
(2) Provide information to clients
• Especially, the provision of health information to clients with no access to primary 
health care services.
(3) Provide training
• Training for both staff and clients, through both formal events and on-the-job support.
(4) Increase understanding of staff and clients of issues relevant to the pharmacy 
profession
• Raise awareness of problems pharmacist's have with drug users and drugs workers
• Raise awareness of staff and clients of the role of pharmacist's in the care of drug 
users, including pharmacist's position on confidentiality.
I
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• Make staff aware of political issues relating to pharmacy.
(5) Provide a supportive link with other professionals
• Provide a professional link that enhances collaboration with and training of other 
pharmacists.
• Advocate harm reduction practices to other health care professionals such a doctors, 
and health board workers.
• Enhance communication with medical-based services
The second question was:
2. Please briefly describe reservations, if any, you have about a pharmacist coming to work at Drugs Action:
Five themes emerged around the team's concerns, which are listed with descriptions of
specific factors.
(1) The attitude of the pharmacist to drug use and drug users would contradict the
agency's philosophy. >
• Specifically, concerns that the pharmacist may be judgmental
• A pharmacist may not support harm reduction within the agency or to colleagues from 
outside
• Concerns that the pharmacist may have a different ethical basis from the agency
• Concerns that the pharmacist may be afraid of drug users and treat them in a manner 
that showed this.
(2) Concerns that the pharmacist may not provide a confidential service
• Concerns the pharmacist may breech confidentiality because of knowledge about 
clients from other work (e.g. tell prescribers of substitute drugs if someone received a 
needle exchange).
• Concerns that clients may worry the pharmacist is not providing a confidential service 
and therefore not trust the service or be honest with the pharmacist
(3) Concerns about the pharmacist's understanding of drug use.
• A pharmacist may not understand the social issues around drug use
• Specifically, a pharmacist may not be able to deal with unrealistic expectations of 
clients
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• A pharmacist may not challenge users about behaviour issues in an appropriate 
manner
• A pharmacist may make assumptions about client's feelings
(4) Must ensure that the pharmacist had adequate supervision and management 
when being integrated into the team.
• Concerns specifically underpinned by the above reservation
• Standard practice for any new member of staff
(5) Demonstration of a useful service may lead to service provision elsewhere but 
not at Drugs Action
• Concerns that if funders saw the service was useful to DA, they may fund such a 
service elsewhere instead of at DA.
Responses to questions asked after the service was delivered
In response to the closed question;
1. Based on your knowledge, experience and opinion of the pharmacy sessions which were provided at 
Drugs Action, do you think there is a role for a pharmacist as part of the team?
Yes No
All staff said yes.
When asked:
If you answered yes to the above question, please expand by stating what you see the main role to be:
The staff gave several examples. From these, five themes emerged, which are listed with 
examples. 1
(1) Be a specialist on pharmaceutical/medical issues relevant to drug use, to 
compliments the team.
• Increase the holistic approach of the agency to deal with all issues around the person 
and their drug use by providing information and advice on health issues both related 
and unrelated to drug use
• Be a source of information for staff and clients on wide range of health issues
• Help staff interpret medical information relevant to clients
• Provide a credible pharmaceutical/medical aspect to the service
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• Provide instant access to information on pharmaceutical/medical issues
(2) Strengthen the knowledge of the team on pharmaceutical/medical issues.
• Help staff keep up to date and aware of current medical based research and practice 
relevant to drug use
• Widen the knowledge base of staff on the physical effects of drugs, both illicit and 
prescribed.
• Provide staff with a necessary level of in-depth pharmaceutical/medical knowledge to 
understand specific situations e.g. prescribing issues.
• Increase knowledge of staff making them confident in challenging bad practice e.g. 
bad prescribing.
• Increase staff knowledge on general health issues
(3) Provide clients with pharmaceutical/medical information
• Provide information on both drug related health and general health issues
• Explain drug issues with a specific pharmaceutical/medical aspect
• Assist clients in assessing the risks and benefits of using specific drugs, in terms of
health and lifestyle. 1
• Assist clients in understanding health issues around stopping using specific drugs
• Assist clients in understanding health issues around receiving a prescription for 
substitute therapy.
(4) Network and negotiate with medical based services and policy makers
• Defend harm reduction practice when working with other professionals
• Add credibility to DA practice and experiences
• Negotiate harm reduction strategies with medical-based professionals on behalf of 
clients
(5) Provide training
• Train staff formally and informally, through joint work with case load
• Train medical based professionals from other agencies and services
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9.2.4 Cost of the service provision 
Cost of pharmacist’s time
The pharmacist spent 22 hours and 30 minutes outwith the session time dealing with 
enquiries. Therefore total time spent on service provision in the 26 week period was:
3 hour session x 26 weeks + 22 hours 30 minutes 
= 100 hours 30 minutes.
Cost @ £14.39 per hour = £1446.20
+ 10 % National Insurance (theoretical)
= £ 1590.82
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Use of agency resources
The pharmacist made 17 A4 photocopies at the agency during the 26 week period.
= £0.68
The pharmacist made three local rate calls, with approximate total duration of 4 minutes = 
4 x 3.95 = £0.16. The pharmacist made seven national rate calls, with approximate total 
duration of 25 minutes = 25 x 7.91 pence = £1.98
The pharmacist distributed three safer injecting booklets at a cost of £1:00 each. The cost 
of other leaflets used was estimated at £6:00
Use of University resources
The pharmacist made 37 A4 photocopies at the University for use in response to 
enquiries = £1:48
The pharmacist made 4 local rate calls, with approximate duration of 25 minutes = 25 x 
3.95 pence = £0.99
The pharmacist made nine national rate calls, with approximate duration of 90 minutes = 
90 x 7.91 pence = £7.12
The pharmacist received 4 papers through inter library loans x £5:00 = £20:00 
The total estimated cost of provision of the pharmacist’s service was: £ 1630.23 
For 87 enquiries, this averages at a cost of £18.74 per enquiry.
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Chapter Ten
Discussion
10.1 Critique o f method
10.1.1 Methods used to provide the pharmacist’s service
10.1.1.1 The researcher as the pharmacist
The decision to use the researcher as the pharmacist who delivered the service should be 
criticised. It could be viewed that when the researcher was investigating the impact of the 
service, she may have had preconceptions of its benefits, since she delivered the service. 
However, there were also benefits to using the researcher as the pharmacist. It allowed 
greater understanding of the cases and eased interpretation of the findings, due to her 
first hand experience. It may also be criticised that the familiarity of the DA team with the 
researcher/pharmacist prior to this work being undertaken could have introduced bias 
when they expressed their opinions on the service, if they already had a favourable view 
of the researcher. However, there were also benefits of this familiarity, in that the 
researcher had an understanding of the policies and practices of the agency. This allowed 
the service to be designed in a way that was considered to complement the existing 
structure. Also, people who have drug problems and their families are seen as a 
vulnerable client group. New workers must be carefully introduced to this group to protect 
those concerned, for example by supervising practice for the first three months of 
employment. The familiarity of the DA team with the pharmacist and her prior research 
experience at the agency1 meant that the team did not consider this necessary, so the 
service could be implemented without an induction period. Steps were taken to minimise 
the bias from these factors. The researcher was conscious that in order to be ethical she 
must be objective in her views. Cost restrictions prevented a separate pharmacist being 
employed to conduct the service, so the system that was used here where the pharmacist 
who delivered the service was also the researcher was the only option. However, it is not 
considered to be ideal. If further work were to be conducted in this area, provision would 
be sought to enable a separate pharmacist would be used. The fact the pharmacist was 
also the researcher and the potential for bias as discussed above, must be born in mind
i
when considering the results.
' O bserving practice  and conducting the interview s w ith IDUs for the w ork in part 1. ' ' ■ .
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10.1.1.2 Structure of the pharmacist’s service
It may be suggested that the input of the pharmacist to the work of the agency was not 
maximised over the 6-month period since she was not present during all opening hours. 
Certainly, the results suggest that had she been present all the time, more opportunistic 
interventions would have been made. However, the purpose of having one 3-hour session 
was to use a situation that would be more likely to represent what could be provided in the 
current climate of partnerships and buying in of services. The provision of funding for 
specialist sessions was considered to be more likely than the funding of a full time post. 
For example, a community pharmacist with an interest in specialising in drug misuse 
could be bought in to deliver one session per week. It may then be criticised that allowing 
the pharmacist to be contactable by telephone at other times was contradictory. However, 
this aspect of the service was done to allow investigation of the suggestion made by 
Gerret et al (1987), that drugs agencies may benefit from a specialist pharmacist 
information service.
The pharmacist hand delivered information to the agency at times outwith the session 
times, when it was needed. Some opportunistic enquiries were received during these 
delivery times. This may be .' criticised as deviating from the defined structure of the 
service. A more rigid service would not have allowed enquiries to be received at other 
times and delivered all urgent information by fax. However, the pharmacist considered 
that this should be done, in order to make the service as accommodating as possible. 
She also felt ethically that she did not want to refuse assistance. Although the number of 
contacts made during these times was small (n = 7), this contribution to the total number 
of contacts made must be borne in mind.
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10.1.1.3 Duration of the pharmacist’s service
Given that no induction period was required and the previous familiarity of the pharmacist 
with the agency and vice versa, a six-month investigation period was considered to be 
adequate to allow the role of a pharmacist at Drugs Action to be explored. In this time a 
total of 87 enquiries were received, which was considered to be adequate to illustrate the 
role the pharmacist carried out. Had the pharmacist been unknown to the agency, a 
longer period of time would have been used.
236
10.1.1.4 Publicity of the pharmacist’s service.
The publicity for the service was not released until one week before the service 
commenced. This was done so the workers were not made-aware of the plans prior to 
their attitudes being measured. Also, it meant that anyone who responded to the publicity 
did not have to wait several weeks to receive the pharmacist’s service. The effectiveness 
of the publicity was not investigated. Asking contacts from outwith DA, who self referred, 
what prompted them to use the service, could have done this. This would be considered if 
such a service were implemented in the future. However, since the number of self­
referrals was low (n = 2 for members of the public and n = 3 for outside organisation 
professionals), this suggests that publicity alone was not very effective compared to 
worker recommendation. At the time the publicity was distributed, a decision was taken 
not to publicise the service to GPs and community pharmacists, as it was felt that they 
already had access to further information. However, on reflection this decision is not 
considered to have been correct and there may have been benefits to inviting them to use 
the service. If such a service were implemented in the future, it would be extended to 
include GPs and community pharmacists. The publicity materials gave examples of 
possible areas of enquiry. These examples may have influenced the nature of the 
enquiries made. Some examples given relate to areas of enquiries received e.g. the 
effects of drugs but others do not e.g. sexual health and contraception was an example 
given but no enquiries were received. However, since this was not investigated it cannot 
be said whether publicity affected the nature of the enquiries received or not. Given that 
the majority of enquiries received from members of the public were referred by a drugs 
worker, the perceptions and opinions of the drugs workers on the appropriateness of 
issues for the pharmacist is likely to have been a large factor in influencing the nature of 
the enquiries received.
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10.1.1.5 Enquiry handling procedure
The enquiry handing procedure was based on the guidelines given to drug information 
pharmacists by the UK Drug Information Pharmacists Group. Where considered 
appropriate, procedures were adapted for the agency setting. The main modification was 
the extent of the client details recorded. These were minimised to provide as much 
anonymity as possible, to encourage service use. The pharmacist recorded enough 
information so that, had a case arisen where there was a need for her to be able to give 
an account of an enquiry, she could do so. Enquiries could be traced based on their date 
and the enquirers' initials, or in the case of workers, first names, being known. When
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considering the need for accountability in information and advice provision on the basis of 
clinical governance, this raises the question of whether community pharmacists and 
others who provide information on an anonymous basis should do so. It can be criticised 
that providing anonymous information with no means of follow.-up prevents the practitioner 
from being able to demonstrate and justify their actions or to audit their practice. 
However, this anonymous and informal system is known to encourage the public to use 
pharmacists as a source of information and advice (Blenkinsopp, 2000). Formalising the 
system might remove such opportunities, which could be detrimental for all concerned. 
However, this does raise a potential area for investigation in view of clinical governance. 
The UKDIPG guidelines were used for the pharmacist’s service as they were considered 
to be the most appropriate guidance available in 1997. However, if a specialist role for 
information pharmacists developed at drugs agencies, it would be desirable for those 
involved to develop their own practice guidelines.
10.1.1.6 Monitoring of the pharmacist’s service
The paper-based form used to monitor the enquiries was based on those used by Gerret 
et al (1987) and the UKDIPG guidelines.. This was considered appropriate, as all 
necessary information was recorded quickly and preferable to designing a completely new 
form that would have required piloting. The electronic database was useful for data 
manipulation by the researcher, but not used at the agency itself as the necessary 
software was not available. The use of progressive focusing once the service was over to 
re-categorise the enquiries and define further the knowledge and skills required, was 
appropriate to extract the maximum amount of information out of the data. Such 
examination is recommended in research methods texts (Coolican, 1994, Bailey et al 
1995).
It may be argued that use of a panel to identify the themes of the enquiries would have 
been more objective than the pharmacist doing this. This was not considered at the time 
of study design. However, the familiarity of the pharmacist with the cases may have 
enhanced the accuracy of categorisation. Use of a panel would be considered in further 
work.
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10.1.1.7 Knowledge and skills categorisation
The methods used to categorise the knowledge and skills used to undertake the service 
are given in 8.2.1.2. It can be criticised that knowledge and-skills are intrinsically linked 
and cannot be separated as easily as it appears in this work. Such categorisation was 
done to enable an outline description of what was required to handle the enquiries to be 
made for future use, so it should not be interpreted as a definitive, distinct summary. 
Knowledge and skills are separated in a similar manor by the RPSGB in their 
competency-based standards defined in the MEP (RPSGB, 2000). As the categorisation 
was undertaken by the researcher, it must be recognised that the categorisation relates to 
her own opinions and experiences only. If a peer-group panel had been used to 
categorise the knowledge and skills, a different set of categories and opinions on sources 
of such may have resulted. Indeed, if several groups had been used it is possible that 
each would have come up different opinions, depending on their experience in the field. 
For future work that focused more on the knowledge and skills needed for such service 
provision, the use of several peer groups would be considered to investigate this in more 
detail.
10.1.2 Methods used to evaluate the pharmacist’s service
10.1.2.1 Methods used to establish DA client outcomes
The outcomes experienced by DA clients after contact with the pharmacist were 
determined through self-reporting by the client to the pharmacist or self-reporting of the 
client to their worker, who in turn reported the outcome to the pharmacist. On four 
occasions this reporting was by the client themselves and on five occasions by a worker. 
Several criticisms of this method can be made. Firstly, if the client wished to please the 
pharmacist, for example because they were grateful for the help they had received or 
were reluctant to disclose that they had not followed advice, they may have reported 
favourable outcomes even if they had not occurred or exaggerated any perceived 
benefits. Also, outcomes reported through the drugs worker relied on the worker correctly 
passing the information on to the pharmacist. Nine clients who had contact with the 
pharmacist were followed up so the group from whom outcomes were gathered did not 
represent the total group (n = 25) who received information and advice from the 
pharmacist. Since it is not known what outcomes were experienced by the other 16 clients 
conclusions on outcomes from the service cannot be drawn. It is possible that an 
unfavourable outcome may have deterred the client from making further contact. There is 
also difficulty because no controls could be performed. For example, the clients could not
Chapter 10
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be matched with similar others with the same enquiry who did not receive information and 
advice. Despite these criticisms of the method, the recommendation of a more 
appropriate method of follow up is difficult in the context of the situation. The use of a 
paper-based questionnaire distributed to all client contacts may have reduced bias but 
this would have limited the extent of the information that could have been collected. 
Clients may have been discouraged by the request for written information. Also, it was 
desirable to assess the outcomes at a time remote from the contact. Defining when to 
return the questionnaire would have been difficult. It is also doubtful whether an adequate 
response rate would have been achieved using a questionnaire for return at a later date.
10.1.2.2 Use of the discussion group to gather staff opinion on the pharmacist’s 
service.
The discussion group was used after the pharmacist’s service had operated to explore 
the key areas that were identified before the service began. This method was considered 
to be the most appropriate at the time of this work, despite the limitations outlined below. 
S.emi-structured interviews could have been used but would have to have been conducted 
by someone other than the pharmacist to avoid bias, which was not possible. However, 
with hindsight greater attempts should have been made to use a member of staff from the 
University to moderate the group, rather than the researcher. Also, the one-to-one nature 
of interviews does not allow for the interaction and exchange of ideas within the group 
that is possible with focus groups. This was considered important so that statements 
made could be disputed or endorsed freely. Similarly, a nominal group would have 
allowed opinions to be identified in the group, but the benefit of this technique is that it 
allows key points to be ranked in order of importance. This was not desirable in this 
instance since all opinions were required and no ranking was needed. Moderation of the 
group by the pharmacist may be criticised as having biased the discussion, as said in
10.1.1.1. The researcher was aware, through her attendance at team meetings, that the 
culture of the team was to constructively criticise each other’s practice and to challenge 
bad practice. At the time of the work, she considered the team likely to be honest in their 
assessment of the pharmacist’s service and that it might be possible to minimise this bias. 
Honesty was an agreed ground-rule between the moderator and the group and several 
facilities for expressing opinion were made available to the workers. It was considered 
that providing a facility for anonymous comment would allow any opinions to be 
expressed that individuals felt unable to raise in the group. However, the honesty of the 
team cannot be demonstrated and it is disputable whether bias was removed. Also, the 
small number of team members may have led workers to believe that they could be
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identified through anonymous typed comment, by the style and nature of their writing. 
Therefore it must be concluded that there was a lack of objectivity in the method used and 
in future work of this nature to avoid such problems an independent moderator would be 
used.
It may be criticised that a liking for the pharmacist could have influenced the responses. If 
this was the case, it might have happened regardless of whom conducted the discussion 
group. The researcher considered it not possible in this case to identify responses given 
because someone is liked from objective evaluation. In future work, guidance would be 
sought on whether the method could be designed to avoid this.
A criticism of the questions used is that the moderator did not ask at the end for any 
further comments, allowing areas not explored to be raised. However, the facility to 
submit written comments may have compensated for this to some extent.
The round table format may be criticised as stifling discussion. However, this was done to 
allow all participants the chance to express their opinions. Opening the discussion up to 
the floor afterwards was done to allow more natural conversation to then occur.
The full discussion was transcribed and from this written account, progressive focusing 
used to identify the key themes. This transcription may be criticised as unnecessary, as 
progressive focusing can be done directly from the recorded discussion. However, the 
researcher transcribed the discussion to protect against data loss, in the event of the tape 
breaking.
10.1.2.3 The measurement of DA workers attitude to the pharmacist’s service 
The design of the attitude questionnaire
The attitude questionnaire was kept short so it took up no more than 2 sides of an A4 
sheet. This was done to prevent the workers tiring, which might encourage less 
consideration to be given to the questionnaire. A five-point Likert scale was used as it is 
reported to be not so fine that respondents have difficulty placing their opinion or too 
coarse so the scale cannot differentiate between opinions (Coolican, 1994). The 
advantage of this method is it illustrates where on a scale between favourable and 
unfavourable a person's attitude to the subject lies, giving more insight than simply asking 
to respondent to chose between ‘agree’ or 'disagree'. It is also simple to construct. The 
weaknesses of this method are that the respondents’ score can only be interpreted 
relative to the distribution of scores of other respondents i.e. X has a more favourable
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attitude to the subject than Y. No measure can be made of how far apart the differences 
in attitude lie i.e. we cannot say X’s attitude is twice as favourable as that of Y. Also, 
including the measure ‘undecided’ can result in ambiguous results. It cannot be 
distinguished if selecting this means attitude to the subject is neutral i.e. cannot decide 
because the respondent has no strong opinion or if they are torn between two feelings in 
both direction i.e. cannot decide because in one context they may agree but in another 
context they may disagree. Also, if someone scores a central value on average, this also 
does not tell us if they have lots of undecided opinions, or if they gave equal numbers of 
strongly in favour and strongly against responses, thus resulting in a score overall in the 
middle. In the latter case this may suggest two different attitudes had been measured. 
This appeared not to be true in this study as no one scored a mid point value on either 
occasion when the questionnaire was administered.
The wording used in the questionnaire referred to 'a pharmacist’ at Drugs Action, but it 
must be acknowledged that it is likely that the responses were made relating to the 
service received and hence the responses more correctly probably relate to the 
pharmacist who conducted the service, not pharmacists in general.
Content validity was used to examine whether the statements covered the attitude being 
measured sufficiently i.e. the attitude of the workers to the pharmacist’s service. The 
supervisory team were used as the assessing panel. However, it may have been more 
appropriate to have used an expert panel of drugs workers from other non-statutory 
agencies, as they may have been in a more suitable position to assess the pertinent 
issues. This would be considered in further work.
Comparing responses to pairs of favourable and unfavourable statements checked 
reliability. The criticism of this method of reliability checking is that it uses scores that are 
from an as yet, unreliable test. However, it is generally accepted as satisfactory (Coolican, 
1994).
Piloting
The attitude questionnaire was piloted on two workers. This number may be criticised as 
being too low. However, the total sample size was small so having a greater number of 
participants in the pilot work was considered undesirable. The purpose of the pilot was not 
for validation but to assess readability and relevance. Inclusion of the pilot workers in the 
final sample was considered appropriate. However, it may be criticised that the pilot 
workers were asked to complete the pre-service questionnaire again when it was
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administered to the team four days later. They may have had time to consider the issues 
in the interim period, which could have influenced their responses. However, on 
comparison their pilot responses were similar to their final responses. Further work would 
use the pilot responses in the data analysis, if appropriate; and not re-administer the 
questionnaire.
Coding
The questionnaires were coded so the researcher could match the respondents’ pre and 
post service questionnaires. The respondents were not, however, made aware of this 
coding. This may be criticised as unethical. In defence, it was considered important that 
the workers were not aware that the researcher would know their responses, as this may 
have introduced bias. For this reason, this was considered by the researcher and the 
supervisory team to be an appropriate situation in which to not inform the participants 
about such codes. However, this may be considered unethical by others. In future work 
the advice of an ethics advisor would be sought on such matters.
Important factors in attitude measurement
Several factors known to be important in attitude measurement must be discussed in 
relation to the method used for this study.
I Self completion
The questionnaire was based on self-assessment, which makes it entirely subjective. 
There is no way of determining if different respondents score attitude in the same way. 
However, Moser and Kalton (1971) suggest that scoring of attitude by the researcher is 
not necessarily more objective, so self-completion was chosen in preference to 
researcher assessment. I
II The ‘halo’ effect
This term is used to describe the situation whereby the respondent has a general liking 
for a subject, so scores all aspects of the questionnaire positively. To reduce this effect, 
statements were included that covered issues that team members were known to feel 
strongly about. For example, statement 6 compared worker’s knowledge on drugs of 
abuse with that of pharmacists, statement 7 related to conflict of interest and statement 
20 related to confidentiality. The researcher considered that since the workers had an 
advocacy role for their service users, it was unlikely that they would favour suggestions 
about a proposed new service if they had concerns.
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III Familiarity with the researcher
All of the DA team knew the researcher was a pharmacist. They had had prior exposure 
to her during the client interviews conducted for part one (chapter 2). Therefore, the 
baseline measurement of attitude to having a pharmacist attached to the team may be 
influenced by this familiarity. Attempts were made to minimise the impact of this 
exposure, as follows:
Introduction prior to questionnaire completion:
The researcher asked staff, during the briefing about the questionnaire, not to consider 
the statements as relating to her as a pharmacist, but to consider them in the context of 
their opinions of pharmacists as a whole. They were informed that no names were to be 
put on the questionnaires, although workers may consider they could be identified from 
their handwriting when responding to the open questions.
Scaling method:
. Boxes were used in place of numbers, which are often used on such scales. This avoided 
the possibility of making the respondents feel like they were allocating a mark out of five 
tq the researcher
10.1.3 Ethical and indemnity considerations
Ethical approval from the Joint Ethical Committee of Grampian Health Board and the 
University of Aberdeen was not sought, on the advice of the Robert Gordon University 
research ethics advisor, who did not consider this necessary. However, in hindsight, the 
researcher considers that application for approval would have been good practice, 
although the University is not obliged to do so.
Also, a matter overlooked at the study design stage was that of indemnity cover for the 
work of the pharmacist. She held her own private policy for indemnity but did not 
investigate whether the work at Drugs Action was covered in this. Employers have a 
responsibility for the actions of their employees, however the researcher was not an 
employee of Drugs Action or the Robert Gordon University, she was a student of the 
latter. Therefore, it should have been investigated whether the University held indemnity 
insurance that covered research activity.
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not include brief contacts made for information and advice only (n = 1009). However, it is 
notable that self-referral to the agency did occur to a greater extent than self-referral to 
the pharmacist’s session. The small number of self referrals may be because the role of 
the pharmacist is perceived by many of the general public and other organisations to be 
one of supply and not necessarily information and advice detached from supply. 
Matheson (1998) found this perception to be true when they explored this issue in semi- 
structured interviews with 124 drug users. There may also have been a fear that the 
pharmacist would make any disclosed drug use known to other health care workers. The 
workers could reassure confidentiality when they offered referral. The small number of 
referrals may also have been due to ineffective publicity. However, without further 
information, these points cannot be confirmed.
Members of the public were asked if they would consider asking a community pharmacist 
similar enquiries (9.1.5). The responses largely suggested they would not. Although this 
matter was not explored in detail, it is interesting to note that no comments were made 
,that suggested the community pharmacist was not perceived to have the necessary 
knowledge. This may however have been because the respondent considered such 
comments would offend the pharmacist asking the question. The attitude of the 
community pharmacist towards drug use appeared to be the factor in the group that 
would influence judgment, with some local pharmacists known to have a good rapport 
with drug users being identified as being potentially approachable. Matheson (1998) 
identified the attitude of the pharmacist towards drug users to be an important factor in 
the perceptions of service users. Two enquiries were presented where members of the 
public had sought previous advice from community pharmacists and had not been 
satisfied with the response received. Although two isolated incidents, this illustrates the 
use of Drugs Action to verify information when doubted.
Had the service been provided for longer, the number of self referrals may have 
increased, as towards the end of the service some clients who had previously seen the 
pharmacist were asking to speak with her or for their drugs worker to pass on information, 
to report on the outcome of their issue. Also, once the service had stopped a small 
number of clients were reported by workers as having asked to speak with the 
pharmacist. However, this information only makes the suggestion that self referral may 
have increased over time, extended service provision would have been necessary to 
confirm this. Further exploration could also be done to establish the importance of word- 
of-mouth in promoting use of the service. Worker referral was found to be the main 
means through which the pharmacist made contact with members of the public and 
highlights the importance of the drugs worker in identifying issues where the pharmacist
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could potentially contribute. Of the seven outside service workers who made contact with 
the pharmacist, DA workers referred four and the remaining three all came from the 
specialist prison officer who worked along side the DA prison worker. This again 
highlights the role of worker referral.
10.2.1.2 Publicity of the pharmacist’s service
Although the effectiveness of the publicity used was not directly monitored, the data on 
the use of the service shows that worker referral was the most effective method of 
encouraging members of the public and outside organisations to use the service. Had the 
publicity distributed to outside organisations been more effective, it may have been 
expected that a greater number of self-referrals would have been seen. Figure 9.2 shows 
the number of contacts made per week over the 26-week period. Figure 9.3 shows the 
same data but broken down into enquirer group. Neither the data overall or the data for 
each group shows any trends in service use. This supports the view of the pharmacist 
that the service was a response service with a workload dictated by issues as they arose 
at Drugs Action. If service activity data per week had been available from Drugs Action, 
this could have been compared with these graphs to look for similarity in the patterns of 
use. i.e. to see if times of greater pharmacist activity corresponded with greater agency 
workload. However, data was only presented for the overall financial year 1997/8 (Drugs 
Action, 1998).
10.2.1.3 The urgency of the enquiries dealt with by the pharmacist
In terms of prioritising workload, the majority of enquiries (n = 49; 64%) were considered 
by the pharmacist to require a response as soon as possible. All but one of the members 
of the public required an immediate response, which is not surprising since the majority 
were seen face-to-face so considered to require a quick response. This illustrates, as with 
many services which work with the public directly, the need for the pharmacist to be able 
to respond quickly. It must be remembered that defining the urgency of the enquiries in 
this way reflects the pharmacist’s interpretation of the urgency but may not have 
represented the enquirers’ interpretation or actual urgency. The term is used to illustrate 
how the pharmacist prioritised the workload, not describe the nature of the enquiries.
Of the contacts requiring a response as soon as possible, 94% (n = 46) received it 
immediately. This shows that the pharmacist was able to meet the priority in the majority 
of cases. For the enquiries that required a response as soon as possible but could not be
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dealt with immediately, the enquirers were kept informed of the reason why their 
response was delayed and the anticipated time it would take to formulate a response.
10.2.1.4 The nature of the enquiries
Eleven different categories of enquiry were identified. As the majority of the enquiries 
received were either from the drugs workers or directed to the pharmacist by the drugs 
workers, the opinion of the drugs workers on the nature of enquiries appropriate for the 
pharmacist will have influenced the type of enquiries received. Also, categorisation was 
based on the pharmacist’s interpretation and opinion, so different classification may have 
been made had this task been undertaken by someone else. However, it was perceived 
that since the pharmacist had first hand experience of the enquiries, her interpretation 
was likely to be more accurate than that of someone who was grouping on the basis of 
having read the recorded information only. Seventy three percent of enquiries were in 
categories that were concerned with matters that related to medicines or illicit drug 
substances. These categories were: Drug information (both prescribed and non 
prescribed), drug testing, drug related health problems, identification and adverse drug 
reactions (both prescribed and non prescribed). This indicates that the pharmacist was 
viewed as a source of knowledge on drugs and their effects. A small number of enquiries 
relating to pharmaceutical services were directed to the pharmacist (n = 3), perhaps not 
surprisingly suggesting that the pharmacist was viewed as a source of advice on this 
area. Interestingly, six enquiries requested medical information that did not involve a 
pharmaceutical component. This suggests recognition that pharmacists have a familiarity 
with the medical profession. These enquiries may have been directed at the pharmacist 
due to the absence of medical input into the team. Seven enquiries related to requests for 
information on harm reduction techniques such as safer injecting. The pharmacist was 
known to the team to have knowledge of this area from the work described in part one. 
These enquiries may reflect recognition of her specialism and not suggest that drugs 
workers, who already have training in the area of harm reduction techniques, would 
regard pharmacists in general as a source of further advice. Overall this data illustrates 
the areas where the pharmacist was viewed as being an appropriate source of 
information and advice. It also classifies pharmaceutical and medical issues that related 
to the agency clients and workers. The absence of drugs workers with a background in 
medical professions may have meant more health and drug related enquiries were 
directed to the pharmacist than would have been in an environment staffed, for example, 
by nurses. This is viewed positively as it might have allowed the identification of a broader 
range of health and drug related issues where there is a need to provide education and 
training to pharmacists and appropriate others who work with drug users.
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10.2.1.5 Methods o f reply
Table 9.4 describes the methods of reply that the pharmacist used to respond to 
enquiries. Because of the nature of the service being directly accessible, it is not 
surprising that verbal response was used, at least in part, in the majority of cases. Also, 
since all the enquiries from members of the public were received face-to-face and all but 
one of these required a response as soon as possible, the use of verbal communication 
was to be expected. However, it is notable that half of the responses to workers were 
supported with additional written information. The request for written information could be 
made by the workers or the decision to endorse verbal informal with written could be 
made by the pharmacist. Therefore, this figure must not be interpreted as the number of 
requests made for written information to the pharmacist. It should be taken as an 
illustration of the number of responses where written information was considered useful 
by one of the parties involved and a demonstration of the need for the pharmacist to be 
able to support the information and advice given with written materials.
The pharmacist produced some written materials In formats considered suitable for the 
intended recipients. These included a fact sheet on carrying methadone abroad for clients 
and staff and three evaluations of technical information to give advice on practice, at the 
request of the staff.
10.2.1.6 Ethical and moral dilemmas.
As anticipated, situations did arise that presented the pharmacist with moral and/or ethical 
dilemmas. The interpretation of such as dilemmas is subject to some degree of 
interpretation, as the belief that something presents a dilemma will be influenced by the 
knowledge, experience, morals, beliefs and to an extent, the characteristics of the 
pharmacist concerned. Had the service been provided by a different pharmacist, the 
classification of issues as dilemmas may have varied, as may their handling procedures.
The pharmacist considered four areas presented dilemmas (9.1.8 and described in 
appendix 28). A total of 24 enquiries, which accounted for 28% of the total number of 
enquiries, were considered to present some moral or ethical dilemma that required 
consideration before responding. No estimate could be found in the literature of the 
overall extent to which either UK drug information or community pharmacists experience 
ethical and moral dilemmas. After considering each situation, the pharmacist was able to 
respond to all the dilemma enquiries in a manner she considered upheld her professional
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requirements. There were no situations where the pharmacist considered it appropriate to 
refuse to give any advice or information. The pharmacist’s rationale for each dilemma 
area is given in appendix 28. As said in 8.1.7.5, it was not considered wise to develop 
protocols for handling dilemmas as the researcher considered this might actually increase 
risk, if individual situations were not considered in their own context. For example, had the 
pharmacist decided that she would not handle any tablet identification enquiries on the 
basis that it may assist someone in participating in illicit drug use, this would have 
precluded the identification of two cases where the enquirers wrongly assumed the 
identity of a drug and could have suffered if their assumption continued. It would have 
also precluded the assistance given to the outreach worker when at a youth project where 
an unknown tablet was found on the floor.
From her experience of the dilemmas presented, the pharmacist considered that there 
were benefits to all enquirers from receiving advice. Once this benefit was established, 
the level of harm from presenting the information had to be considered. Also, professional 
ethics, even if considered to increase the harm to the patient, had to be upheld. On the 
basis of these factors, the information given had to be chosen carefully. It had to minimise
the patient risks without compromising the competing value unnecessarily or unethically.
\
This conclusion may be applied to other situations, although the level of interpretation and 
action taken will be individual.
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10.2.1.7 The knowledge and skills required to provide the service
The greatest proportion (52%) of the knowledge used to respond to the enquiries was 
considered by the pharmacist to be core knowledge, meaning common to all pharmacists. 
A further 25% was considered to be a combination of core knowledge enhanced with 
specialist information. Specialist knowledge, which was considered had to be acquired 
through specialisation in drug misuse, was used to respond to 23% of enquiries. It is 
important to remember that this information cannot be used to generalise about the 
provision of such a service. It is influenced by the background and experience of the 
pharmacist concerned and her opinion. However, what it does illustrate is that 
pharmacists are likely to have acquired knowledge and skills during their training and 
through working in the community or hospital environments which can be applied in the 
specialist drugs setting. Most of the enquiries in the category that contained the greatest 
number of enquiries (drug information (prescribed)) were responded to using core 
knowledge, with only a few requiring core • and specialist knowledge. This general
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grounding can be built on to develop specialist skills, as suggested by the ability of the 
pharmacist to respond to the enquiries she received.
The major topics of the knowledge required to provide the service are defined in 9.1.9. 
This raises the question of whether these topics can be used to define the training needs 
of pharmacists when providing information and advice to drug users. Although the 
pharmacist’s service at Drugs Action was defined by the non-health-based nature of the 
team and the opinions of the workers on what was appropriate to refer, it may be 
expected that the issues that presented are not likely to be unique to Drugs Action. It is 
likely, but not confirmed by this study, that similar issues would arise elsewhere. 
Anecdotal information from others working in the field supported this view. Assuming that 
such issues presented in other situations/agencies, the training needs of the pharmacists 
providing the service may differ due to different experiences from the pharmacist who 
provided this service. Therefore, the list and categorisation cannot be taken definitively, it 
applies only to this case study. However, the lists may be useful as check lists, acting as 
>a guide to direct a pharmacist establishing such a service, in their professional 
development. This list could be added to and modified, based on the monitoring of their 
service.
\
The information sources that the pharmacist used to acquire knowledge will have been 
influenced by the nature of the service and all the factors that defined this. Therefore, it is 
again not a definitive list for future service development. However, it provides a guide to 
appropriate sources to consider acquiring when developing a similar service. Access to 
some of the sources such as databases and journals may be considered to be outwith the 
reach of many community pharmacists at present, hence restricting the possibility of such 
a service being undertaken by a community pharmacist seconded to a drugs agency for 
such sessions. However, information technology is rapidly becoming more accessible and 
important within heath care and as the role of the pharmacist becomes more clinical and 
funding systems change, it is possible that such information will become more to hand. As 
learning styles vary between individuals, the importance placed on each source will vary 
with the individual. Again, this list could be added to with the monitoring of further 
services.
The skills required to provide the service are defined in 9.1.9. Again, they are subject to 
the variability that applies to the knowledge categorisation. It can be questioned as to how 
accurately can it be said where a specific skill was applied. For example, listening skills 
for pharmacists are developed in many of the undergraduate courses, including the 
course the pharmacist undertook. However, it can be argued that such skills may be
t
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learned at an earlier stage and developed through teaching and practice. Similarly, the 
categorisation used in this work assumes that the listening skills the pharmacist used to 
work with drug users and workers were the same as those she learned to apply in other 
situations. It was the opinion of the pharmacist that the listening skills needed for this 
service did not differ, others may argue against this, illustrating again the subjectivity of 
such categorisation. Despite this subjectivity, the list of core skills and one specialist skill 
identified could be used as a guide for others when developing future services and 
selecting appropriate pharmacists.
In summary, this work suggests that specialist training in the philosophy of harm reduction 
and harm reduction techniques, the psychological theories of drug use, drug testing, drug 
misuse statistics and prevalence, social services and welfare right and the drug-using sub 
culture, its terminologies and language would be useful in addition to the core knowledge 
described (9.1.9).
10.2.2 The evaluation of the pharmacist’s service
10.2.2.1 Client follow-up
Nine of the 25 members of the public who made contact with the pharmacist were 
followed up using the methods implemented, which relied upon further contact with the 
agency. This was considered to be a good proportion of contacts, since some contacts 
were not of the nature that would require further contact with the agency. However, as 
discussed in 10.1.2.1, this proportion is small, the numbers involved were not large and it 
is unknown what was the consequence of intervention in the 16 people not followed up. 
Therefore, it cannot be assumed that the results of those followed up indicate that 
interventions made by the pharmacist led to positive outcomes in all cases i.e. the results 
gathered from those followed up cannot be extrapolated to apply to those lost to follow-up 
and therefore it cannot be concluded that all clients benefited from the service. What can 
be said is that of those who were able to be followed up, the majority did appear to have 
benefited from contact with the pharmacist as most of the outcomes reported showed a 
positive effect from the pharmacist’s intervention. In addition, some follow up led to the 
provision of further information and advice, which was considered to be a further 
endorsement of the service. It is notable that the drug users in cases nos. 2 and 8 
(appendix 29) only used the agency for needle exchange and did not wish to receive 
worker input, yet both actively returned to the agency to discuss their outcomes with the 
pharmacist. It is worthy of further investigation, whether some contacts who may not wish 
to formally see a drugs worker, would be willing to use a drop in pharmacist's information
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and advice service, after initial contact. Such a service may give the opportunity to deliver 
general health advice as well as drugs information and advice. It would be important to 
determine whether the formality of the service i.e. drop-in vs. pre-booked one-to-one 
appointment or the professional’s status i.e. drugs worker vs-, pharmacist, influenced the 
use of the service. In one case (no.8), a negative outcome occurred after the 
pharmacist’s intervention, as the client's prescription was stopped. Although an isolated 
incident, this highlights that although joint working is being encouraged in drugs services 
(Scottish Office, 1999), problems can occur when this is attempted. In conclusion, the 
outcomes that could be established mostly showed a positive benefit from contact with 
the pharmacist, however the lack of follow-up of all contacts means that it cannot be 
concluded that the pharmacists service was of positive benefit to the members of the 
public who used it.
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10.2.2.2 Drugs worker discussion group
The opinions expressed were generally agreed upon within the team, conflicting opinions 
did not arise. Others who worked in outreach locations and the base workers agreed with 
the point made by one outreach worker that the service was of greater benefit when 
working in the base. Overall, the team considered that the agency had benefited from the 
service, highlighting that the service had enhanced their knowledge and understanding. 
They also identified that the function of the pharmacist to resource and interpret 
information was beneficial. The team expressed confidence in the service that they had 
received. They did not consider that confidentiality of the service had been a concern of 
the clients, because the trust they had in the agency was assumed to apply to the 
pharmacist. They considered the attitude of the pharmacist had been conducive to being 
part of their team. The team were concerned that the service had created an expectation 
amongst clients that could not be met. Overall, the feedback suggested that the service 
had been well received by the team. The potential for bias caused by the pharmacist 
moderating the discussion group described in 10.1.1.1 and 10.1.2.2 must be considered. 
It could be said that only positive comments were made because the team wanted to 
please the pharmacist, as they were familiar with her and may have had a liking for her. 
The nature of the team is such that criticism of each other’s practice is commonly 
undertaken but the existence of this is difficult to evidence, as extracts from team 
meetings, which could be used to illustrate this are confidential. However, the report of 
the discussion group, which is copied as section 9.2.2, was given to the workers for 
approval and anonymous comment. All workers approved the report to be an accurate 
representation of their views, suggesting that the report did reflect their opinions. In
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addition, the attitude questionnaires, which the team thought to be anonymous, also 
showed a positive attitude towards the service (9.2.2.3). However, the existence of biased 
reporting cannot be eliminated.
The exposure of the team to the service highlighted the capabilities of pharmacists to the 
team, as reported in the discussion group. However, it was the opinion of the team that 
the service received had not changed their opinions of pharmacists in general, as they 
viewed attitude to be a personal characteristic and fundamental to the success of such a 
service. They highlighted the need to judge each individual and how their opinion on a 
profession could not be informed by their experience of one person. They also 
distinguished a difference in the level of specialist knowledge they considered the 
pharmacist to have from that of other pharmacists, specifically referring to community 
pharmacists. This was reflected in the classification of knowledge the pharmacist made, 
which indicated that she considered specialist knowledge was necessary to handle some 
of the enquiries received.
The opinions of the team after exposure to the pharmacist’s service were positive, 
although pre-service discussion with the co-ordinator and advisor identified several areas 
of concern around having a pharmacist as part of the team. Opinions were not gathered 
from the whole team before the service started, which can be criticised. By gathering only 
the opinions of two of the workers, it is assumed that these represented the views of the 
team, however this is unknown. Had a discussion group been carried out before the 
service started, it would have given further information against which the post service data 
could be compared. The co-ordinator and advisor were part of the post service discussion 
group and responded positively to the areas that they initially raised as concerns. This 
shows that their pre-service concerns did not develop when the service was provided.
10.2.2.3 The attitude questionnaires
The reliability of the questionnaire was found to be satisfactory (table 9.5). Most 
respondents gave the same response to both statement pairs and for all but one 
question, all other responses only differed by one. This was considered to indicate 
adequate internal reliability. However, statements 4 and 5 were removed by the reliability 
analysis. It is worthy of discussion that statements 4 and 5 appeared next to each other 
on the questionnaire. This was because the statements were ordered using random 
number tables. Randomisation until paired statements did not appear next to each other 
may have been more appropriate, to reduce the chance of obvious recognition that a
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statement has been presented in positive and negative form. The reliability analysis 
performed in SPSS, removed nine statements from the attitude score calculations (table 
9.6), as they did not give adequate item-total correlation. The final value of Cronbach’s 
alpha was considered to indicate high internal reliability.
The use of Cronbach's alpha should be discussed briefly. It may be criticised that this 
statistic should not have been used in such a small group of respondents since it is based 
on correlation between the items and the total and correlation co-efficients calculated on 
small sample sizes have very wide confidence limits. However, the group were not a small 
sample of a larger population so the results were not used to generalise about a larger 
group. The measurements represented the attitude of the total population i.e. all the 
Drugs Action workers who were employed during the study period. Hence the correlation 
co-efficient calculated is the actual correlation, so confidence intervals are irrelevant. This 
means that for a study that examines a total population, Cronbach’s alpha can be used 
regardless of the population size (Cronbach, 1951, Bowling, 1997, Simpson, 2000).
Nine statements may be considered to be a high number to remove. This suggests that
the statements could have been constructed more carefully, and with hindsight this is
\
believed to be true. There is some difficulty in using attitude scales in a specialist group. 
Attitude scales should measure a range of attitudes to a subject within the sample 
population. However, nature of drugs agency teams may mean the attitude of the worker 
to drug use, drug users and harm reduction is an important factor in selection at 
recruitment therefore polarisation of attitudes may already exist. Several of the removed 
statements were considered on reflection to relate to matters that the team are likely to 
hold similar views on (1 = induction training, 2 & 20 = confidentiality, 4 & 5 = client comfort 
with the service). Statements 6, 11, 18 and 19 were considered to be vague in their 
wording and may have caused some confusion. The use of a peer panel to review the 
statements would be used in further work prior to and after piloting.
A least favourable attitude score would have been 11, a midpoint score 33 and a most 
favourable attitude score 55. As said, a midpoint score may indicate either an undecided 
opinion or that two attitudes have been measured, one positive and the other negative. 
From table 9.7 it can be seen that all workers scored a pre-service attitude which lay 
between the midpoint and favourable. Overall, the attitude of the team became more 
favourable after service exposure. The attitude of two workers became slightly less 
favourable after exposure, whereas the rest became more favourable. There was no 
information provided in the open questions asked on the post-service questionnaire to say 
why this was. The difference in one score was only one, which suggests that this is not
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significant. However, the other had a difference of eight. It would have been interesting to 
have explored this further, however this could only have been done by making the 
respondent aware that their identity was known. This was not considered appropriate. 
Statistically, it was found that there was a significant difference between the pre and post 
service attitudes, indicating the attitude of the team overall became more positive after 
exposure to the service. As said, attributing this change to the service alone is difficult 
since the workers may have been exposed to other factors during the interim that 
influenced their attitude. The team had an attitude that tended towards positive before the 
service was implemented. However, had the experience of the team with the pharmacist's 
service been a bad one, this would likely have caused the average post service attitude 
score to be lower than the pre-service score.
The pre-service open questions established what role the team anticipated a pharmacist 
might have within the team and their concerns. The post service open questions asked 
them, based on their exposure to the service, if they considered a role for a pharmacist 
^existed within the agency and to define what they thought this to be. All drugs workers 
said they did think there was a role for a pharmacist. In the pre-service questionnaire, five 
Aspects to the role of a pharmacist at DA were anticipated. In the post service 
questionnaire, five very similar aspects to the role of a pharmacist at DA were identified. 
This suggests that the pharmacist's service met the expectations of the team. The 
fulfilment of the teams expectations by the service could illustrate why a positive attitude 
towards the service was shown, however the bias discussed in 10.1.1.1 and 10.1.2.2 
must also be remembered.
With regard to the point about training, the provision of training by the pharmacist has not 
been discussed because the training provided was not a planned part of the methods of 
this study or evaluated as such. However, it should be noted that the pharmacist provided 
a training session to the team called 'Drug use and concurrent illness', which focused on 
the use of illicit drugs by people with medical conditions including epilepsy, asthma and 
mental illness. She also participated with the needle exchange worker in establishing a 
support group for the Grampian needle exchange pharmacies, in collaboration with 
pharmacists from Grampian Health Board. This group were given training by the 
pharmacist on two occasions. The first event was entitled ‘Safer injecting' and the second 
‘Medical complications of injecting'.
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10.2.2.4 Cost of service provision
The approximate cost of the service was calculated only to guide potential funders on how 
much investment such a service may need in monetary terms. It should be noted that this 
cost does not include photocopying made at academic libraries outwith RGU, internet 
access, printing costs of letters and prepared materials, start-up costs including pre­
service negotiations and the answering machine, publicity for the service including poster 
production and postage. Therefore, the actual cost would have been higher than the 
approximate costs that could be established. It is very important to note that this is not a 
pharmacoeconomic evaluation and therefore, the economic benefits of the service have 
not been calculated. In such an evaluation, the economic impact of patient care would be 
considered.
If the service were to be established by contracting a community pharmacist into the 
agency for one session per week, it may be expected that the costing would need to 
. include locum fees to cover the absence of the pharmacist from their shop. Similarly, if a 
hospital pharmacist were used, a consultancy fee may be charged by the Trust that is 
greater than the salary costs considered in this study.
10.2.3 Possible future developments
10.2.3.1 Specialisation and accreditation
It has been suggested recently that the future of community pharmacy is through 
specialisation (Kayne, 2000). If such a vision became reality, drug misuse could be one 
area where community pharmacists could establish themselves as experts. Such a model 
could be compared to that suggested in Drug Misuse and Dependence - Guidelines on 
Clinical Management (Department of Health, 1999), where GPs who work with drug users 
are categorised depending on their degree of specialisation. In Kayne’s model, local 
community pharmacists would specialise in different areas, working together to meet the 
needs of their community. In the case of drug users, this differs from the current ‘shared- 
care’ structure in place in some regions, as drug users could form the majority of clients 
presenting at the specialist pharmacies. One of the benefits of shared-care is that it 
distributes the workload amongst pharmacies, aimed to prevent individual pharmacies 
experiencing excessive problems related to working with drug users such as difficulties 
arising from the current controlled drugs laws and shop-lifting (Roberts, and Bryson, 
1999). It might be difficult in practice to find pharmacist(s) from one pharmacy willing to
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specialise in this area. However, implementation of the changes recommended in the 
Working Party on Pharmaceutical Services for Drug Misusers report (1998) might prevent 
the occurrence of some problems in the first place. For example if pharmacists were able 
to take verbal confirmation of instructions for controlled .drug prescriptions from a 
prescriber, followed later by written confirmation, difficulties due to errors in the Misuse of 
Drugs Act prescription handwriting requirements may be minimised. It is the researchers 
personal belief that changes in the framework of community pharmacy from being 
business-based to being part of the NHS would create an environment in which Kayne’s 
model would be more likely to develop. This could encourage specialisation not only in the 
provision of services to drug users but to the general public as a whole. It would also 
remove the belief, reported to be held in the social science field of ethics and professions, 
that community pharmacy is an incomplete or marginalized profession (Latif, 2000). Given 
that in this study the drugs workers played a key role in referring clients to the pharmacist 
and the pharmacist found the majority of enquiries from workers were made on a face-to- 
face basis, it would be more appropriate for a specialist pharmacist to provide and 
information and advice service from within a drugs agency rather than a community 
pharmacy, especially until trust and reputation had developed. It would also be essential 
t^ have a private area available for discussion. However, such changes are also 
recognised as unlikely to happen in the near future.
The results of this study and further multi-centred studies could inform the Schools of 
Pharmacy of specific areas in which to provide training, building on the recommendations 
of the Working Party on Pharmaceutical Services for Drug Misusers (1998). At post­
graduate level, such courses could form the taught element of the accreditation process 
used to benchmark the specialists suggested in Kayne’s model (Kayne, 2000). It is the 
author’s opinion, based on her experiences reported in this study and of pharmacy 
practice, that a practical component would also be essential as part of the accreditation 
process.
10.2.3.2 Links with the statutory sector
Organisations within the voluntary sector vary greatly in size, activity and function. For 
example the sector encompasses large organisations such as Greenpeace and local self- 
help groups (NCVO, 2000). Overall, a large number of people are employed in the 
voluntary sector, accounting for approximately one in 25 full time paid jobs in the UK, with 
further numbers of volunteers (Taylor, 1998). The author refers to her previous work and 
that of Leat, which established that voluntary agencies might have many similarities with
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public sector agencies, if their area of activity, size and population they serve are similar. 
However, she also found in her previous work that voluntary agencies are more likely to 
have a wider spread of activities and a greater advocacy role than statutory sector 
organisations. It is also noted that whereas public sector agencies will be working to 
political frameworks, voluntary agencies may be working under their own autonomy. 
Currently, a government framework to promote partnership between voluntary agencies 
and the public sector exists (Taylor, ibid). The government and bodies representing the 
voluntary sector have signed the Compact agreement, making a commitment to 
partnerships and joint working (Taylor, ibid, NCVO, 2000). A detailed analysis of this is 
not within the remit of this work, however in the future it is likely that individuals working in 
the statutory and voluntary sectors will be working more closely together. This raises the 
question of whether a specialist information and advice pharmacists at a voluntary agency 
might be able to operate a similar service from a statutory service drugs agency, possibly 
in some form of shared contract of employment between both agencies.
• As this study was a case study in the voluntary sector, it does not illustrate that such a 
service could operate. Although issues of the clients may potentially be similar in a 
statutory agency, government frameworks, the composition of the team and other 
services provided would likely influence the use of the service by clients and the 
pharmacist’s role within that team. For example, some statutory services have a 
prescribing arm. If the prescribing protocols were such that identified illicit drug use was 
punished by removal from the service, it is anticipated that clients would be unwilling to 
discuss enquiries relating to illicit drug use with the pharmacist. However, if the protocols 
did not impose such penalties, there may potentially be a role for pharmacists within such 
teams. In teams with medical and nursing input the nature of the enquiries may differ, for 
example, questions relating to safer injecting may be directed towards a nurse specialist 
and medical service questions directed towards a doctor. However, many of the areas 
addressed in this study related to topics that the researcher considered to require the 
knowledge and skills of a pharmacist to be addressed, for example drug information, 
adverse drug reactions and information on pharmaceutical services. Additionally, an 
important matter if providing a service to more than one agency is that of client 
confidentiality. Agreement between all parties on the boundaries of confidentiality would 
have to be agreed before the potential of a shared post could be investigated. If such 
agreement could be reached, there might be potential for future work investigating the 
role of a specialist information and advice pharmacist shared between agencies within the 
voluntary and statutory sectors.
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10.3 Conclusions and further work
The first research question set for this study was: Is there a role for a pharmacist in the 
provision of information and advice within a voluntary sector drugs agency?
The results from this case study suggest that there is a role for a pharmacist at Drugs 
Action, a voluntary sector drugs agency. The pharmacist contributed to the work of the 
agency by providing information and advice to a range of clients, workers and outside 
agency professionals on pharmaceutical and related matters.
The second research question asked: What is the nature of the information and advice 
sought by people who consulted the pharmacist?
Through categorisation of the enquiries by the pharmacist into eleven separate 
categories, the nature of the enquiries the pharmacist handled has been defined and 
, further described. Categorisation by the pharmacist was considered the most appropriate 
method to use compared to using an independent panel, as she had the greatest 
familiarity with the enquiries. Drug information, on both prescribed and non-prescribed 
drugs formed the majority of the enquiries.
The third research question asked: What knowledge and skills were required to provide 
the service?
The knowledge and skills required to handle the enquiries was defined and categorised 
by the pharmacist. This shows what was perceived to be required for this particular case 
study, based on the opinion of the pharmacist who provided the service. Categorisation 
by an expert panel could have been undertaken and might have been more objective. 
However, this would have excluded the opinions of the pharmacist who provided the 
service.
Based on these three research questions, it is considered that the first hypothesis of this 
study, which was: It is possible to implement a pharmacist-led information and advice 
service within a voluntary sector drugs service, has been proven. This case study showed 
that a pharmacist-led information and advice service could be implemented at Drugs 
Action, and further described the use of the service, the nature of the enquiries received 
and knowledge and skills that the pharmacist considered were required to handle the 
enquiries.
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The fourth research question set for this study was: What were the agency client 
outcomes from the service?
As discussed, it is not possible to draw conclusions on the overall service based on what 
was measured, as it is not known what the outcomes were for the agency clients who 
could not be followed up. Those who were followed up showed largely positive outcomes 
from their contact with the pharmacist, but there could be bias in the reporting, as 
outcomes were measured by the pharmacist. In those who could not be followed up it is 
unknown whether they experienced an unfavourable outcome, which could have 
contribute to non-presentation at a later date or whether they experienced a favourable 
outcome and did not present at a later date because of lack of need for further input.
The fifth research question set for this study was: What were the opinions of the other 
agency staff on the service received?
•The agency staff reported favourably on the service they received, considering that the 
pharmacist had contributed positively to the team. However, as discussed, bias due to 
5sing the pharmacist who provided the service to gather this information, cannot be
V
excluded, despite the facility of ways to express opinion anonymously. Hence, although 
the staff reported favourably on the service and did not raise concerns, it is considered 
possible that some opinions could have been withheld due to the biased nature of data 
collection and the possibility of identification from the writing style and nature of typed 
anonymous reports.
The sixth research question set for this study was: What was the attitude of the other 
agency staff to the service?
The attitude measurement suggested that exposure to the pharmacists service had 
caused a positive shift in the attitude of the team towards having a pharmacist as part of 
the team. However, as attitude was measured using paper-based questionnaires in the 
presence of the pharmacist and because of the possibility of identification through hand 
writing style when answering the open questions, the bias in measurement cannot be 
excluded.
Based on the fourth, fifth and sixth research questions, it is considered that the second 
hypothesis for this study, which was: The pharmacist-led information and advice service 
would be of positive benefit to its users, cannot be proven. Although data was gathered 
that suggested those who used the service gained positive benefit, the bias in the
' l i
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assessment of the workers and agency clients and lack of follow up of all agency clients 
who used the pharmacist’s service, casts doubt on the strength of the findings. This 
hypothesis could only be upheld if a further service was implemented by the pharmacist at 
Drugs Action and the outcomes experienced by service users and their opinions on the 
service measured by an independent researcher or team of researchers. Similarly, the 
future work suggested below would have to be researched by different people to those 
providing the services.
The demonstration from this study that it is possible to implement a pharmacist-led 
information and advice service within a voluntary sector drugs agency, suggest that the 
next stage of work would be to conduct a multi-centred study examining the role of 
several information and advice pharmacists in a variety of agency setting. These setting 
could include both voluntary and statutory sector agencies. Additionally, the provision of 
such a service to multiple agencies by one pharmacist could potentially be explored. By 
'using pharmacists from a variety of educational backgrounds, further information could be 
gathered on knowledge and skill requirements, allowing a greater understanding of
educational and training requirements to be established for this role.
\
In addition, if specialisation were to become the way forward for community pharmacy, a 
further area for research is specialisation of the community pharmacist in drug misuse. 
This could enable specialist information and advice services for drugs workers, other 
agency professionals and members of the public to be delivered from such community 
pharmacies. However, the reality of the willingness of community pharmacists to 
specialise in the area of drug misuse can be questioned, given the potential difficulties 
that might arise and the common prejudices seen against drug users. If specialisation in 
this area did occur, this would open up many new areas for research, for example 
education and training needs of pharmacists and staff, service uptake and outcomes, cost 
effectiveness and the impact on the commercial aspect of community pharmacy practice.
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Chapter Eleven
Closing comments
The hypothesis from the first study was upheld by this work and the direction of future 
work in this new area of exploration has been mapped out. The call for a change in the 
paraphernalia supply laws made by Runciman (2000) and supported by others in the field, 
the increasing need for evidence-based practice and the high importance of patient safety 
within the clinical governance framework makes the question of paraphernalia supply to 
IDUs very pertinent at this time. Although injecting drug use is an illegal activity, this does 
not mean that it is acceptable for health care providers to supply injecting paraphernalia 
that is not fit for purpose or could increase the risks. Harm reduction is a realistic and 
pragmatic philosophy, which in turn underpins important health care interventions. There 
is a huge need for further research into injecting paraphernalia to enable harm reduction 
interventions such as the supply of paraphernalia to be made on the basis of scientific 
information, clinical evidence and calculated risk: benefits. The work presented in part 
one of this thesis is the first step towards gathering such evidence.
The first hypothesis from the second study was upheld as it has been shown that a 
pharmacist-led information and advice service can be implemented within a voluntary 
sector drugs agency. The second hypothesis in the second study regarding the benefits 
of the service could not be upheld however as the methods used to evaluate the service 
were not considered robust enough and recommendations for future improved methods 
have been made. The work in part two illustrates a case study of multidisciplinary working 
between a healthcare professional (the pharmacist) and health and social care 
professionals (the drugs workers) within the voluntary sector rather than the more 
traditional locations of pharmacists i.e. the statutory sector (NHS) or commercial 
business. Although the results of one case study cannot be extrapolated to all 
pharmacists and drugs agencies, this serves as a useful first investigation into such 
multidisciplinary working. As the role of the pharmacist changes within the new NHS, 
multidisciplinary and cross-sectorial working is likely to become increasingly important. 
This study provides evidence of such a case study within the drugs field, from which 
further investigation can be developed, as described in chapter 10.
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Both studies in this thesis provided information and knowledge not previously available, 
and thus advanced understanding of the chosen areas. A list of conference presentations 
and reprints of publications from this thesis are given in appendix 30. Initially it was over­
estimated what was achievable within the limits of a PhD project. This over-estimate was 
largely due to the inexperience of the researcher and the fact that this type of study was 
new and unique, so no previous guidance was available. Both the limits of time and the 
limits of the inexact and uncontrollable nature of injecting drug use were not fully 
appreciated when work began. With hindsight this can be said, but at the time the study 
was planned by the author who had limited previous research experience, it seemed 
plausible. Similarly, in both discussion chapters (chapters six and ten), the methodology 
has been criticised retrospectively. The positive aspect of recognising these limits is that 
the experience and knowledge gained can be used to build on what has been learned and 
inform the further work.
This work has examined a few small areas. The diverse and complex nature of drug use 
and harm reduction presents many more challenges for research and practice. The great 
harm that drug use can cause individuals, communities and society makes its reduction 
fundamentally important, as the removal of drug use from society is an unattainable goal. 
Harm reduction must be the underpinning philosophy of drugs and public health policies. 
Scientific evaluation of many new and existing harm reduction interventions must be done 
in order to preserve life, promote health and uphold human rights. Pharmacists can make 
a contribution to this being achieved.
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Appendix 1
Spiral model of the stages of change
Adapted from: Prochaska, J.O., DiClemente, C.C., and Norcross, J.C., 1992. In search of 
how people change: applications to addictive behaviours. American Psychologist. 47(9): 
1104, figure 1.
Appendix 2
A selection of available safer injecting information leaflets
Clockwise from the top:
What Works? Safer Injecting Guide (Exeter Drugs Project, 1992), Not Just Syringes (Viral 
Protection Campaign, 1998), A Guide to Safer Injecting (HIT, 1997) and The Safer 
Injecting Handbook, (Preston and Derricott, 1997).
Centre: Dig: A Guide for Injecting Drug Users (Lifeline, 1999).
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Society. Project will be fully explained to community pharmacists who agree to allowing 
access to their clients.
Researchers are reminded of their responsibilitiesto inform appropriate nursing staff and GPs of 
their patients’ involvement in the research project.
(ii) Please indicate enclosures:
Patient Information Sheet: Not Applicable
Patient Consent Form: Not Applicable
Written account of verbal explanation. YES
Letter to G.P. NOT APPLICABLE
Questionnaire YES
The Committee strongly discourages the exclusive recruitment of persons in any dependent 
relationship with the investigator, (e.g. students, nurses, laboratory technicians etc.) as subjects 
in research projects unless there are special reasons for so doing.
Good Clinical Research Practice: Please state to  which UK Guidelines/standardse.g.. the 
Investigation w ill adhere.
Not Applicable
Any additional relevant information:
Name of Applicant (in block capitals) 
JENNIFER SCOTT BSc (Hon) MRPharmS Nmedically Qualified
Signature of Applicant
Appointment held ..Research Pharmacist studying for a PhD
Department ..The Robert Gordon University, School of Pharmacy....................................
Date ....9 January 1997.............................................................................
NAME OF CONSULTANT/HEADOF DEPARTMENT IF OTHER THAN APPLICANT who has approved 
this project and checked the patients information sheet.
(in block capitals)
..Dr ARTHUR WINFIELD........................................................................................
Signature
School/Hospital/College ..Head of Department of Pharmacy Practice, School of Pharmacy,
The Robert Gordon University...................................................
Please Note:
1. The Committee expect to receive notification of any adverse or unforeseen circumstances 
arising out of this study.
2. In all projects, signature by the Consultant in Charge/Head of Department is essential.
3. Please notify the Committee on completion/abandonmentof the project.
4. Please send a copy of any publication which results. *
5. The Committee may audit a project at any time. *
This form  should be com pleted and returned to  Ms L Conway, Clerk to  the Jo in t 
Ethical Committee, Grampian Health Board, Summ erfield House, 2 Eday Road, 
Aberdeen, AB15 6RE.
Any enquiries can be directed to  e ither Ms L Conway, (01224) 663456 Ext 75225 
or
Professor E Russell, Consultant in Public Health Medicine, Medical School, 
Foresterhill, Aberdeen, AB9 2ZD o r to  the Chairman or Vice-Chairman. *
* Please note: Publication rights and right to audit must remain with my employers, The 
Robert Gordon University.
GRA M PIA N HEALTH BOARD 
AND
UN IVERSITY O F ABERDEEN
JO IN T  E TH IC A L C O M M ITTEE
C hairm an: C lerk  to  the  C om m ittee
N orth  H u t
ForestcrhU l
ABERD EEN
P ro f C  Kidd
Institu te  o f  M edical Sciences 
D ept o f  Bio-M edical Sciences
M s Lynn Conw ay
D ept o f Public H ealth  M edicine
G ram p ian  H ealth  Board
Sum m erfleld H ouse
2  Eday Road
ABERD EEN , AB1S 6R E
T el: (01224) 273005 
F ax : (01224) 273006
Tel: (01224) 663456 Ext. 75225 
F ax : (01224) 404014
Our Ref: LCMAA Project No: 97012
31 January 1996
Ms Jennifer Scott
The Robert Gordon University
School of Pharmacy
Schoolhill
Aberdeen
AB10 1FR
Dear Ms Scott
Development, Implementation and Evaluation of Harm Reduction Techniques for Intravenous 
Drug Misusers
The above project was considered at the Joint Ethical Committee meeting of 30th January 1997, and I 
am pleased to confirm that ethical approval for this project has now been granted.
With regards to medical indemnity, I enclose a form which should be completed and returned to 
either; (i) Dr J Hem, Clinical Director, Aberdeen Royal Hospitals NHS Trust, Foresterhill House, 
Ashgrove Road West, Aberdeen, (ii) Dr R Scorgie, Medical Director, Grampian Healthcare NHS 
Trust, Westholme, Woodend Hospital, Aberdeen, or (iii) Clinical Director, Moray Health Services 
NHS Trust, 317 High Street, Elgin, as appropriate, if you wish one of the above Trusts to accept 
liability for medical indemnity for this project Where drugs are received from a drug company for 
use in a trial, these must be stored in the Pharmacy Department for reasons of good practice.
We would be very glad to receive, in due course, copies of any publications arising from this research. 
Thank you for bringing this study to the Committee’s attention.
Yours sincerely
Lynn Conway 
Clerk to the Committee
Please quote project number in all correspondence
_____________________ _ _____________________________________ ________Appendix 4
Tables 4 and 53, reproduced from the Scottish Drug Misuse Statistics. 1995. with
permission from the Information and Statistics Division, Scotland (October. 1999).
4 Main drug o f m isuse; by health board in which agency is located; year ending 31 March 1995 MEDICAL ANO NON-MEDICAL NEW INDIVIDUAL PATIENTS/CUENTS
Scotland P6na/ Health Boards (exduding Penal establishment Inmates)
meni
inmales
A /yyi 
A Ctyde
Ayrshire 
A Arran
Borders Dumfries 
A Gateway
We Forth
Valey
Grampian Greater
Glasgow
Hghland Lanark­
shire
Lothian Tayside Shetland
ToW Injec1 ToW Total Injec ToW Injec ToW h |« ToW h iK ToW h i« ToW h i« ToW h i« ToW h i« ToW Injec ToW h *c Total Total h i« ToW h i«
H*w Individu»!
I1S9 2 070 773 2SS 476 71 .263 74 60 17 H 67 159 52 149 23 <05 145 2 558 1242 20 3 204 69 1050 <9 137 14 17 1
Heroin 2 327 1686 235 165 131 63 69 57 14 11 63 47 33 25 IS 11 1*5' • 127 1462 1078 3 3 72 56 33 16 2 1
Morph«# 51 40 7 7 «. 2 1 • 1 1 . 22 18 3 2 13 10 1 1 1
M«th*don#
- preserved 0<*f 816 24 74 3 15 1 47 4 3 5 9 22 6 69 1 328 6 8 3 194 1 39 2
•«her* 450 15 49 6 • 69 2 2 7 15 5 47 1 57 1 5 1 136 2 57 3
Whydrocod#«#
• pr#sot*d only 268 3 20 1 10 2 . 2 5 14 1 54 2 1 152 1 5 . 1
•CXh#*' 449 6 34 22 • 4 • 7 1 5 6 1 140 3 2 5 211 1 12 . .
Dwanon# 25 21 4 4 1 1 4 2 2 2 3 1 6 6 1 1 2 2 2 2
Buprenorphin# 245 175 36 23 33 5 5 5 3 3 9 6 11 7 1 1 123 105 3 16 15 5 5
Mwr Opiates 32 3 1 3 j , 1 1 1 4 3 9 1 1 2 4 1
IXazepam
• presaged only 119 18 4 6 . . 5 13 3 12 2 1 43 3 - 1
• oe#r‘ 185 2 24 1 5 1 . 4 18 3 11 5 100 1 3 1 1 .
T#mai#p#m
• priscrfced only 4« 7 7 .  2 . . 2 3 . 7 1 4 7 1 . .
•Oth#f' 565 SO 154 24 126 2 16 2 2 1 2 . 24 8 3 156 21 46 26 2 . .
0»* Iwodaap»« 21 1 5 . . 4 1 7 2 1 .
Oher $#d*8v*j 7 2
Amph#Um«e» 180 41 17 6 28 14 2 7 1 2 1 5 1 7 1 22 10 32 9 12 1 27 7 1
Cocain# 23 3 8 2 4 . • 1 1 8 1 .
Ecstasy 74 18 8 1 1 2 5 6 14 5 12
H*»ucinog#o* 31 11 2 • 2 2 3 1 1 3 2 4 .
Cannabis 266 34 41 * 18 7 • 8 10 17 46 26 48 5 6
Solvents 33 2 4 1 * 4 3 2 6 4 6 1 *
Other Drugs 25 1 2 3 - • 1 2 7 1 10 -
No drug CorM 121 17 • 1 3 12 3 56 1 3 16
1 Total nunber o l incfvtduals misusing the drug isled  as fcs main drug. Sourcs: Scottish Drug Wsuse Database
2 Number (out o l the total) «4)0 are injecting. *
3 Includes cases where some or i l  ofthe drug mentioned was obtained R d ty  or where Ihe
source is unknown. .. y  •
C  All drugs o f m isuse; by health board in which agency is located; 
*/ 3 year ending 31 March 1995 MEDICAL AND NON MEDICAL NEW INDIVIDUAL PATIENTSCUENTS
Scotland Health Boards (exdufng Penal estabSshmert inmales) 12345
menl
inmates
Argyf 
A Oyde
Ayrshire 
A Arran
Borders Dumlries
AGaloway
We Forni
Valey
Grampian Greater
Glasgow
Hghiand Lanark
shire
Lothian Tayside SheSand
TOW mjec* ToW h i« ToW h i« ToW Injec ToW hjec ToW Injec ToW tyac ToW h i« ToW h |K ToW Mac ToW ln|ec ToW Injec Tow h j« ToW h i« ToW Injec
MewIndMduel
piStnütôenif1 •  359 773 478 263 60 88 159 149 405 2 558 20 204 1050 137 17
Htroin 2 842 2 046 266 228 156 7« 102 84 16 13 72 54 54 39 24 19 2S8 170 1724 1261 5 4 83 62 54 31 6 5
Morphin# 12t 78 11 13 4 1 4 2 1 1 1 1 44 28 1 ! 4 3 X 24 1 5 3 2 1
Melden#
• presetted only 1 059 2« 117 4 22 1 54 4 8 6 20 25 6 83 1 453 7 16 204 1 40 2
-other* 769 31 82 5 20 104 2 3 9 16 1 29 11 103 4 129 1 . 8 1 200 3 66 3
Dhydrocodeine
• prescribed only 497 7 43 2 27 10 2 4 3 3 9 ■ . 15 1 186 1 4 181 1 7 1
-< *« * 1005 23 17 3 67 31 2 9 11 1 18 2 16 24 2 370 11 17 1 307 1 43
Drprpancn# 118 88 16 16 1 1 13 7 1 1 8 7 6 4 18 11 26 18 4 1 8 8 16 14
Buprenorphine 571 361 80 41 55 6 28 19 6 6 14 7 30 17 4 2 9 ( 276 20« 2 1 11 2 41 32 15 14
Oter Opiates 109 24 10 6 11 1 9 4 3 4 2 16 4 S • « 1 22 2 1 6 1 10 2 1 1 1
Diazepam
•prescribed only 684 2 86 2 41 24 12 15 30 34 148 12 2S9 17
•ofcer* 962 16 124 7 75 2« 17 3 22 1 43 40 17$ 3 9 365 2 41 3
Temazepam
■ prescribed only 365 9 51 2 I t 14 2 2 5 . 17 26 52 4 6 151 22 1
Ot#r* 2319 497 354 75 231 13 102 48 16 10 22 7 42 3 44 7 64 7 1024 303 2 107 g 270 B 7
C»# tonfetpm i 211 2 19 1 33 7 1 9 • 7 10 97 1 5 22
Other Sedatrves 95 5 9 7 1 1 1 1 * 9 * 11 34 • 1 16 4 1 1 1
Amphetamines 545 143 57 17 67 1 44 21 23 6 7 2 19 4 24 4 42 16 105 3« 2 1 32 1 98 24 13 7 12 1
Cocah# 80 17 14 4 10 1 4 1 . 2 ( 29 9 5 1 • 1 1 1
Ecstasy 321 14 66 3 X 1 13 10 3 13 . 13 1 31 1 53 2 20 62 8
Hefcjdnogen# 198 1 41 16 I t 12 12 • • 13 2« 1 21 X 6
Cannabis 1365 93 155 87 22 24 47 • 29 142 361 57 297 38 12
Solvents 46 3 1 1 4 3 • 2 1 , S 8 2 2
A to rd ' 482 30 54 * 17 17 3 19 15 31 134 • • 43 98 6 13
Other Drug* 15« 1 7 12 5 1 S 5 • 1 11 70 S • 2 32 1 i
No Drug Coded 121 17 « 1 1 3 12 - 3 56 • » • 3 16
1 Total number of individuals misusing Ihe drug ksted
2 Number (out of tie  total) who are miecimg
3 The total drugs reported is greater Hen ihe numb« o l new ndrvxJual patrentsfckenis because ndneduats m ar ha»« reported use o l more te n  one drug.
4 Includes cases where some or aB ol ihe drug mentioned was obtained «¡city or »here Ihe source is unknown
5 Alcohol is reported only M is  used as a secondary drug
Source: Scottish Drug Misuse Database
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Needle exchange agencies visited as part of baseline data collection process.
Drugs Action 
48a Union Street 
Aberdeen 
AB101BB
tel: 01224 624555
The Harm Reduction Team 
25-29 Spittai Street 
Edinburgh 
EH39DU
tel: 0131 2 2 9  5 9 9 5
The Harm Reduction Centre 
Constitution House 
55 Constitution Road 
Dundee 
DD1 1LB
tel: 01382 201919
The Exchange
16a Cleveland Street
London
tel: 0171 5 3 0  4 5 8 0
Appendix 6
Interview Schedule for Filter Study ..CONFIDENTIAL
The project:
I am testing filters in the lab and need information about drugs and filters used. Hopefully I shall then be able 
to produce some safer injection advice about using filters and will be able to provide scientific data that could 
potentially be used to support funding for filter distribution. I will also be looking at injection site injuries, so 
I will ask about this too.
The questionnaire is designed to find out information I need to know to support my lab work. I want to know 
about the stages involved in preparation o f the hit so I can copy them. I also want to know about the process 
of injecting and injection site injuries. Any information provided will be useful. Not all questions may be 
applicable to you or you may feel you do not wish to answer certain questions, this is fine you have the option 
to decline to comment.
Confidentiality:
I am looking to talk to about 25 people and need to make sure that I interview a broad range. Therefore 
before I begin the questions I need to ask a few details about yourself.
This interview is completely confidential. Do you object to the interview being taped, to avoid time being 
spent writing down answers? The interview will be identified only with the number o f the interview (i.e.: first, 
second etc.) and time started and time stopped. Otherwise, answers will be written down, which is fine but 
will take longer. Taped interviews will last approximately 20 minutes, written ones probably an hour.
Honesty:
It is easy when being asked about something such as drug use to tell people what you think they want to hear 
which is not always the same as what is the case. It is really important to be honest if  I am to get some 
accurate results from my work, and therefore to produce the best information for users. It’s not a test to see 
who has the safest injection technique, the interviews will not be heard by Drugs Action staff or anyone else 
except myself. Everything is completely confidential.
General Information:
• Sex o f client: M F
• Age of client:
•  Age when first injected:
•  Are you still injecting?
If yes, how often do you inject? If no, why did you stop?
If no, how long ago did you stop injecting?
Appendix 6
CONFIDENTIAL
Interview Questions:
Preparation o f  Hit:
• Who prepares your hits? (self/ partner/ friend?)
• (If self) How did you learn how to prepare hits? (friend?)
•  Have you ever taught someone else how to inject?
• What needles and barrels do you use? (orange, green needles, 1ml, 5ml barrels etc.)
•  Have you ever had any safer injection advice? (if  yes where from? Needle X centres, pharmacies doing 
needle X, other medical people, friends. Leaflets or verbal?)
********************************************************* *
Drugs:
•  What drugs do you use or have you used by injection? (timescale?)
• Have you ever injected tablets or capsules?
•  If yes: what have you used? (examples?)
•  Do different types o f tablets get mixed together in a hit?
•  How many go into each hit? (what factors influence this? e.g. not used before, mixing
with other drugs)
• Do you test the strength of the hit first? (toot helps steady hand)
Crushing:
• What drugs do you crush? (e.g. heroin, speed, tablets-which ones?)
•  How do you crush? (e.g.: between two spoons, with a book)
Acids:
• What acids do you use? (e.g. citric, ascorbic (vit C) vinegar, lemon Juice)
• What drugs would you add acid to? Oust skag or speed or to tablets too?-which ones?)
• How much do you add? (e.g.: pinch, like salt on chips, few drops o f lemon juice?
' The line of asterisk indicate the point at which in the post-piloting interviews the question ‘Please tell me 
how you prepare your hits’ or Please tell me how your hits are prepared' was asked.
Appendix 6
CONFIDENTIAL
Water:
•  What kind of water gets used? (from boiled kettle, from tap, from cup that gets shared?)
• How much water would get added? (indicate in teaspoons, e.g.: half a tsp., one tsp. etc. or
volume in mis such as half a 2ml barrel)
Heating:
•  What drugs would you heat? (skag, speed, tablets, capsules?)
•  What is used as the heat source? (lighter, candle, match, cooker?)
• How long do you heat for? (till it dissolves, till it boils?)
Filtering:
•  Do you worry about particles in the hit? (understand the risks?)
• Do you worry about bacteria in the hit? (understand the risks?)
• How do you get rid of the stuff that doesn’t dissolve? (if at all)
(tip spoon more common or filter?)
• Does filtering take away some of the hit?
•  ,What drugs would you filter? (skag, speed, tabs, caps?)
•  What would you use as a filter? (cigarette end, cotton wool ball or bud, toilet tissue?)
• Do filters get reused?
• Do you keep old filters to use them to make another hit? (if so, how?)
• Should filters be available from places that exchange needles? If so what type? 
*********************************************************2
2 The line of asterisk indicate the point at which in the post-piloting interviews the question 'Please tell me 
how you Inject' or 'Please tell me how you are Injected' was asked
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Injecting process:
• Do you alternate injecting sites? (if yes how often?)
• Do you swab site before injecting?
• What are the stages o f injecting?
Tourniquet?: Where? When is it released?
Flush back to check got vein?
Do you do anything to avoid bruising?
Inject slowly?
Do you press on site after?
•  Have you ever had any injection site injuries?
If yes: What? (e.g.: track marks, collapsed vein, abscess, clot)
What did you do?
( What do you think would be the best way for people to get injection site
injuries treated?
Why?
•  What do you think would be the best way to get new advice across to people? (leaflets designed by DA 
users, Leaflets designed by others, video made by DA staff,)
• What factors do you think make people not practice safer injecting ? (desperate for hit, injecting with 
people who don’t do it, already being stoned)
Thank you once again for your time and input. Just to reinforce this 
interview is in the strictest confidence. The tapes/ transcripts will be kept 
in a locked office and only used by researcher.
T
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Information Sheet for Drug Action/Pharmacv Clients asked to
participate in Interviews.
You have been asked if you are willing to be interviewed as part of a research 
project. The information on this sheet is designed to tell you what the project is 
about:
What is the project about?
I am testing filters in the lab and need information about drugs and filters used. Hopefully I 
shall then be able to produce some safer injection advice about using filters and will be able 
to provide scientific data that could potenitailly be used to support funding for filter 
distribution. I will also be looking at injection site injuries, so I will ask about this too.
The interview is designed to find out information I need to know to support my lab work. I 
want to know about the drugs you have used and how you prepare hits, so I can copy this in 
the lab, as closely as possible.I also want to know about any injuries you have had due to 
injecting. Any information provided will be useful. Not all questions may be applicable to 
you or you may feel you do not wish to answer certain questions, this is fine you have the 
option not to comment. If you feel at any stage in the interview you don’t want to carry on 
with it, you can leave without question. The decision to take part and continue is entirely up 
to you.
Confidentiality.
I am looking to talk to about 25 people and need to make sure that I interview a broad range. 
Therefore before I begin the questions I need to ask a few details about yourself to make sure 
I am speaking both men and women with a range of ages.
This interview is completely confidential. You will be asked if you mind the interview 
being taped, to avoid time being spent writing down answers. The interview will be identified 
only with the number of the interview (i.e.: first, second etc.). Otherwise, answers will be 
written down, which is fine but will take longer. Taped interviews will last approximately 20 
minutes, written ones probably an hour. The choice to have your interview written or taped is 
yours.
Honesty:
It is easy when being asked about something such as drug use to tell people what you think 
they want to hear which is not always the same as what is the case. It is really important to be 
honest if I am to get some accurate results from my work, and therefore to produce the best 
information for users. It’s not a test to see who has the safest injection technique, the 
interviews will not be heard by Drugs Action/pharmacy staff or anyone except myself. I am 
not a DA employee nor do I work for any other drug treatment agency. The only contact I 
have with pharmacies is occasional work filling in when pharmacists are off (this is called 
locum work). Everything is completely confidential.
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Consentforms:
If you agree to take part, you will be asked to sign a consent form to say you are willing to be 
interviewed. Just like the tapes and written interviews, these will be kept in a locked office 
and will only be seen by the researcher. They will be destroyed after the research is over. 
You can sign a false name or just your initials, you do not have to give your own name. 
Consent forms are something that is a standard part of any research project and the reason for 
having them is so I have something in writing that said you agree to the interview taking 
place.
I  am very grateful to those who agree to being interviewed, for giving up their time and 
contributing information to my research.
Thankyou
Jenny Scott
Robert Gordon University
Interview with Drugs Action/Pharmacv Clients,
Consent form
I have read the information sheet about the interviews and agree to take part.
I understand that I can withdraw from the interview at any time and this will not affect my 
treatment from Drugs Action or the pharmacy. I understand that the interview is completely 
confidential.
date
signed
Scottish Drug Misuse Statistics 1995-6
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Summary of Information estabished from the Statistics
Data is collected from the SMR form which is completed by agencies at initial contact with 
drug users.These agencies are defined as: Penal Establishments, General Practice, Police 
surgeon, Specialist Drug Services, Out patient services, Inpatient services and Residential 
rehabilitation. Initial contact is defined as: person attending the agency for the first time or 
previous attendance more than six months ago.
By means of matching certain criteria (initials, D.O.B and sex) and an adjustment is made 
for double counting of individuals who may have been to more than one agency (e.g. GP 
and needle exchange). However, true matches cannot be guaranteed and it is likely some 
will have been wrongly matched and some missed.
Clients are asked to report their main drug of misuse. This is defined as the drug to which 
they are most addicted or they are using most often. Table 4, page 26 of the bulletin details 
the main drug of misuse indicated and the number of clients who reported injecting their 
main drug. This is given as a total for Scotland and by healthboard in which the agency is 
located. Below, this information is shown for each drug mentioned as the percentage of the 
total number of injectors (n) who reported it as their main drug.
Clients report drugs used in the past month. This cannot be taken as representing the drugs 
likely to be used by all the drug using population, since many who have established 
connections with services or who have no need for services, will have more stable drug 
using careers. What this does indicate is the drugs being used at the time over the past 12 
months when users access services (NB: this access can be volountary as in needle 
exchange or compulsory as in penial establishments).
Table 1: Percentage (%) o f  clients who reported drug as main drug o f  misuse by 
injection.
Drug > V1 ‘ - î'V V Scotland (r i= 2 0 7 0 )^  ^ Qfampian(n== 145) v
heroin 81.4 87.6
morphine 1.9 1.4
methadone * 1.9 1.4
dihydrocodeine* 0.4 1.4
dipipanone 1.0 0.7
buprénorphine 8.5 0.7
other opiates 0.1 0.7
diazepam* 0.1 0.0
temazepam* 2.4 0.0
amphetamines 2.0 7.0
cocaine 0.1 0.0
other drugs 0.1 0.0
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Table 2a: Decending order o f percentage (%) o f clients who reported drug as main drug 
o f  misuse by injection. Shown for Scotland.
DrugV' : ■:. V * • Scotland (n=2070) v.Yv
heroin 81.4
buprénorphine 8.5
temazepam* 2.4
amphetamines 2.0
morphine 1.9
methadone * 1.9
dipipanone 1.0
dihydrocodeine* 0.4
other opiates 0.1
diazepam* 0.1
cocaine 0.1
other drugs 0.1
Table 2b: Decending order o f  percentage (%) o f  clients who reported drug as main drug 
o f misuse by injection. Shown for Grampian.
Drug V Grampian (n= 145) • •
heroin 87.6
amphetamines 7.0
morphine 1.4
methadone * 1.4
dihydrocodeine* 1.4
dipipanone 0.7
buprénorphine 0.7
other opiates 0.7
diazepam* 0.0
temazepam* 0.0
cocaine 0.0
other drugs 0.0
Table 5a, page 27 of the bulletin details all drugs reported to have been used in the past 
month. The number of clients who indicated having used each drug by injection is also 
given. Table 3 below, shows this as percentage of clients who reported having used a drug, 
who used it by injection.
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Table 3: Percentage (%) o f clients who indicated drug had been used in past month by 
injection.
Drug '' « • ' •/-; /Scotland Grampian
heroin 72.0 65.9
morphine 62.9 75.0
methadone* 6.5 5.1
dihydrocodeine* 3.7 15.0
dipipanone 74.6 61.1
buprénorphine 63.2 66.7
other opiates 22.0 12.5
diazepam* 2.0 0.0
temazepam* 23.9 10.9
other benzodiazepines 0.9 0.0
other sedatives 5.2 0.0
amphetamines 26.2 38.1
cocaine 21.3 0.0
ecstasy 4.3 3.2
hallucinogens 0.5 0.0
other drugs 5.1 0.0
Table 4a: Decending order o f  percentage (%) o f clients who indicated drug had been 
used in past month by injection. Shown for Scotland.
: Drug ■; >| : { 'h *"'V 'Scotland
dipipanone 74.6
heroin 72.0
buprénorphine 63.2
morphine 62.9
amphetamines 26.2
temazepam* 23.9
other opiates 22.0
cocaine 21.3
methadone* 6.5
other sedatives 5.2
other drugs 5.1
ecstasy 4.3
dihydrocodeine* 3.7
diazepam* 2.0
other benzodiazepines 0.9
hallucinogens 0.5
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Table 4b: Decending order o f percentage (%) o f clients who indicated drug had been 
used in past month by injection. Shown for Grampian.
Drug • . •
- " ‘v .  .'i t ,-1 .‘ /  j. ' m . . . . . - ■  -
G r a m p i a n ! 7 1
morphine 75.0
buprénorphine 66.7
heroin 65.9
dipipanone 61.1
amphetamines 38.1
dihydrocodeine* 15.0
other opiates 12.5
temazepam* 10.9
methadone* 5.1
ecstasy 3.2
diazepam* 0.0
other benzodiazepines 0.0
other sedatives 0.0
cocaine 0.0
hallucinogens 0.0
other drugs 0.0
Note: SMR form asks for route(s) of administration so it is understood from this that all 
routes used for a particular drug should be recorded.
\
* note: Separate statistics for these drugs are recorded on the SMR distinguishing whether 
they have been prescribed or obtained from other/not stated source. The figures indicated 
here are a sum of both prescribed and non prescribed use.
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REGIONAL PROCURATOR FISCAL FOR 
GRAMPIAN, HIGHLAND AND ISLANDS
Athol! House DX AB67
84-88 Guild Street 
ABERDEEN AB11 6QA
Tel: 01224 585111 Fax: 01224 585550
Ms Jennifer Scott MR PharmS
The Robert Gordon University
School of Pharmacy
Schoolhill
ABERDEEN
AB10 1FR
Your Ref:
Our Ref: R/E/l/GN/LR
1 May 1997
Dear Ms Scott
RESEARCH PROJECT - ROBERT GORDON UNIVERSITY
I refer to this matter. I have now heard from Crown Office who indicate that so 
long as you may lawfully be in possession of the drug samples there would be no 
objection to this research. The only condition which we would insist upon is that 
the samples could only come from seizures in cases which have been concluded. These 
Samples could only be taken therefore from drugs which are destined for destruction.
I suggest therefore that you confirm that the School of Pharmacy will have a licence 
from the Home Office to allow -you to have access to these drugs for research 
purposes, agree arrangements via Grampian Police regarding your obtaining possession 
Of these drugs and agree with them, with the assistance and advice from their 
forensic Science Laboratory, methods of ultimate destruction including the 
Certificate procedure if destruction is carried out at the University.
I would be pleased to hear from you whether you are in fact able to proceed with 
Vour research and would also be interested in knowing the ultimate results of this 
Research.
fours sincerely .
<5 NAPIER
Acting Regional Procurator Fiscal
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REGIONAL PROCURATOR FISCAL FOR 
GRAMPIAN, HIGHLAND AND ISLANDS
Atholl House DX AB67
84-88 Guild Street 
ABERDEEN AB11 6QA
Tel: 01224 585111 Fax: 01224 585550
Ms Jennifer Scott MR PharmS
The Robert Gordon University
School of Pharmacy
Schoolhill
ABERDEEN
AB10 1FR
Your Ref:
Our Ref: R/E/l/GN/LR
1 May 1997
Dear Ms Scott
RESEARCH PROJECT - ROBERT GORDON UNIVERSITY
I refer to this matter. I have now heard from Crown Office who indicate that so 
long as you may lawfully be in possession of the drug samples there would be no 
objection to this research. The only condition which we would insist upon is that 
the samples could only come from seizures in cases which have been concluded. These 
samples could only be taken therefore from drugs which are destined for destruction.
I suggest therefore that you confirm that the School of Pharmacy will have a licence 
from the Home Office to allow -you to have access to these drugs for research 
purposes, agree arrangements via Grampian Police regarding your obtaining possession 
of these drugs and agree with them, with the assistance and advice from their 
Forensic Science Laboratory, methods of ultimate destruction including the 
certificate procedure if destruction is carried out at the University.
I would be pleased to hear from you whether you are in fact able to proceed with 
your research and would also be interested in knowing the ultimate results of this 
research.
Yours sincerely
G NAPIER
Acting Regional Procurator Fiscal
HOME OFFICE
Action Against Drugs Unit
50 Queen Anne's Gate, London, S W 1H 9AT
D irectL ine 0171 273 3806 Fax 0 1 7 1 2 7 3  2157
1 2 AUG 1997
Prof. R Richards
Head O f School O f Pharmacy
The Robert Gordon University
Schoolhill
Aberdeen
AB101FR
Your reference:
Our reference: DDA/1621/1/1
Date: 11 August 1997
Dear Prof. Richards 
MISUSE OF DRUGS AC T 1971
MISUSE OF DRUGS REGULATIONS 1985 (AS AMENDED)
I refer to your application o f 20.05.97 to have "street" heroin added to your licence, 
to possess, no 97/MM/4546 to enable one o f your PhD students, Ms Jennifer Scott 
to conduct a research project.
Following referral to our inspectorate, I am now in a position to advise you that, 
under Regulations 8(2)(f) and 10(1)(a) o f the Misuse O f Drugs Regulations, you are 
exempt from requiring a licence to possess heroin.
I should .however, take the opportunity to remind you that the samples, used in the 
research project must o n ly  be obtained from Grampian Police in accordance with 
the directions o f the Acting Regional Procurator Fiscal, outlined in his letter to Ms 
Scott o f 01.05.97.
I hope that this satisfactory, but if you have any further questions, please do not 
hesitate to contact me on the above numbers.
Yours sincerely
Mr S A  Winch
G:\RESEARCU\SCOTT.DOC
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JOINT ETHICAL COMMITTEE  
OF
GRAMPIAN HEALTH BOARD  
AND
THE UNIVERSITY OF ABERDEEN
Staff undertaking medical research work involving human subjects are invited to provide the following 
details of the project for consideration by the Joint Ethical Committee of the Grampian Health Board and 
the University of Aberdeen.
The Joint Ethical Committee consists of members nominated by the Grampian Health Board and the 
University of Aberdeen and its function is to examine and give an opinion on the ethical aspects of all 
clinical research investigations referred to it, including therapeutic innovation, or any experimentation 
involving human subjects.
The Joint Ethical Committee meets on the last Thursday of each of the following months: 
January, March, May, July, Septemberand November.
Projects must be in typescriptand submitted by 12 noon two weeks in advance of meetings. This 
deadline will be strictly adhered to. 18 copies of the application must be submitted. The 
proforma is held on disc by the Secretary.
Investigators are asked to provide information in the form of answers to the following questions. Where 
questions are not relevant or not applicable please indicate. Please use extra sheets if necessary and 
insert these in the appropriate places. If the Model Consent form and the APB1 terms for compensation 
are being used, these forms should NOT be included.
The Consultant in charge/Head of Department is particularly requested to check the technical aspects of 
the project and to make sure that the Patient Information sheet is readily understood with the signature 
confirming that this responsibility has been accepted.
1. (a) Names of investigators responsiblefor the project
Project team consists of:
Research project student: Jennifer Scott
Director of studies: Dr Arthur Winfield (Senior lecturer, RGÜ) 
Project Supervisors: Dr Emily Kennedy (Teacher practitioner, 
Boots the Chemists & RGU)
Dr Christine Bond (Dept. General Practice, Univ.of Aberdeen) 
Advisors to project: Dr Jennifer Hall (Drug Development 
Officer, GHB)
Miss Luan Bruce (Needle Exchange Worker, Drugs Action)
(b) Names and background of Individuals directly involved in carrying out the 
project
Jennifer Scott. Pharmacist. This project is expansion of 
Honours project carried out in 1994. Previously worked in
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Pharmacy R&D at Roche Products (UK) Ltd as pre-registration 
pharmacist and Pharmacy Department, Queen Elizabeth II 
Hospital, Welwyn Garden City, Hertfordshire, as Clinical 
Services Pharmacist. Currently research pharmacist, RGU and 
part time locum pharmacist and drugs worker.
2. (a) Name o f Consultant o r GP in charge o f patients:
Not Applicable
(b) Names o f o ther consultants/departments/laboratories/recordsdepartment who 
are involved in a s ign iflcantam ountof extra work.
Has permission/agreementbeen obtained? YES /  NO
Not Applicable
(c) Name o f any other Individual (and the ir department) involved:
Not Applicable
3. State the title  o f the proposed project (and project number o f previous application,
where relevant):
Development, Implementation and Evaluation of Harm Reduction 
Techniques for Intravenous Drug Misusers.
4(i) Give an outline o f the project and indicate its intended value:
In January 1997 the Ethics Committee approved a research proposal for this 
study. This application, is to extend one aspect of the work.
This is the extract that was given in the Jan 1997 approved proposal:
'To a s s e s s  in  th e  la b o r a to r y  c u r r e n t an d  new m eth ods u sed  to  rem ove  
p a r t i c l e s  from  s o lu t i o n s  o f  d ru gs o f  a b u se  p r e p a r e d  f o r  in tr a v e n o u s  
i n j e c t i o n ,  u s in g  a te c h n iq u e  which m im ics th a t  u se d  b y  in tr a v e n o u s  d ru g  
m is u s e r s . From th e  r e s u l t s  in fo rm a tio n  on harm r e d u c tio n  te c h n iq u e s  w i l l  b e  
p r e p a r e d  f o r  d ru g  u s e r s ,  d ru g s  w orkers , GPs, p h a r m a c is ts ,  h o s p i ta l  s t a f f  and  
o th e r s  who work in  th e  harm r e d u c tio n  f i e l d .  To e s t a b l i s h  th e  te c h n iq u e s  
u sed  in tr a v e n o u s  d ru g  m is u s e r s ,  s e m i- s t r u c tu r e d  i n te r v ie w s  w i l l  b e  c a r r i e d  
o u t w ith  tw e n ty  f i v e  d ru g  u s e r s .
L a b o ra to ry  b a s e d  in fo r m a tio n  a b o u t th e  p r o c e s s  o f  p r e p a r a t io n  o f  s o lu t i o n s  
w i l l  a l lo w  e v id e n c e  b a s e d  in fo r m a tio n  to  b e  a v a i l a b l e  to  s u p p o r t  v a r io u s  
harm r e d u c tio n  te c h n iq u e s . S a f e r  i n je c t i o n  a d v ic e  w i l l  l e a d  to  l e s s  i n j u r i e s  
and m ed ic a l c o m p lic a t io n s  o f  in tr a v e n o u s  d ru g  m isu se , th u s  r e d u c in g  th e  
w orkload  o f  th o s e  who d e a l  w ith  th e s e  p ro b le m s  such  a s  GPs and A&E s t a f f .  ’
This is the details of the extended part of the study, for which I seek 
approval:
Data is being collected in the laboratory on the effectiveness of filters on 
removing particles from injections, and predicted benefits to health of 
injecting drug users (IDUs) made. This study has created much interest both 
nationally and internationally. Once this work is complete, it is proposed 
that the most effective filter, the pre-syringe filter, be assessed for user 
acceptability. To do this, it is proposed to distribute a small number of 
pre-syringe filters to IDUs for use and collect their views and opinions on 
the suitability for purpose of the filters, using a questionnaire. It is 
currently forbidden to distribute any injecting paraphernalia according to 
the Drug Trafficking Act, Section 9a (except needles and syringes which are 
exempt). The Police Federation are currently reviewing this act. If a change 
in the law does happen, this work will provide valuable evidence for
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purchasers and providers when deciding which filters to supply to IDCJs, to 
reduce harm and thus save costs in healthcare. I have contacted The Crown 
Office and Regional Procurator Fiscal, to seek exemption from prosecution 
under the current legislation to allow this study to be done. They are 
considering this matter. Obviously, this part of the study can only be done 
with their approval. Therefore, approval from the Ethics Committee is being 
sought for this part of the study, but it will only go ahead if also 
approved by the Crown Office. The Ethics Committee obviously have the 
ethical side of this application to consider and the Crown Office the legal 
issues. The contact person at the Crown Office is Mrs Angiolini. The 
information which follows is for this proposed work:
4(H) Give a brief description o f the protocol o f this investigation
See attached protocol
4(iii) Has statistical advice been sought? YES / NO / NOT RELEVANT
(Previously sought: refer to earlier application).
4(iv) Specify whether it is part o f a larger (e.q.multl-centre/internatlonaDstudy 
Please give details and numbers o f patients fo r  Grampian
Not Applicable
5. (a) Specify the procedures involved and indicate those which are likely to cause
distress or d iscom fort
Not Applicable
(If venepuncture is one of the procedures involved, please indicate the quantity of blood to be 
taken per sample and whether part of routine sampling).
(b) Indicate those which are not standard/routinepractica Not A p p lic a b le
(c) If a questionnaire is to  be used, please enclose a copy. If the questionnaire is a 
standard one, it w ill be s u ff ic ie n ts  give its title.
See enclosed.
6. (a) Specify the number and type o f patients/volunteers likely to be involved o r
excluded from the p ro ject
Numbers will depend on recruitment. This is a very small project to 
gather users opinions. It is hoped that at least 5 people could be 
recruited, maximum will be 20. These are the figures given to the 
Crown Office. All volunteers be current injectors of street heroin who 
use the Drugs Action needle exchange. See protocol for specific 
inclusion criteria.
(b) How w ill the patients/volunteers be identified/recruited?
They will be a non-randomised quota sample recruited from the Needle 
Exchange at Drugs Action. They must be frequent users of the needle 
exchange (i.e. at least one visit every 2 weeks). They will be 
identified by the drugs workers to the researcher, who will then 
explain the study and ask details to see if they fit the selection 
protocol (see details) . The researcher will then give them the 
volunteer information sheet, and ask them to decide if they would like 
to be included. They will then sign a form to say they understand the 
study and have had it fully explained to them. This will say they can 
pull out at any time and that the forms are confidential, no names are 
to be used in the study report or disclosed to third parties. They
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will be required to give a contact number and agree to being 
telephoned, to arrange follow up and check on safety issues, if they 
do not return to DA within 14 days.
7. (a) Where w ill project be undertaken.
School of Pharmacy at RGU for preparation and data analysis.
Drugs Action, 48a Union Street, Aberdeen for subject recruitment and 
questionnaire distribution.
(b) What is the likely duration o f the study:
Short time period, of approx two to four weeks.
8. State the potential hazards, if  any, and the precautions to be taken to  meet them:
Clients will be assessed for suitability before being included in this 
study. The selection protocol has been designed to minimise this risk (see 
above).
The effect of the filter on drug concentration and particle load will be 
explained. The data on drug concentration has yet been completed. If the 
pre-syringe filter shows significantly less drug retention than the
makeshift filters, there is obviously a risk to health. so clients will
only be recruited who do not normally use a makeshift filter. If the
difference in drug concentration is not significant, clients who use
makeshift filters can be included. The use of the presyringe filters will 
need to be explained to the clients to ensure they are using them correctly. 
Injecting technique will be assessed and harm reduction information given at 
time of recruitment. This project focuses on reducing the risks associated 
with injecting heroin, which in itself carries large risks. This risk will 
NOT be increased by this study.
9 (a) Does the project Involve exposure to x-ravs o r radioactive substances? NO
If YES, has the Radiation Protection Advisor (Dr B Heaton. Department o f Bio-Medical 
Physics and Bio-Chemical Engineering) given approval o f the dosage involved? YES/NO
(b) Does the project Involve the use o f isotopic tracers? NO
If YES, have you contacted Dr F W Smith. Consultant In Nuclear Medicine. ARI o r Dr B 
Heaton fas above) fo r advice.
YES/NO
10. In the case o f a project involving the adm inistration o f a drug, the following questions 
must be answered: Not Applicable
(i) Specify the Drug:
(ii) Is this drug available:
(a) on prescription YES/NO
(b) by issue of a trial certificate YES/NO
(c) or has it been exempted YES/NO
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(¡¡i) To what extent and to  which categories o f patients/volunteers has the drug been 
administered prio r to  th is project?
(iv) W ill the use o f this drug involve suspension o f standard o r alternative treatment during 
the project? What w ill be the implications, if  any, fo r the patient?
(v) Involvem entof Drug Companies (Where relevant) Not Applicable
(a) Please give precise details o f any financial arrangements which exist w ith a drug 
company including name o f funding account o r use to  which moneys w ili be p u t The 
project w ill not be approved until th is information is provided.
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For all other projects, state what arrangements are in place for compensation in the event 
o f injury or death. Not applicable.
(b) Does the company accept the Association o f the British PharmaceuticaHndustrv's 
guidelines:
"Clinical trials compensation fo r medicine-induced injury?
(See Appendix I) If yes, Appendix I sheet should not be included. YES/NO
Patient/Volunteerlnformation and Consent 
Patients* right to  w ithdraw
Do you undertake to inform the patients/volunteers that they are free both to  refuse to 
participate and to w ithdraw at any stage and that this w ill not alter their medical care in 
anyway?
Yes, they will be informed that refusal to participate or desire to 
withdraw, will not alter the treatment they receive from Drugs Actioa
Patient/Volunteerlnformation
The Committee expects to receive a Patient Information Sheet which explains in clear concise 
lav-man's terms how the patient/volunteerwill be involved in the research project including, in 
particular, details of any risks or likely side-effects and freedom not to participate or to withdraw 
affecting their medical care.
A COPY SHOULD BE GIVEN TO THE PATIENT TO KEEP.
Please enclose a copy o f vour Patient Information Sheet See enclosed 
Consent
(i) Consent, which should be as fuliy informed as possible, should be obtained in all 
circumstances from  the patients/volunteers. The model consent form should 
normally be used (when it need not be included). Do you propose to use it? YES / NO
If not please enclose a copy and state the reason for its use.
I have modified the Model Consent form to suit the purpose of needle 
exchange clients, not GP or hospital doctor patients. The basic 
structure has been retained. See enclosed.
(ii) Where informed consent cannot be obtained, that of a responsible relative should be 
obtained BUT it must be realised that this has no legal force.
(iii) Children. The consent of a child should be obtained, regardless of age provided he/she 
can understand what is being asked of him/her. Parental consent must also be 
obtained.
(iv) Only in exceptional circumstances will the Committee accept a verbal explanation on its 
own. In that event the Committee will require a detailed written statement of the 
investigator's verbal explanation.
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(i) Communication with other professionals involved in the care of the patients e.a. 
nursing staff, general practitioners etc.
Drugs Action Staff will be made fully aware of the project and what it involves. They have 
agreed to allow me access to their clients. I have signed the Drugs Action Confidentiality 
Agreement and am also bound by the Code of Ethics of the Royal Pharmaceutical 
Society.
Researchers are reminded of their responsibilities to inform appropriate nursing staff and GPs of 
their patients’ involvement in the research project
(ii) Please indicate enclosures:
Patient Information Sheet YES
Patient Consent Form: YES
Written account of verbal explanation. YES
Letter to G.P. NOT APPLICABLE
P ro to c o l f o r  v o lu n te e r  in c lu s io n ....................................... Yes
Questionnaire YES
Instruction Sheet for Volunteers YES
Thè Committee strongly discourages the exclusive recruitment of persons in any dependent 
relationship with the investigator, (e.g. students, nurses, laboratory technicians etc.) as subjects 
in research projects unless there are special reasons for so doing.
Good Clinical Research Practice: Please state to which UK Guidetines/standardse.g.. the 
investigation w ill adhere.
Not Applicable
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* Please note: Publication rights and right to audit must remain with my employers, The 
Robert Gordon University.*
A list of publications from this study and copies where available have been enclosed.
\
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14. Any additional relevant inform ation:
Name of Applicant (in block capitals)
JENNIFER SCOTT BSc (Hon) MRPharmS....................Ncr medically Qualified
Signature of Applicant . ............................................... £ ? .//? /? .£ . 
Appointment held ..Research Pharmacist studying for a PhD................
Department ..The Robert Gordon University, School of Pharmacy.....
Date ...22 Septmeber 1998....................................
NAME OF CONSULTANT/HEAD OF DEPARTMENT IF OTHER THAN APPLICANT who has 
approved this project and checked the patients information sheet.
(in block capitals)
..Dr ARTHUR WINFIELD.........................................
Signature ......... .....................................................................
School/Hospital/College ..Head of Department of Pharmacy Practice,
Pharmacy, The Robert Gordon University..
School of
Please Note:
1. The Committee expect to receive notification of any adverse or unforeseen circumstances 
arising out of this study.
2. In all projects, signature by the Consultant in Charge/Head of Department is essential.
3. Please notify the Committee on completion/abandonment of the project.
4. Please send a copy of any publication which results. *
5. The Committee may audit a project at any time. *
This form  should be com pleted and returned to  Ms L Conway, Clerk to  the Jo in t 
Ethical Committee, Grampian Health Board, Summ erfield House, 2 Eday Road, 
Aberdeen, AB15 6RE.
Any enquiries can be directed to either Ms L Conway, (01224) 663456 Ext 75225 o r 
Professor E Russell, Consultant in Public Health Medicine, Medical School, 
Foresterhill, Aberdeen, AB9 2ZD o r to the Chairman o r Vice-Chairman.
* Please note: Publication rights and right to audit must remain with my employers, The 
Robert Gordon University.
A list of publications from this study and copies where available have been enclosed.
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APPENDIX (II)
CONSENTFORM
CONSENT BY PATIENT/VOLUNTEERTO PARTICIPATE IN:
Collection of drugs users opinions on the suitability for use of pre-syringe filters when 
preparing injections of street heroin.
Name o f Patient/Volunteer: (Initials, DOB and Drugs Action client reference number)
Name o f Study: Development, Implementation and Evaluation of Harm Reduction Techniques 
for Intravenous Drug Misusers.
Principal Investigator: Jennifer Scott
I have read the patlent/volunteerlnformatlon sheet on the above study and have had the 
opportunity to discuss the details w ith  Jennifer Scott and ask questions. Jennifer has explained 
to me the nature and purpose o f the study to be undertaken. I understand fu lly  what is proposed 
to be done.
I have agreed to  take part in the study as it is has been outlined to me, but I understand that I am 
completely free to  w ithdraw from  the study o r any part o f the study at any tíme I wish and that 
this w ill not affect the service I get from  Drugs Action in any way.
I understand that th is investigation is part o f a research project designed to  promote harm 
reduction knowledge, which has been approved by the Jo in t Ethical Committee and the Crown 
Office.
I hereby fully and freely consent to  participate in the study which has been fu lly  explained to me.J 
agree to  follow  the instruction sheet and information supplied.
Signature o f Volunteer: ............................................................................................................
Date: ...........................................................................................................
I confirm that I have explained to  the volunteer named above, the nature and purpose o f the tria l 
to  be undertaken.
Signature o f Investigator: 
Date:...................................
Please note: This form will be kept in confidential in a locked cabinet 
until the study is finished. No names are disclosed to anyone else. 
These forms will be destroyed after the study is finished.
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GRAMPIAN HEALTH BOARD 
AND
UNIVERSITY OF ABERDEEN
GRAM PIAN RESEARCH ETHICS COMMITTEE
Chairman Cleri; to the Committee
Mrs M Ross 
Senior Lecturer 
Dept of Law 
University of Aberdeen 
Regent Walk 
ABERDEEN. ABM 3FX
Mrs Diane Murray 
Dept of Public Health 
Grampian Health Board 
Summerfield House 
2Eday Road 
ABERDEEN, AB 15 6RE
Tel: (01224) 663456 Ext 75225
Tel: (01224)272421 Fax:(01224)404014
Rut: (01224) 272442
Project No: 98/00263
5 th November 1998
Ms J Scott 
Research Pharmacist 
Robert Gordon University 
School of Pharmacy 
Schoolhill
Aberdeen, AB10 1FR 
Dear Ms Scott
Development, implenentation and evaluation of harm reduction techniques for intravenous drug misusers
The above project was considered at the Grampian Research Ethics Committee meeting of 29th October 1998, 
and I am pleased to confirm that ethical approval for this project has now been granted subject to the following 
amendments:
1. The Committee had concerns about the disposal of the filters. Can you please clarify to the Committee 
what will happen to the used filters.
2. The Committee were concerned that you stated in your application that the right to audit remains with 
your employers. The Ethics Committee may wish to audit this project at a later date as part of the post 
approval monitoring process. I would be grateful if  you could clarify the Robot Gordon University’s 
position.
3. In the Patient Information Sheet, please add a sentence that if the patient refuses to take part, there will 
no detriment to their future care.
With regards to medical indemnity, I endose a form which should be completed and returned to either; (i) Dr J 
Broom, Research & Development Director, Research & Development Offices, Aberdeen Royal Hospitals NHS 
Trust, Aberdeen Royal Infirmary, Fores terhill, Aberdeen, (ii) Medical Director, Grampian Healthcare NHS 
Trust, Westholine, Woodcnd Hospital, Aberdeen, or (iii) Medical Director, Moray Health Services NHS Trust, 
317 High Street, Elgin, as appropriate, if you wish one of the above lYusts to accept liability for medical 
indemnity for this project
We would be very glad to receive, in due course, copies of any publications arising from this research. Thank 
you for bringing this study to the Committee’s attention.
Yours sincerely \ 1  r \  V 1
Mrs Diane Murray ^  —a
Clerk to the Grampian Research Ethics Committee *
Please quote project number in all correspondence
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In form ation Sheet fo r Volunteers
‘G athering users opin ions on the use o f filte rs ’
Injections made from street heroin contain solid particles which don’t dissolve. Some of 
these particles are too small to see but can still cause problems if they get into your blood 
stream (such as hard lumps). I have been testing filters in a lab to find out which ones work 
best at removing solid particles from injections made with street drugs. I spoke to some 
users at Drugs Action before I did the experiments to find out how they prepared their 
injections. I then copied their techniques as best I could, so the tests were as realistic as 
possible.
The filters which worked best are called ‘syringe filters' and my tests showed they take out 
99% of all particles, and the amount of drug in the hit is similar to that in hits filtered with 
cigarette filters. Now I have found these filters work best, I am looking for volunteers to test 
them. I want to give a few filters to some people who regularly inject heroin and then find out 
what they thought about using them (by asking them to fill out a questionnaire). All 
information about the people involved will be treated confidentially.
Legally, needle exchanges are not allowed to give out filters, but I have been given special 
permission to give out filters for this study from the Procurator Fiscal. This law is being 
reviewed, so if it changes in the future, this study will provide information on which kind of 
filters to distribute.
For safety, volunteers must not be on a script for any substitute drugs (e.g meth, vallies, 
Dfs etc)
If you are not on a script and can answer yes to the following questions, you are suitable to 
volunteer:
• Do you inject street heroin on a regular basis (at least twice a day, every day)?
• Have you been using for at least 3 months?
• Do you usually visit the Drugs Action needle exchange at least once a fortnight?
People who agree to volunteer will be asked some questions about their drug use. This is 
for safety, to make sure they are suitable volunteers. They will then be told if they can be 
included. People who volunteer will be asked to sign a consent form, this is to prove they 
willingly agreed to take part. Grampian Health Board Ethics Committee have approved 
this study and may ask to look at the results once the study is finished. No names will be 
given to them, just information on results.
Please note, volunteers can pull out at any time and don’t  need to  give a reason.
Volunteers who agree to take part will be asked to give their first name or nick name, 
initials and date of birth. They will also be required to give a contact address and 
telephone number, so they can be followed up if they have not been back to the Drugs 
Action needle exchange in the next 2 weeks. This is purely a safety measure. All 
information will be kept confidential and destroyed once volunteers have returned to the 
agency. No one will be told that you are a volunteer fo r this study.
•
The volunteer will be given a few filters and then it will be explained how to use them by 
the researcher or drugs worker. A new safer injecting booklet will also be given.
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A questionnaire asking what the volunteer's thought about using the filters will then be 
attached to the volunteer’s needle exchange card. Next time the volunteer is in the needle 
exchange, they will be asked to fill out the questionnaire. It will take about five minutes to 
complete. The questionnaire must be filled out in the exchange, it cannot be taken away.
The researcher will check the cards 2 weeks after the filters have been given out. If any 
volunteers have not yet returned to Drugs Action, they will then be contacted by 
telephone. If this is done, the researcher will ask for the volunteer by first name but not 
disclose that she is calling from Drugs Action.
Volunteers can pull out of the study at any time. Even if they have taken filters away, they 
can decide later not to use them. All that is asked is that they write on the top of the 
questionnaire when they return that they didn’t use the filters. Unused filters must be 
handed back to the researcher, by giving them to a Drugs Action worker at next visit. 
Used filters must be disposed of in your cin bin.
The researcher will have checked that volunteers are suitable to be in the study, by 
asking questions. Therefore, it is important that volunteers do not distribute filters to 
anyone else for use when injecting. They must only be used by the volunteer.
If you have any questions about this study please ask the person who gave you this 
sheet.
Refusing to take part in this study w ill not have any adverse affect on the service 
you receive from Drugs Action. It is your choice to participate.
All information is treated confidentially.
Thank you very much,
Researcher, RGU.
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‘G athering users op in ions on the use o f filte rs*
Protocol fo r Study
a) The researcher will be present at Drugs Action needle exchange to recruit 
volounteers personally, on the basis of a non random quota sample.
b) Potential volounteers will be given the information sheet to read and the questions 
on it asked.
c) The researcher will then ask the potential volunteer: Do you usually visit the 
Drugs Action needle exchange at least once a fortnight?
d) If the answer to this question is yes, the person’s needle exchange card will be 
retireived from the filing cabinet and the details of initials, dob and frequency of visits 
verified. Any mismatch, will exclude the volunteer.
e) Then the flow diagram shown overleaf will be used to identify potential volunteers:
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Inclusion criteria fo r vo lunteers
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f) The person will then be asked if they wish to volunteer and told they can pull out at 
any time.
g) If the person wishes to volunteer, they will then be asked if they understand the 
information sheet and have any questions. It will be drawn to their attention, as 
detailed on the information sheet, that they must agree to supply a contact telephone 
number and agree they can be contacted if they haven’t returned to the Drugs Action 
needle exchange within two weeks and filled out a questionnaire.
h) If the person agrees to go ahead with participaton, they will then be asked to 
briefly describe the process they use to prepare and administer their injections. The 
researcher will interject appropriate harm reduction information on the basis of the 
techniques used, (e.g using clean, sterile needle each time to avoid transmission of 
hepatitis C and HIV, ways to reduce the risks of overdose, ways reduce injuries etc). 
They will be advised that injecting drugs is dangerous and should not be done alone.
i) The researcher will then show the volunteer a filter of the type for this study and 
explain how it is used and the rules of the study (see Instruction sheet). The user 
must agree to only use it with a small bag of heroin (£10 beg) and not to use filters 
more closely together than every fourth hit (e.g one hit with filter, three without etc).
j) The volunteer will again be asked if s/he wishes to participate.
k) If yes, the volunteer will be told not to give the filters to anyone else to use, as 
they personally have been assessed for the study. They will be reminded that 
injecting street drugs is dangerous, and offered harm reduction literature to take 
away, if required. They will be given an instruction sheet for using the filters and 
advised that they must follow the instructions on this sheet.
l) The volunteer will then be invited to ask questions and then asked to sign the 
consent form.
m) The volunteer will then be given 4 filters to test according to the instructions 
supplied and thanked for their participation in the study.
n) The person’s first name, initials, DOB and contact details will be recorded on 
confidential participants list. A questionnaire will be attached to their NX card. If they 
have not returned to DA within 2 weeks, they will be contacted.
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Please follow these steps when testing the filters. Not only does this tell you how to  
use the filters, it includes advice to help reduce the harm from injecting.
Remember: Only use the filte r fo r a V* gram hit o r less, do not use it fo r bigger 
hits as it has not been tested w ith bigger amounts. Only use w ith heroin, no 
other drugs. Also, don’t use all fou r filters fo r fou r consecutive hits, filte r one 
in every fou r hits maximum.
1. To stop bugs, viruses and dirt getting into your hits wash your hands before you prepare 
anything.
4*
2. Use your own kit, including spoons, water, citric and cook up in your own space (e.g on a 
newspaper). Other people’s kit should be in their own space, not yours. This is to stop 
viruses like hep C or HIV passing between people.
4*
3. Take a new detachable syringe (1ml) and spike (usually orange for arm veins). If you 
usually use the end of the works to stir when you are cooking up, take the spike and 
syringe out of their packets before you cook up and fit them together.
4*
4. Cook up, stirring with the covered spike.
4*
5. Once you’ve cooked up, take the spike off the end of the syringe (do not remove the 
cover yet).
6. Take the filter out of the packet and fit it onto the nozzle of the syringe. (Only one end fits)
as shown in the drawing below: -
ciki-i.u.ivvbui y^ru"Vje 
^ Click-iYlffc t ip
( v l t t T
Hvis iiw t «joes „ ifv  U c,ii \ (.i
7. Put the tip of the filter into the clear liquid in the hit and draw back the plunger of the 
syringe slowly. The filtered liquid will fill the springe, but it is quite slow.
8. When all the liquid has drawn through remove the filter and put on the covered spike 
firmly.
*
9. The hit is now prepared. Follow the safer injecting advice in the leaflet provided.
4*
10. The filter will look stained from the hit. This is the particles and dirt that doesn’t dissolve, 
the heroin drug will be dissolved in the hit. DO NOT reuse the filters, as bugs can grow in 
wet filters. DO NOT break open the filter to try to cook up the bit inside. Trying to cook it 
up may damage you. Put used filters into vour cin bin and return to Drugs Action. Unused 
svrinae filters must be returned to Drugs Action too.
Remember: Dprh‘ inject atone, if you QD'.'iljefe''̂ vyiirbe no one around to help. If you are worri&i 
• that someone haS'PD’d'phone 999,;forahJa m b u la ^  tbe.Drugs Action ̂ ja fr if;
.you waht.more'te^jlets, adyi.ce or info.' . ; .'/..V
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Client initial, DOB & DA ref. No.___________
Questionnaire for svrinae filter testers.
1. What filters do you usually use when preparing your hits? 
e.g cigarette end, Rizla filter, cotton bud, don’t  usually filter?
2. You were given 4 syringe filters. How many of these did you use? (please circle): 
none one two three four
If you didn’t  use all the syringe filters, what was your reason for this?
3. What injecting site(s) did you use when you tested the filters? e.g: arms, hands, 
feet, groin? (Please write them below):
4. Do you usually use insulin syringes for your hits?
Yes No
5. If Yes to Q4, is it a problem to use detachable syringes and spikes instead of the 
insulin ones?
Yes (please write the problems below) No
6. Did you have any problems using the syringe filters?
Yes (please write the problems below) No
7. Do you think the hit was any different when you used the syringe filters?
Yes (please explain below) No
Please turn over the page-^
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8. Compared to your usual filters, how easy do you think the syringe filters were to 
use? (please tick)
Much easier □
A bit easier □
No difference □
A bit more difficult □
Much more difficult □
9. Overall, what do you think of the syringe filter compare to your usual filters? 
(please circle and write any further comments):
The syringe filter My usual filter,
is better is better
There is no difference.
Please comment why you think this?:
10.Do you think users would need a bit of practice with the syringe filters to get the 
hang of using them?
Yes No
11.If the law changed and it became legal to give out filters from needle exchanges, 
what kind would you prefer to be given out?
Syringe filters Cigarette filters Other (please state)
Please write any further comments you have on the filters you tested below:
TOanklyou for vèfi^elp.Vitfth t t ^ É ^  j^ t  is^Veatlv appreciafed. If vou want to speak 
directly to Jennyjillfe re ^a rc t^P ^ |^^^o u rE x p e rie n c e s  With thé filters please ask 
the needle exchapgfi workers conrie and speak to you.____________ -
Pharmacist Session Enquiry Form
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Enquiry No.________ Date___________ Enquirer ref.
Last date of use (if applicable):__________  ASAP_
Details of Enquiry:
Clients, if applicable:
Would you consider asking a chemist in a shop about a query such as this? 
(note response and why)
C W
Response:
R esponse  d e ta ils
T im e Im m e d ia te N o n  Im m e d ia te  
(s ta te)
M e th o d V erb a l W ri tte n P h o to co p y
(state)
L eaflet
(s ta te)
O th e r
(state)
S o u rce K n o w led g e  b a se F u rth e r
K n o w led g e
l i t e r a tu r e
(state)
O th e r
(sta te)
C a te g o ry
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Pharmacist Enquiry Form
Date:________ Name of worker making enquiry:_________________
Last date of use of reply (if applicable):________ ASAP □ (please tick)
Method of reply required (please tick):
Verbal □ Written □ Published Info. Requested □
Please note Jenny will be at Drugs Action every Tuesday afternoon.
If you need a reply before her next session please phone her office on 01224  
262522. An answer phone w ill take your message if she is not available.
D etails o f Enquiry:
F o r re feren ce use:
R esponse  deta ils
T im e Im m e d ia te N o n  Im m e d ia te  
(s ta te)
M e th o d V erb a l W ritte n P h o to co p y
(sta te)
Leaflet
(s ta te )
O th e r
(state)
S o u rce K n o w led g e  b a se F u rth e r
K n o w led g e
L ite ra tu re
(sta te)
O th e r
(s ta te )
C a te g o ry
What if I cant make it on 
Tuesday afternoons?
&Phone anytime during 
opening hours and leave your 
query with a Drugs Action 
worker
You can leave a number for 
reply or phone back the 
following Tuesday afternoon.
!H!Ask in writing: the staff can 
give you a pharmacist enquiry 
form. Fill out your 
enquiry and state your 
preferred method of reply, 
e.g. written reply (to collect at 
Drugs Action or have posted) 
or telephone reply.
This is a Free and 
Confidential Service
How to Find us:
Other Services at Drugs Action include: 
Helpline
Needle exchange 
Free Condoms 
Counselling 
Women Only Sessions 
Joint work with maternity services 
Outreach Services 
Recreational Drugs Team 
Family Support Group 
HIV worker 
Prison work
Drugs Actioi
48A Union Street 
Aberdeen 
01224 624555
ADVICE SESSION
Tuesday Afternoons 
2-5pm
No appointment 
needed
Free and 
Confidential App
Pharmacist's Advice 
Session
From September 1997 a 
pharmacist will be available at 
Drugs Action every Tuesday 
afternoon from  
2-5pm for a six month trial 
period to provide information 
and advice.
This service is available to drug 
users, family members, friends 
and people who work with drug 
users.
What kind of information 
and advice?
Any aspect of drug use or 
health problems which you 
would like to discuss with a 
qualified pharmacist
e.g:
♦ How drugs affect the body
♦ Drug interactions
♦ Drug related injuries and 
illnesses e.g. abscesses, hep C
♦ Non drug related health problems 
e.g. colds, flu
♦ Sexual health and contraception
♦ Children's Health
Confidentiality
As with all Drugs Action 
services, this is a confidential 
and free service.
Making Contact
You dont need an appointment, 
just drop in.
Tuesday 2-5pm.
Drugs Action are at 
48a Union Street 
see map overleaf
or phone 6 2 4 5 5 5  and ask to 
speak to the pharmacist.
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Pharmacist’s Session
From September a Pharmacist will be 
available at Drugs Action every Tuesday 
afternoon from 2-5pm to provide 
Information and advice on a range of 
subjects, 
e.g.
♦ How drugs affect the body
♦ Drug interactions
♦ Drug related injuries and illnesses e.g. abscesses, 
hep C
♦ Non drug related health problems e.g. colds, ‘flu
♦ Sexual health and contraception.
♦ Children's health
This is open to anyone and as with all 
Drugs Action services it is completely 
anonymous and confidential.
Please drop in Tuesdays between 2-5pm or ask 
the staff fo r a confidential Pharmacist Enquiry
fo rm K l o r phone on 01224 624555 S
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Grampian Lesbian, Gay and Bisexual
Switchboard
POBox 174
Aberdeen
Grampian Welfare Rights 
47 Belmont Street 
Aberdeen
Grampian Racial Equality Council 
9a Little Belmont Street 
Aberdeen
Grampian Women’s Aid 
10-16 Exchequer Row 
Aberdeen
Home Start Mastrick 
Mastrick Parish Church 
Green fern Road 
Aberdeen
Incest Survivors Group 
PO Box 91 
Aberdeen
SACRO
18 Little Belmont Street 
Aberdeen
Social Work Department 
Quarry Centre 
Cummings Park Crescent 
Aberdeen
Substance Misuse Service 
(formerly Drug Problem Service) 
Old Irvine Ward 
Royal Comill Hospital 
Westbum Road 
Aberdeen
The Samaritans 
60 Dee Street 
Aberdeen
Torry Advice Centre 
26 Menzies Road 
Aberdeen
Victim Support 
Regional Office 
47 Belmont Street 
Aberdeen
Victim Support 
Aberdeen Branch 
4 Albyn Place 
Aberdeen
Victim Support
Buchan: 01771 623741
Deveron & District (Banff): 01261 842735
Gordon, Wyness Hall, Jackson Street,
Inverurie.
Victoria House 
West North Street 
Aberdeen
Women’s Centre 
Shoe Lane 
Aberdeen
Volountary Service Aberdeen 
38 Castle Street 
Aberdeen 
AB1 1AB
Services that received Pharmacists Session publicity 
(taken from the DA service publicity distribution list)
Aberdeen Alcohol Counselling Service
62 Dee Street
Aberdeen
Aberdeen Counselling and Information 
Service
44 Castle Street 
Aberdeen
Aberdeen Friendship Group 
14 Dee Court 
Dee Street 
Aberdeen
Aberdeen Rape Crisis Centre 
54 Frederick Street 
Aberdeen
Aberdeen Women’s Aid 
66 The Green 
Aberdeen 
AB11 6PE
Aberlour Childcare Trust 
31 Auchinyell Road 
Aberdeen
Aberlour Childcare Trust 
8 Sunnybank Road 
Aberdeen
Alford Centre 
8 Alford Place 
Aberdeen
Benefits Agency 
Greyfriars House 
Gallowgate 
Abereen 
AB10 1ZU
Children’s Family Trust 
16 Nothrburn Avenue 
Aberdeen
Citizen’s Advice Bureau 
47 Market Street 
Aberdeen
Craiginches Prison Drug Team
Grampian Place
Torry
Aberdeen
Cruse Bereavement Care 
19 Fonthill Road 
Aberdeen
Cyrenians Day Centre 
62 Summer Street 
Aberdeen
Cyrenians: 
Women’s Hostel 
c /o  Caroline
Cyrenians:
Stopover
61 Langstane Place 
Aberdeen 
01224 210194
Cyrenians: 
Stopover 
252 Union Street 
Aberdeen
Cyrenians: 
Cygnet Project 
Union Street 
Aberdeen
Deeside Family Centre 
Gidleness Road 
Tony 
Aberdeen
Family Planning Centre 
13 Golden Square 
Abeeen
Fersands Family Centre 
19b Sandilands Drive 
Aberdeen
G.U.M Clinic 
Woolmanhill Hospital 
Woolmanhill 
Aberdeen
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Outcome Results from Pharmacist’s Session Interventions
Enquiry No._____  Drugs worker:________ Date of follow up:_________
Key issues at query:
Key interventions:
Outcome (including time indicators):
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DRUGS ACTION STAFF QUESTIONNAIRE
Section 1.
Please read the statement on the left and tick the box which best fits your response to it on 
the right.
1. I think it is vital that a pharmacist attached to the team receive 
induction training from DA.
2. I think the clients would feel confident that a pharmacist working 
at DA was providing a confidential service.
3. I think a pharmacist could contribute to staff training.
4. I think the clients would feel comfortable talking to a pharmacist 
at DA.
5. 1 think the clients would not feel comfortable talking to a 
pharmacist
6. I think drugs workers know more about ‘drugs of abuse’ than 
pharmacists.
7. I think a pharmacist may have a conflict o f interest when working 
with DA clients
8. I think the information a pharmacist could contribute is already 
available to the team i.e. in text books, leaflets, from outside 
organisations.
9. 1 think the clients would benefit from having a pharmacist at DA.
10. I think a pharmacist would not be able to contribute positively to 
the team. 1
11. I think I would feel happier a pharmacist gave out medical advice 
than a drugs worker.
12. I think attitude is a personal thing and not moulded by profession.
13. I think a pharmacist would not be much use to DA clients.
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14. I think a pharmacist could contribute to training for outside 
organisations.
15. I think communications with medical-based services would be 
improved if  done by a pharmacist.
16. I think a pharmacist could contribute positively to the work o f the 
team.
17. I think a pharmacist would have problems communicating with 
clients.
IS. I think it unlikely that a pharmacist will be able to have a non 
judgmental attitude to clients because of their profession.
19. I think a pharmacist would not understand the nature o f  drug use.
20. I think clients on a script may worry about confidentiality when 
talking to a pharmacist at Drugs Action.
1. Please briefly describe what you see, if  any, the main role o f  a pharmacist at Drugs Action to be:
2. Please briefly describe reservations, if  any, you have abput a pharmacist coming to work at Drugs Action:
76 f ym fr* camjdetùtf fuetffamaine
Jenny Scott 
The Robert Gordon University 
tel: 01224 262522
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DRUGS ACTION STAFF QUESTIONNAIRE [post service]
Section 1.
P lease read the sta tem en t on the left and tick  th e  box w hich  b est fits  your response to it on  
the right.
1. I think it is vital that a pharmacist attached to the team receive 
induction training from DA.
2. . I think the clients would feel confident that a pharmacist working
at DA was providing a confidential service.
3. I think a pharmacist could contribute to staff training.
4. 1 think the clients would feel comfortable talking to a pharmacist 
at DA.
5. I think the clients would not feel comfortable talking to a 
pharmacist
6. I think drugs workers know more about ‘drugs o f  abuse’ than 
pharmacists.
7. I think a pharmacist may have a conflict o f interest when working 
with DA clients
8. I think the information a pharmacist could contribute is already 
available to the team i.e. in text books, leaflets, from outside 
organisations.
9. I think the clients would benefit from having a pharmacist at DA.
10. I think a pharmacist would not be able to contribute positively to 
the team. 1
11. I think I would feel happier a pharmacist gave out medical advice 
than a drugs worker.
12. I think attitude is a personal thing and not moulded by profession.
13. I think a pharmacist would not be much use to DA clients.
Continued over
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14. I think a pharmacist could contribute to training for outside 
organisations.
15. I think communications with medical-based services would be 
improved if  done by a pharmacist.
16. I think a pharmacist could contribute positively to the work o f the 
team.
17. I think a pharmacist would have problems communicating with 
clients.
18. I think it unlikely that a pharmacist will be able to have a non 
judgmental attitude to clients because o f their profession.
19. I think a pharmacist would not understand the nature o f  drug use.
20. I think clients on a script may worry about confidentiality when 
talking to a pharmacist at Dmgs Action.
1. Based on your knowledge, experience and opinion of the pharmacy sessions which were 
provided at Drugs Action, do you think there is a role for a pharmacist as part o f the team?
Yes □  No □
If you answered yes to the above question, please expand by stating what you see the main role to 
be:
If you answered no, please expand by explaining why you think no role exists:
Thank you for completing this questionnaire
Jenny Scott 
The Robert Gordon University 
tel: 01224 262522
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Examples of enquiries received by the pharmacist at Drugs Action. 
Category: Adverse Drug Reaction (Prescribed)
Example 1: a male amphetamine user presented to the duty worker shortly after his 
release from prison and was referred to the pharmacist. He was concerned that while he 
was in prison and drug-free his asthma had become much worse. He wanted to know if 
his symptoms could be a withdrawal effect due to stopping his amphetamine use? He 
described his asthma as mild before his imprisonment. On questioning, he reported he 
had been experiencing chest pain and tightening infrequently for several months, which 
was not accompanied by wheezing. He had received ibuprofen 400 mg tds for these 
symptoms while in prison and had been given further supply for the same on release. He 
had no knowledge of having taken ibuprofen previously and was unsure if he had ever 
taken aspirin. The ibuprofen had been given regularly in prison, however he was taking it 
less frequently since his release. The pharmacist considered the worsening of the clients’ 
asthma to possibly be an adverse reaction to the ibuprofen. She advised the client of this 
and suggested he discontinue the ibuprofen and consult his doctor about the chest pain 
and tightening. [She considered the chest pain and tightening could be attributable to his 
heavy and prolonged amphetamine use, so this was categorised a drug-related health 
problem (see below)]. The client reported not being registered with a GP, so the 
pharmacist informed him of the procedure to obtain one. An appointment was also made 
for him with a drugs worker to look at issues identified around his drug use.
Example 2: the duty worker referred a male ex-heroin user to the pharmacist. He had 
received naltrexone from his GP, who was in another city. He had returned to Aberdeen 
the previous day for the festive period and commenced his therapy that same day, 
previously having received lofexidine. He reported shakiness and “feeling nervous’ since 
waking on that day. Since he was unable to see his GP for two weeks he came to Drugs 
Action for advice. He wanted to know if the naltrexone could be responsible for his 
symptoms. The pharmacist questioned him on his therapy, and on his feelings around 
returning to Aberdeen. She informed him that naltrexone can cause anxiety and 
nervousness, so may be responsible for his symptoms. She also identified he was worried 
about returning to the city. There were pressures from being with his family and 
temptation from being in the near vicinity of people who he had known when he was using 
heroin. She offered further support from a drugs worker during his period in Aberdeen.
Category: Adverse Drug Reaction (Not Prescribed)
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Example 1: A young woman telephoned the help-line. She told the duty worker that she 
had taken a ‘half gram wrap of speed' the previous evening and now could not see very 
well. She also reported being epileptic. The worker encouraged her to go to her GP but 
she insisted she was unwilling to do so and she would not speak directly with the 
pharmacist. The duty worker contacted the pharmacist for assistance in formulating a 
response. He wanted to know if amphetamine could affect vision and what information the 
pharmacist could supply on the use of amphetamine in epileptic people. He did not know 
what treatment she received for her epilepsy. The pharmacist informed the duty worker 
that, although not a common side effect, amphetamine might cause visual impairment. 
She also acknowledged that the problem could be attributed to an unknown adulterant in 
the drug. The pharmacist also told the worker that stimulant use, such as amphetamine 
and ecstasy, was particularly inadvisable in epileptics as the stimulant effect can induce 
seizures. She advised the worker that the client should be strongly persuaded to consult 
her GP and the confidentiality of GPs explained. The duty worker relayed this information 
to the client, explaining that although there was harm reduction advice given for stimulant 
use, in her case, it was considered that any use would result in a high level of risk.
Example 2: A drugs worker consulted the pharmacist after a regular appointment with a 
male client, who was a poly-drug user. The client used stimulants and sedatives on a 
frequent basis. The client reported recent memory loss and feeling ‘vague’. He had 
recently started using ketamine. The drugs worker was working with the client to try to 
reduce the number of different drugs he consumed and place boundaries on those he did 
use. The drugs worker wanted to know if the memory loss and vagueness could be a 
reaction to the ketamine, so he could prioritise the use of this drug in context with the 
others. The pharmacist confirmed that memory impairment had been attributed to heavy 
ketamine use. The impairment has in some cases been long term. However, it was 
possible that other drug use may be contributing to the problem, particularly the use of 
benzodiazepines. The pharmacist provided the drugs worker with written information on 
ketamine and supported discouraging the client from using it.
Category: Drug Information (Prescribed)
Example 1: The duty worker referred a male heroin user to the pharmacist for information. 
Previously, the client had been on a methadone reduction programme, but had relapsed 
and his prescription had been stopped. Although he now wished to stop using heroin, he
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was reluctant to begin another methadone programme as he reported feeling very
lethargic when receiving methadone and having experienced severe withdrawal on dose 
reduction. He was keen undertake a detoxification programme using lofedixine and had 
been referred to the specialist prescribing service. On assessment, he was informed that 
he was not suitable for such a programme as his blood pressure (B.P) was too low. The 
client wanted to know ‘if this was true’? He had been asked to return in one week for 
further assessment. The pharmacist explained that lofexidine has to be used with caution 
in people with low blood pressure and the information from the specialist service was true 
and they were safeguarding his welfare. Since he had only had his B.P taken on one 
occasion, she also advised the client to request his blood pressure to be monitored again 
on his next appointment, to check if it remained low. The pharmacist also explained that 
heroin can reduce blood pressure in large doses, so advised the enquirer not to use any 
before his appointment.
Example 2: A drugs worker asked the pharmacist for information to give a client in her 
next appointment. The woman was taking paroxetine, prescribed by her GP, for 
depression. She did not usually drink alcohol, but with the forthcoming festive season, 
wanted to know if it was safe to do so, along with her medication. She was a relative of a 
drug user and took no other drugs herself. The pharmacist informed the drugs worker that 
paroxetine does not commonly interact with alcohol so the majority of people experience 
no problems. However, as a precaution, she suggested only consuming a moderate 
amount of alcohol and experimenting first with half a glass of wine, to investigate for 
increased sedation.
Category: Drug Information (Not Prescribed)
Example 1: An outreach worker requested more information from the pharmacist in 
relation to a contact she had made at a youth project. A young female had recently found 
out she was four months pregnant and had been smoking cannabis on a frequent basis. 
She would not discuss this with her doctor or midwife and asked the drugs worker what 
the effects of cannabis would be on the foetus. The drugs worker asked the pharmacist 
for information on the effects of cannabis at all stages of pregnancy and breast-feeding. 
The pharmacist undertook a literature review and provided the outreach worker with a 
summary of the information she had gathered and copies where appropriate. In relation to 
the contact, the pharmacist advised the drugs worker that although some evidence had 
suggested a risk of low birth weights, this had not been proven. Overall there was 
considered to be no risk of an increase in foetal abnormalities or developmental
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retardation. However, the evidence on risks of childhood cancers was inconclusive. It is
certain there would be risks from the tobacco smoke. The pharmacist advised the worker 
to encourage the contact to stop smoking cannabis and, if applicable, cigarettes.
Example 2:
The agency received a report from the police forensic laboratory on the analysis of 
recently seized Ecstasy tablets in the Aberdeen area. All analysed tablets contained more 
than one active compound and none contained MDMA. The Incite workers asked the 
pharmacist to review the report, provide further information on some of the compounds 
and to suggest harm reduction advice that could be given to Ecstasy users on these 
particular tablets, acknowledging that guarantee of contents cannot be given on 
appearance alone. The pharmacist prepared a report summarising the risks from each 
identified compound and combination of compounds, making recommendations on advice 
for users. She also provided published information to the workers, where appropriate.
Category. Drug Testing
Example 1: A female was referred to the pharmacist after contacting the duty worker for 
information. Until one week previously, she had been using cannabis on a daily basis. 
She had also received paroxetine from her GP for depression, which she had stopped 
taking 10 days previously. Her reason for discontinuing both drugs was that she had a 
pre-employment medical for an administration job with an oil company. She wanted to 
know if either drugs would be detectable if she was given a urine test. The pharmacist 
informed the woman that cannabis use with a frequency such as hers could be detectable 
for at least 30 days. She gave the woman an information leaflet on cannabis. The 
pharmacist established that the woman had not received advice from her GP on stopping 
paroxetine. She reported feeling ‘better without /('although asked if recent dizziness could 
be due to stopping treatment. The pharmacist explained that since she was receiving the 
paroxetine from her GP she should not be penalised by the company if it was screened 
for and detected. The woman indicated she felt embarrassed at having to take an 
antidepressant, so had not declared this on her application. The pharmacist also informed 
the woman that some people do experience withdrawal symptoms if they suddenly stop 
taking medicines such as paroxetine, but her dizziness should be investigated. She 
suggested the woman explain her reasons for stopping her treatment to her GP, just as 
she had to the pharmacist. She identified several personal pressures that the woman 
reported being under, so gave her information on a generic counselling agency where she 
could get support.
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Example 2: A drugs worker referred a male client, with a history of poly-drug use,
including heroin, cocaine and amphetamine, to the pharmacist. He was under the care of 
a specialist prescribing service and no longer using street drugs. He had been prescribed 
thioridazine for periods of irritability and violent outbursts and had hoped they would ‘calm 
him down’. On taking one dose he slept for 18 hours and felt ‘knocked out’ on waking. He 
did not intend continuing this prescription and wanted to know if the specialist prescribes 
would be able to tell by his urine test if he substituted his prescribed medication with 
diazepam bought on the streets. The pharmacist informed the client that the two drugs 
were not similar and they could be differentiated in urine screening. She discussed the 
different effects of diazepam and thioridazine and the potential risks from self-medicating 
with diazepam. These included the risk of dependence, increased involvement with 
dealers that could promote relapse onto other drugs, and the dangers of mixing diazepam 
with other drugs if he did relapse. She also discussed the dangers of mixing either drug 
with alcohol. The pharmacist also discussed the reasons why the client received the 
prescription and what he had hoped the thioridazine might do. The clients’ next 
appointment with the specialist service was in two weeks. He was reluctant to take further 
thioridazine, so the pharmacist discussed the possibility of the client splitting the tablets 
and taking half his prescribed dose. He said he might be willing to try this to see if there 
was less sedation. The pharmacist encouraged the client to tell the specialist service 
about his experience with the thioridazine and if he continued it, to tell them what dose he 
was taking.
Category: Health Problem (Drug related)
Example 1: A woman presented at the needle exchange for advice from the duty worker, 
who sought the pharmacist’s advice. The client had had an abscess on her arm some 
weeks previously and had at the time taken antibiotics from her GP. She was no longer 
injecting and had switched to inhaling vaporised heroin as an alternative method of 
administration. Although no longer painful or red, the abscess had not healed completely 
and the centre was described by the worker as 'black and hard’. The woman wanted to 
know whether this was normal and would heal in its’ own time or should she go back to 
her GP? The pharmacist inspected the site and observed the centre of the abscess to be 
filled with a necrotic plug. She advised the woman that this was unlikely to clear without 
further medical attention and suggested she go back to her GP or practice nurse for 
wound care.
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Example 2: A drugs worker asked the pharmacist for advice that he could give to a client
in his next one-to-one appointment. The client was taking 70 ml of methadone 1mg/ml 
daily, diazepam and temazepam, all of which were being prescribed. The doses of the 
benzodiazepines were unknown by the worker. The client was severely constipated and 
experiencing bleeding on defecation. The client had informed his GP, who had explained 
that methadone causes constipation. However, the client reported that he had not 
received further advice or treatment and was reluctant to discuss the matter with his GP 
again. He was embarrassed to talk to his community pharmacist. He asked his worker if 
he knew what he should buy to relieve his constipation. The worker had discussed eating 
habits with the client and established that he had a very poor diet. The pharmacist 
discussed the treatment of constipation with the worker. She informed the worker that for 
immediate relief, glycerine suppositories may be suitable, however she was concerned 
about the reported bleeding. For continued relief lactulose may be of benefit. She 
suggested the worker establish what fruit juices, fruit and vegetables the client liked and 
suggested trying to incorporate some into his diet. She also told the worker to encourage 
the client to drink plenty of liquids. The pharmacist suggested that at the next 
appointment the worker tried again to encourage the client to speak with his GP for 
advice on the bleeding and report any over-the-counter medicines used.
Category: Harm Reduction Technique
Example 1: A drugs worker asked the pharmacist to give advice to one of her clients. The 
client had begun injecting cyclizine tablets. The drugs worker was aware of general 
information on the injecting of tablets and had discouraged the client from doing so. 
However, she wanted to know if there was any information that particularly applied to this 
formulation. The pharmacist informed the worker that cyclizine causes some other drugs 
to precipitate if they are mixed together in solution. Therefore, in theory, mixing it with 
other drugs, which was a known practice of some local IDUs, would be especially risky. 
Potentially, the precipitate could block veins. The worker informed the client that injecting 
tablets was especially dangerous and best avoided. If she insisted on injecting cyclizine 
tablets, she should not mix them with other drugs and she should filter them.
Example 2: The DA co-ordinator had received information on research into the use of the 
rectal route as a safer alternative to injecting. He asked the pharmacist to review this 
information and give comments, based on her knowledge of this route for drug delivery 
and street drugs. The pharmacist assessed the information and prepared a report for the 
co-ordinator.
Category: Identification
Appendix 27
Example 1: A client presented at the needle exchange with a tablet and asked the duty 
worker if he could confirm its’ identity. The worker asked the pharmacist for advice. On 
questioning the client, the pharmacist established that he owned the tablet, having 
purchased several from someone else. He had bought them under the premise that they 
were temazepam tablets, strength unknown. He was concerned because the lettering on 
the tablets was different from temazepam tablets he had bought previously. He intended 
to prepare and administer several by injection. The pharmacist used the Tic-Tac service 
to identify the tablets, which were found to be carbamazepine 100 mg. She told the client 
what they were and discussed the potential risks of taking them. She advised strongly 
against consuming them in any way. She provided a leaflet on the general risks from 
injecting tablets.
Example 2: An outreach worker contacted the pharmacist after a tablet was found on the 
floor of a community centre where she was working. The community education staff 
asked the worker to identify it and for advice on the action to be taken. The worker asked 
the pharmacist for help. The pharmacist took a description of the tablet from the worker 
and used the Mims identification directory to identify it. She told the worker that from the 
description, the tablet appeared to be the antihistamine preparation ‘Clarityn®’ (loratidine). 
She discussed its’ uses with the worker who also wanted to know if there was potential for 
misuse and overdose risks.
Category: Medical Information
Enquiries in this category were requests for the provision of information on medical as 
opposed to pharmacological matters.
Example 1: The women’s worker contacted the pharmacist for information. The request 
stemmed from a discussion she had had with the medical staff at the recently established 
‘Golden Square Clinic’ (9.1.1). The worker asked the pharmacist if she could provide any 
information on whether people who were hepatitis C positive should breast-feed.
The pharmacist supplied the worker with papers that reported studies investigating 
vertical transmission of hepatitis C and included breast-feeding, for review by the clinic 
team
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Example 2: An outreach worker contacted the pharmacist regarding a male client, who
was a heroin user. The client had had a seizure two years ago and earlier in the week of 
contact he had experienced another. The client saw his GP who made a referral to the 
hospital neurology department. In his appointment with his worker, the client told her he 
was worried he would be treated badly if the hospital found out he was a drug user and he 
did not know what the appointment would entail. He had not felt able to discuss the matter 
with his GP, so asked the outreach worker if she knew what the neurology dept, visit 
would involve. The worker asked the pharmacist. The pharmacist told the worker that she 
could only advise from her general knowledge of epilepsy and suggested the client asked 
for the planned investigations to be explained when he attended or reconsidered asking 
his GP for further advice. The pharmacist told the worker that the activity of his brain 
waves would probably be monitored using attached electrodes. She reassured the worker 
that this was not painful and no anaesthetic was required. She also told the worker to 
encourage the client to be honest about his drug use with the hospital, as it may be a 
factor relating to the seizures. She also pointed out that the clients GP and the hospital 
would communicate on his referral.
Category: Pharmaceutical Services
Example 1: One of the workers told the pharmacist that they were receiving an increased 
number of help-line calls from people who were unable to find a pharmacy willing to 
dispense their methadone or supervise its consumption. The worker asked the 
pharmacist what could be done to help people find a place to get their prescription 
dispensed. The pharmacist contacted the department of primary care at Grampian Health 
Board and spoke with one of their pharmacists. They discussed work in place to 
implement a shared-care scheme, which aimed to spread the workload amongst 
pharmacies in providing services to methadone patients. In the interim period before the 
scheme was launched, the pharmacist was told that people having problems finding a 
pharmacy should be referred back to their prescriber or the dept, of primary care for 
assistance.
Example 2: A mother whose daughter was an ex-heroin user and receiving a regular 
prescription of diazepam and zimovane contacted the help-line. She wished to make a 
complaint to the Pharmaceutical Society regarding service she had received in a 
pharmacy, whilst collecting her daughters’ prescription. She contacted the help-line to ask 
for the RPSGB phone number. The duty worker asked the pharmacist to speak with the 
mother. The pharmacist established the details of the situation. She suggested the
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mother wrote a letter rather than making a telephone call, as this would allow her to
reported all the facts clearly and calmly. The pharmacist considered the issue to be more 
appropriate to be referred to the Health Board in the first instance, so gave the caller the 
name and address of the person that complaints should be directed to.
Category: Other
Example 1: A drugs worker asked the pharmacist to explain the legal situation around 
‘poppers’. This was shortly after the reclassification of amyl nitrate to POM. The 
pharmacist explained the legal reclassification and copied two news items from journals 
for the worker.
Example 2: A male ex-heroin user contacted the agency to ask how long names were 
kept on the addicts index and if employers could access it. The pharmacist explained the 
recent end to the keeping of the index. She explained it was now archived and could be 
accessed for research purposes but employers would not use it for checking up. His 
name would still be on record, but any use of the index for research reporting would be 
anonymous.
Appendix 28
Ethical dilemmas faced by the pharmacist and the handling procedures used. 
Provision of information to third parties
The request for information from people secondary to the person about whom an enquiry 
related was considered to present an ethical dilemma. The competing values were the 
wishes and needs of the enquirer versus the wishes and needs of the person about whom 
the enquiry related. Two enquiries arose where the pharmacist was asked to provide 
information by a person secondary to a drug user. One was from a mother who had found 
a tablet in her child’s bedroom and wanted to know what it was. The other was from a 
care worker in a children’s home who had found a cellophane wrapping of a powder in a 
dormitory and again, wanted to know its identity. In both cases the children were under 
16.
Before giving a response, the pharmacist considered relevant ethical and legal guidance 
from professional bodies and the literature. The RPSGB (1997) gave no guidance on 
requests for information from third parties, except in the case of requests from coroners, 
judges or court officers, where information must be supplied1. The Code of Practice for 
Drug Information Services (UKDIPG, 1997a and b) infers the enquirer is the one to whom 
the pharmacist has a responsibility to provide information, but does not categorically state 
this. This code also discusses necessity to supply non-patient information when 
requested to do so by a legal body. Kelly et al (1990) discuss the provision of information 
to a third party, where both parties are adults. The pharmacist is not considered to have a 
duty of confidentiality to the person about whom the enquiry is made, since the breach of 
privacy is on the part of the caller not the pharmacist. The authors suggest establishing 
whether the caller has a right to the information requested, then making a decision on 
whether the information should be given. Daly and Bower (1997) again set a case study 
and asked selected pharmacists to indicate how they would respond. In this case the 
caller was the parent of a minor. One respondent suggests the pharmacist must establish 
to whom the duty of confidentiality belongs, the enquirer or the child. It is considered that 
when the pharmacist has no prior knowledge of the child, the enquirer should be provided 
with the information. Another states the mother has ‘a right to know’, but reports to be 
responding as a mother and not in her professional capacity. In Scotland, the provision of 
confidential medical care and legal services is governed by the Age of Legal Capacity 
(Scotland) Act 1991 (The Law Society of Scotland, 1991). This act dictates that if a 
medical practitioner believes a child (under 16) is able to understand the nature and 
possible consequences of a treatment/procedure they can consent to their own treatment.
1 S ince  th is w ork w as undertaken, the R PSG B have expanded the ir gu idance In th is a rea . S ee  R P S G B , 2000.
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Doctors should encourage children to allow their guardians to be informed, except in
circumstance where it is clearly in their best interest not to do so. However, if the child is 
capable of understanding the nature and consequences of the treatment and refuses to 
allow their guardians to be informed, the doctor should respect their confidentiality. If the 
child is believed incapable of understanding, parental consent is necessary, except in 
emergencies. The existence of this act means that it cannot be assumed that a parent or 
guardian has knowledge of their child’s medical care. Therefore, requests for information 
on such should be handled carefully. Identification of the provision of medical care without 
the guardians knowledge, informs the pharmacist that a doctor has made the decision 
that the child is capable of consent and is up-holding their right to confidentiality. The 
pharmacist is ethically required not to compromise the wishes of the patients’ doctor, as 
stated by the RPSGB (1997 and 1999) and UKDIPG (1997b). Providing information to the 
parent or guardian that suggests why medication was being prescribed could be seen as 
compromising the wishes of the doctor. When illicit drug use is suspected, there are 
further implications from revealing the identity of the substance. If the substance is 
controlled by the Misuse of Drugs act, there are implications for the person responsible 
for the house (Tyler, 1995). Knowledge of the presence of a controlled drug without 
reporting of the drug to the authorities could be interpreted as conspiring in illicit drug use.
In both cases that presented dilemmas, the pharmacist established: (i) who the enquirer 
was and their perceived right to the information, (ii) if the person the enquirer is calling 
about was under medical care (or anything from the enquiry indicated this to be the case), 
(iii) the background to the enquiry being made, such as how the enquirer came to be in 
possession of the tablet/powder. The pharmacist then arranged for contact to be made 
with the enquirer later in the afternoon. First it was noted that although the identity of the 
drugs was suspected, they could not be confirmed without analysis. The tablet found 
fitted the description of recently reported Ecstasy tablets. This was confirmed by Tic-Tac. 
The pharmacists suspected the powder to be heroin. The potential consequences of 
information provision, including benefits and harms to both the enquirer and the owner of 
the drugs were considered. The legal status of the drugs was also considered. Divulging 
the identity of prescribed drugs may interfere with the patient-prescriber relationship, or 
the patient may have a specific reason for not informing the enquirer of their treatment. In 
such cases, the pharmacist considered it would have been appropriate to declare the 
prescription status but not the identity. This would allay fears of illegal drug use and 
encourage discussion between the enquirer and the patient. However, in both cases the 
drugs were suspected to be illegal. The pharmacist considered it appropriate to inform the 
enquirer that knowledge or suspicion of the identity of the drug, carried legal implications 
and they would have to make a decision on what course of action to take if they were 
given a suspected identity. They were also asked to consider what they would do with
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information on possible identity of the drug. Giving a suspected identity of the drugs
carried potential consequences for the drug owner, but the pharmacist considered in the 
given situations that the rights of the enquirer were her priority. The enquirers were 
informed of the suspected identity of the drugs. The reasons surrounding discovery of the 
drugs by the enquirers were also explored, which lead to further discussion on prior 
suspicion of drug use, possible action and privacy. Knowledge of the enquirers on the 
drugs concerned was discussed and information leaflets sent. Discussion with the drug 
owner was encouraged, with the importance of maintaining communication highlighted.
Verification of information from another professional source
Nine enquirers [seven members of the public and two DA workers] asked the pharmacist 
for verification of information received from another health professional. In seven cases 
this was a GP, in one case a specialist nurse and in one case a pharmacist. In three 
cases the reported information was considered by the pharmacist to present an ethical 
dilemma when formulating an honest response. Pharmacists are encouraged to respond 
to information enquiries from members of the public, but must not undermine any 
•established relationship with their doctor (RPSGB, 1997). The competing areas of the 
dilemmas were upholding trust of the practitioner versus allowing patients to believe 
information that was incorrect or had been interpreted as such. The recommendations 
made by UKDIPG (1997b) again endorse the need for care not to undermine any 
established relationship with a doctor or pharmacist. However, pharmacists are advised to 
correct any inaccurate knowledge and inform the relevant practitioner, where appropriate. 
The three dilemmas that presented were as follows:
(i) See appendix 27, Adverse Drug Reaction (prescribed), example 1. This presented the 
dilemma that the enquirer had been given ibuprofen by a doctor and monitored by the 
nursing staff. The pharmacist identified an adverse reaction that had not been identified 
by the doctor or nurses and advised the enquirer to discontinue treatment. Although this 
advice did not support the medical advice, it was considered in the enquirers’ best 
interest. The prison doctor was not informed since he was no longer responsible for the 
enquirers’ medical care. The enquirer was urged to register with a GP and obtain further 
advice.
(ii) A drugs worker asked the pharmacist for information regarding one of her clients, who 
had been prescribed fluoxetine. The drugs worker knew the medication was prescribed 
for depression and eating disorders, but was concerned because the client had reported 
being told by her GP that the drug was a substitute for heroin. The client had not been
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told that she suffered from depression and was aware that fluoxetine was an
antidepressant. The drugs worker asked if the pharmacist knew if fluoxetine had been 
used in opiate dependency and for advice on how to deal with the situation as the client 
wanted to know if what the GP had said “was true’. After obtaining information on trials on 
the use of fluoxetine in dependence, the pharmacist considered that the benefits 
demonstrated had been restricted to relieving depression co-existing with opiate or 
cocaine dependence. Although the drugs worker reported the client had no knowledge of 
suffering from depression, the pharmacist told the drugs worker care was needed, as a 
diagnosis may have been made but the doctor believed it was in the patient’s best interest 
not to be informed. The drugs worker was advised to suggest the client returned to her 
GP to ask for further information on her treatment. The pharmacist also suggested the 
drugs worker discuss the matter with the clients GP if the client was willing to consent to 
this.
(iii) A male telephoned the help-line and was referred to the pharmacist. He wanted to 
query information he had received from his community pharmacist. He was on a 
maintenance dose of methadone and planned to go abroad on holiday. He knew there 
were regulations that applied to carrying methadone abroad, so asked his community 
pharmacist for advice. He reported the pharmacist had informed him that if he transferred 
from methadone mixture 1 mg/ml to methadone tablets 5 mg, he could carry the 
necessary quantity of tablets abroad, without a licence. The pharmacist established where 
the enquirer intended travelling to and for how long. She confirmed the information she 
believed to be true with the Home Office. The client was informed of the correct 
procedures that applied to his situation and in doing so the pharmacist confirmed that the 
information received from the community pharmacist was wrong. An information sheet 
was produced that summarised the guidelines and procedures for taking controlled drugs 
abroad. A copy was sent to the enquirer to use in discussion with his GP. Further copies 
were kept in the agency for future use.
Provision of information on drug testing
In Grampian, two main groups undertake drug testing. These are specialist prescribing 
services and oil companies who screen employees. Thirteen enquiries related to drug 
testing of body fluids. Nine of these were from drugs workers and four were from 
members of the public. The pharmacist considered that such enquiries presented moral 
and in some cases ethical dilemmas. The moral dilemma was whether providing 
information on drug testing was colluding in illicit drug use. The ethical dilemma was
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whether providing information could compromise the intentions of a practitioner by
assisting their client in avoiding an undesirable test result.
The dilemmas that arose for the pharmacist were not around the provision of information 
per se. The DA workers reported their difficulty was not accessing information but 
interpreting the diversity of published information available. Information sheets for clients 
on testing produced by the Institute for the Study of Drug Dependence were available. 
The pharmacist found information on drug testing already in the public domain such as in 
music magazines and on the world-wide-web. At www.homedrua-test.com/ testing kits 
could be purchased for use at home and www.druqtest.com/ offered a lab based testing 
service. Details of drug detection times were on the web pages. Three enquiries from 
drugs workers were requests for assistance in interpreting published information. The 
pharmacist considered it appropriate to assist drugs workers in interpreting information 
generally, as it would assist them in their jobs.
Ten enquiries related to specific client issues. Four of these did not create any dilemmas. 
The six that created dilemmas will be discussed. Three related to employment. One was 
from a person who had an interview for a job at an oil company and had used cannabis 
' one week previously (appendix 27, Drug testing, example 1). They wanted to know 
whether this would show up if a urine test was done. The second was from a person who 
was employed by an oil company who had been informed he had a urine test in one week 
and had used cannabis two weeks previously. The third was through a drugs worker 
regarding a help line call. This was from a person who had a past history of heroin 
dependency and had successfully detoxified using methadone prescribed by his GP. He 
had set up his own business some years previously and was in the process of changing 
his insurance provider for his company. His GP had noted on in the medical report for the 
insurance company that the person had a past history of heroin use. The company 
requested a urine test. The person had used cannabis a few days ago and wanted to 
know if there was a home testing kit they could buy to ensure that the urine test was not 
done until they had cleared all the cannabis from their system.
Kelly et al (1990) considered the responses of drug information pharmacists to a request 
for information on the detection time of marijuana in urine in relation to an employment 
screening; 59% said they would provide all relevant information. The authors state the 
caller must demonstrate a legitimate and non-harmful intention with the information. It is 
argued that undertaking employment such that of a bus driver or nuclear power plant 
technician would endanger the public, therefore there is harmful intention and the 
pharmacist has a social responsibility not to provide information. However, a positive urine 
test result indicates recent drug use, the pharmacist considered further evidence was
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necessary to establish the person has or intends to work while experiencing
pharmacological effects that impair functioning. It cannot be assumed that the person’s 
drug use poses a threat to public safety, without establishing the nature and frequency of 
use or the job involved. The pharmacist therefore established whether the drug use of the 
clients would affect public safety. She considered identification of risk to others, would 
make her responsible for its prevention. Prevention could only be undertaken through 
discussion of the issues with the person responsible. Denying information alone would not 
remove the risk. Both the enquiries that related to oil companies were in relation to clerical 
jobs, considered unlikely to pose any risk to public safety. However, the conflict of 
undermining the employer was still pertinent. Both enquirers had however, already 
consumed the drugs concerned. The pharmacist considered it acceptable to inform them 
of the average time to clear cannabis from the system based on their patterns of use, but 
she did not advise the callers on ways to change the drug detection time after 
consumption. She took the opportunity of discussing responsibilities for public safety and 
offering information on the health and legal risks from using cannabis. The enquiry 
regarding testing kits presented the dilemma that the pharmacist considered it more 
harmful to the individual and society if the person lost his business than the risks to the 
individual and society from his occasional cannabis use. However, this presented the 
dilemma that cannabis use is illegal and the pharmacist should not impede the activity of 
the insurance company. The worker had informed the enquirer of the clearance times of 
cannabis. Aware of the availability of testing kits on the world-wide-web, the pharmacist 
suggested the worker ask if the enquirer had considered looking on the Internet. She was 
careful not to collude by divulging any web addresses or recommending any specific 
service.
Three enquiries related to drug testing by the specialist prescribing service. All three were 
from people who were using on top of their prescribed medication because they were not 
coping with the rapid reduction of their prescription. They all wanted assistance in 
interpreting the ISDD information regarding time to clear specific drugs and advice on 
when it was ‘safe’ to use. The dilemma for the pharmacist was that the protocol used by 
the local specialist prescribing service dictated that patients on substitute therapy who 
provided two contaminated urine tests during the course of their treatment, should be 
removed from the treatment list. There was a one-year waiting list for this service, so 
anyone removed from care would have to wait at least one year for further care if his or 
her GP was unwilling to provide substitute therapy. This conflicted with the pharmacist’s 
understanding of substitute therapy. She acknowledged that some degree of illicit drug 
use may continue and that the benefits of receiving substitute therapy experienced by her 
clients and their communities would be removed if treatment was withdrawn. The 
pharmacist believed urine testing could be a useful adjunct in patient management only if
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honesty with treatment providers was possible. She was also aware that testing
laboratories are familiar with avoidance techniques and employ methods to avoid or 
detect their use (Simpson et al, 1993). The pharmacist considered she should not collude 
in assisting clients to avoid being removed from the specialist service list, even though 
she believed it to be wrong, as was a professional responsibility not to undermine the 
work of other professionals. Therefore, she confirmed that the ISDD information was 
correct and offered to negotiate with the specialist prescribers on behalf of the clients to 
discuss changing their care plans. She also used the opportunity to discuss the overdose 
risks of using on top of methadone.
Identification o f unknown tablets/capsules
Seven enquiries fell into this category, three from drugs workers, three from members of 
the public and one from an outside service worker. One did not present a dilemma. Four 
have already been described, two under the identification category in appendix 27 and 
two under provision of information to third parties above. A further two related to clients 
who had bought tablets on the street and wanted to confirm their identity. The drugs 
workers informed the pharmacist that when they are asked to identify unknown 
pharmaceuticals, they use a published identification guide. However, they reported 
sometimes having difficulty finding information because generics are not included. All the 
enquiries presented to the pharmacist in this category were ones that the drugs workers 
were unable to answer themselves. The pharmacist considered an ethical dilemma could 
potentially arise from such enquiries as the pharmacist may be seen to be assisting in an 
illegal or immoral activity. However, she also considered refusing to answer the enquiries 
could cause harm, for example if the drug user mistook one drug for another and took it 
at a harmful dose or in a dangerous combination.
The pharmacist consulted the literature for guidance. No specific advice was given by the 
RPSGB (1997) or UKDIPG (1997a, b). Kelly et al (1990) investigated and critically 
evaluated the responses of pharmacists from Dl centres across the USA to six ethical 
dilemmas. Although the responses were from pharmacists working to the American 
Pharmaceutical Association code of ethics, the ethical requirements described were 
sufficiently similar to those outlined by the RPSGB (1997), thus the guidance given was 
considered relevant to practice in the UK. When discussing the identification of 
pharmaceuticals, the authors support establishing the rights of the individual to the 
information. If the individual was not the owner of the pharmaceutical, this brings in the 
issues relating to the provision of information to third parties. In general, the authors 
advocate the provision of such information and conclude Yhe good of offering such a
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service generally outweighs the possibility of the misuse of the information provided’. In
the paper by Daly and Bower (1997), the authors present a case study where a mother 
asks a pharmacist to identify a tablet she found in her daughter’s room. The identification 
of the tablet is not viewed as the debate, it is around the provision of information to 
someone other than the tablet owner. In a paper of a similar style, where an ethical 
dilemma is debated by several pharmacists, Uretsky (Veatch, Uretsky and Kelly, 1992) 
describes the purpose of drug information as being to provide information not withhold it 
and points out that in most cases the information can be established from other more 
inconvenient sources. This in itself, was not considered enough to justify the provision of 
information if there is concern that the information may be used to cause harm to oneself 
or others, or to bring about deceit. The pharmacist decided that if the purpose of the 
request was required to bring about deceit or harm others, she was under no professional 
requirement to supply the information. This is also the view of Kelly in the above paper. 
However, this did not apply to the cases encountered. The drug users who wished to 
verify identification did so because they intended to consume the drugs themselves. The 
pharmacist considered this an appropriate harm reduction opportunity as in two cases she 
could prevent mistaken identity. She could also use the opportunity to discuss relevant 
health and legal issues and the risks from tablet injection, if applicable. It could be argued 
' that withholding information would have been morally wrong, as mistaken consumption 
could have lead to serious harm. In one case carbemazepine was thought to be 
temazepam and in the other temazepam was thought to be dihydrocodeine. Another drug 
user knew the correct identification of his tablets, but the tablets [nitrazepam] were 
stained with what looked like methadone. This provided an opportunity to discuss the 
interaction and risks of combined use. Enquiries that related to provision of information to 
third parties raised the further issues previously described.
Appendix 29
Pharmacist’s service client follow-up: description of cases 
Case study 1.
Background:
A couple came into DA to ask the drugs workers for advice. The man, who had previously 
been a client of the agency, specified that he trusted the workers so wanted to ask their 
advice. The woman was not known to the agency. The duty worker asked the pharmacist 
to join the drop-in appointment to provide advice. The woman received a methadone 
maintenance prescription, the man reported being drug free for several years. The couple 
had recently had a baby who was in the Special Care baby unit, being treated for opiate 
withdrawal. The pharmacist dealt with three of the issues that presented:
Issue (1): The baby was receiving morphine. The couple were worried about dosage 
information they had read on the baby’s drug chart, as they perceived it to be very high. 
They were also concerned that the dose had not yet been reduced. They came to DA to 
ask if the dose they reported the baby to be receiving was ‘safe’.
Response: From the reported dosage, the pharmacist suspected that the units of dosage 
had been misunderstood (milligrams instead of micrograms) and she informed the couple 
of this. She identified the woman felt an incredible amount of guilt about the situation their 
baby was in, and was being blamed by her partner. The woman had not discussed her 
baby’s care with hospital staff because she feared judgement and her baby being 
removed by social work. Instead, the couple had been reading the care notes by the crib 
unguided. The pharmacist explained to the couple what a care plan was. She suggested 
the couple ask to meet with a doctor and nurse looking after their baby and ask for the 
care plan to be explained. The drugs worker discussed issues around guilt, self-esteem 
and child protection.
Issue (2): The woman had an older child who had a form of autism. She wanted to know 
if taking methadone during her pregnancy would increase the chances of the baby being 
autistic.
Response: The pharmacist informed the woman that there was no evidence that use of 
methadone in pregnancy caused autism in children. The pharmacist suggested the 
woman discuss the issue of autism with the paediatrician.
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Issue (3): When the woman began her methadone prescription, her GP had told her she
must not drive. Although not usually a problem, she was finding this increasingly difficult 
as she lived 15 miles from the hospital. She feared the staff would judge her as uncaring 
as the times of the rural bus service she used and other child-care responsibilities meant 
she did not arrive at the hospital until half way through the visiting time. The pharmacist 
also felt her partner was pressurising her into driving and the woman sought support in 
her belief that she shouldn’t.
Response: The pharmacist asked the woman to consider the issues around driving when 
taking sedative medicines and the risks to others. She also asked the woman to consider 
the potential consequences for her, her family and other people, if she ignored the advice. 
She explained the doctor was safeguarding her welfare and that of others. She suggested 
the woman discuss the issue with her GP at her next appointment. She suggested the 
woman ask the social worker on the ward if she was entitled to financial assistance with 
travel. The pharmacist also suggested the woman explain to the staff why she arrived 
later on.
Was the inform ation used o r advice followed?
The woman telephoned the pharmacist one week after contact. She reported that they 
had met with a doctor and nurse and the baby’s treatment had been explained. The 
couple had misinterpreted information from the notes and were happy with the information 
they had received. The doctor had also reassured them around the issues of autism. The 
woman had not approached the social worker about travel expenses, but she had 
explained to the nurses why she would be late. She had not yet seen her GP, but was 
happier to travel by bus having been reassured by the ward staff that she was not 
expected to attend every visiting session for the whole duration.
Further input?
The pharmacist did not make further input to this case. The woman’s worker continued to 
provide support.
Case study 2.
Background:
The duty worker asked the pharmacist to see a needle exchange client who came to DA 
for advice. The 17-year-old male heroin user presented with swelling in the left testicle 
and pain down the left leg, causing extreme difficulty in walking. Due to vascular collapse 
of peripheral veins he was injecting into his left femoral vein. One week previously he had
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presented at A&E, where he received antibiotics and non-steroidal anti-inflammatories.
The client did not want to return to A&E because he was still injecting. Also, he 
considered that he would be hospitalised and feared experiencing opiate withdrawal 
during this period.
Issue (1): The client's presenting symptoms.
Response: From the presenting symptoms and examination the pharmacist suspected 
the client could be suffering from a deep vein thrombosis (DVT). She explained her 
suspicion to the client and advised that he must return to A&E urgently.
Issue (2): The client’s reluctance to return to A&E or be an inpatient.
Response: The pharmacist asked the client if he would be willing to go to A&E if she 
made contact with a staff nurse known to her and discussed his case. The client agreed. 
The pharmacist liaised with an A&E nurse whom she knew, she gave his name to the 
client and explained that the nurse was waiting for him. She also passed on information 
from the nurse that admission couldn’t be enforced, only advised strongly if it was 
considered in his best interest.
Was information used or advice followed? The pharmacist saw the client two weeks 
later. He had acted upon the pharmacist’s referral to A&E, and spent 7 days in hospital. 
He received substitute prescribing during this time and surgical and medical treatment for 
a DVT. The clients’ stepmother also reported this information to the pharmacist at a later 
date.
Further input?
The client informed the pharmacist on follow-up that he had been prescribed warfarin. 
The pharmacist established what the client knew about warfarin. She advised him to go 
back to A&E if his symptoms returned or he experienced any uncontrolled bleeding and 
stressed the importance of monitoring. The client reported he was no longer reluctant to 
use A&E services if needed. The pharmacist explained that he was at greater risk from 
continued heroin injection and discussed the possibility of substitute therapy.
Case study 3.
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Background: A client asked her drugs worker for information about injecting cyclizine 
tablets. The contact is summarised in 9.1.6 under the Harm Reduction Techniques 
category, example 1.
Issue (1): The client was injecting cyclizine tablets and wanted harm reduction advice.
Response: The pharmacist considered the risks from this practice to be large and the 
safest option was not to inject the tablets at all. However, the pharmacist and drugs 
worker both considered it likely the client would continue this practice and advised on the 
use of a filter and not to mix the tablets with other drugs.
Was inform ation used o r advice followed?  At next contact with her drugs worker, the 
client reported continued use. However, she did report not mixing the tablets with other 
drugs and having used a filter.
Further input?  Further input from the pharmacist was not considered necessary.
Case study 4.
Background: The pharmacist was asked by a worker to speak to a mother and her son, 
who was a heroin user, during a joint one-to-one appointment. The son had a past history 
of a severe head injury as a child. His GP was willing to prescribe methadone. However, 
the mother was concerned, as she had read that methadone shouldn’t be given to people 
who have experienced head injuries.
Issue (1): The concern over the safety of methadone in this case.
Response: The pharmacist explained to the mother that in people who have just had a 
head injury, drugs like methadone have to be monitored carefully. However, a history of a 
head injury did not carry the risks that an active head injury did and the pharmacist 
considered methadone could be used, if the GP felt it appropriate. The pharmacist 
suggested the mother and son discuss the issue with the GP. The pharmacist also 
discussed safety issues around methadone use. The drugs worker considered the 
mother had several concerns about methadone and provided information on the benefits 
and risks to both her and her son.
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Was in form ation used o r advice follow ed?  On follow-up, ten days later, the drugs
worker considered the mothers fears to be reduced. The son had seen the GP regarding
a methadone prescription and was in contact with a worker for support.
Further input?  Further input was not considered necessary.
Case study 5
Background: The pharmacist was asked by a drugs worker to speak to a client in a one- 
to-one appointment. The client was a poly-drug user, using diazepam, temazepam, 
methadone and dihydrocodeine, all orally. Only the latter was received on prescription. 
The client had no history of heroin use. The client was on a waiting list to see the 
specialist service. He was not willing to inform his GP of his current illicit drug use in case 
his prescription was stopped. He asked his drugs worker for advice on reducing his illicit 
consumption. The drugs worker asked the pharmacist to input.
Issue (1): Advice on reducing the clients’ poly drug use.
Response: The pharmacist confirmed that the client was not willing to seek the advice of 
his GP. She suggested beginning with the benzodiazepines and discussed the issues 
around benzodiazepine withdrawal. The client considered he was able to stop using 
temazepam as it was used occasionally. She advised consumption of a steady amount of 
drugs was preferable to binges and to avoid alcohol, although the client did not drink so 
this was not relevant. She devised a reduction plan for the client, on the basis of gradual 
reduction only when able to cope, avoiding rapid removal. She advised this to be followed 
until his referral came through, at which point he was advised to declare his level of use 
with the specialist service.
Was in form ation used o r advice followed?  The client began the reduction plan and 
reported to his worker that he felt more ‘control’ over his drug use. After a short period of 
time he began care from the specialist service.
Further input?  Input on this issue was not necessary due to the specialist service 
referral. The client did however bring his wife, who was not a drug user, to see the worker 
and pharmacist, for support.
Case study 6.
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Background: A client was referred to the pharmacist by the duty worker for information 
on naltrexone. The contact is summarised in 9.1.6 under discussion of the category 
Adverse Drug Reaction (Prescribed), example 2.
Issue (1): The client wanted to know if naltrexone could be responsible for the symptoms 
he was experiencing.
Response: The pharmacist considered naltrexone could be responsible for the symptoms 
and also identified other issues the client had around his return to Aberdeen.
Was inform ation used o r advice follow ed?  The pharmacist arranged an appointment 
for the client with a drugs worker in one week. He had continued taking the naltrexone 
although the symptoms had not reduced. He reported feeling reassured by talking with 
the pharmacist.
Further input?  This was not considered necessary.
Case study 7
Background: An outreach worker asked the pharmacist to see one of her clients in a 
one-to-one appointment. The client had previously been receiving 80 ml methadone daily, 
but reported feeling exhaustion and heaviness. His GP changed his prescription to 
dihydrocodeine at the clients’ request, prescribing ten 90 mg slow release tablets per day. 
The client asked the drugs worker for advice on swapping from methadone to 
dihydrocodeine. He was scared of withdrawal effects and doubted the GPs advice to take 
the dihydrocodeine in two divided doses.
Issue (1): Client unsure how to swap from one prescribed medicine to another.
Response: The pharmacist explained that the dose of dihydrocodeine was slightly higher 
than the equivalent dose of methadone, so the client should not experience any physical 
withdrawal effects. There may be some psychological effects experienced in the first few 
days until the client feels reassured with the change. The pharmacist confirmed the GP’s 
suggestion of taking the tablets in two doses of 5. She suggested the client try to take the 
tablets twelve hours apart and explained what the slow release formulation meant.
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Was inform ation used o r advice follow ed?  The drugs worker saw the client one week
later. He made the transition smoothly without any withdrawal effects.
Further input?  Further input was not necessary on this matter, but the drugs worker later 
asked the pharmacist for further advice for this client. The client had received 
confirmation of a place in a residential rehabilitation unit and needed to reduce the level of 
his prescribed drug to an amount acceptable for entry. The drugs worker had attended a 
joint appointment with the client’s GP and it had been agreed that the drugs worker and 
client would devise a reduction plan for discussion with the GP. The worker told the GP 
she could consult the pharmacist, and the GP supported this. The pharmacist, worker and 
client negotiated a plan that they all considered realistic. The GP approved the plan and it 
was followed. The client reached the acceptable level in time to enter the unit.
Case study 8.
Background: The pharmacist was asked to advise on an injection site abscess that a NX 
client showed to the duty worker. During the examination, the pharmacist established the 
client was receiving 4 ml methadone daily and not coping on this low dose. She was 
regularly injecting heroin again. She had not told her specialist prescriber for fear of her 
prescription being stopped. She reported selling sex to obtain money for heroin. The only 
contact she had with DA was through her use of the NX and would not approach her GP 
as he was a family friend and she feared ‘letting him down’.
Issue (1): The client had an abscess that looked infected and would not consult her GP.
Response: The pharmacist referred the client to A&E, reassuring her that they were 
willing to treat such injuries.
Issue (2): The client reported not coping with her prescribed amount of methadone.
Response: The pharmacist discussed issues around the clients drug use, including her 
goals and psychological difficulties. She also discussed prostitution health and safety 
issues. She suggested the client see a drugs worker, but she was unwilling. The 
pharmacist offered to discuss the issues with the prescriber, the client agreed and 
consented to all information discussed being divulged. The pharmacist did this and the 
prescriber agreed to review the prescription in light of the information received.
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Was inform ation used o r advice followed?  The client came to the agency to see the
pharmacist one week later. She had attended A&E for treatment and the abscess 
appeared to be healing. The prescriber had discharged her from treatment for non- 
compliance.
Further input?  The pharmacist contacted the prescriber who explained she had acted 
according to the protocols of her service. The client returned to the agency to see the 
pharmacist, but at times outwith the session, so no further contact occurred during the 
period of the service.
Case study 9.
Background: A drugs worker asked the pharmacist for advice he could pass on to a 
client regarding constipation. The contact is summarised in 9.1.6 under discussion of the 
category Health Problem (Drug Related), example 2.
Issue (1): The client reported severe constipation and wanted advice from his worker.
Response: The pharmacist made an OTC recommendation and suggested dietary 
advice. She also suggested further discussion by the client with his GP.
Was inform ation used o r advice followed?  The client was reluctant to return to his GP, 
so the drugs worker went with him to discuss the issue, as he considered the client may 
be experiencing difficulties making himself understood. The GP prescribed lactulose. The 
drugs worker was did not know if the dietary advice had been followed.
Further input?  This was not required.
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Abstract
In je c tin g  d ru g  u se rs  a r e  a t  r isk  o f  a n d  c a n  su f fe r  f ro m  se r io u s  h e a lth  p ro b le m s  d u e  to  in t ra v e n o u s  a d m in is t r a t io n  
o f  in so lu b le  p a r t ic le s  fro m  s tre e t  d ru g s  a n d  ta b le ts .  M a k e s h if t  filte rs  a r e  u se d  to  t r y  to  re m o v e  p a r t ic le s  f r o m  th e  
in je c tio n s . T h e  d e c is io n  to  d is t r ib u te  f ilte rs  f ro m  H a rm  R e d u c tio n  C e n tre s  c a n n o t  b e  b a s e d  o n  ev id e n c e  o f  e ff icacy  a n d  
sa fe ty  a s  n o  su c h  p u b lish e d  d a ta  e x is ts . T h e  w o rk  p re s e n te d  h e re  is p a r t  o f  a  la rg e r  s tu d y  w h ic h  a n tic ip a te s  to  p ro v id e  
su c h  ev id en c e . L a b o ra to ry  m e th o d s  w e re  d e v e lo p e d  b a se d  o n  in fo rm a t io n  g a th e re d  f ro m  d r u g  u se rs . In je c tio n s  w ere  
p re p a re d  u s in g  d ru g s  o f  a b u s e  a n d  f ilte re d  e i th e r  th r o u g h  m a k e s h if t  o r  c o m m e rc ia lly  a v a ila b le  filte rs . T h e  re s u ltin g  
so lu tio n s  w ere  a ssa y e d  fo r  p a r t ic le  s ize  a n d  n u m b e r  (u s in g  C o u l te r  C o u n te r® ). C o m p a r is o n s  w e re  m a d e  w ith  u n f ilte re d  
in je c tio n s . T h e  re s u lts  p re s e n te d  h e re  a r e  f ro m  th e  f irs t p a r t  o f  th is  s tu d y , w h ic h  in v e s tig a te d  th e  e ffe c tiv e n e ss  o f  
v a r io u s  filte rs  o n  re d u c in g  p a r t ic u la te  c o u n t  a n d  size  ra n g e  o f  in je c tio n s  m a d e  f ro m  ta b le ts .  T h e  c o m m e rc ia lly  
p ro d u c e d  filte r (A cro d isk ® ) sh o w e d  a  m u c h  g re a te r  re d u c t io n  in  p a r t ic le  n u m b e r  a n d  size . T h is  s tro n g ly  su g g e s ts  th e  
risk s  to  h e a lth  c o u ld  b e  re d u c e d  b y  th e  u se  o f  su c h  f ilte rs . O f  th e  m a k e s h if t  f ilte rs , th e  R izla®  a c e ta te  filte r  sh o w e d  
th e  m o s t s a t is fa c to ry  re d u c t io n  in  th e  n u m b e r  o f  p a r t ic le s ,  su g g e s tin g  th e i r  u se  m a y  b e  p re fe ra b le  t o  th e  c u r r e n tly  
p o p u la r  c ig a re tte  filte r. T h e  o n g o in g  w o rk  is lo o k in g  a t  th e  e ffe c t o f  th e  f i l t ra t io n  m e th o d s  o n  a m o u n t  o f  d ru g  in  
in je c tio n s  m a d e  f ro m  ta b le ts  a n d  re p e a t in g  th e  w o rk  u s in g  s tre e t h e ro in . ©  1998 E lse v ie r  S c ien ce  B .V . A ll r ig h ts  
re se rv ed .
K eywords: F il te rs ; In tra v e n o u s ;  D ru g  u se rs
1. Introduction
Public health and health care policies increas­
ingly have to be evidence based. Harm reduction 
» Corresponding author. is one area where there is difficulty in making
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some practice evidence based, purely because the 
only evidence available is anecdotal and not re­
search based (Paxton, 1998). One such example 
is the provision o f injecting paraphernalia. In the 
UK it is an offence under section 9A o f the 
Misuse o f  drugs Act (1971) to supply any article 
believing it to be used or adapted for use to 
administer a controlled drug except clean needles 
and syringes. This applies to swabs, citric acid, 
filters etc. At the 1997 UK Association o f  Chief 
Police Officers conference this matter was de­
bated and a firm recommendation made that the 
law be changed to permit supply o f  such para­
phernalia from recognised agencies including 
pharmacies (Wray, 1997). The high prevalence o f  
hepatitis C and the link o f transmission through 
sharing filters, water, swabs etc. makes such a 
change in the law not only very welcome but 
vital for harm reduction. If such a change in the 
law does occur, we will then be faced with the 
decision o f what kinds o f equipment to supply. 
Even with no change in the law, evidence o f  
effectiveness is necessary to provide drug users 
with accurate information. One such example is 
the use o f filters to remove insoluble materials 
from injections. Intravenous (IV) drug use carries 
many risks o f  harm and associated medical com­
plications. Direct access to the vascular system 
and administration o f drugs which are not pre­
pared to pharmaceutical standards for injection 
(such as street drugs and tablets) are related to 
some medical problems. Insoluble particles are 
often present in amounts far higher than those 
that are considered to be safe in pharmaceuti­
cally manufactured injections. Both the size of 
the particles and the number present in injections 
are important. In the microcirculation o f the 
body the smallest vessels are the capillaries, 
which are « 8  pm in diameter. Next are the 
terminal arterioles which are between 20 and 50 
pm. The more particles there are and the bigger 
they are, the greater the risk to health. Conse­
quently, there are limits placed on the particulate 
content o f  commercially made injectables. The 
British Pharmacoepia (B.P) stipulates that for 
large volume parenterals (fluids for IV adminis­
tration, >  100 ml), there should be no more than
1000 particles per ml over 2 pm and o f these no 
more than 100 per ml should be over 5 pm 
(British Pharmacoepia, 1993). There is no limit 
given in the B.P for small volume parenterals. 
Obviously, the injections prepared by IDUs will 
contain greater numbers o f particles than those 
made commercially because o f  the presence o f  
insoluble adulterants in street drugs and diluents 
in tablets that are crushed up to make injections. 
Also the ID U  is not preparing injections in an 
aseptic environment, unlike pharmaceutical in­
dustry formulated injections.
Examples o f  the problems caused by insoluble 
particles include: phlebitis, abscesses, blocked 
blood vessels (which can lead to deep vein 
thrombosis, varicose ulcers and gangrene) and 
endocarditis. (The latter is more commonly due 
to bacterial seeding from infected wounds but 
can be caused by the build up o f insoluble adul­
terants and diluents behind the valves in the 
heart leading to irritation). (Posner and Guill, 
1985, Haverkos and Lange, 1990, Stein, 1990, 
ANSW ER, 1996, Scott and Bruce, 1997). There 
is a belief amongst some drug users that certain 
materials are better to be used as filters than 
others. It is also believed that filtering certain 
drugs reduces the concentration o f drug in the 
injection, resulting in the loss o f  the hit.
The definition o f an effective filter, devised for 
the purpose o f  this study, is as follows: For an 
ID U ’s filter to be effective it must reduce the 
particulate content o f  the injection to a level that 
presents a lower risk o f  harm. It must be accept­
able to the user, so must not remove the drug 
and has to be quick and easy to use. It is the 
first part o f  this statement which is being investi­
gated in the work presented here. The overall 
aim o f this study is to provide evidence from the 
laboratory and liaison with drug users to investi­
gate the effectiveness and predicted safety o f  
filters. If such evidence can be produced its use 
will be two-fold: to support bids for funding 
from needle exchanges to enable the distribution 
o f suitable filters and the creation o f  harm reduc­
tion information for ID U s to advise on effective 
filtering methods.
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2. Method
Semi structured interviews were carried out 
with twenty current or ex-IDUs to explore the 
drugs that are used by injection and the methods 
used to prepare injections. From this, the most 
commonly used drugs by the IV route were es­
tablished. For financial reasons and constraints 
on time, it was decided to investigate three phar­
maceuticals and one street drug, the most popu­
lar drugs being selected for investigation. From 
the interview data, it was established that heroin 
was the most commonly used ‘street drug’ by the 
IV route. Several pharmaceuticals were also 
stated as being injected. Data on the use if these 
were compared with national statistics (Drug 
Misuse Statistics Scotland, 1996). From this the 
three pharmaceuticals chosen for investigation; 
these were Physeptone tablets, Temgesic tablets 
and Diconal tablets. Use o f the latter appears to 
vary greatly between region, but because o f  the 
continuing popularity in some Scottish areas and 
many beliefs amongst IDUs which warn against 
filtering o f  Diconal, it was decided to select this 
drug for investigation.
It became clear that the method o f preparation 
used by each ID U  for heroin was similar, but the 
preparation method used for tablets varied. Safer 
Injecting Guidelines published for ID U s were 
therefore also consulted to assist in establishing 
the preparation method (Exeter Drugs Project, 
HIT, 1995).
The type and quantity o f tablets used were as 
follows: Physeptone® (methadone 5 mg, Glaxo 
Wellcome) nine tablets in 5 ml o f water; D i­
conal® (dipipanone 10 mg and cyclizine 30 mg, 
Glaxo Wellcome) two tablets in 2 ml o f  water; 
Temgesic® (buprenorphine 0.2 mg, Reckitt and 
Coleman) five tablets in 2 ml o f  water. The injec­
tions were prepared by crushing the tablets be­
tween paper with a spoon and mixing the 
resulting powder on the spoon with water from 
the kettle which had been boiled and cooled. The 
methods o f filtration investigated were as fol­
lows: a piece o f  a cigarette filter (Lambert and 
Butler®) prepared by removing the surrounding 
paper and tearing it in two down the middle
then halving one piece with a scissors and 
smoothing any stray fibres with the fingers be­
fore placing it in the edge o f the solution. A 
hand rolling filter (Rizla Extras® 7 mm acetate 
filter tips), used whole, placed in the solution. A 
cotton bud tip (Unichem 100% cotton), removed 
from the plastic stalk by pulling and the end 
twisted to smooth the stray fibres and then 
placed in the edge o f  the solution. In all o f  these 
cases the needle was attached to the syringe and 
the solution drawn up through the filter. A com ­
mercially available syringe filter was also tested 
(5 pm Acrodisk®, Gelman Sciences). This was 
placed on the end o f  the syringe and the solution 
drawn through, then removed and the needle 
attached. Also investigated were unfiltered solu­
tions prepared in this way and unfiltered solu­
tions prepared by breaking the tablets in half 
and shaking them with water in the syringe bar­
rel. Controls were tested using boiled and cooled 
water and Water For Injections BP (Antigen 
Pharmaceuticals®) to investigate the contribution 
o f the filtration and preparation methods on par­
ticulate content.
Particle count and size range were measured 
using the Coulter Multisizer®, using 0.5 ml sam­
ples withdrawn from the injections immediately 
after preparation. Each test was repeated three 
times and the average result taken. It was de­
cided to do this instead o f  taking three consecu­
tive readings from each sample, as there could be 
a reduction in the particle count as the sample is 
stirred. The Multisizer operates on the electrical 
zone sensing principle: there are two electrodes in 
a conducting fluid (saline which has been filtered 
twice using a 0.2 pm filter) separated by an 
orifice o f  known diameter. A  stirrer keeps any 
particles suspended in the saline. When a particle 
passes through the orifice there is a change in 
resistance (measured as a voltage pulse at a fixed 
current), the magnitude o f  this relates to particle 
size. Total number o f particles that are drawn 
through the orifice in a given time (12 s) and 
number o f particles within a size channel can be 
measured. In this case the 100 pm orifice was 
used, which measures particles in the size range 
2 -6 0  pm.
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Table 1
Percentage reduction in total number o f particles
Drug Crush and mix {%) Shake in barrel Cigarette filter Rizla filter C otton bud Acrodisk
Physeptone 100 36 — — — —
Diconal 100 15 29 39 36 99.0
Temgesic 100 24 24 42 56 99.9
3. Results
Changes in trends seen in particle size and 
number before and after filtration were looked 
for. The total number o f particles present in the 
injections can be estimated by extrapolating the 
count from the 0.5 ml sample, but is o f  little value 
because there will be a large variation in numbers 
depending on the volume o f water the ID U  uses 
to make injections, how finely the drug is crushed, 
etc. Therefore, the number o f  particles in the 
unfiltered sample was taken to be 100% and the 
effects o f filtration shown as the percentage reduc­
tion in the total number o f  particles. This is 
shown in Table 1.
The Physeptone solutions were thick and did 
not pass through the filters quickly or easily. 
Several filters had to be used as they clogged and 
it took longer than was deemed acceptable by the 
IDU. Since this does not fit with the definition o f  
an effective filter given earlier, it was decided not 
to continue with the Physeptone filtration investi­
gations at this stage. From Table 1 it can be seen 
than all methods o f  filtration cause a reduction in 
the total number o f  particles in the prepared 
injections. Preparation by splitting the tablets in 
two and shaking them in the syringe barrel also 
reduces the number o f  particles. However, in pre­
liminary work on the effect o f  filtration on drug 
concentration, the amount o f  methadone was 
found to be only 90% of the drug contained in the 
nine Physeptone tablets when they were split and 
shaken, compared with 100% when they were 
crushed. A slurry was seen to collect at the bot­
tom o f the syringe indicating clumping o f excipi­
ents and drug, explaining why not all the drug 
dissolved. This material could block the needle or 
break down enough to pass down the needle and 
enter the veins as a solid mass. As expected the
commercial Acrodisk gave the greatest reduction 
in the total number o f particles. O f the makeshift 
filters, the Rizla gives the best overall perfor­
mance for both drugs. The cotton bud showed a 
good reduction in particle count with Temgesic 
injections, but was not as effective with Diconal. 
The cotton bud also has loose fibres which could 
enter the injections after filtering. Because the 
Multisizer sizes particles as spheres, a long thin 
fibre passing through the orifice may be counted 
as several smaller spheres. The cigarette filter was 
identified in the interviews as being the most 
commonly used filter, but this preliminary work 
suggests the Rizla filter to be more effective.
The total number o f particles in the sample was 
taken to be 100% and the distribution o f  these 
according to size range is given for each drug in 
the Table 2.
As said, the particle size analyser gives the total 
number o f particles in the sample and the number 
of particles in each o f the channels within the size 
range 2 -6 0  pm. Since some o f the particles may 
be <  2 pm or > 6 0  pm, the percentage distribu­
tion within the size range 2 -6 0  pm does not 
necessarily add up to 100%. Obviously these parti­
cles will still, however pose a risk to health. Table 
2 show that all filters cause a shift in size range to 
the smaller end o f the scale for the drugs tested. 
Again, the Acrodisk shows the greatest reduction 
in size range with the majority o f  particles in the 
filtered solution being smaller than the capillaries 
in the body. O f the makeshift filters, the reduction 
in size range appears to be greatest with the 
cotton bud filter. Splitting and shaking the tablets 
in the syringe also gives more particles in the 
smaller size ranges. Thus if no filter was used, this 
would be preferable to crushing the tablets to a 
fine powder first.
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Table 2
Percentage of particles detected shown by size range for (a) Physeptone, (b) Diconal, and (c) Temgesic injections
Size range (|im) Crush and mix Shake in barrel Cigarette filter Rizla filter C otton bud Acrodisk
(a) Physeptone
2 -5 24 43 — — — —
5-10 18 15 — — — —
10-20 33 23 — — — —
20-50 3 3 — — — —
(b) Diconal
2 -5 23 32 45 40 39 99
5-10 23 22 25 26 27 1
10-20 37 29 19 26 27 0
20-50 1 1 0 0 0 0
(c) Temgesic
2 -5 9 10 13 12 23 76
5-10 27 30 37 32 33 18
10-20 45 46 38 37 35 6
20-50 1 3 0 1 1 0
Table 3 shows the total number o f particles that 
were counted without the drug present in the 
injections as a percentage o f the total number 
detected when the drug is present.
This indicates the contribution to the total 
number o f particles that is made by factors such 
as the kettle, cup, water, spoon, filters, injecting 
equipment and the non-aseptic environment, in­
cluding the person preparing the injections (e.g. 
skin shedding). The contribution to particle count 
not from the drug is low except in the case o f  
kettle water and the Acrodisk. This is because the 
total number o f particles present is low, so the 
contribution from the equipment and the environ­
ment become significant. It is also shown that in 
terms o f particle count, there is no benefit from
using Water For Injections. However, there are 
obvious microbiological advantages.
4. Discussion
It has been shown that makeshift and commer­
cial filters reduce the particle count and particle 
size in injections o f Diconal and Temgesic. This 
suggests that the health risks attributed to the 
injection o f insoluble materials could be reduced 
by filtering the injections prior to administration. 
The commercially produced syringe filter would 
be the most appropriate choice, the cost implica­
tions o f  supplying such filters needs to be consid­
ered. Clients who inject these drugs should be
Table 3
Percentage of total particle count that can be attributed to sources other than drug (i.e. controls)
Mix on spoon Shake in barrel Cigarette filler Rizla filter Cotton bud Acrodisk
Physeptone Kettle 0.1 0.1 ___ ___ ___ ___
W FI 0.1 0.3 • ------ — — —
Diconal Kettle 0.2 0.2 0.2 0.4 0.3 31.5
WFI 0.1 0.6 0.2 0.1 0.8 0
Temgesic Kettle 0.2 0.2 0.2 0.5 0.3 230.0
WFI 0.1 0.6 0.1 0.1 1.1 0
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encouraged to filter. The Rizla acetate filer ap­
pears to be more effective than the popular 
cigarette filter. The filters should be handled to a 
minimum to reduce contamination risks from the 
hands, and re-use o f  filters discouraged. However, 
many users do not use filters because they claim 
to loose the ‘hit’. Therefore the next stage in this 
work will develop methods to measure the effects 
o f filtering on the concentration o f the drug. Also, 
since many more people use heroin than tablets 
by injection, it is important to carry out this work 
using samples o f  street heroin. Work is ongoing to 
fulfil these objectives. When the final results are 
collated, work will be done with ID U ’s to test the 
most effective makeshift and commercially pro­
duced filters for user acceptability.
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